annual report new ambitions patients shareholders people made major progress journey towards significant corporate change gsk years track separate create two new leading companies opportunity impact human health scale deliver compelling performance shareholders gsk haleon gsk unite science talent technology haleon global leader focused get ahead disease together prioritise consumer health clear purpose innovation vaccines specialty medicines deliver better everyday health humanity maximising increasing opportunities prevent focused strategy deliver sustainable abovemarket treat disease growth attractive returns shareholders step change growth strong prospects growth expected sales growth adjusted exceptional portfolio categoryleading brands operating profit growth attractive global footprint competitive capabilities compound basis compelling strategy outperform growing rd focused science immune system billion plus sector relevant ever human genetics advanced technologies annual organic sales growth medium term positively impacting health billion sustainable moderate margin expansion high cash people ten years conversion leading esg performance maintained attractive growth profile capacity invest deliver shareholder returns set new purpose growth commitments set strategy capabilities growth rd catalysts investor update june ambitions consumer healthcare capital markets detail see gskcom day february detail see gskcom contents strategic report board committee information financial statements business model board architecture notes financial statements performance summary board activity financial statements chairs statement board progress glaxosmithkline plc prepared ceos statement boards approach continuous uk gaap financial performance engagement longterm priorities boardled purpose culture investor information culture board performance quarterly trend key performance indicators board committee reports fiveyear record external environment section statement product development pipeline innovation directors report products competition performance intellectual property trust remuneration report principal risks uncertainties consumer healthcare chairs annual statement share capital share price stakeholder engagement annual report remuneration dividends risk management remuneration policy summary financial calendar group financial review remuneration policy report annual general meeting tax information shareholders corporate governance financial statements shareholder services contacts board gsk leadership team directors statement us law regulation chairs governance statement responsibilities group companies board roles responsibilities independent auditors report glossary terms cautionary statement see inside back cover document cautionary statement regarding forwardlooking statements nonifrs measures use number adjusted noninternational financial reporting standards ifrs measures report performance business total reported results represent groups overall performance ifrs adjusted results nonifrs measures may considered addition substitute superior information presented accordance ifrs adjusted results nonifrs measures defined pages reconciliations nearest ifrs measures pages gsk annual report strategic report governance remuneration financial statements investor information business model prepare new future continue help improve health hundreds millions people around world discovering developing manufacturing innovative medicines vaccines consumer healthcare products develop deliver medicines vaccines consumer central success people experts science healthcare products impact human health scale technology manufacturing regulation intellectual property operations span value chain identifying researching commercialisation also collaborate worldleading developing testing groundbreaking discoveries experts form strategic partnerships complement regulatory approval manufacturing commercialisation existing capabilities value create future greatest contribution make improve health aim modern employer developing people people around world included delivering offering broad range benefits including preventative billion medicines million vaccines billion healthcare services help us attract retain best consumer healthcare products looking ahead gsk people clear ambition positively impact health employ people across countries work billion people next ten years directly suppliers paid billion create value shareholders investing business corporation tax well significant amount provide shareholder returns paid dividend business employmentrelated taxes pence per share made new commitments growth step change performance next five years delivering strategic transformation prioritising innovation performance trust recent years transformed gsk improve performance delivered investing effectively performance strengthen capabilities prepare business people executing competitively new future done prioritising innovation ability launch new products successfully grow sales performance trust across entire company existing portfolio key commercial success driving multiyear programme improve rd productivity next five years base year expect gsk commercial execution group structure capital allocation deliver highly attractive growth sales adjusted underpinned new culture ambition operating profit accountability respectively compound basis innovation critical improve health create trust underpins everything maintained financial value total rd expenditure acknowledged leadership environmental social billion aer robust governance esg issues demonstrated sectorleading latestage rd pipeline many assets potential position dow jones sustainability index long first best class continue believe rapid standing leadership access medicine index convergence science technology biopharmaceuticals remain deeply committed addressing issues provides significant opportunity rd matter sustainability company including pricing continue focus science immune system human access global health environment inclusion genetics use advanced technologies diversity working integrity care including adjuvant sales performance summary strong commercial execution drives growth across pharmaceuticals vaccines consumer healthcare excluding divestmentsbrands review billion group turnover stable aer cer pharmaceuticals billion aer cer new specialty medicines billion aer cer vaccines billion aer cer covid solutions sales billion consumer healthcare billion aer stable cer excluding brands divestedunder review cost discipline supports delivery adjusted eps growth total eps p aer cer adjusted eps p aer cer contribution growth covid solutions aer cer total operating profit billion aer cer adjusted operating profit billion aer cer dividend p continued momentum rd delivery strengthening pipeline three major product approvals phase iii starts vaccines medicines pivotal trials strong pipeline vaccines medicines many offer potential best firstinclass opportunities patients deals executed securing access novel clinical programmes including immunooncology immunoneurology flu plus technologies expand capabilities human genetics artificial intelligencemachine learning aiml track create two new leading companies demerger mid new gsk investor update june set new purpose growth commitments rd catalysts detail see gskcom consumer healthcare capital markets day february highlighted strategic priorities key growth drivers detailed financial information detail see gskcom leading esg performance st pharmaceutical industry dow jones sustainability index st access medicine index gold recognition sps sustainability yearbook cdp climate change gsk annual report gsk annual report strategic report governance remuneration financial statements investor information chairs statement made significant progress towards demerging gsk two leading competitive companies mid gsk delivering programme fundamental strategic made considerable advances distinctive transformation since emma started ceo five years ago approach rd based science immune system designed tackle root causes companys longterm human genetics advanced technologies chief underperformance including shareholder returns scientific officer cso hal barron tony wood transition role cso august part carefully board pleased emmas leadership considered succession plan build significant saw progress clear priorities set enable progress already made tony one worlds leading improving pipeline rd productivity sharpening chemists impressive track record medicine commercial execution cost discipline tackling development year career uk us groups structure capital allocation priorities underpinned shift culture progress started reflected share price performance however board building significant progress made period management recognise sustaining long term believe firmly track demerge gsk depend consistent performance delivery two worldclass companies mid one focused strengthened competitiveness pharmaceuticals vaccines one focused consumer healthcare targets sustained performance delivery well performance inyear board maintains clear focus oversight companys strategy plans board remains focused ensuring gsks fundamentals separate proposed subject shareholder approval continue enhanced ensure companies fully happen mid competitive point split investor update june purpose strategy covid pandemic continued mean highly new gsk set clear performance targets dynamic operating environment board pleased sales operating profit margin growth beginning company exceeded earnings per share guidance set communicated achieved would represent top start year achieved overdelivery quartile performance sector similar stretching ambitions across business including excellent commercial execution set consumer health business key markets therapy areas showing ability compete grow market share board also pleased course management must deliver targets see commercial performance patient impact set clear remuneration must tied enhancing xevudy leading monoclonal antibody covid shareholder value linking executive developed partnership vir biotechnology remuneration reward outperformance details proposals laid later report savings programmes announced early delivered chance shareholders vote agm may result gsks cost base competitive versus peers capital allocation priorities clear invest addition new gsk board fully focused rd pipeline new product launches delivering returns company operates clear agenda esg shareholders environmental social governance leadership gsk strong tradition build areas including maximising access medicines across world ensuring progress matters prioritychairs statement continued shareholder engagement board transition move closer separation also continuing period considerable transition board assess skills capabilities experience gsk board management maintained significant engagement need pure biopharma business delighted shareholders clear vast majority welcome anne beal board may anne brings extensive support strategy direction company taking healthcare experience doctor entrepreneur combined clear distraction sustained delivery passion patient advocacy january dr harry hal message heard board whose c dietz joined board hal worldleading expert accountability first foremost act interests human genetics professor genetic medicine johns shareholders hopkins university school medicine us confident appointments continued input hal key part strategy separation consumer barron august nonexecutive board director healthcare broad base support among scientific credentials gsks board among shareholders direct ownership outstanding business strongest industry demerger course gsk board fiduciary duty remain open consider alternative proposals also want take opportunity thank lynn elsenhans demerger could create superior value shareholders stepping separation consumer proposals received date health business mid lynn made outstanding contribution board development current final stages creating strategy ten years including notably chair exceptional company im delighted designate corporate responsibility committee increasingly appointments sir dave lewis lead board brian centre boards work missed mcnamara ceo strongly believe new company board offers attractive profile prospective investors reflected growth outlooks set capital markets day finally would like thank employees partners february shareholders customers support commitment last year look forward promises exciting gsk sir jonathan symonds chair gsk annual report gsk annual report strategic report governance remuneration financial statements investor information ceos statement ended strongly enter good momentum going landmark year company pleased report gsk delivered course one priority contribute solutions strong operational performance pipeline progress covid pandemic successfully developed new time completed multiyear programme monoclonal antibody treatment xevudy partners vir far reaching transformation tackle longstanding issues biotechnology medicine proven effective impacting companys success multiple variants including omicron securing rapid regulatory approvals worldwide adjuvant ready deliver significant corporate partnerships stand ready supply new vaccines change gsk years creating two new exceptional data reads broadly also increasing investment companies ambitious targets growth clear mrna capability major new platform validated purpose positively impact health lives billions pandemic people never role vaccines widely appreciated performance provides momentum understood world right opportunity group sales billion cer gsk protect people deliver growth broad range products meaningfully helped patients across range vaccines remains significant different disease areas including respiratory immuno much progress seen rd last four inflammation oncology hiv protected people viruses years due outstanding leadership hal barron like shingles meningitis prevented hospitalisations cso august hand responsibility tony wood deaths covid helped improve oral health key partner hal tony outstanding reduce pain treat everyday ailments scientist deep expertise science data new strong operational performance enabled us increase technologies perfectly placed take capture investment rd billion realise earnings per value opportunities see gsks rd approach share excess expectations year addition also delighted hal remain part gsk generated billion free cash flow supporting nonexecutive board director investments dividend pence per share year new purpose new ambition improvements made commercial execution demerger consumer healthcare establish cost base together strengthening portfolio new gsk purely focused biopharmaceuticals last year pipeline mean momentum deliver step announced new purpose new growth ambitions change growth starting new company accelerating innovation gsks new purpose unite science talent technology continue believe rapid convergence science get ahead disease together prioritising technology biopharmaceuticals provides significant innovation vaccines specialty medicines maximising opportunity gsk rd continue focus opportunities prevent treat disease aim science immune system human genetics positively impact health billion people use advanced technologies approach delivering next ten years deliver stronger sustainable returns improvements rd pipeline shareholders company outstanding people thrive last months reported regulatory approvals three new medicines including firstever longacting set ambitious fiveyear sales operating injectable prep treatment option hiv well starting profit compounded growth targets eight phase iii clinical trials currently assets respectively aim deliver pivotal clinical studies time reporting also billion annual sales sales existing late concluded deals external partners securing stage pipeline assets contribution yet included access novel clinical programmes oncology neurology earlystage assets future business development hiv well innovative technologies notably targets represent new level ambition gsk would expansion capabilities human genetics deliver topquartile sector performance functional genomics use artificial intelligence embedding commitments deeply company achievements spearhead strengthening pipeline including incentive programmes drive focus action vaccines medicines clinical development many potential first bestinclassceo 's statement continued culture performance support succeed haleon new worldleading consumer strongly believe gsk company people health company thrive creating right culture deliver haleon compelling prospect completely dedicated new purpose performance aspirations priority consumer health worldclass portfolio category team focused gsk place leading brands offers attractive proposition brings deep people ambitious patients accountable impact human understanding together trusted science deliver right thing better everyday health humanity world leader new standalone company offer prospective also enormous responsibility inspire support investors highly attractive financial profile abovemarket people succeed continue look ways invest sales growth sustainable margin expansion high cash peoples growth development help generation balance work personal lives includes strong focus management skills training support mental fantastic leadership team led ceo designate health wellbeing well health safety brian mcnamara board led sir dave lewis work gsk brings wealth international consumer sector experience last year put place additional new programmes creation haleon reflects successful delivery series support priorities committed developing progressive strategic moves took last years true approach inclusion equity altogether estimate acquisitions integrations diversity made good progress new businesses targeted divestments close billion aspirational targets female ethnically diverse value created business representation senior roles also taking steps time shareholders access value invest ensure clinical trials representative patients believe strong highly successful growth aim help orientated business capable delivering sustainable performance returns esg leader operating responsibly core gsk aim continue landmark year deliver sectorleading esg performance recognised pandemic shone spotlight like never latest rankings dow jones sustainability index difference industry make society see access medicine index antimicrobial resistance people scientists factory teams supply experts benchmark reflects progress across six core esg work healthcare professionals many thousands areas environment access global health inclusion others risen challenge ensuring patients diversity product governance ethics clear people parts world continue receive products longterm goals ambitions complacent need deeply inspiring reflects deep want go commitment people working gsk people set carbon netzero nature positive goals serve recognising increasing need importance provide people reason gsk haleon investors stakeholders evidence tangible successful years come want thank esg performance developing new measures achieved momentum delivering reporting validated third parties audit teams excited optimistic future share investors later year hope landmark year gsk committed demonstrate commitment bestinclass esg rely us excited achieve together performance transparent reporting emma walmsley chief executive officer gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial performance operating profit operating performance total operating profit million compared turnover million primarily reflected unfavourable comparison net profit disposal q horlicks growth growth consumer brands resultant sale shares cer hindustan unilever partly offset lower major pharmaceuticals restructuring costs lower remeasurement charges vaccines contingent consideration liabilities unwind consumer healthcare fair market value uplift inventory arising completion group turnover consumer healthcare joint venture pfizer adjusted operating profit million lower financial results aer higher cer turnover increase cer adjusted operating margin growth cer percentage points lower aer percentage points higher turnover cer basis increase adjusted total operating profit operating profit primarily reflected benefit incremental total earnings per share p pandemic sales sales growth pharmaceuticals tight adjusted operating profit control ongoing costs favourable legal settlements adjusted earnings per share p benefits continued restructuring across business net cash operating activities offset lower sales vaccines higher supply chain free cash flow costs vaccines consumer healthcare divestments consumer healthcare increased investment rd across turnover vaccines pharmaceuticals strong commercial execution drives growth across pharmaceuticals vaccines consumer healthcare earnings per share excluding brands divestedunder review total eps p compared p group turnover million year stable aer primarily reflected unfavourable comparison cer sales covid solutions sales xevurdy benefited net profit disposal horlicks related pandemic adjuvant contributed approximately percentage transactions partly offset credit million taxation points growth year resulting revaluation deferred tax assets lower major restructuring costs lower remeasurement pharmaceutical turnover year million charges contingent consideration liabilities adjusted aer cer sales xevudy monoclonal eps p compared p antibody treatment covid million contributed aer cer cer increase adjusted approximately percentage points total pharmaceuticals operating profit primarily reflecting incremental pandemic sales growth sales increases pharmaceuticals tight cost control vaccines turnover million year favourable legal settlements lower interest costs partly aer cer primarily driven pandemic offset lower sales vaccines higher supply chain costs adjuvant sales partially offset lower demand routine vaccines increased rd investment higher effective adult vaccination due covid vaccination programme tax rate deployment disease circulation across regions vaccines cash flow turnover excluding pandemic vaccines decreased aer cer million net cash inflow operating activities year million million decrease consumer healthcare turnover million primarily reflected adverse exchange impacts increased trade aer remained stable cer reflecting dilution receivables adverse timing returns rebates rar divestments given completion portfolio rationalisation increased separation costs partly offset improved adjusted end q sales excluding brands divestedunder operating profit cer reduced tax payments including tax review decreased aer increased cer reflecting disposals underlying strength brands across portfolio categories continuing growth ecommercefinancial performance continued total adjusted results total reported results represent groups overall may directly comparable similarly described performance measures used companies gsk also uses number adjusted nonifrs measures gsk encourages investors analysts rely report performance business adjusted results single financial measure review gsks annual reports nonifrs measures may considered addition including financial statements notes entirety substitute superior information presented gsk undertaking number boardapproved major accordance ifrs adjusted results defined restructuring programmes response significant changes nonifrs measures defined groups trading environment overall strategy following gsk believes adjusted results considered material acquisitions costs cash noncash together total results provide investors analysts programmes provided individual elements stakeholders helpful complementary information approved meet accounting recognition criteria understand better financial performance position result charges may incurred number years group period period allow groups following initiation major restructuring programme performance easily compared majority peer companies measures also used management planning reporting purposes divestments intangible intangible significant total asset asset major transaction legal separation adjusted adjusting items results amortisation impairment restructuring related items costs results turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures loss disposal interest associates profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p intangible asset amortisation impairment divestments significant legal items amortisation intangible assets excludes computer software proceeds costs disposal associates products capitalised development costs impairment intangible businesses significant settlement income significant legal assets excluding computer software goodwill charges net insurance recoveries expenses settlement litigation government investigations major restructuring operating income royalty income items major restructuring costs include impairments tangible including impact revaluation deferred tax assets assets computer software specific board approved liabilities following enactment increase headline programmes structural significant scale rate uk corporation tax effective costs individual related projects exceed million including integration costs following material acquisitions separation costs additional costs establish consumer healthcare transactionrelated independent business well admission listing transactionrelated accounting adjustments related demerger costs significant acquisitions gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial performance continued adjusted results growth turnover turnover cer turnover cost sales gross profit selling general administration research development royalty income operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p increase adjusted operating profit primarily reflected performed benefit incremental pandemic sales contributing cost sales approximately aer cer adjusted operating profit growth adjusted operating profit also benefited sales adjusted cost sales percentage turnover growth pharmaceuticals including benefit prior period percentage points higher aer percentage points rar adjustments tight control ongoing costs including higher cer compared primarily reflected reduced promotional variable spending across three higher pandemic sales xevudy well higher supply chain businesses result covid lockdowns favourable costs vaccines resulting lower demand higher legal settlements compared increased legal costs inventory adjustments higher commodity freight costs benefits continued restructuring across business consumer healthcare partly offset price benefits partly offset lower sales vaccines primarily pharmaceuticals including benefit prior period rar shingrix higher supply chain costs vaccines consumer adjustments contribution restructuring savings healthcare divestments consumer healthcare increased across three businesses favourable mix vaccines investment rd across vaccines pharmaceuticals selling general administration tax adjusted sga costs percentage turnover tax adjusted profit amounted million representing percentage points lower aer effective adjusted tax rate percentage points lower cer basis adjusted sga costs decreased aer cer reflected tight control noncontrolling interests ongoing costs reduced variable spending across allocation adjusted earnings noncontrolling interests three businesses result covid lockdowns amounted million million continuing benefit restructuring pharmaceuticals reduction allocation primarily reflected reduced allocation consumer healthcare support functions decrease viiv healthcare profits million million also reflected favourable legal settlement compared partly offset higher net profits groups increased legal costs well oneoff benefits entities noncontrolling interests allocation pensions insurance partly offset oneoff consumer healthcare joint venture profits million benefit restructuring postretirement benefits million partly offset increased investment behind launches hiv vaccines earnings per share adjusted eps p compared p research development aer cer cer increase adjusted adjusted rd expenditure million operating profit primarily reflecting incremental pandemic sales turnover higher aer higher cer sales increases pharmaceuticals tight cost control operating profit favourable legal settlements lower interest costs partly offset lower sales vaccines primarily shingrix higher adjusted operating profit million lower supply chain costs vaccines increased rd investment aer higher cer turnover increase higher effective tax rate contribution growth cer adjusted operating margin covid solutions approximately aer cer percentage points lower aer percentage points higher cer basis longterm priorities put innovation performance trust first realise ambitions patients shareholders people delivered strong performance track successful demerger create two new leading companies innovation performance trust invest scientific technical deliver growth investing responsible company excellence develop launch effectively business commit use science pipeline new products developing people technology address health meet needs patients executing competitively needs make products payers consumers affordable available modern employer objectives objectives objectives deliver innovation sales excellent continue prioritise spending deliver continue deliver ontime infull supply commercial rd supply chain growth return investment products execution oncology hiv vaccines continue deliver twoyear programme improve manager capability motivate accelerate strengthen pipeline prepare gsk separation two focus develop care people robust commercial input including new leading companies continue deliver progress trust business development build stronger diverse workforce commitments two new leading companies progress progress progress received three major approvals strong commercial execution across maintained sectorleading rankings apretude longacting hiv prevention pharmaceuticals vaccines consumer esg indices including dow jones medicine jemperli endometrial cancer healthcare sustainability index access medicine xevudy covid pharmaceuticals billion aer index antimicrobial resistance strong pipeline vaccines cer doubledigit growth benchmark medicines many offer potential new specialty medicines aer maintained supply manufacturing best firstinclass opportunities cer without significant disruption throughout patients pivotal trials vaccines billion aer cer pandemic deals executed securing access consumer healthcare aer stable made progress deliver net zero novel clinical programmes including cer aer cer excluding impact climate net positive impact iteos immunooncology alector divestmentsbrands review nature immunoneurology vir biotechnology track deliver separation plans rolled new training programme flu plus technologies expand mid develop managers support capabilities human genetics ai ml great managers lead care continued prioritise diversity good progress made gender ethnicity targets improve representation senior roles recommended wider use rtss vaccine children regions moderate high malaria transmission priority objectives priority objectives priority objectives deliver innovation sales excellent deliver sales growth deliver leading esg performance commercial rd supply chain adjusted operating profit effective risk management disciplined execution compound basis next five years compliance accelerate strengthen pipeline continue prioritise spending deliver dedicated inhouse expertise growth return investment robust commercial input including deliver successful demerger mid optimised capital allocation business development culture move towards creation two new leading companies embedding culture ambitious patients accountable impact continue right thing track cultural change range indicators increasingly embedding assessments hr processes board receives regular updates see pages principal risks risk management framework designed support longterm priorities see pages innovation sales defined gsk annual report gsk annual report strategic report governance remuneration financial statements investor information culture culture powers purpose get ahead disease together drives delivery strategy makes gsk place outstanding people thrive past four years focused embedding know leaders managers play crucial role culture anchored purpose performance weve made bringing culture life people continue great progress demonstrated strong engagement pride develop managers focused training support gsk contributed improved rd productivity great managers motivate teams help performance commercial teams supply focus matters support performance chains time impact covid development lead care everyone pandemic driven teams work dynamically individuals measure effectiveness global deeper connection purpose manager population annual one feedback continue build refresh expertise senior leaders gsks purpose unite science talent technology get top leaders appointed ahead disease together puts people heart broader hr processes including reward succession success deliver purpose help outstanding planning continue based assessments people thrive focus culture gsk place deliver ie cultural behaviours ambitious patients accountable impact right thing approach hybrid working performance choice anchored driving individual collective performance means helping people constantly strive things creating flexibility officebased people better faster always focused matters get work done helps means setting clear objectives ensuring accountability perform best based role team personal results giving everyone support space need circumstances pandemicrelated restrictions began ease succeed ever means everything responsibly many countries officebased people care integrity people people around either already changed way work started discussing world count us manager officebased workers measure progress range indicators approximately quarter people worked part looking people experience gsk place week home continually look ways work embody culture affects support people role types balance work performance engagement remains high settling personal lives back levels boost early phases know strongest cultures need built pandemic part changes make approach top bottom inside measuring culture increasingly dynamic augment successful year bringing people annual survey pulse surveys quickly together around world representing every role type identify areas success areas focus company business area region help us accelerate culture respect people core gives us across company ready excited continue opportunity build inclusive culture internally make progress culture gsk together force good improving inclusion diversity society deliver step change competitive growth build continue focus building inclusive culture successful company improves lives people across inclusion training people leaders alongside world work evolve policies processes practices consumer healthcare culture see key performance indicators see progressing three longterm priorities use ten key performance indicators gsk leadership team glt board review track operating kpis internally give key performance indicators kpis regularly also update data report externally commercial sensitivities people progress every quarter decide peoples mean cant publish data operating kpis shown nr bonuses based relevant subsets ten kpis report business performance use adjusted nonifrs also use reward executives performance see measures including adjusted results free cash flow cer pages growth rates described pages innovation innovation sales r pharmaceuticals vaccines sales products launched last five years bn bn bn consumer healthcare sales products new market last three years total sales pipeline value progress r value products pipeline rd milestones achieved nr nr nr performance group turnover r flat aer cer bn bn bn profit r total operating profit aer cer bn bn bn adjusted operating profit aer cer bn bn bn total operating margin adjusted operating margin free cash flow r bn bn bn market share market share relation competitors nr nr nr top talent succession plans key roles talented employees key roles succession plans place nr nr nr trust employee feedback employee engagement scores global employee survey supply service level percentage orders delivered ontime infull nr nr nr corporate reputation reputation index among stakeholders informed public measured globally top markets nr nr nr r linked executive lti awards annual bonus see pages executive lti awards annual bonus based mix total sales growth adjusted operating profit growth pipeline esg targets see pages includes products benefited significant lifecycle innovation comparative information reflects sales products meet definition nr reported externally due commercial sensitivities gsk annual report gsk annual report strategic report governance remuneration financial statements investor information external environment world changing shaped major social economic trends continue influenced covid pandemic contribution vaccines medicines healthcare clearly highlighted year challenges remain respond dynamic environment working governments regulators industry partners deliver innovation healthcare systems demonstrates value patients payers reopening global economy driven outlook global healthcare market healthcare innovation prepandemic trends use medicines spending events gave clear demonstration remain relatively constant higher income countries contribution industry make world adoption new treatments offset patent lifecycles pandemic continued collaborations companies competition generics biosimilars expected governments regulators international organisations continue main driver medicine spending growth brought new vaccines medicines world record global medicine spending totalled trillion time regulatory processes got faster companies invested expected grow cagr reaching rd deliver novel products expanded manufacturing trillion total market size excluding spending capacity rollout vaccine programmes enabled global covid vaccines us market forecast grow economy reopen later year regulatory approval cagr next five years spending top five granted covid treatments gsk contributed european markets expected increase billion global response agreements us eu china expected increase uptake new original number governments supply covid medicines growing billion spending therapeutic xevudy sotrovimab ongoing vaccination emerging markets likely increase billion global development programmes sanofi medicago sk spending vaccines predicted grow reaching bioscience curevac billion time virus continues take lives forecast specialty medicines account world still dealing economic social impact nearly total expenditure highincome markets pandemic worst predictions prolonged economic remainder predominantly older traditional recession materialised global economic forecasts therapies becoming progressively lowercost time predicting growth although two leading global therapy areas oncology immunology uncertainty uniformity recovery forecast grow cagr respectively management debt inflationary trends similarly lifted significant increases new continued economic social threats posed new treatments medicine use expected variants omicron although global healthcare spending oncology treatments come market five years expected rise competing funding demands frontline staff costs ongoing need pandemic position medical products catchup programmes tackle growing performance suggests well positioned waiting lists governments healthcare systems capitalise forecast growth specialty medicines evaluate cost new pharmaceutical innovation role increased investment key rd programmes expanded helping address burden illness across therapy areas support new ongoing launches resulted sales growth driven strong uptake new medicines new specialty medicines grew cer recorded doubledigit sales growth immunoinflammation respiratory oncology see results encouraging demonstration strong progress strategic priorities new medicines forefront exciting highvalue pipeline continue build across prevention treatment disease imf world economic outlook recovery pandemic october iqvia global use medicines january iqvia global medicine spending usage trends outlook april external environment continued healthcare environment opportunities challenges us medicines policy pricing access several legislative efforts address drug pricing equal access healthcare us throughout year pricing became focal point attempts pass trillion social safety climate governments equal access healthcare growing package build back better act towards end year policy priority challenge bringing covid vaccines drug pricing reform proposals provided direct equitably global population highlighted dilemma negotiations federal government 's medicare industry manufactured distributed billion insurance programme industry price ten vaccine doses disproportionally gone high costliest drugs diseases cancer diabetes income countries people lowincome countries one supplier new prices taking effect received least one dose governments attempt measures sought address outofpocket expenditures balance immediate access respective populations seniors capping spending per person per year global health responsibilities companies raised price medicines inflation though global initiatives covax helped parts b medicare would penalised inflation cap access vaccines disparity led governments would also apply private insurance markets international organisations question intellectual property ip though outofpocket measures improve affordability frameworks notably world trade organizations seniors industry concerned taken together agreement traderelated aspects intellectual property package could reduce patient choice limit access rights trips waiver provisions however concern innovation future agreement reached exact moves alter ip protections wont address terms build back better act year end extent problem could destabilise innovation within life sciences effect drug reform package remained unclear turn could threaten future collaborations like ones important creating vaccines treatments european pharmaceutical reform used tackle pandemic europe continues considerable scrutiny need demonstrate value innovation public drug pricing growing trend towards centralised private healthcare payers growing expenditure procurement vaccines medicines wideranging review pharmaceuticals heavily scrutinised renewed calls eu pharmaceutical legislation began part eus transparency price setting however pharmaceutical strategy strategy based four pillars significant moderation pharmaceutical expenditure covering access competitiveness innovation crisis last decade across major markets surveyed iqvia preparedness strong eu voice world review medicines expenditure represents total healthcare also looking improved regulatory procedures spending remained relatively flat even though reliance vulnerability supply medicines pharmaceuticals increased last year european commission centralised continued genericisation medicines across therapeutic procurement covid vaccines behalf member classes including cancer increased use biosimilars states concluded joint procurement agreement continually improving affordability access however purchase monoclonal antibodies outlook continue challenging demand data realworld evidence support continued reimbursement beyond europe many countries implementing various new products likely increase work payers reforms ranging regulatory pathways cost containment design innovative solutions manage risk china government committed accelerating patient uncertainty access health insurance cover innovative medicines china completed update national reimbursement drug also likely greater emphasis health resilience list nrdl add new highvalue medicines role preventative care play improving future however access nrdl result price health outcomes health protection interventions including reductions average immunisation represent significant value terms return investment estimated every pound spent uk position aim bring new medicines vaccines consumer healthcare products patients across world matter live industryleading track record world economic forum zero covid vaccines billion shown continued top ranking access year january medicine index working ensure medicines world data coronavirus vaccinations january become specialised maintain commitment iqvia drug expenditure dynamics october access making products widely available abpi economic societal impacts vaccination responsible prices sustainable business hr build back better act th congress pharmaexeccom china nrdl readout january gsk annual report gsk annual report strategic report governance remuneration financial statements investor information external environment continued getting balance right responsible pricing across regions major regulatory initiatives sustainable business fundamental innovation announced including uk china us europe performance trust priorities setting prices us negotiations industry food drug medicines mature markets use valuebased approach administration fda prescription drug user fee act balances reward innovation access affordability pdufa vii concluded potential regulatory innovations see aim provide truly differentiated innovative covered resulting commitment letter moving products offer effective health outcomes patients legislative process eu industry continues payers products deliver value prepare european commissions revision general pharmaceutical legislation industry also working pricing see esg performance report uks medicines healthcare products regulatory agency mhra establishing new enhanced partnerships regulatory environment regulators outside eu following brexit still significant regulatory challenges around implementation growing flexibility cooperation northern ireland protocol industry continues engage despite obstacles posed pandemic regulators uk eu agencies resolve industry continue prioritise supply essential vaccines medicines also accelerating position development new products new regulatory approaches gsk closely monitors engages relevant facilitated innovation particularly digital healthcare appropriate improve regulation happens mainly cell gene therapies complex clinical trials big data uk europe us china japan realworld evidence example scientific innovation moving beyond scope regulators worked close cooperation industry current regulation standards continue learn often across regulatory jurisdictions supranational experience covid working peers bodies international coalition medicines engaging governments create balanced regulatory authorities potential permanent regulatory framework supports discovery delivery adoption regulatory adaptations support development vaccines medicines developed emerging approval broader range new vaccines medicines technologies techniques also opportunity simplify regulatory processes global environment opportunities challenges advances science technology help us respond changing needs growing demand healthcare created changing ageing populations increasing global demand preventive demographics greater patient control demand therapeutic health solutions changing way digital health healthcare delivered worldwide acceleration digital health telemedicine revolutionised delivery position healthcare last two years patients increasingly changing demographics contribute rising demand managed healthcare home global digital health healthcare respond diverse portfolio market expected reach billion cagr spanning infectious diseases hiv oncology immunology patients becoming engaged respiratory disease aim positively impact health healthcare companies adopting patientcentric billion people next ten years products approaches focused patient outcomes patient satisfaction line innovation priority investing pipeline user experience vaccines specialty medicines meet changing predictions suggest global population grow billion healthcare needs believe new technologies enable billion despite pandemic earlier identification diseases develop decreasing life expectancy countries precision medicines target treatments groups number overyearolds set double patients likely benefit vaccines technological people living cities becoming affluent innovation allowing us address unmet medical needs living advanced age particularly true china across age groups experiencing worlds fastestever expansion middle class projections billion people middle class igital health global market report covid growth change research markets march united nations world population prospects revised brookings chinas influence global middle class homi kharas meagan dooley october external environment continued climate change focus advances science technology recent political economic challenges may slowed exciting time medical discovery fuelled progress uns sustainable development goals genetic revolution last decade combined need action remains urgent top priority addressing expansion patientdriven healthcare data advanced environmental issues extreme weather events new scientific technology like artificial intelligencemachine learning aiml data climate change civic activism rapidly advanced advances functional genomics crispr gene case sustainable energy solutions stronger editing already started redefine possible protections natural world biodiversity glasgow drug discovery allowing researchers unravel mysteries cop summit focal point international biology help pinpoint novel drug targets higher climate change solutions led glasgow climate pact probability success driving phenomenon call includes new emissions pledges fulfilled limit digitisation biology allows scientists explore human global warming degrees preindustrial levels biology way never possible holds much promise first time cop plan also set reducing treating diseases previously reach requires ai global use coal responsible annual co machine learning emissions researchers regulators payers also exploring technologies help improve clinical trials generate recognising good esg management better insights product effectiveness even new societal expectations business continue increase combinations products improve health businesses expected play part addressing biggest challenges facing society international rapid advances science technology fundamentally investment community responding context placing changing life sciences rd pandemic accelerated higher value businesses actively manage esg risks vaccine innovation including mrna technology enables opportunities businesses seen offer better bodys cells produce specific proteins antigens foundation longterm sustainable growth good immune system prevent fight infectious disease environmental stewardship climate risk mitigation planning position becoming priority investors forefront advances science technology position working create innovative solutions kinds healthcare trust essential deliver purpose create challenges longterm value shareholders society advanced technology platforms central commitments support trust priority deeply rd approach expertise ai functional committed addressing issues matter including genomics dedicated global inhouse ai team using pricing access global health environment machine learning unlock potential complex genetic inclusion diversity data neverbeforeseen levels speed precision made good progress across many scale see details areas retain sectorleading position dow jones vaccines use diverse platform technologies sustainability index leading work improving global health adjuvants improve vaccine effectiveness mrna tackling antimicrobial resistance recognised technology heart pipeline differentiation access medicine foundation top rankings collaborations partnering teams cutting access medicine index amr benchmark edge fields within outside pharmaceuticals vaccines recommended malaria vaccine wider use children help steer new science develop therapeutics see pages regions moderate high malaria transmission details launched new aspirational gender ethnic diversity targets increase representation senior levels alongside review recruitment processes levels make sure responsible business reaching attracting diverse candidates made societys expectations businesses remain high companies strong progress climate nature goals across sectors face increased scrutiny social including largescale renewable energy investments two environmental impacts operations time major manufacturing sites joining coalition curb longterm socioeconomic trends continue drive trust deforestation investing rd cut greenhouse gas business organisations must meet expectations emissions metered dose inhalers engage benefit society economy see environment companies partnering policymakers nonprofit organisations finding new collaborative solutions complex longterm issues climate change global health inequalities lewis maslin five things need know glasgow climate pact world economic forum november ritchie h roser co emissions fuel world data last accessed january gsk annual report gsk annual report strategic report governance remuneration financial statements investor information innovation innovation core continued strengthen pipeline vaccines medicines apply growing expertise partnerships technology data increase productivity rd year new launches regulatory approvals important clinical studies turning expertise transformational vaccines medicines patients pharmaceuticals vaccines highlights strong pipeline vaccines medicines many approval jemperli treatment endometrial potential first bestinclass opportunities cancer certain solid tumours patients pivotal trials positive phase iii data daprodustat patients approval us apretude longacting hiv anaemia chronic kidney disease preventative therapy deals executed securing access five novel clinical xevudy sotrovimab monoclonal antibody treatment assets covid approved authorised conditional approximately targets research temporary use us uk eu genetically validated published scientific research countries shows genetically validated targets least twice likely become medicines innovation heart achieving purpose unite prioritise research vaccines medicines across science talent technology get ahead disease four therapeutic areas infectious diseases hiv oncology together discovering developing new vaccines immunology including respiratory also remain open medicines help patients make largescale opportunities outside core areas science aligns positive impact human health prevention strategic approach treatment disease pipeline consists potential vaccines medicines rd core innovation invested modulate immune system billion rd aer enhance moved assets phase phase ii trials pipeline vaccines medicines work partnerships businesses academia speeding pace discovery currently vaccines medicines development development many potential first bestinclass productivity rd increasing since encourage teams pursue bold research backed weve doubled number assets phase iii clinical data science underpinned clear accountability development cut overall cycle times across streamlined rd governance allow us development addition anticipate keep pace switched separate clinical milestones potential new vaccines development organisations vaccines medicines medicines identified key future growth drivers including single combined organisation help us make sure apretude approved end invest programmes biggest impact patients respiratory syncytial virus rsv vaccine candidate unlock scientific synergies across prevention treatment older adults growing pace helps us make difference approach rd peoples lives instance blenrep belantamab mafodotin deliver transformational vaccines medicines rd treatment multiple myeloma gained regulatory approval approach focus science immune system two years start first pivotal study human genetics advanced technologies artificial covid treatment sotrovimab achieved emergency use intelligence machine learning authorisation fda months partnership vir biotechnology began april molecule still preclinical phaseinnovation continued leading progress shingles vaccine shingrix approved wider weve major new vaccines medicines approved use several markets including us canada since puts us top quartile industry expansion clinical trial programme zejula new greater success rate indications breast lung cancer pivotal studies compared across industry contribution trelegy ellipta respiratory disease number launches per billion dollars rd lung health continues evolve trelegy expanded spending better peer median indicated use chronic obstructive pulmonary disease copd include asthma us lifecycle innovation well developing new treatments look innovation strategic partnerships joining forces make across lifecycle existing vaccines medicines progress finding new ways help patients either strategic partnerships business development combined therapies since join forces commercial academic partners open increased number lifecycle projects per asset new avenues discovery advance development examples new potential medicines alone announced benlysta treatment systemic lupus partnerships collaborations provided us erythematosus lupus nephritis access five novel clinical assets including iteos immunooncology alector immunoneurology vir nucala anti il biologic also approved biotechnology flu also invested technologies us europe severe eosinophilic asthma expand capabilities human genetics artificial hypereosinophilic syndrome eosinophilic granulomatosis intelligencemachine learning aiml polyangitis chronic rhinosinusitis nasal polyps genetics genomics technology success rd rests finding new gsk partner world 's best minds leading treatments getting better find institutions areas also investing key combining genetics genomics advanced capabilities including london ai hub using technologies biomedical information aiml computing platforms unlock new insights genetic clinical data fulfil purpose get ahead disease together prioritise genetically validated targets increase probability capabilities found new potential successfully delivering approved vaccine medicine combinations existing therapies blenrep approximately targets research genetically combination gamma secretase inhibitor could validated published scientific research shows allow greater patient benefit genetically validated targets least twice likely become medicines able harness advanced forming right partnerships genetics technologies convert insights human genetics genomics genomics improve probability success rd collaboration consumer genetics research company andme yielded novel research making better predictions help patients programmes one phase treatment last decade seen revolution genetic data cancer weve also worked uk biobank since genomics ai machine learning help us find patterns founding joined uks recent bioresource data larger scale far quickly future health additionally supporting newer leading digitisation biology allowing us datasets feature diverse populations genes better understand root cause many diseases health consortium east london black representation genetic research study andme late announced fiveyear collaboration university oxford focus neurodegenerative diseases new institute leverage advanced technologies build insights human genetics accelerate promising areas drug discovery gsk annual report gsk annual report strategic report governance remuneration financial statements investor information innovation continued genomics partners include worlds preeminent extensive vaccine platform technologies experts broad institute boston laboratory work vaccine platform technologies broadest genomics research lgr established portfolio industry enables us select university california theyre helping us find promising technology approach combinations different genetically validated drug targets investigating areas platform technologies develop new vaccines previously including genetic variations consequences thought possible platform technologies adjuvants function cells working pioneers crispr bioconjugation generalised modules membrane antigen technology lgr uncovering new knowledge gmma adenovirus vectors used make vaccines disease mechanisms immunology oncology neurology range different pathogens allow tailored different programmes meanwhile work uk approach deliver success includes mrna key focus biotech adrestia leveraging new area called synthetic area development see critical platform viability find novel drug targets hard treat diseases like technology major opportunity future vaccines frontotemporal dementia ftd investing significantly including also funding phd studentships multiple universities collaboration curevac building inhouse institutes including crick institute university endtoend mrna development manufacturing capabilities adelaide australia university oxford stanford focusing efforts modified nonmodified university cambridges centre ai medicine mrna technologies optimised high protein expression warwick university help make sure sustained improve mrna potency tolerability talent pools right skills coming years digitisation machine learning ai helping us speed using aiml build scale speed vaccine research manufacturing process announced successful proof concept digital twin started new partnership kings college approach vaccine manufacturing siemens atos london using aiml understand patients respond digital twin uses machine learning modelling provide cancer treatment disease progresses others new insights optimising development manufacturing technology tell us role tumour genetics vaccines tumour microenvironment response therapies addition technology aid creation tools help make better clinical decisions personalised treatment nvidias cambridge supercomputer performing similar role us immunooncology fusing different datasets building largescale models help us determine best treatment patients largest ever chip processor ai built silicon valley startup cerebras helping us construct largerscale genetic models learn dna help deconstruct genes operate different disease contexts infectious diseases world faces persistent threat infectious moved multiple vaccine candidates clinical diseases claim lives also put strain trials include meningitis abcwy second generation healthcare systems almost half vaccines vaccine vaccine candidates klebsiella pneumoniae medicines pipeline address infectious diseases cytomegalovirus cmv new strains varicella chickenpox latest trials also include proteinbased targeting several new launches including adjuvanted covid vaccines developing vaccine candidate rsv older adults gepotidacin collaboration companies antibiotic treat uncomplicated urinary tract infections uuti potential first bestinclass also aim complete five proof concept studies new vaccine candidates successfully demonstrate proof concept ready move registrational clinical trialsinnovation continued combined expertise vaccines medicines means rsv uniquely positioned focus connections respiratory syncytial virus rsv common virus treatment prevention examples include leading cause acute respiratory infections older adults covid working treatments rsv exacerbate underlying conditions lead vaccines pneumonia causes hospitalisations deaths overs year highincome countries yet rsv respiratory conditions efforts remains one major infectious diseases without vaccine develop rsv vaccines populations risk rsv leading cause severe respiratory infections well develop future respiratory medicines infants causes hospitalisations influenza hepatitis b antisense oligonucleotide vulnerable group vaccine technologies development programme help prevent rsv consists two candidate influenza developing vaccines vaccines advanced tested adults antibodies aged years uses recombinant prefusion f close collaboration rd across research areas antigen combined adjuvant adjuvant helps us innovate areas multiple tools might key ingredient shingrix boosts immune response required antimicrobial resistance amr pandemic helping overcome challenges associated protecting response drawing crossovers work older people anticipate phase iii data candidate vaccines pharmaceuticals enhance ability vaccine first half stopped enrolment develop innovative solutions meet patient needs vaccination trials rsv maternal candidate vaccine february following feedback independent data shingles monitoring committee idmc analysis better around one three people develop shingles lifetime understand safety data trials ongoing shingrix vaccine signalled step change stopped developing phase ii rsv paediatric preventing painful potentially serious illness first candidate vaccine based adenovirus vector nonlive shingles vaccine combines specific subunit using prefusion f antigen unlikely antigen adjuvant sustain immune response meet efficacy target currently investigating new continued expand access shingrix technologies address important medical need launched nine new markets australia singapore hong kong macau italy spain denmark finland austria meningitis uk switzerland followed early million people develop invasive meningococcal regulators us canada australia hong kong disease imd every year infants young children singapore also extended indication vaccine adults adolescents particularly vulnerable even early diagnosis years older increased risk shingrix first shingles adequate treatment patients bacterial vaccine indicated expanded use meningitis die often within hours symptoms starting left untreated meningitis fatal cases also achieved regulatory approvals vaccine south cause brain damage hearing loss disability korea brazil switzerland taiwan including survivors increased risk population gained new recommendations vaccine italy spain australia switzerland leader imd protection ten million patients vaccinated alone bexsero meningitis b vaccine addition uss national comprehensive cancer network menveo meningitis acwy vaccine together help nccn survivorship guidelines updated preferentially protect imd cases recommend shingrix cancer survivors aged years older nccn guidelines prevention gsk filed submission fda fully liquid treatment cancerrelated infections updated version menveo would simplify administration shingrix recommendations autologous hematopoietic cell vaccine healthcare providers transplantation hct multiple myeloma lymphoma developing two menabcwy pentavalent patients global initiative chronic obstructive lung vaccines would mean one vaccine rather two disease gold guidelines also updated recommend could used help protect five major disease shingles vaccination protect shingles adults causing serogroups first generation menabcwy vaccine copd aged years older candidate phase iii clinical trials created combining technologies used develop existing bexsero menveo vaccines also started phase iii trial second generation pentavalent candidate broader age indications strains gsk annual report gsk annual report strategic report governance remuneration financial statements investor information innovation continued covid following positive phase ii data vaccine collaboration globally million cases covid sanofi began phase iii trials may parallel recorded since outbreak emerged resulting deaths programme booster studies december five half million people partners announced positive preliminary results showing single developing treatments well several vaccines booster dose adjuvanted recombinant proteinbased covid vaccine candidate delivered consistently strong treatment harnessing monoclonal antibodies immune responses across primary vaccines received alongside vaccines effective treatments critical support february announced intention submit patients communities next phases applications regulatory approval vaccine us pandemic covid patients higher risk europe following positive read outs booster hospitalisation death due risk factors old age primary phase iii trials vaccine candidate comorbidities patients remain important access early effective treatment options including december reported positive phase iii data monoclonal antibodies adjuvanted plantbased vaccine developing medicago building positive phase ii results announced collaboration vir biotechnology began earlier year based data vaccine covifenz developed xevudy sotrovimab sarscov approved canada february monoclonal antibody works prevent virus entering infecting healthy cells within body first third vaccine using adjuvant technology development half gsk vir announced results comet sk bioscience successful intend distribute ice phase iii trial investigated intravenous iv infusion vaccine globally covax facility gpb sotrovimab adults mild moderate covid high vaccine selfassembled nanoparticle vaccine targeting risk progression severe disease receptorbinding domain sarscov spike protein started phase iii trials august sotrovimab authorised emergency use us brand name xevudy granted marketing also developing second generation mrna covid authorisation eu conditional provisional marketing vaccine candidates using modified nonmodified rna authorisations great britain switzerland australia saudi vaccine technologies part collaboration curevac arabia also approved via japans special approval august november announced encouraging emergency pathway temporary authorisations sotrovimab results range preclinical studies also granted several countries infectious diseases sotrovimab binds specifically region spike protein diphtheria tetanus pertussis less likely change increasing potential may europe healthcare providers give boostrix remain effective variants emerge time data combination tetanus diphtheria pertussis vaccine preclinical vitro studies demonstrate sotrovimab together one additional vaccine shingrix retains activity tested variants concern interest unadjuvanted inactivated seasonal influenza vaccine date including delta omicron save patients multiple vaccination visits make along vir continuing progress clinical healthcare efficient development programme sotrovimab exploring chronic hepatitis b convenient methods administration november million people suffer chronic hepatitis b received positive results comettail trial year around die decompensated investigating intramuscular im route administration cirrhosis liver cancer cause sotrovimab early treatment mildtomoderate covid highrisk nonhospitalised adults candidate vaccine currently phase iii targeted paediatric patients knowing greatest immunotherapy combining different technologies including need effective prophylactic treatments likely come adjuvant also used shingrix rsv candidate immunocompromised people gsk vir also vaccine older adults aims activate functional virus supporting clinical studies specific population specific tcell bcell responses restore immune competence hepatitis b virus hbv immune covid vaccines using technology boost restoration could lead functional cure chronic hepatitis b immune response defined controlling virus without eradicating working several companies covid vaccines body functional cure could reduce risk using proprietary adjuvant technology adjuvants make longterm complications chronic hepatitis b infection liver vaccines effective boosting extending bodys inflammation cancer expect proof concept data immune response also make possible produce doses less antigen enabling production vaccine doses address global needsinnovation continued also developing bepirovirsen hbv antisense us clostridium difficile causes oligonucleotide potential firstinclass cases hospital patients leads around deaths functional cure chronic hbv designed restore every year progressed phase firsttimein immune systems natural ability eliminate infected liver human study candidate vaccine pathogen cells provide longterm control hbv phase iia klebsiella pneumoniae cause severe infections lungs programme demonstrated bepirovirsen reduce bladder brain liver eyes blood well types hepatitis b surface antigen four weeks treatment meningitis approved vaccine resistance anticipate data ongoing phase iib programme many treatments growing candidate vaccine developed limmatech started cytomegalovirus clinical development july succeeds could help cmv serious health risk babies infants prevent klebsiellaassociated infections people congenital cmv asymptomatic birth still risk highest risk including older people underlying longterm health problems including hearing sight loss conditions like diabetes kidney disease chronic liver disease delayed development seizures us cmv vaccine tetravalent bioconjugate including oantigen leading infectious cause birth defects one target serogroup causing infections combine babies born congenital cmv infection one antigens proprietary adjuvant system five longterm health problems shown vaccines like shingrix help theres currently approved vaccine working provide strong immune responses people ages change adjuvanted subunit vaccine entered including older adults phase iii trials shigella causes deaths every year second leading cause diarrheal death globally rotavirus antibiotics antimicrobial resistance currently widely available licensed vaccines antimicrobial resistance amr urgent threat public protect shigella related threat growing health undermining effectiveness antibiotics antimicrobial resistance significant issue currently contributes deaths every year globally started phase trial quadrivalent shigella vaccine figure expected increase significantly unless action candidate based innovative gmma technology taken focusing organisms highest risk unique approach creating bacterial vaccines replicating developing amr characterised centers disease surface characteristics bacteria membrane control prevention cdc world health organization vesicles medicines developing new mechanisms early science additional collaborations developing gepotidacin novel mechanism partnerships infectious diseases include work topoisomerase inhibitor uncomplicated urinary tract curevac mrna vaccines covid infections uuti gonorrhea partnership also five additional targets including seasonal universal flu biomedical advanced research development authority building understanding microbiome chronic barda us first time new oral antibiotic diseases addressed infections years gepotidacin currently phase iii developed collaborations two companies generate scientific insights turn innovation vaccines targeting resistant pathogens microbiome engineering optimisation new therapies using new scientific insights technologies including adjuvants mrna bioconjugation generalised modules october expanded collaboration viome membrane antigens gmma target pathogens create life sciences started investigating role significant health burden likely develop antibiotic microbiome chronic diseases combines expertise resistance immunology viomes mrna analysis ai platforms give us new insights chronic diseases cancers ageing four vaccines clinical trials staphylococcus aureus clostridium difficile shigella klebsiella also aim generate data pathogens cause programmes could major impact exacerbate chronic diseases including autoimmune reducing cases diseases directly indirectly contributing inflammatory conditions immunooncology help amr including rsv tuberculosis us build predictive model tell us targets therapies build vaccine technology prevent even staphylococcus aureus often resistant antibiotics reverse chronic diseases multiple drugresistant strains already circulation us methicillinresistant strains cause cases eligo biosciences focusing developing hospital patients estimated deaths ways treat acne means using eligos crispr candidate vaccine prevent primary recurring soft bacteriophage technology remove unwanted bacteria skin tissue infections pathogen entered phase ii leaving beneficial bacteria intact gsk annual report gsk annual report strategic report governance remuneration financial statements investor information innovation continued hiv hiv urgent global health threat million new robust industryleading clinical trial programme cases year including new cases us driving confidence twodrug regimens goal new cases eu however million make dovato successful dolutegravirbased regimen people living hiv worlds cases fewer reactions drugs reduces exposure million people come subsaharan africa antiretrovirals three years efficacy safety data dovato sets bar high work hiv viiv healthcare worlds twodrug oral treatment regimens us european specialist hiv pharmaceutical company majority treatment guidelines include dovato recommended pfizer shionogi shareholders goal adult patients new therapy well stably limit impact hiv peoples lives treating preventing suppressed patients need switch hiv therapy ultimately curing developing longacting medicines supporting people living hiv range potential dramatically change peoples experience giving options alternative daily medicine also working single medicine works people living hiv longacting therapies prevent hiv offer innovative choices help address evolving needs replacing daily medicines longacting portfolio approved antiretroviral medicines offers range regimens therapeutic options includes tivicay triumeq contain dolutegravir aim offer innovative choices help address evolving needs people living hiv despite incredible received european marketing authorisation progress made current oral hiv medicines people first ever dispersible tablet formulation dolutegravir form living hiv face challenges taking pills every day tivicay treatment children four weeks old transforming lives people living hiv reducing three kilogrammes living hiv europe also made number days take treatment per regulatory submissions fda ema approval year spares daily reminder living hiv new dispersible tablet formulation fixed dose well relieving pressure take medicine combination abacavir dolutegravir lamivudine triumeq every day lower minimum weight child prescribed medicine january received fda approval cabenuva firstever complete longacting injectable regimen hiv europe received approval february rukobia offering people living hiv us new approach fostemsavir firstinclass hiv attachment inhibitor care studies show cabenuva dosed oncemonthly addresses unmet need heavily treatmentexperienced effective threedrug oral regimens patients currently adults hiv arent responding current antiretroviral take every day treatment exhausted options european approval followed us approval fast received approval dosing every two months tracked fda breakthrough therapy us early europe regimen approved combination preventing hiv longacting cabotegravir prep vocabria cabotegravir rekambys rilpivirine dosing preventing hiv essential reinforced every two months us governments goal reduce acquisition hiv launching innovative treatment regimen established viiv healthcare industry leader developing longacting december fda approved viiv healthcares hiv medicines apretude first longacting injectable preexposure prophylaxis prep option reduce risk sexually acquired giving patients twodrug regimen option hiv integrase inhibitors gold standard hiv treatment studies reported showed onceeverytwomonth medicine dolutegravir widely prescribed regimen superior daily pills effectiveness three world million people living hiv almost nine times higher men women respectively oral currently hiv medicine taking medicine preventing hiv acquisition dolutegravirbased regimen twodrug regimen oral therapies dovato juluca based dolutegravir shown well tolerated effective threedrug regimens allows people living hiv maintain viral suppression taking fewer hiv drugs lifetime h ivgovhivbasicsoverviewdataandtrendsglobalstatisticsinnovation continued increasing ambition patients also announced licensing agreement life pipeline includes number medicines new sciences company halozyme recombinant human mechanisms action could combined hyaluronidase called ph ph injected integrase inhibitor cabotegravir create medicines subcutaneously creates temporary expansion extend interval doses two objectives skin allowing increased volumes medicine delivered one produce worlds first selfadministered longacting without added discomfort patient ability give medicine people want take medicine home larger dose hope expand interval doses develop ultralongacting regimen dosing opens opportunities combine cabotegravir intervals three months longer products pipeline create ultralongacting regimens treatment prevention hiv particular theres potential year history success developing integrase us use technology increase dosing interval inhibitors hiv including dolutegravir cabotegravir cabotegravir prevention every two months long collaboration shareholder shionogi every six months year signed exclusive collaboration licence agreement shionogi thirdgeneration integrase ultimate goal remains find cure hiv inhibitor preclinical candidate called vh believe continuing progress unique industryacademic partnership give us potential offer medicines longer dosing university north carolina chapel hill intervals cabotegravir could anchor future pipeline jointlyowned qura therapeutics expect start innovative longacting therapies hiv beyond phase trial cure medicine oncology cancer second heart disease worlds continuing dreamm trials understand biggest killer develop transformational cancer potential blenrep used earlier lines treatment medicines lifechanging potential patients monotherapy combination standard novel therapies well exploring dosing scheduling accelerated research areas including synthetic modifications example dreamm platform study lethality next generation immunooncology agents drawing investigating novel combination treatments expertise functional genomics science nirogacestat gamma secretase inhibitor gsi immune system partners isatuximab cd targeting monoclonal antibody oncology medicine jemperli dostarlimab approved patients means three marketed gynaecologic cancers therapies nine assets development numerous gynaecologic cancers common cancers preclinical targets represents rapid progress since affecting women nearly million women around approved medicines eight assets world diagnosed gynaecologic cancer development advanced phase approval jemperli treat endometrial cancer blood cancers new cases globally endometrial cancer cancer begins lining multiple myeloma third common blood cancer uterus patients limited treatment options cancer worldwide people develop every year progresses firstline therapy blenrep belantamab mafodotin treatment patients april jemperli dostarlimab received accelerated relapsed refractory multiple myeloma approval us certain patients dmmr endometrial received least four therapies first therapy cancer conditional approval europe certain patients kind humanised antibody drug conjugate targeting dmmr msih endometrial cancer treats advanced protein bcell maturation antigen bcma recurring endometrial cancer worsened despite blenrep received regulatory approval us previous treatment platinumbased chemotherapy jemperli europe following pivotal dreamm trial activates immune system better attack cancer cells demonstrated deep durable responses patients august jemperli received accelerated approval advanced multiple myeloma launching us us patients dmmr solid tumours progressed germany expanded another six eu countries despite earlier treatment means jemperli available well united kingdom hong kong patients confirmed dmmr solid tumours satisfactory alternative treatment options gsk annual report gsk annual report strategic report governance remuneration financial statements investor information innovation continued also investigating jemperli firstline treatment ignyteeso phase ii trial evaluating letecel patients combination chemotherapy patients advanced synovial sarcoma myxoidround cell liposarcoma recurring endometrial cancer ruby phase iii trial accelerated development path receiving european evaluating combination zejula jemperli prime fda breakthrough status maintenance treatment see also focused developing next generation cell treating ovarian cancer zejula therapies include approaches technologies women diagnosed ovarian could enhance anticancer activity cancer collaboration lyell immunopharma treatment zejula niraparib oral oncedaily poly exploring ways enhance tcells ability attack kill adpribose polymerase parp inhibitor monotherapy tumour cells engineering cells could longer maintenance treatment women advanced ovarian lasting potent also collaborating cancer regardless biomarker status responded immatics biotechnologies build capabilities cell therapy platinumbased chemotherapy received approval solid tumours patients benefit kind firstline maintenance treatment us eu treatment evaluating zejula pivotal trials assessing activity early science collaborations across multiple tumour types exploring combinations zejula therapeutics pivotal first phase iii trial across rd oncology invest new technologies studying zejula combination jemperli treatment partnerships push boundaries combatting cancer one firstline ovarian cancer important areas immunooncology additionally functional genomics helps us identify new treatment targets solid tumours synthetic lethality approach cancer treatment targets genetic mutations cancer cells healthy cells exploring zejula treatment lung breast cancer continuing advances immunooncology currently conducting phase iii trials zejula lung immunooncology fastdeveloping area search breast cancer new targets important far less patients respond certain immunooncology treatments phase iii lung cancer trial zeal investigating zejula firstline maintenance therapy patients advanced work aiming help immune system nonsmall cell lung cancer squamous nonsquamous recognise kill cancer cells effectively studying histologies received platinumbased combinations treatment jemperli enhance chemotherapy trial studying efficacy safety antitumour activity utilising cd axis expressed zejula combination standard care treatment surface tcells natural killer cells including checkpoints cd tigit pvrig phase iii breast cancer trial zest exploring efficacy safety zejula earlystage treatment trial uses company access antibodies targeting circulating tumour dna technology first time pivotal three cd axis checkpoints gsk anticd breast cancer study offers potential detect tumour phase development monotherapy combined cells earlier molecular level identify women higher jemperli june partnered iteos therapeutics risk recurrence means therapy zejula could start develop tigit antibody gska currently burden disease still low may create phase ib safety trial also combination jemperli opportunity effectively slow stop cancers exploring potential functional genomics progress synthetic lethality harnessing cell therapy internal work functional genomics identified cell therapy important avenue treating cancer ten target candidates research evaluation field addressing cell therapy programme solid synthetic lethality partnering ideaya biosciences tumours combines strategies across research clinical oncologyfocused precision medicine company development supply chain address patients unmet exploring mata inhibition tumours mtap deletion needs common feature solid tumours study moved phase together also developing two new assets lead cell therapy asset development letetresgene expect move clinic next years autoleucel letecel gsk tcell receptor tcell therapy tcrt harnesses immune system develop personalised treatment extracting patients tcells genetically modified express tcell receptor tcr targets nyeso antigen found various solid tumoursinnovation continued immunology including respiratory focus science immune system helps us november alector announced encouraging new data develop medicines immunemediated conditions like open label infront phase ii trial data lupus rheumatoid arthritis range inflammatory showed consistent slowing clinical progression patients diseases years also produced ftd treated al compared historical innovative medicines helping millions people matched ftd subjects groups progranulin respiratory conditions breathe easily gene mutation trend towards normalisation stabilisation diseaseassociated biomarkers infront helping lupus patients benlysta phase iii trial currently enrolling ftd patients mutation benlysta belimumab first biologic approved progranulin gene confirm phase ii data chronic autoimmune disease systemic lupus partnership brings together alectors immunoneurology erythematosus sle lupus nephritis ln kidney expertise rd focus science immune inflammation caused lupus monoclonal antibody system human genetics well drug development targets blys underlying cause sle ln reduces capabilities autoantibody levels help control disease received approval benlysta adult patients growing respiratory portfolio tackling active lupus nephritis several markets including brazil eosinophildriven diseases eu member states japan also received one broadest portfolios respiratory medicines approval china indication followed us approval industry continues grow since use launched five new inhaled therapies well biologic nucala mepolizumab firstinclass monoclonal antibody moving towards new way treat rheumatoid targets interleukin il leading research arthritis eosinophildriven diseases like asthma many people worldwide suffer rheumatoid years inflammatory conditions associated arthritis ra chronic inflammatory disease cause elevated levels eosinophils type white blood cell pain joint swelling inflammation lead acute occur range tissues organs chronic disability needs great trials studied nucala could change lives ra patients achieving remission despite use targeted people affected conditions severe eosinophilic therapies currently available around patients asthma sea hypereosinophilic syndrome hes eosinophilic reporting daily pain debilitating granulomatosis polyangitis egpa chronic earlystage trials otilimab novel monoclonal antibody rhinosinusitis nasal polyps crwnp targeting il targeting gmcsf demonstrated rapid substantial nucala reduces number eosinophils excessive improvement pain moved phase iii studies numbers cause inflammation trials led expect results three pivotal studies end important new approvals nucala addressing unmet needs positive pivotal trial results otilimab could become broad group patients first new medicine ra decade fda approved nucala adults crswnp common chronic condition cause difficulty breathing finding new disease targets immunoneurology sleeping interfere taste smell focusing human genetics science immune approval nucala indicated us four eosinophil system given us unique insights pinpoint potential targets driven diseases november received approvals patients neurodegenerative diseases nucala europe crswnp hes egpa july announced partnership alector january received fda approval extend develop two monoclonal antibodies al al marketing authorisation nucala include specific neurodegenerative diseases including frontotemporal dementia paediatric presentation prefilled safety syringe enabling ftd amyotrophic lateral sclerosis als parkinsons disease healthcare professionals caregivers administer nucala alzheimers disease antibodies designed raise home appropriate patients also awaiting european levels progranulin regulates immune activity approval indication brain al pivotal phase iii trial people high risk developing ftd due mutation progranulin gene also phase ii trial patients als al development parkinsons disease alzheimers disease phase ia trial healthy volunteers gsk annual report gsk annual report strategic report governance remuneration financial statements investor information innovation continued nucala also phase iii trial determine whether help earlyphase portfolio patients copd high eosinophil counts started phase ib trial existing il copd patients increased risk exacerbations monoclonal antibody atopic dermatitis phase trial additionally focused developing depemokimab novel monoclonal antibody targeting il multiple longacting antiinterleukin il monoclonal antibody sclerosis informed access genetic current phase iii programme assessing safety efficacy databases identified indications highest severe asthma eosinophillic phenotype far results probability success show reduce suppress eosinophil levels longer also completed worldwide licence agreement periods antiil monoclonal antibodies would arrowhead pharmaceuticals gsk arohsd mean treatment could extended one injection every six genetically validated investigational rna interference rnai months therapeutic currently phase iii development patients nonalcoholic steatohepatitis nash agreement covers medicines development commercialisation outside greater china phase pipeline also consists molecules targeting immune system celiac disease osteoarthritis pain neurodegenerative disease opportunity driven alongside balanced portfolio across key therapy innovating patients primary biliary areas also led science pursue cholangitis opportunities also developing linerixibat ileal bile acid transporter ibat inhibitor treatment cholestatic pruritus transforming treatment anaemia patients primary biliary cholangitis pbc condition million people suffer chronic kidney disease significant unmet need new worldwide estimated one seven suffers pharmacologic therapy since following data anaemia many limited treatment options today glimmer phase iib trial initiated glisten daprodustat potential novel oral treatment dialysis phase iii trial glimmer study first time andme nondialysis settings approved daprodustat could bring helped us identify recruit enrol patients opted ease use oral treatment potential improve participate research glisten phase iii study also current injectionbased standard care work effectively use andme database help match patients also manage haemoglobin levels first us pivotal trial allows assessment participants home using technology homebased app track daprodustat based compelling human genetics nobel progress prizewinning science demonstrated cells sense adapt oxygen availability already approved japan following fda orphan drug designation linerixibat name duvroq data read positively five also received positive decision orphan drug designation phase iii studies independently met primary efficacy european commission safety endpoints demonstrating daprodustat improved maintained patients within target haemoglobin ranges also showed primary safety analysis intention totreat population similar rates major cardiovascular events compared injectionbased standard care esa therapy within trial data ascend programme used support regulatory filings health authorities worldwideinnovation continued pipeline overview assets development latestage phase iiiregistration bexsero infants us vaccine xevudy sotrovimabvir covid covid medicago vaccine blenrep antibcma adc multiple myeloma covid sanofi vaccine jemperli pd antagonist l endometrial cancer covid sk bioscience vaccine letetresgeneautoleucel nyeso tcr ssmrcls menabcwy st gen vaccine zejula parp inhibitor ovarian lung breast cancer menveo liquid vaccine al antisortilin frontotemporal dementia mmr us vaccine depemokimab la antiil antagonist asthma rotarix liquid us vaccine nucala copd rsv maternal vaccine otilimab agmcsf inhibitor rheumatoid arthritis rsv older adults vaccine daprodustat hifphi anaemia chronic kidney disease gepotidacin bti inhibitor uuti gc linerixibat ibati cholestatic pruritus primary biliary cholangitis phase ii malaria fractional dose vaccine bepirovirsen hbv aso hbv aureus vaccine leucyl trna inhibitor tuberculosis shigella vaccine maturation inhibitor hiv therapeutic hbv vaccine broadly neutralising antibody hiv menabcwy nd gen vaccine cobolimab tim antagonist nsclc varicella new strain vaccine phase c difficile vaccine sting agonist cancer klebsiella pneumoniae vaccine nyesotgfbr tcr cancer sam covid model vaccine nyesocda tcr cancer sam rabies model vaccine lag antagonist cancer cmv vaccine mata inhibitor cancer bvlgsk ethionamide booster tuberculosis eos tigit antagonist cancer vir neutralising monoclonal antibody influenza cd antagonist cancer mtb inhibitor tuberculosis al antisortilin neurodegenerative diseases crk inhibitor visceral leishmaniasis anticcl osteoarthritis pain proteasome inh visceral leishmaniasis tg inhibitor celiac disease fimh antagonist uuti antiil atopic dermatitis pik inhibitor viral copd exacerbations antiil multiple sclerosis vir covid arohsd sirna nonalcoholic steatohepatitis maturation inhibitor hiv trpv blocker diabetic macular edema cabotegravir mgml formulation hiv heart failure capsid protein inhibitor hiv advanced indications shown asset inlicence alliance relationship phase iii trial patients progranulin nsclc nonsmall cell lung cancer uuti third party gene mutation uncomplicated urinary tract infection additional indications also investigation g sk exclusive option codevelop gc gonorrhea ss synovial sarcoma gsk contributing pandemic adjuvant post phase ii mrcls myxoidround cell liposarcoma phase iii trial enrolment vaccination stopped february analysis better transition activities underway enable understand safety data trials progression partner ongoing potentially registrational phase ii trial gsk annual report gsk annual report strategic report governance remuneration financial statements investor information performance strong financial performance driven first class commercial execution strong uptake new products pharmaceuticals highlights vaccines highlights total turnover billion aer cer total turnover billion aer cer sales new specialty pharmaceuticals billion covid pandemic sales vaccines million aer cer including pandemic adjuvant sales million sales xevudy million reflecting ongoing shingles shingrix sold countries including nine fulfilment contracts across world markets launched significantly us meningitis increased market share us bexsero strong commercial execution key growth products menveo including trelegy nucala exceeded billion maintained market share key products despite sales first time significant disruption covid better digital capabilities support effective excellent supply performance shingrix supply fully engagement healthcare professionals higher unconstrained productivity efficient supply chain accelerated digital transformation helping drive datadriven decisions manufacturing supply read read pharmaceuticals performance oncology continued show strong doubledigit sales growth pharmaceuticals turnover year million sales zejula million aer cer aer cer impacted ongoing lower diagnosis rates due covid pandemic particularly us blenrep sales xevudy sotrovimab monoclonal antibody approved launched us europe q treatment covid million contributed ongoing launches throughout europe blenrep approximately percentage points pharmaceuticals growth sales globally totalled million december less year since first pivotal phase iii data sotrovimab used treat covid immunoinflammation sales million grew aer patients sold reserved million doses cer benlysta sales aer cer agreements eu dozen million benefiting lupus nephritis launches us countries including us uk japan australia canada japan h singapore uae sales established pharmaceuticals decreased aer hiv sales aer cer cer million million growth dovato juluca partly offset adapting covid pandemic tivicay triumeq broad portfolio includes new products cabenuva longacting injectable treatment apretude covid pandemic continued affect healthcare longacting injectable hiv prevention rukobia systems globally seen interruption usual care highly treatment experienced patients many healthcare facilities delay diagnosis subsequent treatments patients preexisting medical maintained lead position respiratory amid higher conditions remain particularly vulnerable demand pandemic strong commercial execution respiratory sales aer cer amidst ongoing restrictions access customers million sales trelegy nucala exceeding continued perform strongly across markets areas like billion per year first time approvals launches oncology used online digital tools maintain strong eosinophildriven disease indications nucala engagement healthcare professionals continued increased uptake therapys home administration options meet needs patients patient support also boosted performance trelegy ellipta markets programmes increased market share chronic obstructive pulmonary disease made gains asthma aided approval japan late see group financial review detailperformance continued driving growth next decade transforming interactions healthcare portfolio pharmaceuticals made innovative professionals patients established medicines leading global positions essential us maintain strong connection hcps respiratory disease hiv developing presence meet needs patients specialty therapy areas including oncology many businesses pandemic accelerated use immunoinflammation broad portfolio supplies innovative technology make effective commercially highquality medicines making positive impact weve increased use virtual calls keep hcps informed lives millions patients next five years expect clinical data launches products pipeline specialty medicines key driver gsks growth helps understand science behind products best use complemented newly defined general medicines business contains primary care ran successful pilots best engage brands including trelegy anoro classic hcps coordinated way across online traditional established products support broader investment channels scaled brands innovation rd markets using dataled automatically orchestrated mix traditional digital promotion well deploy hiv business also positioned growth remain refine using novel data sets commercial innovation leaders anticipate continued growth analytics orchestration engine let us tailor longacting injectable therapies cabenuva deliver plus hcp global data treatment hiv apretude hiv prevention looking driven customer experience programme recognised beyond multiple opportunities sustain growth externally winning three silver awards international latestage assets excited early customer experience awards helps us improve stage pipeline innovative longacting medicines competitiveness eu digital investment led strengthening capabilities organisation immediate increase hcps attending webinars china reaching ten times hcps wechat want best brightest people specialty website alone medicines marketing medical teams continued focus appointing right leaders led us naming new well virtual meetings educational activities weve general managers countries since brought clinical experience customers global attracting top external people right expertise speakers programme follows feedback hcps compete oncology alone hired people told us like receive information peertopeer setting commercial rd expert practitioners leadership positions leadership changes improving continue engage patients patient support interface commercial rd functions early programmes benlysta cares us programme commercial input select develop pipeline assets information guidance including text reminders help create lasting value benefits savings nurse support exclusive content optimised policies collaboration marketing help patients taking benlysta get treatment medical sales teams made sales force september wed enrolled patients effective competitive across key markets changes time benlysta cares sales incentives policy made positive impact sales shown help patients stick treatment teams higher engagement personal accountability us patient engagement liaison pel team ran internal audits show achieved without compromising patient education programmes patients ethical standards engagements healthcare across diseases pel partnered national professionals hcps january introduced individual local patient advocacy groups pags give patients targets sales representatives drive disease awareness resources productive competitiveness conversations care providers used data predictive analytics deliver engaging china yinchuan copd patient support programme chinas customer interactions monitor improve sales first digital copd patient management programme enabled performance market share big data g internet things iot weve worked national healthcare commission nhc embed smart digital technology inhalers helps doctors make sure patients follow prescriptions gsk annual report gsk annual report strategic report governance remuneration financial statements investor information performance continued investing supply chain keeping supply consistent dependable supply chain transformation continues line success rests maintaining highquality reliable portfolios shift innovative specialty care products new ways supply products patients consumers reduced working response pandemic agile resource total costs supply chain continue increase allocation prioritise return investment helped us make productivity simplify supply network cost reductions savings sets gsk leaner productive together sales growth improved gross profit financially efficient margin investing facilities people manufacturing partnerships strengthened internal external quality oversight continue help us launch specialty medicines rapidly model modernised quality management system accelerate delivery across portfolio new facility simplify ways working improved deviation rates barnard castle uk site start manufacturing medicines pharmaceutical supply chain continued first quarter coming years support industrys top quartile fda recalls per billion sales manufacturing majority key existing new regulatory inspections pharmaceuticals sites biopharmaceutical assets pipeline since satisfactory invested million expansion next generation safety performance critical success weve biopharma manufacturing facility upper merion pennsylvania taken extra measures make serious incidents less likely set open expanded facility rockville strengthen safety culture include deploying life maryland begin commercial supply saving rules help employees understand apply streamlined supply chain helps us control costs allocate basic safety rules work launching operational safety capital effectively bigger share directed leadership programme strengthening safety monitoring specialty medicines simplified network central systems functions completing divestment site pozna reliability supply improved median poland closure xochimilco mexico commercial performance ontime infull supply chain teams collaborating initiatives lower despite covid disruption well applying cost goods sold cogs protect margin increase profit supply chain segmentation weve also improved performance work includes reducing active pharmaceutical ingredient investing technology like resilinc tool using ai costs optimising capacity improving processes working highlight emerging supply chain risks piloting digital twins suppliers simplifying portfolio weve also reduced optimise planning increase operational efficiency brands sell four years skus weve accelerated data digital analytics dda adoption use enterprise systems managing data investing automation aiml improving efficiency documents planning operations include value chain reducing variability supply chain demonstrated us mapping supply chain planning cognitive supply chain track reach topquartile days inventory outstanding models lower logistics costs dio frees working capital expect digital investments next three years help us improve planning productivity accuracy reduce inventory vaccines performance hepatitis vaccines sales aer cer vaccines turnover million year million adversely impacted deprioritisation aer cer anticipated vaccines routine us adult vaccination increased hepatitis b vaccine business faced significant disruption given competition unfavourable cdc stockpile movements governments prioritisation covid vaccination us covidrelated travel restrictions europe programmes measures contain pandemic international resulted lower demand routine adult vaccination including meningitis sales decreased aer cer million shingrix hepatitis vaccines vaccines turnover excluding driven primarily unrepeated international tender volumes pandemic adjuvant sales decreased aer cer meningitis vaccines bexsero sales stable aer million grew cer million reflecting increased market shingrix decreased aer cer million share us menveo sales aer cer sales fell us international sales grew europe million primarily driven cohort catchup driven germany launches uk spain italy vaccinations higher demand well increased shingrix sold countries including nine markets market share us launched see group financial review detailperformance continued adapting covid pandemic plan launch several new vaccines including pandemic continued dominate highly programme help prevent rsv vaccination transmissible variants emerged countries around world older adults significant medical commercial opportunity cycled stayathome orders countries access support goals drawing strong covid vaccines made available adult manufacturing capability scale well global populations children healthcare systems adapt reach commercial execution significantly enable huge vaccination endeavour another area focus attracting retaining repercussions across many aspects health provision including right people strategic areas strengthening lower priority vaccines diseases covid capabilities including mrna focus pandemic also meant always much approximately people access customers usual despite maintained digital capabilities market share key vaccines strategic countries held virtual meetings hcps attended events virtually continue build capabilities vaccine virtual provide educational support material vaccination days bringing hcps together bringing us closer continued inform people importance immunisation customers sharing scientific discourse worlds disease awareness branded campaigns leading experts vaccines new econgress meningitis shingles diphtheria tetanus pertussis dtp platform extended second edition event hcps countries including china offered driving growth next decade translations eight different languages attracted portfolio marketed vaccines broadest registrants received net promoter score industry includes vaccines helping protect hcp feedback score industry standard people worldwide range diseases throughout event played role helping improve protect public lives including meningitis shingles flu polio measles many health everywhere vaccines sales efficacy level also continue work philips pregnancy baby apps partnership philips live countries commercial terms vaccines tend longer lifecycle reaching approximately million parents continues medicines generate significant revenues effective tool educating parents vaccines decades example engerix vaccine help prevent paediatric portfolio following success launched hepatitis b virus infection available digital partnership fourth quarter focused years remain important part portfolio adults time partnership san franciscobased november cdcs advisory committee nextdoor neighbourhood network used almost one immunization practices voted unanimously recommend three households us hepatitis b vaccination adults aged years global momentum behind vaccination vaccines expected one largest drivers growth covid vaccination programmes required countries gsk high singledigit percentage sales growth populations adapt learn believe cagr anticipated period aim positive longterm impact vaccinations widely double revenues shingrix shingles vaccine particularly adults attitudes vaccination shifted fiveyear period double meningitis flu vaccine well research among people aged years older sales next decade helping protect millions people eight largest vaccine markets showed diseases increase positive attitudes vaccination result pandemic gsk annual report gsk annual report strategic report governance remuneration financial statements investor information performance continued real opportunity healthcare systems harness continue apply codevelopment model colleagues momentum need vaccination remains rd manufacturing work handinhand scale strong us commissioned published report production effectively efficiently possible ongoing avalere health showed adolescents adults example preparing accelerated launch may missed million doses recommended rsv candidate investment wavre clinical vaccines january july compared commercial activities findings demonstrate routine immunisation made great strides unlocking capacity getting continued lag prepandemic levels original existing assets good example avalere report followed cdcs analysis shingles vaccine shingrix improved yield missed vaccine doses calls government public policy throughput across supply chain reductions lead times groups media prioritise recovery vaccination also mean fully unconstrained shingrix supply rates diseases covid support growth aspirations supply performance also met covid commitments scaling pandemic adjuvant production respond fluctuating continue strengthen manufacturing capability demand agility meant delivered adjuvant make sure support growth vaccines portfolio agreements pandemic adjuvant sales made important despite supply chain disruptions caused pandemic contribution revenue covid another strong year supply solutions see performance time weve continued accelerate digital proud fact strategic vaccines sites transformation including investment manufacturing approved multiple regulatory agencies including execution system production lines ten sites fda network manufacturing sites nine switching paper batch recording electronic system countries produced delivered million doses deployed next three years benefits throughout year continued invest network including operational efficiency leadtime reduction modernising automating filling packaging activities improvements compliance yield stability building mrna production capabilities adding launch investment along many others accelerate capacity pipeline products rsv also datadriven decisions manufacturing supply examples investing infrastructure needed future data analytics technology improvements include robotic planned lyophilisation freeze drying unit site wavre automation material handling activity bots replace belgium support manufacturing capacity repetitive manual tasks automating visual inspection priority products innovation pipeline syringes vials using aiml worked across supply chain reduce also embedding lean six sigma tools techniques endtoend lead times improve agility marketplace processes systems capabilities improve effectively manage demand uncertainty close ways working cooperation shop floor delivery end customer allows us make betterinformed decisions investments making manufacturing facilities sharing data free cash increased efficiency people help us many ways example ensuring competitive tenders customers right mrna capabilities talent place together investments help make manufacturing ready redesigning supply chains reducing lead times support bright future vaccines making sure right inventory right place win marketplace part multiyear effort use working capital effectivelytrust trust one three longterm priorities trust build better perform value create shareholders people society trust priority covers work across esg factors esg governance integral overall strategy approach esg helps us boardlevel corporate responsibility committee crc deliver sustainable performance longterm growth well oversees progress commitments building trust stakeholders see stakeholder addressing views expectations stakeholders engagement also reduces risk operations glt senior management responsible delivery see risk management helps us make trust commitments report regularly crc positive social impact progress see commitments esg areas approach reporting make biggest difference commitments help us respond challenges opportunities industry broader section report highlights progress society see external environment pages also trust commitments provide contribute many un sustainable development goals detailed reporting data commitment esg especially goal ensure healthy lives promote wellbeing performance report report also includes un global ages compact communication progress global reporting initiative index sustainability accounting standards board index gskcom contribution sdgs assurance statements social environmental data g skcom esg performance report external benchmarking maintained acknowledged leadership esg continues key driver goal deliver health impact shareholder returns detailed perform key esg ratings frequently asked investors dow jones sustainability index djsi st cdp climate change b water b forests pharmaceutical industry group palm oil timber supplier engagement leader sp global sustainability award gold class sustainalytics low risk rating access medicine index atmi ranked st atmi msci aa rating industry leader antimicrobial vigeo eiris ranked nd pharmaceuticals sector resistance benchmark ftsegood member ftsegood index since gsk annual report gsk annual report strategic report governance remuneration financial statements investor information trust continued using science technology address health needs commitment progress new medical innovations saw three major approvals medicines eight phase iii starts vaccines develop differentiated medicines pipeline details see innovation section pages highquality needed medicines vaccines consumer healthcare products improve health global health commitment improve global health impact rd infectious diseases improve global health impact access medicines vaccines recognised access medicines index rd infectious atmi ranked number one last seven years every year since diseases affect children inception young people low rtssase malaria vaccine first vaccine shown longterm clinical income countries focusing trials reduce malaria children recommended broader deployment vaccine reduce illness deaths children subsaharan africa regions hiv malaria tb moderate high malaria transmission followed new data showed vaccine combination seasonal antimalarials lowers clinical episodes malaria hospital admissions severe malaria deaths around compared antimalarials alone december gavi announced decision provide funding procurement introduction vaccine routine child immunisation programmes gavi eligible countries made good progress improving availability ageappropriate hiv treatment options children around world generic dolutegravir dispersible tablet made available key subsaharan african countries less year us fda approval treatment work facilitated publicprivate partnership clinton health access initiative unitaid two generic manufacturers mylan part viatris group macleods shigella second biggest cause morbidity mortality diarrhoea worldwide rotavirus approved vaccine widely available late first subjects vaccinated quadrivalent shigella vaccine candidate firsttimeinhuman clinical phase iii study goal develop affordable vaccine giving broad protection prevalent shigella serotypes richest pipeline focused global health priority diseases industry including ten medicines vaccines currently clinical development launched collaboration novartis project africa gradient support scientific research link genetic diversity patients response malaria tuberculosis drugs three african regions health security taken broad approach developing covid solutions see help world better applied science finding covid innovations see prepare future disease one five companies sit pandemic preparedness partnership steering outbreaks pandemic group convened uk government bringing together industry international potential tackle organisations experts advise g governments speed response antimicrobial resistance future pandemic trinity challenge founding member also announced winners inaugural competition find innovative ways better predict prevent outbreaks disease using data analytics winners included vaccineledger tracks vaccines manufacture patient using blockchain technology commitment preventing antimicrobial resistance amr recognised access medicine foundations amr benchmark gsk industry leader third consecutive time benchmark highlighted particular diversity depth rd pipeline particularly amrrelevant vaccines full details progress commitments please see esg performance reporttrust continued making products affordable available commitment progress pricing developed markets pricing new products reflects value deliver patients improve health millions healthcare systems wider society compared available alternatives supports people year making work meet future healthcare needs offer patient support us products available provided prescribed vaccines medicines lowincome uninsured underinsured medicare part patients gsk viiv healthcares patient responsible prices assistance programs foundation sustainable business pricing low income countries lics lower middle income countries lmics use innovative pricing structures extend product reach vaccines business tiered pricing model based world bank gross national income country classifications file patents medicines enforce historic patents lowincome countries lics product reach access strategies continued reach many underserved people lower income use access strategies reach countries made good progress target reached million underserved million people products using access strategies strategies include people lower income advanced market commitments provide vaccines lower income countries countries products gavi partnership gavi includes supplying cervarix critical tool lower income countries addressing cervical cancer synflorix pneumococcal vaccine rotarix vaccine rotavirus common cause severe diarrhoeal disease children five also made commitment supply rotarix humanitarian mechanism civil society organisations serving vaccination needs refugee emergency situations builds existing commitment humanitarian mechanism synflorix viiv healthcare voluntary licensing agreements generic manufacturers allowed least million people living hiv across lics lmics access generic product containing dolutegravir end donated ten billion albendazole tablets including million support efforts end lymphatic filariasis control intestinal worms schoolage children healthcare access number partnerships ngos multilateral organisations improve partner improve disease disease prevention awareness access healthcare services prevention awareness programmes reached million people next year developing ambitious access healthcare services global health strategy gsk include setting new target million people partnership save children increased emergency preparedness response capability investing data analytics earlyaction protocols provide efficient timely healthcare crises partnerships save children amref health africa care international trained frontline health workers since reached million people prevention treatment infectious diseases plus providing maternalchild healthcare vaccination hygiene sanitation nutrition viiv healthcares positive action programme aims explore ways support peoplecentred communityled interventions help meet un targets end aids programme reached approximately people funded grants across countries full details progress commitments please see esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statements investor information trust continued modern employer commitment progress engaged people early launched new allcompany survey focused purpose strategy achieve maintain engagement culture progress engagement remains high general competitive employee industry benchmark settling back levels extra boost early phases engagement score pandemic inclusion diversity aspiration women hold least vp svp roles end accelerate progress women held roles vp ftse women inclusion diversity leaders ranking showed top ftse companies based including aspirational targets proportion women board leadership positions also published fifth annual uk gender pay gap report showed continue outperform female ethnically national average diverse representation senior aspiration least ethnically diverse leaders roles vp roles end us least uk end representation december recognition disability showed ethnically diverse leaders vp roles uk confident employer us ethnically diverse leaders roles vp lgbt indices progress supported rigorous focus equal employment opportunity launched programmes accelerating difference ethnic diversity supports development ethnically diverse employees building strengths addressing development gaps individual group coaching publish gsks ethnicity pay gap data uk developed threeyear plan increase disability confidence part rolled workplace adjustments programme biggest markets making available employee population far also signed international labour organizations global business disability network promote inclusion people disabilities workplaces continue recognised global lgbt indices including designated best place work lgbtq equality human rights campaign foundations corporate equality index health wellbeing gsks leadership team continued oversee covid response including development health wellbeing engagement employees locations continuously leading company monitor impact covid employees public health vaccination support employee health programmes continue helping educate raise awareness wellbeing personal public health vaccination programmes available committed offer development vaccinations minimal cost employees eligible dependents continued make mental health training available employees managers completed since launched make confidential support available global employee assistance programme successfully piloted new wellbeing programme focused resilience strategies energy management continue implement global rollout run health safety training people covers identify take measures reduce workplace risks reportable injury illness rate remained per hours worked fatalities employees access internal development portal keep growing campus offers extensive development courses videos articles range topics including decision making building change capability coaching influencing others health wellbeing people completed leadership business courses data employees gender including total employees board management provided nonfinancial information statement f full details progress commitments please see esg performance reporttrust continued responsible business commitment progress reliable supply priority make sure highquality reliable supply products commit quality safety patients consumers continued high importance throughout reliable supply products pandemic put increased strain global supply chains patients consumers manage continuity supply see pages quality management systems allow continuous improvement helping us keep high standards product quality safety external regulatory inspections manufacturing sites local operating companies many conducted virtually pandemic respond inspection findings matter minor also ran quality audits suppliers audits clinical trials run behalf gsk assess quality safety find areas improve create improvement plans track progress ethics values everyone gsk complete training company expects operate ethical values renamed mandatory employee code conduct training working gsk driven culture improved content focus risk compliance well diversity creating issues responded swiftly inclusive workplace employees contract workers completed training transparently anyone inside outside gsk raise concerns speak independent third party speak reporting channels confidentially anonymously without fear retaliation continue take every concern raised seriously review every report identify whether need investigate formally investigations show employee breached policies take action changed way report disciplinary data expanded scope include cases initiated previous years employees concerns raised additional employees concerns raised prior years open cases disciplined employees initially concerns raised previous years increase primarily driven late completion mandatory training either left voluntarily dismissed received written warning cases took action short written warning end cases awaiting investigation disciplinary decision undertook independent assessment approach managing human rights help us better understand continue improve manage priority human rights areas assessment showed good understanding human rights impacts reviewing addressing findings year come third parties act direct impact us meeting priorities important manage relationships well including way choose contract monitor thirdparty oversight tpo programme evaluates mitigates risks introduced engaging thirdparties provide goods services gsk complete assessments portion third parties may present greater potential risk example interactions government officials annual transfers value certain predefined limits ran assessments higher risk third parties across risk areas identifying highrisk one areas third parties goods services providers contract manufacturers external suppliers distributors wholesalers evaluating tpo programme simplify upfront assessment broaden focus risk management throughout thirdparty relationship using user feedback findings ongoing monitoring full details progress commitments please see esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statements investor information trust continued responsible business continued commitment progress data engagement simplified privacy notices made easier access portal websites privacy key part mandatory working gsk annual training people complete helps employees understand everyone gsk responsible handling personal information right way patient panels give us insights advice well building trusting longterm relationships patients carers help us develop medicines meet patients needs ran panels disease areas including cancer rheumatoid arthritis hepatitis b part commitment data transparency clinical studies published clinical study reports summaries results listed studies data sharing via wwwvivliorg wwwclinicalstudydatarequestcom want clinical trials representative accessible possible reflecting patient populations disease including age race ethnicity sex gender past five years endeavoured improve patient diversity clinical trials implementing training support personnel investigator sites including awareness training conducting clinical trials served communities formed global demographics diversity team coordinate learning epidemiology burden disease health equity relate age sex gender race ethnicity apply lessons planning trials environment climate net zero impact achieve ambitious net zero goal set targets across value chain carbon climate net positive footprint targets accredited science based targets initiative aligning impact nature oc pathway reduced operational carbon emissions scope compared primarily increased use renewable energy september announced million investment uk us manufacturing sites secure renewable power generation includes new wind turbines year power purchase agreement supply solar electricity irvine facility scotland solar energy oak hill facility new york latest available data emissions suppliers logistics people using products scope reduced reflecting evolution product portfolio reductions business travel commuting result pandemic metered dose inhalers asthma copd account carbon footprint started rd programme find lowerimpact propellant could reduce emissions nature collaboration important part strategy year joined nine global pharmaceutical companies launch energize programme first collaboration kind use scale single industrys global supply chain drive greater use renewable electricity principal partner un global climate change conference cop glasgow championed need action climate nature protect health also joined health systems task force sustainable markets initiative drive collective action digital healthcare supply chains patient care pathways accelerate shift net zero make climaterelated financial disclosure pages along energy carbon emissions data gsks carbon reduction pathway become net zero found gskcom energy carbon emissions data provided climaterelated financial disclosure pages f full details progress commitments please see esg performance reporttrust continued responsible business continued commitment progress environment involved developing standardised guidance measuring impact nature continued working science based targets nature initiative taskforce naturerelated financial disclosures tnfd achieve net nature positive goal reducing environmental impacts across water materials biodiversity investing protecting restoring nature reduced overall water use operations compared sites high water stress regions sites good water stewards line alliance water stewardships definition year joined water resilience coalition wrc partnering develop approach water neutrality water stressed regions deliver water resilience projects ground cape town site south africa first network embark journey towards water neutrality working wrc local partners address shared water challenges clearing alien plant species replanting local flora create greater resilience basin reduced waste sites recovered materials circular routes like reuse recycling consumer healthcare launched million recycleready toothpaste tubes markets piloted approach biodiversity stevenage site uk working partnership kew gardens deliver increase biodiversity site aim measurable effective biodiversity plans place across gsk sites joined publicprivate lowering emissions accelerating forest finance leaf coalition contributes highquality emissions reductions supporting countries protect tropical forests deforestation full details progress commitments please see esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare future standalone consumer healthcare business haleon track separate gsk mid new world leader focused consumer healthcare consumer healthcare firstmarket launches committed producing one billion recyclable toothpaste new innovations tubes total turnover billion aer cer significant investment onsite solar power towards goal excluding brands divestedunder review source electricity renewable sources ecommerce represented total sales delivered billion consumer healthcare products announced growth ambitions annual organic sales growth medium term sustainable moderate margin expansion high cash conversion sector relevant ever passing key milestones looking ahead global consumer healthcare growing billionplus despite challenges weve faced pandemic market events last two years underscored successfully completed integration pfizer consumer industrys importance pandemic continues healthcare delay timings well impact across world means consumers focusing delivering synergy targets complex health wellness whether managing integration impacted multiple parts business symptoms proactively looking wellbeing including commercial manufacturing rd completion vitamins minerals supplements marked major milestone separation planning new consumer healthcare company haleon selfcare supports healthcare ukbased listed october announced burden healthcare systems increasing driven proposals new company headquarters located ageing population rising middle class population weybridge newly built campus also feature consumer healthcare sector particularly overthecounter otc innovation centre due open end subject products play important role addressing challenge consultation planning approvals ambition data shows every spent otc medicines reflect ambitious sustainability targets set us healthcare system saves amounts billion annually set success grown business opportunity standalone consumer billion annual sales operating margin one sales billion healthcare company operating margin worldleading consumer consumer healthcare sectors role supporting broader healthcare business public health presents significant opportunity standalone company focused consumer healthcare industryleading portfolio announced plan separate consumer world leader consumer healthcare hold leadership healthcare business uklisted company positions five categories operate oral health demerger vitamins minerals supplements vms pain relief since made significant progress preparing respiratory health digestive health separation due happen mid growth strategy based prioritising investment june confirmed intention separate nine power brands number strategically demerger july brian mcnamara named important brands concentrated key countries regions ceodesignate new consumer healthcare company previously described operating model designed december sir dave lewis appointed drive performance brands chairman designate february laid strategic divestment low growth brands focused portfolio priorities key growth drivers detailed financial information geographically number one two otc name haleon future consumer healthcare vms markets operate includes priority business see gskcom information markets us china therapeutic oral health segment nicholas hall 's db consumer healthcare otcvms database store ecommerce salesconsumer healthcare continued performance covid pandemic also accelerated consumer consumer healthcare turnover year million shift towards greater proactivity managing health decreased aer stable cer reflecting dilution wellness research highlighting consumers divestments given completion portfolio us example took supplements rationalisation end q twoyear cagr prior year research also uncovered sales excluding brands divestedunder review grew overall centrum consumers favour solutions despite adverse impact covid pandemic targeted multivitamin based insight launched tailored solutions scientifically blended centrum sales excluding brands divestedunder review decreased number key markets australia moved beyond aer increased cer reflecting underlying strength multivitamin launched new centrum benefits range brands across portfolio categories continuing multiingredient combinations order cater consumer growth ecommerce overall sales benefited strong needs across mind body beauty including mind memory growth across categories excluding respiratory health rest renew immune defence recovery collagen negatively impacted q historically low cold boost glow china successfully launched centrum flu season decrease cold flu sales resulted dual probiotics proposition specially designed approximately drag fullyear growth appeal growing consumer trend around gut health international sales excluding brands divestedunder review grew body 's selfdefence power us continued high single digit cer basis double digit growth innovate new formats expanding centrum minis emerging markets including india china middle east centrum gummies portfolios including launch centrum africa excluding brands divestedunder review us sales grew organic multigummies innovations help us evolve low single digits european sales stable cer brand single multivitamin pill bring number basis regions particularly negatively impacted personalised solutions based trusted science historically low cold flu season q informed clinical data see group financial review detail continued see increased interest emergenc brand us consumers continue look sciencebased innovation address unmet ways support immune health research revealed consumer needs consumers looking botanicals natural qualities innovation continues driver growth order support wellness goals launched delivered major innovations based trusted science formulation combines natural goodness plant human understanding meet needs consumers across based botanicals nutrients core emergenc world total delivered firstmarket launches new formula antioxidants b c vitamins electrolytes innovations brandmarket launches overall also continue invest locally relevant innovation research shows third tooth sensitivity sufferers china one key markets launched contac multi searching trusted longlasting solution address symptom innovation biggest otc launch sales cause pain rather treat symptoms business china provides fast relief address key consumer need innovated develop multiple cold flu symptoms contac multisymptom launch sensodyne repair protect deep repair comprises three active ingredients single pill relieve markets product scientifically proven seven cold flu symptoms fever headache sneezing runny provide deep targeted repair within dentine tubules nose limb pain sore throat nasal congestion holes tissue beneath tooth enamel source investment digital driving growth pain also providing longlasting protection sensitivity pandemic also seen explosion digital commerce digital engagement well positioned oral health also expanded gum health expert capture digital opportunity offering paradontax brand us research shows third people globally suffer bleeding gums may ecommerce sales grew mid range versus sign gum disease parodontax active gum repair overall ecommerce represents total sales innovation clinically proven help reverse early signs saw good growth key ecommerce markets gum disease also strengthens appeal brand including china consumers gum problems reinforcing also invested capabilities around digital media credentials dental experts significant proportion total advertising spend digital media allowing us efficient effective targeting consumers gsk annual report gsk annual report strategic report governance remuneration financial statements investor information consumer healthcare continued purpose culture guiding running responsible business serve hundreds millions across world strong esg strategy performance critical brands significant effect everyday health expectation future standalone company integral part future standalone company rooted purpose live purpose deliver better everyday health deliver better everyday health humanity guide humanity key pillar strategy esg everything choices make increasingly important stakeholders success depends creating right culture health world affects health people people consumer healthcare business clear cant enjoy better everyday health world matters environment threat society increasingly unequal divided heightened economic inequality manifesting culture starts always right thing acting growing health inequalities focus esg integrity nonnegotiable means always strategy therefore tackle environmental social proud operate culture focuses three barriers everyday health behaviours environmental tackling carbon emissions climate go beyond hunger desire drive change developing sustainable packaging using better move pace outperform trusted ingredients sustainably sourced competition taking steps create healthy environment people matters prioritising live important things challenging unnecessary social improving health inclusivity tackling bias keep human dedication discrimination prejudice holds people back consumers customers serve equally important everyday health educating empowering people dedication commitment towards better sustainable selfcare help create demands unmatched understanding empathy healthy social environment people live building right culture starts diverse workforce governance defining strategy governance creating inclusive environment colleagues reflect increasing stakeholder expectations supported thrive believe inclusion diversity id leads appointment board led sir dave lewis brings business success unleashing enormous potential wealth international consumer sector experience people strengthening ability respond year stepchanged action sustainability differing needs patients consumers including significant investment onsite solar power part commitment accelerate progress id remains goal source electricity renewable priority including working towards aspirational targets sources committing make billion toothpaste tubes female ethnically diverse representation senior roles recyclable achieving full palm oil derivatives end accreditation otrivin actions breathe cleaner project campaigning help children learn air pollution identify best way minimise exposure scaled education topic broader population high profile presence cop ahead becoming standalone company continue work define social sustainability strategy governance reflecting increasing stakeholder expectationsstakeholder engagement engaging building trust broad range stakeholders vital longterm success summarise key stakeholders engage issues matter responding see enable board management understand stakeholders views include decision making see section statement patients consumers matters patients consumers differentiated product innovation based patient consumer insights patients consumers enable us develop needs products better meet needs access reliable supply highquality products engage pricing healthcare products particularly outofpocket expenses advisory boards diseasespecific patient panels patient advocacy leaders summits provide patient insights strengthening pipeline innovative products engagement support patient groups disclosed gskcom maintaining high standards product quality safety initiatives empower patients get involved medicine development continuing take valuebased approach pricing balance reward innovation access affordability market research including consumer sensory labs investors matters investors sustainable performance longterm shareholder value maintain regular constructive dialogue investors communicate strategy performance order promote understanding rd strategy successfully developing investor confidence ensure continued access capital pipeline commitment strong management esg issues engage ongoing communications including agm quarterly results calls inperson virtual roadshows detailed company information creating two new leading companies demerger online onetoone meetings board members senior executives good financial performance transparent reporting institutional investors business rd updates events key pipeline milestones biennial investors analysts perception study driving leadingedge esg performance culture ambition accountability responsibility healthcare professionals medical experts matters hcps medical experts work healthcare professionals hcps medical access product scientific information experts understand patients journey partner resolve responsible sales marketing practices unmet medical needs make sure products used safety efficacy differentiated innovation safely effectively engage increasing use digital channels deliver personalised scientific dialogue increase understanding disease management effective sharing information hcps patient experience ensuring attract retain best talent uphold responsible providing highquality balanced information vaccines sales marketing standards medicines using hcp insights disease management patient experience collaborating clinical trials research inform development vaccines medicines rd partners academia matters rd partners academia finding right partner identify accelerate potential vaccine partner scientific institutions national health systems medicine reach patients need academia industry partners help us develop effective vaccines medicines meet unmet patient needs pushing science technology far go advance human health engage dissemination advancement scientific knowledge collaborating outstanding scientists academic institutions accelerate discovery development new vaccines medicines licensing advanced technology potential vaccines medicines working worldleading experts biotechs research institutes biotechs universities improve drug vaccine discovery increase productivity rd pipeline establishing joint ventures strengthen innovation improve efficiency collaborating broad range partners support rd focus science immune system human genetics advanced technologies see pages supporting advancement scientific knowledge longstanding commitment sharing research see gsk annual report gsk annual report strategic report governance remuneration financial statements investor information stakeholder engagement continued governments regulators matters governments regulators investment innovation life sciences work governments regulators advocate policies encourage innovation promote efficient management scientific funding collaboration healthcare spending medicines pricing reimbursement engage public health threats covid antimicrobial resistance amr meeting regulatory bodies throughout development process investment preventive health strengthening health systems ensure highquality new products engaging government health agencies demonstrate value engaging us policy pricingreimbursement debates products patients economies phrma commenting legislative proposals healthcare reform working governments protect strengthen operating partnering across industry governments tackle amr environment life sciences innovation new medicine vaccine engaging governments including us uk eu regarding launches production procurement covid vaccines treatments participating international efforts address global health threats pandemic ngos multilateral organisations matters ngos multilateral organisations access vaccines medicines work partners improve access healthcare services products advocate policy environment un sdgs targets specific disease areas successful deliver ambitions universal health coverage future health systems patients financing global health including covid solutions engage working nongovernmental organisations ngos partners focusing unique role global health partner develop research develop products address global health challenges products scientific expertise collaborating ngos generic manufacturers sustainably partnering organisations complementary capabilities supply products lower income countries reach create sustainable models share risk including partnering strengthen health systems lower income countries partnership gavi support access vaccines lower income drive progress global health priorities countries leveraging community investment programmes support scientific expertise deliver greater impact patients suppliers matters suppliers prompt payment agreed terms work thousands suppliers large small provide goods services support us delivering reliable supply understanding gsk policies ensure compliance highquality safe products patients consumers opportunities innovate grow relationship engage regular direct engagement suppliers ensure support engaging suppliers develop improvement plans track gsks strategies targets progress identify areas improvement engaging suppliers thirdparty oversight programme providing proactive support thirdparty ehs team conducting indepth audits countries priority suppliers located participating forums pharmaceutical supply chain initiative consumer goods forum improve supply chain sustainability people matters people purpose able see difference make involve listen people increase employee engagement drive business performance retain talented great line manager people feeling understood valued engage part inclusive diverse workplace regular interactive broadcast events glt senior leaders fostering culture accountability ambition underpinned facilitating dialogue collaboration internal integrity humanity communications platforms works councils employee forums launched new leadership programmes help managers motivate employee resource groups focus care develop teams providing feedback managers via global allcompany survey campaigns programmes support safety mental wellbeing one questions enable worklife balance driving diversity inclusion activities support new aspirational targetsrisk management risk management internal control framework wellembedded mature continuously reviewed overseen board identifying evaluating managing risk rocc conducts annual risk review assess principal risk management internal control framework well emerging risks company review supported embedded provides ability board evaluate extensive analysis external trends insights senior level oversee company manages principal emerging risks interviews recommendations risk management line longterm objectives companywide compliance boards risk owners rocc shares annual policy sets requirements roles responsibilities review arc board assessment forms management governance risks controls basis following years risk management focus supporting guidance essential elements internal putting risk management plans place control framework routinely evaluate framework improvements define enterprise risk plans include description risk context assessment risk appetite treat governance risk actions businesses need take line board oversees risk management system internal control framework mitigate risk also enable establishes risk appetite supported audit risk board committees assess effectiveness risk committee arc corporate responsibility committee management strategies year along annual business crc science committee assess effectiveness risk reports continued quarterly reporting risks rocc risk management strategies pertinent defined remits board committees drive dynamic datadriven risk oversight compliance council rocc helps discussions agile risk management strategies oversight arc crc oversee risks strategies used report existing control measures implementation emerging address risks external insights outoftolerance key risk indicators tolerance aligns risk appetite include risks risk management compliance boards across group mitigations associated covid promote tone top also establish risk culture oversee effectiveness risk management risk management framework complements culture activities well communicating information internal speak processes ensuring risks actively controls business accountable delivering effectively identified mitigated also provides reasonable objectives line established risk appetite assurance material misstatement mitigates potential losses could arise ordinary course business enterprise risk owner responsible principal risk monitors important risks takes action address oversight glt member risk owners report risk issues annual confirmation exercise checks key risks mitigation rocc glt appropriate board well managed actions place address gaps committee legal compliance support efforts business advising business strategies activities risks controls audit assurance provides assessments adequacy business continuity planning embedded framework effectiveness framework principal risks include controls responding problems within risk plans also business continuity planning considering current emerging risks critical processes continue business operations event crisis risk assessment process considers likelihood impact risks timescale risk could occur changes risks consider current emerging risks could affect ability achieve longterm objectives emerging risks november annual risk review rocc agreed threeyear horizon line viability principal risks remain largely unchanged statement also define risks way need know evolution privacy data ethics privacy non likely materialise impact promotional engagement scientific patient engagement theyd evaluate additional investigation transformation separation separation additionally required classifying principal risks risk agreed environmental sustainability managed management compliance boards levels esg areas focus also identified two new organisation identify emerging risks ongoing basis emerging risks geopolitical tensions healthcare reform rocc discusses emerging risks meeting also scan evaluated classified risk horizon throughout year identify external trends principal risks may opportunities andor emerging risks monitor table following pages shows current principal business activities internal environment new emerging risks respective trends assessments mitigation changing risks activities year order significance full risk definitions potential impact context mitigating viability statement see risks associated activities please see principal risks uncertainties covid see arc report see pages internal control framework see gsk annual report gsk annual report strategic report governance remuneration financial statements investor information risk management continued principal risks summary risk trend assessment mitigation activities patient safety macro risk level stable remains challenging public awareness drug safety increased following media coverage safety efficacy covid vaccines therapies misinformation negative characterisations industry fuelled vaccine hesitancy highly publicised information security threats data breaches require us consider securely collect safety information external sources gsks risk exposure stable portfolio evolving greater focus advanced therapy medicinal products may require specialised pharmacovigilance need carefully balance resources execute routine pharmacovigilance manage change initiatives including separation consumer healthcare business accelerated pace drug development simplification safety processes product quality macro risk increased following covid regulators resuming multiple onsite inspections check product quality expectations met continues focus data governance data integrity requirements evaluation products presence nitrosamines gsk 's risk exposure increased need respond heightened inspectorate presence launched inspection readiness programmes ensure full preparedness continued invest technology digital platforms strengthen controls around good data management practices governance control strategies deployed timely nitrosamine evaluations mitigations require focus diligence gsk undergoes significant organisational change financial external environment remains challenging due political uncertainty proposed increases controls obligations directors auditors increasing threats cyber attacks information security fraud reporting increasing environmental disclosure requirements gsks risk exposure remained stable due ongoing focus resilience personnel testing internal control framework implement optimal risk mitigation transformational programmes technology centralised processes risk control assessments maintain effective tax treasury strategies continually strengthen control frameworks collaborate external bodies standard setting antibribery macro risk level bribery corruption remained unchanged continued see corruption ongoing impact pandemic governments people businesses rigorous antibribery abac corruption standards aided improved technology continued enforcement focus third party intermediaries gsks risk exposure unchanged continuously improve anti bribery corruption programme ensure appropriate controls training capability building awareness raising strong monitoring use data analytics commercial covid consequences continue impact macro level competitive pressure increased practices many therapy areas market segments future innovation requires successful launches key medicines products vaccination rates impacted accessibility political issues governments remain focused initiatives drive medicine vaccine costs consumers gsks risk exposure level remains stable due mature robust control environment continue evolve commercial practices competitively invested new technologies support virtual customer engagement maintain proportionate controls training monitoring employees engage healthcare organisations professionals train senior business leaders delivering performance managing risk non macro environment nonpromotional activities scientific engagement hcps promotional patients stable continues characterised complex dynamic disease areas treatments engagement increased patientcentric focus increasing diversity engagement platforms continued increase virtual engagements since pandemic gsks risk exposure remained stable digital practices continued develop modernise applied internal principles policies designed mitigate risk rapidly evolving environment internal networks foster collaboration best practice sharing well identification emerging risks associated nonpromotional activities conduct compliance gsks values policies local laws regulationsrisk management continued principal risks summary continued risk trend assessment mitigation activities privacy macro risk continues increase priority gsk markets uk eu us china india instituting new privacy laws court rulings invalidating established international data transfer mechanisms international companies relied increasing trend data sovereignty initially targeting tech companies could affect healthcare companies ability drive medical innovation effectively operate internationally gsks risk exposure increasing due impact unstable privacy regulatory environment preventing us standardising privacy framework globally due scale changes necessary prepare creation two new datadriven companies research macro risk level unchanged always need continually assess rd context practices future ambition benchmarks evolving global regulations quality standards particularly vital expectations change countryspecific requirements human genetic resources administration china schrems ii gsks risk exposure unchanged laws regulations continually evolving regulations change accountable rd function develops action plan include risk impact assessments determine internal control framework needs change meet new requirements rd regularly scans external environment membership professional organisations consortiums attendance industry agencysponsored meetings review publicly posted regulatorylegal reports environment macro risk level unchanged covid protocols embedded ways health working site staffing moved essential workers mostly full staffing meant safety able resume consistent management oversight onsite global support ehs senior leaders subject matter experts audit teams gsks risk exposure levelled due consistent work practices related covid control measures however organisational change continues factor placed continued focus safety leadership training embedding life saving rules adhering ehs standards environmental macro risk level continues increase investors regulators stakeholders expect sustainability companies understand actively reduce environmental footprint operations across value chain mitigate impacts climate change could operations supply chains gsks risk exposure unchanged set ambitious new environmental sustainability goals end established enterprise transformation programme addressing climate water waste biodiversity across operations also increased scope depth task force climaterelated financial disclosures tcfd analysis continued monitor trends physical reputational regulatory risks climate change impacts information macro risk level continues rise large multinationals increase digital footprints threats security hackers become sophisticated risks identified increasing pandemic levelled continue ongoing threat time governments tightening regulatory frameworks expect enforcement increase gsks risk exposure increased targeting pharmaceutical vaccine intellectual property thirdparty service availability intensified response cyber security programme continues improve controls increase cyber threat intelligence capabilities protect critical information systems including operational technology networks supply macro risk level remains high due ongoing impact pandemic product supply continuity also continuing potential increasing protectionism brexit uncertainty covid issues management team actively managing supply risk mitigation ongoing basis gsks risk exposure stabilised procurement task force crossfunctional group procurement supply chain accountable identification management potential bottlenecks supply components transformation macro risk level unchanged remains challenging set two new companies highly separation competitive external labour market gsks risk exposure level remains unchanged transformation separation projects progressed planned throughout employee engagement remaining priority gsk annual report gsk annual report strategic report governance remuneration financial statements investor information risk management continued climaterelated financial disclosure gsk climaterelated disclosures consistent programme steering team coordinate recommendations recommended disclosures task sustainability programme associated workstreams force climaterelated financial disclosures tcfd oversight monitoring performance progress compliance requirements lr r uk listing rules enablers deliver sustainability programme gsk reporting climaterelated financial disclosures capital allocations board cab includes accordance tcfd recommendations since cfo group financial controller review climate purpose building trust connecting related capital expenditure part annual planning strategic financial disclosures climate change capital allocation process expanded disclosure undertaking detailed finance sustainability network includes leaders review gsks manufacturing operations inhaler across finance sustainability procurement focuses portfolio largest contributor gsks current key financial enablers deliver sustainability carbon footprint within portfolio medicines vaccines programme consumer products gsks carbon reduction pathway become net zero found gskcom strategy risk management continue evolve future climaterelated disclosures methodology assumptions building climate risk assessments external since disclosed longterm risks climate supply chain change across value chains key products account approximately revenue expanded governance assessments focus risks manufacturing environmental sustainability includes climate change operations developed threeyear plan assessed principal risk gsk board embed climaterelated analysis across significant areas overall accountability management gsks business principal risks support glt used two climate scenarios based internationally boardlevel corporate responsibility committee crc recognised data sets oversees environmental sustainability principal risk businessasusual bau assuming little mitigation progress environmental targets nonexecutive leading c warming director lynn elsenhans chair see crc report lowcarbon future assumes global temperature risk oversight compliance council rocc increase limited well c rapid helps crc oversee risks strategies used changes legislation technology address quarterly reporting refer details board board committees architecture using enterprise risk plan carried scenario analyses risks opportunities prioritising regis simard president pharmaceuticals supply chain physical transitional risks opportunities according glt member management responsibility environmental likelihood magnitude potential impact sustainability includes climate change responsible gsks manufacturing operations staff governance oversight risks opportunities ensures effective framework place identify risk opportunity analysed potential manage risks opportunities across business impact profit classified either low million units along delivering commitments made medium million million high million net zero impact climate net positive impact nature consider climaterelated issues within time horizons refer detailed risk management plan used strategic capital planning processes shortterm established specialised teams across gsk working less months mediumterm years longterm together deliver environmental strategies embed years focused climate risks business usual including material risks identified falling short medium term gsk sustainability council chaired regis simard includes leaders business units global tested resilience gsks climaterelated strategy functions including manufacturing rd procurement taking consideration different scenarios risks facilities management ethics compliance finance opportunities identified result continuing play key role delivering environmental strategy improve management climaterelated risks council supported dedicated programme steering opportunities team run global sustainability team also provide specialist expertise advice business httpswwwgskcommediagskcarbonglidepathpdf scenarios based ippc representative concentration pathways iea world energy outlook new policy scenario current policy scenario sustainable development scenario data sets wwf wri water stress flood risk modellingrisk management continued risk management internal control framework established specific dedicated environmental sustainability enterprise environmental sustainability including appointment risk management plan put place details dedicated senior leaders environmental sustainability see risk management risk management plan ensure governance processes place effective covers expectations gsk addressing impact performance reducing carbon emissions energy environment environment increasing impacts water utilisation waste continue delivered operational resilience access energy water managed mature programmes enhanced natural resources used products along including ecodesign considerations products anticipated cost increases regulatory changes packaging environmental taxes summary gsks risks opportunities potential physical risk profit impact description scenario risk management timeframe metrics targets increasing levels bau performed water stewardship risk low sites achieve good water stress low assessments manufacturing sites achieved water water stewardship reduces carbon identified ten sites current long stewardship availability water network currently areas highwater years sites water use operations risk operations reduce overall gsk uses freshwater developing plans sites water use sites main source become water neutral partner operations supplier sites water manufacture organisations address shared medicines vaccines water challenges currently piloting achieved water water neutral consumer health approach cape town site working neutrality products partners including wwf water operations resilience coalition water availability key suppliers restricted factory tcfd process helped us develop water stressed production watch list additional sites potentially regions operations would longterm threat monitor changes interrupted risk levels update site water risk assessments appropriately increasing frequency bau performed risk assessments low sites sites extreme weather low manufacturing operations business response events causing carbon business continuity plans place long continuity extreme disruption reviewed annually respond impact years plans weather events extreme weather events including adopting business extreme weather appropriate mitigation plans continuity plans events flooding storms etc tcfd process helped us identify result shortterm watch list sites places interruptions flood risk expected increase time manufacturing however risk flooding remains operations low gsk wellestablished loss prevention risk engineering programme identify range risks could impact sites flood risks exist taken action mitigate risk increased number bau gsk operations countries already low scope net zero hot days experience hot temperatures periodically carbon emissions across c resulting already control temperature long emissions operations reduced productivity humidity inside buildings part years ehs control framework sites conduct risk extreme heat could net zero assessments hot days including result heat stress emissions across adaptations outside work affecting staff full value chain defined alliance water stewardship gsk annual report gsk annual report strategic report governance remuneration financial statements investor information risk management continued potential transitional risk profit impact description scenario risk managed timeframe metrics targets regulations bau started rd programme find medium scope net zero governing use low lowerimpact propellant could reduce carbon emissions across high global warming carbon emissions metered dose inhalers emissions operations potential gwp long substances years already portfolio dry powder net zero updated uk inhaler products use propellants emissions across eu us impacted risk full value chain could lead monitoring evolving regulations increasing cost governing use fluorinated gases restrictions use review assessments future declarations high gwp propellant hfaa metered dose inhaler mdi products uncertainty low carbon transitioning renewable low scope net zero future regulatory electricity starting carbon emissions across policy responses investigate options renewable heat long emissions operations address climate technology reduce carbon emissions years change countries energy around world sales fleet aim transition electric develop including vehicles reducing scope carbon pricing carbon emissions anticipate shadow carbon pricing embedded carbon pricing capital investment process per operational carbon tonne driving conversations emissions come decisions around carbon emissions levels force organisation regions medium long term could increase operating costs potential profit impact opportunities scenario opportunity managed timeframe metrics targets cop bau reducing scope carbon low scope net zero november low carbon emissions turn reduces scope carbon emissions across footprint customers suppliers long emissions full value chain countries around years started new ecodesign programme total waste world committed reduce impacts products non zero operational provide low carbon packaging circular waste waste including healthcare systems eliminating gsk certified published carbon could lead singleuse plastics footprints portfolio respiratory inhalers increasing demand launched first carbon neutral low carbon vaccines inhaler uk enables healthcare medicines providers patients make informed choices environmental impact reduction started rd programme find products lowerimpact propellant could reduce packaging emissions metered dose inhalers waste reduction supply chain risk management continued metrics targets details progress making towards achieving commitment net zero impact climate climate targets found additional net positive impact nature across value chain background climate also nature targets additional details targets carbon reduction glidepath progress making approaches adopting contribute goals available gskcom meet targets found esg performance science based targets initiative validated near report public responses cdp climate term carbon targets align c pathway delivering water forest questionnaires goals acting priority impact areas working order align approach climate nature stakeholders across value chain including suppliers targets remuneration executive directors customers also working external partners senior executives introducing esg target world business council sustainable development measure initially short longterm remuneration un water resilience coalition incentive plans include setting measuring short longterm performance participants nature net positive climate net zero ambitions details please see remuneration report pages energy carbon emissions carbon emissions carbon emissions tonnes coe scope emissions energy scope emissions scope emissions marketbased scope emissions available report uk scope emissions energy scope emissions energysales revenue tonnes coem scope emissions energyfte tonnes co efte total energy used gwh uk energy used gwh carbon emissions calculated according greenhouse gas protocol corporate accounting reporting standard revised edition gsk uses marketbased scope emissions reporting purposes reports scope emissions across categories esg performance report ask external assurance providers dnv provide limited assurance isae energy scope selected scope carbon emission data methodologies reporting measurements provided esg performance report kpi definitions gsk asks dnv provide limited assurance isae energy scope selected scope carbon emissions water waste wastewater data methodologies reporting measurements provided esg performance report kpi definitions pages refers emissions sales force vehicles propellant emissions released manufacture inhalers onsite waste wastewater treatment refrigerant gas losses collect publish scope data across categories recent scope data available process compiling data yet complete publish data becomes available included esg performance report gsk annual report gsk annual report strategic report governance remuneration financial statements investor information risk management continued viability statement accordance provision revision metrics subject sensitivity analysis code gsk assessed prospects group involves flexing number main assumptions underlying longer period months required going forecasts individually combination along concern provision directors confirm mitigating actions could realistically taken avoid reasonable expectation gsk continue operate reduce impact occurrence underlying risk meet liabilities fall due next three years future separation consumer healthcare joint venture directors assessment made reference gsks pfizer approved board shareholders likely current position prospects strategy boards risk occur within period covered viability assessment appetite gsks principal risks managed directors therefore considered ability group detailed pages strategic report continue current form ie scenario board reviews internal controls risk management demerger proceed threeyear period ending policies approves governance structure code december well viability new gsk conduct also appraises approves major financing demerger proceeds planned investment licensing decisions evaluates monitors following hypothetical downside scenarios performance prospects gsk whole focus evaluated largely improving longterm financial performance delivery company three business strategies scenario business performance risks include key aligned innovation performance trust priorities performance risks including lower sales new products greater adverse impact generic competition board reviews gsks strategy makes significant capital competitive launches gsk products well investment decisions longterm time horizon based possible supply manufacturing challenges multiyear assessment return capital performance company three business units market scenario external macroeconomic risks scenario opportunity pharmaceutical vaccines consumer reflects incremental risks business driven outside sectors approach aligned gsks model achieving factors intense competition increased pricing balanced growth investing highquality innovative pressure us europe well potential products patients consumers healthcare providers impact material negative changes macroeconomic however since many internal external parameters become healthcare environment increasingly unpredictable longer time horizons gsk scenario principal risks scenario includes severe focuses detailed bottomup plan threeyear cycle assessment potential loss impact principal risks plan reviewed least annually directors approve related patient safety product quality supply chain continuity business forecasts showing expected financial impact environmental sustainability well antibribery directors believe threeyear assessment period corruption consequent regulatory actions fines viability statement appropriate aligns could fundamentally threaten operations risks groups well established business planning processes managed mitigating activities described pages balance longterm nature investments pharmaceutical vaccines consumer sectors scenario put option exercise scenario evaluates assessment period analysis nearterm additional funding requirements assuming earliest potential business performance realistically visible exercise outstanding put option held partner plan stress tested series robust operational hiv business principal risk downside scenarios part boards scenario demerger consumer healthcare joint review risk include potential risks associated venture ch final scenario focuses impact ch ongoing covid pandemic considered demerger early q well downside assessment within plan stress test downside scenarios scenarios applied new gsks cash flows plan assumes next several years challenging healthcare industry continued uncertainty related threeyear review also makes certain assumptions impact covid pandemic adult vaccinations normal level capital recycling likely occur considers continued pressure pricing pharmaceuticals gsk whether additional financing facilities required assumes premature loss exclusivity key products respective level funding flexibility headroom period gsk also expects volume demand products results stress testing show certain combinations increase particularly shingrix healthcare systems hypothetical scenarios could increase funding expected return normal following disruption demands gsk require mitigating changes governments prioritisation covid vaccination groups funding strategy however light liquidity programmes ongoing measures contain pandemic available group based analysis directors downside scenarios consider gsks cash flows reasonable expectation even sustainability dividends funding strategy insurance provision severe stress tests group without demerger recovery well key financial ratios period able continue operation meet liabilities fall due threeyear period assessmentrisk management continued risks associated covid potential impact covid pandemic gsks continue remain confident underlying demand trading performance principal risks vaccines encouraged rate assessed mitigation plans put place covid vaccinations boosters administered anticipated pandemic impacted group performance many countries provides support healthcare systems primarily demand vaccines reflected prioritisation eventual return normal continues dynamic covid vaccination programmes governments situation future severity duration impact unknown including social distancing rules resulting covid point including potential impacts trading results clinical affected customers ability willingness access vaccination trials supply continuity employees situation could services across regions change time assurance covid pandemic material adverse impact future results group nonfinancial information statement following aligns nonfinancial reporting requirements contained sections ca cb companies act description business model human rights policy due diligence outcomes value create ethics values summary principal risks data engagement principal risks uncertainties social matters third parties viability statement global health audit risk committee report health security anticorruption bribery affordability availability ethics values nonfinancial key performance reporting investigating concerns indicators employees antibribery corruption key performance indicators employee engagement diversity environmental matters policies wellbeing development carbon water waste public policies codes gender pay gap climaterelated financial disclosure standards available gskcom ethics values board diversity employees gender male female total board management employees senior managers defined companies act strategic report directors report regulations gsk annual report group financial review section reporting framework approach tax financial performance adjusting items cash generation conversion financial position resources treasury policies critical accounting policies gsk annual report strategic report governance remuneration financial statements investor informationgroup financial review reporting framework total adjusted results costs ordinary course smaller scale restructuring group financial review discusses operating legal charges expenses retained within total financial performance group cash flows financial adjusted results position resources results year adjusted results include benefits major restructuring compared primarily results preceding year programmes exclude significant costs amortisation intangible assets except computer software total results capitalised development costs significant legal major total reported results represent groups overall restructuring transaction items performance regarded complete picture groups financial gsk also uses number adjusted nonifrs measures performance presented total results report performance business adjusted results exclusion adjusting items may result adjusted nonifrs measures may considered addition earnings materially higher lower total earnings substitute superior information presented particular significant impairments restructuring accordance ifrs adjusted results defined charges legal costs excluded adjusted earnings nonifrs measures defined higher total earnings gsk believes adjusted results considered together gsk undertaking number major restructuring total results provide investors analysts programmes response significant changes groups stakeholders helpful complementary information trading environment overall strategy following material understand better financial performance position acquisitions costs cash noncash group period period allow groups programmes provided individual elements performance easily compared majority approved meet accounting recognition criteria peer companies measures also used result charges may incurred number years management planning reporting purposes may following initiation major restructuring programme directly comparable similarly described measures significant legal charges expenses arising used companies settlement litigation government investigations gsk encourages investors analysts rely normal course materially larger single financial measure review gsks annual reports regularly occurring individual matters also include certain including financial statements notes entirety major legacy matters adjusted results reconciliations total adjusted results providing adjusted results exclude following items total results information key adjusting items together tax effects items set five years set pages amortisation intangible assets excluding computer software capitalised development costs gsk provides earnings guidance investor community basis adjusted results line peer companies impairment intangible assets excluding computer expectations investor community supporting easier software goodwill comparison groups performance peers gsk major restructuring costs include impairments able give guidance total results reliably tangible assets computer software specific forecast certain material elements total results board approved programmes structural particularly future fair value movements contingent significant scale costs individual related consideration put options given rise projects exceed million including integration costs significant adjustments driven external factors following material acquisitions currency movements capital markets transactionrelated accounting adjustments related significant acquisitions proceeds costs disposals associates products businesses significant settlement income significant legal charges net insurance recoveries expenses settlement litigation government investigations operating income royalty income items including impact revaluation deferred tax assets liabilities following enactment increase headline rate uk corporation tax effective separation costs include costs establish consumer healthcare independent business well admission listing demerger costs gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information reporting framework continued historical record adjusting items reconciliations total adjusted operating profit last five years summarised follows total operating profit intangible asset amortisation intangible asset impairment major restructuring transactionrelated items divestments significant legal items separation costs us tax reform adjusted operating profit analysis impact transactionrelated items operating profit last five years follows novartis consumer healthcare joint venture put option contingent consideration former shionogiviiv healthcare jv including shionogi preferential dividends viiv healthcare put options pfizer preferential dividends contingent consideration former novartis vaccines business release fair value uplift acquired pfizer inventory adjustments transactionrelated items full reconciliations total adjusted results set pages explanations adjusting items reported noncontrolling interests viiv healthcare acquisitionrelated arrangements trading profit allocations consideration acquisition shionogis interest former shionogiviiv healthcare joint venture shionogi viiv healthcare subsidiary group received equity stake viiv healthcare viiv operating results turnover operating profit profit tax healthcare also agreed pay additional future cash included within group income statement consideration shionogi contingent future sales portion earnings allocated noncontrolling performance products developed joint interests owned shareholders line venture dolutegravir cabotegravir ifrs business respective equity shareholdings pfizer shionogi combinations gsk required provide estimated shareholders including gsk also entitled fair value contingent consideration time preferential dividends determined performance acquisition required update liability latest certain products shareholder contributed estimate fair value subsequent period end relative performance products changes time liability contingent consideration recognised proportion overall earnings allocated shareholder balance sheet date acquisition million also changes particular increasing proportion sales subsequent remeasurements reflected within dolutegravir cabotegravircontaining products operating incomeexpense within adjusting items favourable impact proportion preferential dividends income statement period allocated gsk adjusting items allocated shareholders based equity interests gsk entitled cash payments settle contingent consideration approximately total earnings made shionogi viiv healthcare quarter based adjusted earnings viiv healthcare actual sales performance income relevant remeasurements liabilities preferential dividends products previous quarter payments reduce allocated pfizer shionogi included within balance sheet liability hence recorded income operating incomeexpense statement cash payments made shionogi viiv healthcare million liability required recorded fair value estimated future payments significant timing difference charges recorded total income statement reflect movements fair value liability actual cash payments made settle liabilitygroup financial review continued reporting framework continued cash payments reflected cash flow statement however q gsk notified shionogi partly operating cash flows partly within investing irrevocably given right accordingly recognised activities tax relief payments reflected liability put option groups balance sheet groups adjusting items part tax charge part q initial value million q payment relating original estimate fair shionogi irrevocably agreed waive put option value contingent consideration acquisition result gsk derecognised liability put option shionogiviiv healthcare joint venture million groups balance sheet directly equity value reported within investing activities cash flow statement liability million derecognised part payment relating increase gsk also call option shionogis shareholding liability since acquisition reported within operating cash viiv healthcare original agreements flows exercisable sixmonth windows commencing movements contingent consideration payable shionogi gsk irrevocably agreed waive first follows two exercise windows last sixmonth window remains call option fair value value accounting purposes contingent consideration beginning year remeasurement income statement settlement gilead sciences inc gilead cash payments operating cash flows february viiv healthcare reached agreement cash payments investing activities gilead settle global patent infringement litigation relating contingent consideration end year commercialisation gileads biktarvy terms global settlement licensing agreement gilead made contingent consideration payable posttax basis upfront payment billion viiv healthcare shionogi december million december received february addition gilead also million expected paid within one year pay royalty future us sales biktarvy exit rights respect bictegravir component future bictegravircontaining products sold us royalties pfizer may request ipo viiv healthcare time payable gilead viiv healthcare february either gsk consent ipo offering expiry viiv healthcares us patent completed within nine months pfizer could require gsk october gileads obligation pay acquire shareholding original agreements gsk royalties extend period regulatory paediatric unconditional right long made subsequent exclusivity awarded settlement resulted distribution shareholders withhold consent remeasurement existing liabilities contingent exercise pfizer put option result accordance consideration pfizer put option year end ifrs gsk recognise liability put option balance sheet however q gsk notified impact settlement gilead contingent pfizer irrevocably given right accordingly consideration liability ccl increase million recognised liability put option groups balance posttax basis q due obligation viiv sheet q initial value million healthcare pay future cash consideration shionogi consistent revised treatment end q share upfront future us sales performance gsk also recognised liabilities future preferential biktarvy products containing bictegravir including dividends anticipated become payable pfizer shionogi impact settlement december liability groups balance sheet discounted stood million posttax basis closing balances liabilities related pfizers shareholding follows pfizer right require gsk acquire shareholding viiv healthcare certain circumstances time put option liability therefore recorded groups balance pfizer put option sheet current liability measured gross pfizer preferential dividend redemption basis derived internal valuation viiv healthcare business original agreements shionogi could also impact settlement pfizer put option liability requested gsk acquire shareholding viiv healthcare increase million included sixmonth windows commencing remeasurement december gsk unconditional right long made see explanation post balance sheet subsequent distribution shareholders withhold event impact consent exercise shionogi put option result gsk recognise liability put option balance sheet gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information reporting framework continued free cash flow year compound annual growth rate free cash flow defined net cash inflow operating cagr defined compound annual growth rate activities less capital expenditure property plant shows annualised average rate proforma revenue growth equipment intangible assets contingent consideration two given years assuming growth takes place payments net finance costs dividends paid non exponentially compounded rate consumer healthcare controlling interests plus proceeds sale property year revenue cagr presented showing plant equipment intangible assets dividends annualised average rate proforma revenue growth received joint ventures associates used management planning reporting purposes discussions presentations investment analysts covid solutions rating agencies free cash flow growth calculated covid solutions include sales pandemic adjuvant reported basis reconciliation net cash inflow covid solutions including vaccine manufacturing operations free cash flow set xevudy associated costs include reinvestment rd categorisation used cer aer growth management believe helpful investors order illustrate underlying performance groups providing clarity results group showing practice discuss results terms constant exchange contribution growth covid solutions rate cer growth represents growth calculated exchange rates used determine results overseas general medicines companies sterling remained unchanged general medicines usually prescribed primary used comparative period cer represents growth care community settings general healthcare practitioners constant exchange rates aer represents growth gsk includes medicines inhaled respiratory actual exchange rates dermatology antibiotics diseases return capital employed specialty medicines return capital employed calculated total profit specialty medicines typically prescription medicines used taxation percentage average net assets year treat complex rare chronic conditions gsk comprises medicines infectious diseases hiv oncology net debt immunology respiratory please see note net debt calculation net debtgroup financial review continued approach tax business makes major contribution public purse seek maintain open constructive relationships tax contribution includes direct taxes tax authorities worldwide meeting regularly discuss tax corporate income tax indirect taxes vat affairs real time business updates wherever possible customs duties well taxes employment also monitor government debate tax policy key taxes property taxes therefore important jurisdictions understand share informed companies explain approach tax helps inform point view regarding potential future changes tax law dialogue tax tax policy relevant provide pragmatic constructive supportive efforts ensure companies business input tax policy makers either directly appropriately transparent tax affairs industry trade bodies advocating reform support economic managed part tax strategy set growth job creation well needs patients detail within public policies section website key stakeholders support exchange countrybycountry reporting group corporate tax charge million cbcr data tax authorities validated million profits tax million existing information held taxpayers support ability million representing effective tax rate ensure multinational groups pay right amount tax made cash tax payments right places million year million addition taxes pay profits pay duties levies transactional global healthcare company substantial business employment taxes employment presence many countries around world pay significant amount tax includes corporate adjusted tax rate income tax business taxes tax associated rate benefited closure open issues tax employees also collect significant amount tax authorities various jurisdictions following separation behalf governments along supply chain including consumer business subject material changes employees product mix material changes tax regulations laws countries operate groups average subject taxation throughout supply chain effective adjusted tax rate medium term expected worldwide nature operations means crossborder around supply routes necessary ensure supplies medicines numerous countries result conflicting claims tax groups total tax rate authorities profits taxed individual countries lower adjusted tax rate mainly due enactment lead double taxation profits taxed increase uk corporate income tax rate one country resulting increase value balance sheet tax assets due magnitude gsk reported credit profits recognised territories reference activities adjusting item obscure key performed value generate ensure trends groups performance period profits recognised jurisdictions aligned activity undertaken line current oecd guidelines oecd eu continue develop new policies base transfer pricing policy arms length principle lead substantially increased tax compliance support transfer prices economic analysis reports burden may case oecds project address tax challenges digitalisation fundamentally change engage artificial tax arrangements without international corporate tax landscape therefore tax business commercial substance seek avoid tax profiles multinational companies including gsk use tax havens transactions would fully reallocating countries taxing rights largest disclose tax authority zerotolerance approach profitable multinationals ii set new minimum global tax evasion facilitation tax evasion corporate tax rate project achieved political tax risk countries operate managed consensus plan effective implementation robust internal policies processes training compliance however detailed rules still discussion programmes board directors audit risk therefore possible accurately forecast impact committee responsible approving tax policies gsk stage risk management arrangements part wider internal details corporate tax charges year control framework set note gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information financial performance group turnover bn total results group set bn aer growth cer growth growth turnover turnover cer turnover cost sales selling general administration research development royalty income operating expensesincome operating profit net finance costs total operating profit bn share aftertax profits associates bn aer growth cer growth joint ventures loss disposal interest associates profit taxation taxation profit taxation year profit attributable shareholders earnings per share p p earnings per ads us adjusted operating profit bn adjusted results group set reconciliations total results adjusted results bn aer growth cer growth set growth turnover turnover cer turnover cost sales selling general administration research development gsk uses number adjusted nonifrs measures report royalty performance business adjusted results income nonifrs measures may considered addition adjusted substitute superior information presented operating accordance ifrs adjusted results nonifrs profit measures defined pages adjusted profit attributable shareholders adjusted earnings per share p p group financial review continued financial performance continued pharmaceuticals group turnover pharmaceuticals turnover year million group turnover business aer cer sales xevudy monoclonal antibody treatment covid million contributed growth growth cer approximately percentage points pharmaceuticals growth pharmaceuticals hiv sales aer cer vaccines million growth dovato juluca partly offset tivicay consumer healthcare triumeq respiratory sales aer cer million growth trelegy nucala oncology corporate immunoinflammation therapy areas continued unallocated turnover show strong doubledigit sales growth sales established pharmaceuticals decreased aer cer million group turnover geographic region us sales grew aer cer including sales growth growth cer xevudy contributed approximately percentage points us total growth continued strong performance trelegy nucala europe benlysta dovato also drove growth new specialty products region established products stable international aer grew cer reflecting strong demand established respiratory products covid environment group turnover million year stable aer certain supply challenges faced generic competitor cer sales covid solutions contributed products plus benefit favourable prior period rar approximately percentage points growth year adjustments europe sales decreased aer cer decreases pharmaceuticals established pharmaceuticals portfolio impacted generic competition including seretide duodart volibris turnover bn lower antibiotic demand divestment cephalosporin products start fourth quarter decrease bn aer growth cer growth partly offset strong growth trelegy benlysta oncology products dovato doubled year sales xevudy totalling million also contributed group turnover approximately percentage points total growth international sales decreased aer grew cer decreases established pharmaceuticals reflected impact covid suppressed antibiotics markets increased generic competition first half year offset strong growth respiratory dovato tivicay tenders sales xevudy added approximately percentage points international total growth pharmaceuticals turnover revised growth growth cer respiratory hiv immunoinflammation oncology pandemic new specialty established pharmaceuticals g sk reviewed presentation pharmaceuticals products january moved sales arnuity ellipta incruse ellipta relvarbreo ellipta respiratory therapeutic area established pharmaceuticals therapeutic area comparative information revised onto consistent basis gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information financial performance continued respiratory immunoinflammation total respiratory sales aer cer immunoinflammation sales million grew aer sales trelegy nucala exceeding billion per year cer benlysta sales aer cer first time international respiratory sales grew aer million benefitting lupus nephritis launches us cer including nucala aer cer japan h trelegy aer cer including impact trelegy asthma launch japan q europe oncology respiratory grew aer cer double digit cer sales zejula parp inhibitor treatment ovarian cancer growth trelegy nucala us respiratory grew million aer cer impacted aer cer driven continued strong performance ongoing lower diagnosis rates due covid pandemic trelegy nucala particularly us sales included million us sales nucala million year grew million europe aer cer consistent strong growth across three blenrep treatment patients relapsed refractory regions us sales aer cer multiple myeloma approved launched us million international sales million grew aer europe q ongoing launches throughout europe cer europe sales million grew aer blenrep sales globally totalled million cer pandemic sales trelegy sales aer cer million driven growth regions us sales continue grow sales xevudy million year reflecting strongly including benefit asthma indication approved ongoing fulfilment contracts across world launched q sales aer cer significantly us reported sales million europe sales grew aer cer international international recorded sales million europe trelegy asthma approved japan q million sales grew aer cer million established pharmaceuticals hiv sales established pharmaceuticals year hiv sales million decrease aer million aer cer growth cer year triumeq sales established respiratory products decreased aer million aer cer tivicay sales cer million includes impact generic million aer cer mature portfolio competition xyzal japan advairseretide globally resulted less percentage point cer sales decrease decrease partially offset approximately new hiv products juluca dovato rukobia cabenuva percentage points impact growth favourable prior period delivered sales million representing total rar adjustments hiv portfolio sales two drug regimens remainder established pharmaceuticals portfolio juluca dovato million million decreased aer cer million lower respectively combined growth aer cer demand antibiotics covid pandemic period rukobia sales million cabenuva first long acting divestment gsks cephalosporin products start injectable recorded million sales full year fourth quarter impact government mandated us total sales million decrease changes increasing use generics markets including france aer growth cer new hiv products delivered japan china sales million including dovato million growth aer cer juluca million growth aer cer rukobia million cabenuva million combined tivicay triumeq sales million declining aer cer europe total sales million decrease aer growth cer new hiv products delivered sales million including dovato sales million doubled aer cer juluca million growth aer cer combined tivicay triumeq sales million declining aer cer international continued grow strongly total sales million growth aer cer driven tivicay tender business new hiv productsgroup financial review continued financial performance continued influenza vaccines fluarixflulaval sales decreased aer cer million result unfavourable prior period rar movements turnover bn us partially offset higher volume us strong bn aer growth cer growth southern hemisphere demand international shingles group turnover shingrix decreased aer cer million primarily driven lower demand us international routine adult vaccination due covid vaccination programme deployment disease circulation europe sales growth driven germany launches uk spain italy shingrix sold countries including markets launched established vaccines vaccines turnover hepatitis vaccines sales aer cer million adversely impacted deprioritisation routine growth growth cer us adult vaccination increased hepatitis b vaccine competition meningitis unfavourable cdc stockpile movements us influenza covid related travel restrictions europe international shingles sales dtpacontaining vaccines infanrix pediarix established vaccines boostrix decreased aer grew cer infanrix pediarix sales decreased aer cer million pandemic vaccines reflecting lower tender volume europe international well change recommendation dosing schedule germany partly offset increased demand us boostrix vaccines turnover year decreased aer grew sales grew aer cer million largely driven cer million primarily driven pandemic demand recovery tender volumes international well adjuvant sales partially offset lower demand routine adult higher demand share us vaccination due covid vaccination programme deployment disease circulation across regions resulting rotarix sales aer cer lower shingrix hepatitis vaccines sales unfavourable us million reflecting demand recovery international prior period rar adjustments reduced overall vaccines growth synflorix sales decreased aer cer approximately percentage points particularly fluarix million primarily due lower tender demand emerging flulaval shingrix impact product growth markets decrease decrease respectively mmrv vaccines sales stable aer grew cer vaccines turnover excluding pandemic vaccines decreased million largely driven higher demand international aer cer million pandemic vaccines meningitis pandemic vaccines sales million included million meningitis sales decreased aer cer million pandemic adjuvant sales us canadian driven primarily unrepeated international tender volumes governments meningitis vaccines bexsero sales stable aer grew cer million reflecting increased market share us menveo sales aer cer million primarily driven cohort catchup vaccinations higher demand well increased market share us gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information financial performance continued oral health consumer healthcare oral health sales decreased aer grew cer million sensodyne delivered high single digit growth turnover bn reflecting underlying brand strength continued innovation aer growth cer growth strong growth across key markets including us china india bn japan gum health also delivered broad based high single digit growth across key markets denture care grew low single group turnover digits driven partly return growth q pain relief pain relief sales increased aer cer million panadol benefitted seasonal demand last quarter grew double digits voltaren grew midsingle digits offsetting expected shortterm decrease second half year us introduction private label competition earlier excedrin delivered growth consumer healthcare turnover versus prior year decrease reflecting supply improvements growth growth cer vitamins minerals supplements oral health pain relief vitamins minerals supplements sales stable aer vitamins minerals supplements grew cer million building significant cer growth centrum grew midteens percent respiratory health driven successful innovation improved supply capacity digestive health us continued consumer focus health wellness caltrate grew midsingle digits emergenc decreased brands divestedunder review highsingle digits reflecting particularly challenging comparator due unprecedented demand early stages pandemic growth growth cer respiratory health us respiratory health sales decreased aer cer europe million q cold flu sales rebounded international strongly levels europe slightly levels us full year cold flu consumer healthcare turnover year million products midsingle digits h rebound decreased aer stable cer reflecting dilution insufficient offset considerable decrease first divestments given completion portfolio quarter resulted historically low demand rationalisation end q twoyear cagr cold flu products effectively halving global market sales excluding brands divested review grew overall period allergy products grew midsingle digits despite adverse impact covid pandemic digestive health sales excluding brands divestedunder review decreased aer increased cer reflecting underlying strength digestive health brands sales decreased aer brands across portfolio categories continuing grew cer million digestive health brands growth ecommerce overall sales benefited strong highsingle digits particularly strong growth growth across categories excluding respiratory health tums eno skin health smokers health brands negatively impacted q historically low cold midsingle digits offset partly decrease small flu season decrease cold flu sales resulted nonstrategic brands approximately drag full year growth international sales excluding brands divestedunder review grew high single digit cer basis double digit growth emerging markets including india china middle east africa excluding brands divestedunder review us sales grew low single digits european sales stable cer basis regions particularly negatively impacted historically low cold flu season q group financial review continued financial performance continued cost sales research development growth growth growth growth cer cer total cost sales total research development adjusted cost sales adjusted research development total cost sales percentage turnover total rd expenditure million turnover percentage points lower aer percentage points aer cer including increase impairments lower cer terms compared primarily partly offset decrease major restructuring charges reflected lower writedowns number manufacturing sites adjusted rd expenditure million unwind fair market value uplift turnover higher aer higher cer inventory arising completion consumer healthcare pharmaceuticals rd expenditure million joint venture pfizer turnover stable aer cer primarily driven excluding adjusting items adjusted cost increased investment specialty portfolios including sales percentage turnover percentage early stage research projects efficiency savings continued points higher aer percentage points higher cer implementation one rd programme compared primarily reflected higher pandemic pharmaceuticals vaccines part separation sales xevudy well higher supply chain costs vaccines preparation restructuring programme resulting lower demand higher inventory adjustments growth specialty portfolio primarily higher commodity freight costs consumer driven two programmes covid treatment xevudy healthcare partly offset price benefits pharmaceuticals otilimab along otilimab programme including benefit prior period rar adjustments rheumatoid arthritis bepirovirsen hbv antisense contribution restructuring savings across three oligonucleotide depemokimab antiil asthma businesses favourable mix vaccines partly offset reduced spend daprodustat due selling general administration completion programmes oncology continued investment reflecting commitment synthetic lethality growth growth cer blenrep together bintrafusp alfa total selling general accelerated closeout costs programme administration largely offset reduction spend feladilimab adjusted selling general following decision terminate programme april administration rd expenditure vaccines million total sga costs percentage turnover turnover aer cer reflecting increased percentage points lower aer percentage points investment clinical programmes meningitis rsv lower cer compared included increased investment mrna platform partly offset efficiency separation costs partly offset lower restructuring charges savings implementation one development excluding adjusting items adjusted sga costs programme variable spending result covid percentage turnover percentage points lockdowns rd expenditure consumer healthcare lower aer percentage points lower million cer basis adjusted sga costs decreased aer cer reflected tight control ongoing costs royalty income reduced variable spending across three businesses royalty income million million result covid lockdowns continuing benefit aer cer primarily driven higher sales restructuring pharmaceuticals consumer healthcare gardasil support functions decrease also reflected favourable legal settlement compared increased legal costs well oneoff benefits pensions insurance partly offset oneoff benefit restructuring postretirement benefits partly offset increased investment behind launches hiv vaccines gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information financial performance continued operating incomeexpense contingent consideration cash payments made net operating expenses million shionogi companies reduce balance sheet liability million income primarily reflected accounting charges hence recorded income statement million million arising total contingent consideration cash payments remeasurement contingent consideration liabilities amounted million million included related acquisitions former shionogiviiv cash payments made shionogi million healthcare joint venture former novartis vaccines million business liabilities pfizer put option pfizer shionogi preferential dividends viiv healthcare adjusted operating profit business included remeasurement charge million pharmaceuticals operating profit million million contingent consideration liability due aer cer turnover increase cer shionogi result unwinding discount operating margin percentage points higher million charge million primarily aer percentage points higher cer adjustments sales forecasts settlement gilead basis primarily reflected price benefits pharmaceuticals see partly offset number asset including benefit prior period rar adjustment disposals including disposal royalty rights reduced supply chain costs tight control ongoing costs cabozantinib disposal cephalosporin business short term benefits changes ways working favourable disposal number consumer healthcare brands fair legal settlement compared increased legal costs value uplifts investments included net profit continuing benefit restructuring partly disposal horlicks consumer healthcare brands offset support launches hiv increased investment million partly offset related loss sale rd shares hindustan unilever million vaccines operating profit million aer operating profit cer turnover increase cer operating margin percentage points lower aer total operating profit million compared percentage points lower cer basis million primarily reflected unfavourable primarily driven higher supply chain costs resulting comparison net profit disposal q horlicks higher inventory adjustments lower demand along consumer brands resultant sale shares higher rd spend support key strategic priorities hindustan unilever partly offset lower major increased sga investment support business growth partly restructuring costs lower remeasurement charges offset higher royalty income pandemic adjuvant contingent consideration liabilities unwind beneficial mix fair market value uplift inventory arising completion consumer healthcare joint venture pfizer consumer healthcare operating profit million aer cer stable turnover cer operating excluding adjusting items adjusted operating margin percentage points higher aer profit million lower aer percentage points higher cer basis higher cer turnover increase cer adjusted primarily reflected sales growth continuing brands price operating margin percentage points lower increases favourable mix synergy delivery pfizer aer percentage points higher cer basis joint venture integration tight cost control partially offset impact divestments percentage points increased increase adjusted operating profit primarily reflected advertising promotion investment increased commodity benefit incremental pandemic sales xevudy adjuvant freight costs investment manufacturing sites contributing approximately aer cer adjusted operating profit growth adjusted operating profit also benefited sales growth pharmaceuticals including benefit prior period rar adjustments tight control ongoing costs including reduced promotional variable spending across three businesses result covid lockdowns favourable legal settlements compared increased legal costs benefits continued restructuring across business partly offset lower sales vaccines primarily shingrix higher supply chain costs vaccines consumer healthcare divestments consumer healthcare increased investment rd across vaccines pharmaceuticalsgroup financial review continued financial performance continued net finance costs charge million represented effective tax rate total results reflected different finance income tax effects various adjusting items including credit interest income million resulting revaluation deferred tax fair value movements assets following enactment increase headline rate uk corporation tax effective april reflected disposal horlicks consumer brands finance expense subsequent disposal shares received hindustan unilever interest expense tax adjusted profit amounted million unwinding discounts provisions represented effective adjusted tax rate remeasurements fair value movements finance expense lease liabilities issues related taxation described note taxation finance expense annual report group continues believe made adequate provision liabilities likely arise total net finance costs million compared periods open yet agreed tax authorities million adjusted net finance costs ultimate liability matters may vary amounts million compared million provided dependent upon outcome agreements decrease primarily result reduced interest expense relevant tax authorities lower debt levels favourable movements foreign exchange rates premium paid early repayment noncontrolling interests refinancing bond debt reduced interest tax allocation total earnings noncontrolling interests partly offset lower interest income overseas cash post amounted million million increase closing divestment horlicks consumer primarily due increased allocation consumer healthcare nutrition products india number healthcare joint venture profits million countries million increased allocation viiv healthcare profits million million including reduced share tax profits associates joint credits remeasurement contingent consideration liabilities ventures allocation adjusted earnings noncontrolling interests share tax profits associates joint ventures amounted million million million million reduction allocation primarily reflected reduced allocation viiv healthcare profits million million loss disposal interests associates partly offset higher net profits groups net loss disposal interests associates entities noncontrolling interests allocation consumer million primarily driven loss disposal healthcare joint venture profits million interest associate innoviva inc million profit tax earnings per share taking account net finance costs share profits total eps p compared p associates loss disposal interest associates profit primarily reflected unfavourable comparison net taxation million compared profit disposal q horlicks consumer million brands partly offset related loss sale shares hindustan unilever partly offset credit million taxation taxation resulting revaluation deferred tax assets following enactment increase headline rate uk corporation tax effective april lower major restructuring costs lower remeasurement charges uk current year charge contingent consideration liabilities rest world current year charge charge respect prior periods adjusted eps p compared p total current taxation aer cer cer increase total deferred taxation adjusted operating profit primarily reflecting incremental taxation total profits pandemic sales sales increases pharmaceuticals tight cost control favourable legal settlements lower interest costs partly offset lower sales vaccines primarily shingrix higher supply chain costs vaccines increased rd investment higher effective tax rate contribution growth covid solutions approximately aer cer gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information financial performance continued dividends reflecting factors new gsk expect sales board declared four interim dividends resulting total grow cer adjusted operating profit dividend year pence line dividend declared grow cer compared see note financial statements dividends includes future benefit royalty income settlement license agreement gilead sciences inc gilead dividend policy announced february june new gsk investor update gsk set june gsk announced expected new gsk progressive dividend policy implemented deliver sales growth adjusted operating profit growth dividend policy total expected cash distribution respectively cagr constant respective dividend payout ratios new gsk new exchange rates five year period consumer healthcare remain unchanged base year financial outlooks exclude contribution covid related revenues new gsk gsk expects declare p per share dividend payable expects improve adjusted operating margin mids current group first half comprises pence per share cash generated new gsk pence per share representing consumer operations expected exceed billion healthcare first half whilst part group new gsk aims deliver sales billion second half new gsk continues expect declare constant exchange rates p per share dividend previously communicated new gsk would expect declare dividend pence per share medium term outlooks provided consumer healthcare capital markets day scheduled february time formal criteria treating consumer healthcare following separation dividend policy new consumer discontinued operation satisfied currently healthcare company responsibility board expected q gsk continue present directors expected guided per cent consumer healthcare business within continuing operations payout ratio basis expect secondhalf consolidate business reporting purposes dividend new consumer healthcare company equivalent demerger completed payout around pence per share subject boards decisions intrayear phasing dividend payments based known binding agreements governments expected distribution per share second half year expect covid solutions contribute similar sales adjusted highlighted gsk investor update level substantially reduced profit contribution due june reflect total number shares circa increased proportion lower margin xevudy sales billion shares new consumer healthcare company expect reduce new gsk adjusted operating profit growth expected issue upon demerger june including covid solutions years planning assumption investor update reflected continue discuss opportunities gsk shares issue time circa billion shares governments aggregate would represent full year basis equivalent group dividend around p per share dividends payable consumer healthcare receivable shareholders remain invested consumer healthcare postseparation appropriate record dates guidance outlook expect continue deliver strategic priorities plan increase targeted investment rd build invest behind top line momentum key growth drivers deliver demerger consumer healthcare business midyear assuming global economies healthcare systems approach normality year progresses expect sales specialty medicines grow approximately cer sales general medicines show slight decrease primarily reflecting increased genericisation established respiratory products vaccines sales expected grow low teens percentage cer year whole however governments prioritisation covid vaccination programmes ongoing measures contain pandemic expected result continued disruption adult immunisations impact weighted first half shingrix despite potential shortterm pandemic disruption continue expect strong doubledigit growth record annual sales based strong demand existing markets geographical expansiongroup financial review continued adjusting items divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal separation adjusted results amortisation impairment restructuring related items costs results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs loss disposal interest associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal separation adjusted results amortisation impairment restructuring related items costs results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information adjusting items continued major restructuring integration total cash payments made million within pharmaceuticals sector highly regulated million million million relating manufacturing operations supply chains long life separation preparation restructuring programme cycle business mean restructuring programmes million million relating consumer particularly involve rationalisation closure healthcare joint venture integration programme million manufacturing rd sites likely take several years million major restructuring complete programme including settlement certain charges accrued previous quarters million million major restructuring costs related specific existing combined restructuring integration programme boardapproved major restructuring programmes excluded adjusted results major restructuring analysis major restructuring charges business programmes including integration costs following material follows acquisitions structural significant scale costs individual related projects exceed million ordinary course smallerscale restructuring pharmaceuticals costs retained within total adjusted results vaccines consumer healthcare total major restructuring charges incurred million million analysed follows corporate central functions total major restructuring charges non non cash cash total cash cash total analysis major restructuring charges income major statement line follows restructuring programme incl tesaro cost sales consumer selling general administration healthcare joint venture integration research development programme operating incomeexpense separation total major restructuring charges preparation restructuring benefit year restructuring programmes programme billion benefit separation preparation combined restructuring programme billion benefit restructuring consumer healthcare joint venture integration billion integration benefit restructuring programme programme billion major restructuring programme including tesaro cash charges million separation preparation cost billion end cash costs programme primarily arose restructuring billion noncash costs billion administrative central manufacturing functions well delivered annual savings around billion end commercial pharmaceuticals rd functions noncash rates savings fully reinvested charges million primarily reflected writedown assets help fund targeted increases rd commercial support administrative locations rd sites new products programme substantially complete cash charges million consumer healthcare therefore gsk cease external reporting total costs joint venture programme primarily related severance benefits major restructuring programme integration costs noncash credit combined onwards restructuring integration programme primarily reflected completion consumer healthcare joint venture write back disposal site pfizer realised substantial cost synergies largely delivered expected total annual cost savings billion cash costs expected billion noncash charges expected billion plus additional capital expenditure billion cost savings intended reinvested business support innovation growth opportunitiesgroup financial review continued adjusting items continued group initiated q twoyear separation million charge relating contingent preparation programme prepare separation gsk consideration former shionogiviiv healthcare joint two companies new gsk biopharma company venture represented increase valuation rd approach focused science related immune contingent consideration due shionogi result system use genetics new technologies new unwind discount million charge leader consumer healthcare programme aims million primarily adjustments sales forecasts settlement gilead well updated exchange rate drive common approach rd improved capital assumptions million charge relating viiv allocation healthcare put option pfizer preferential dividends align improve capabilities efficiency global represented increase valuation put option support functions support new gsk result settlement gilead offset lower cash optimise supply chain product portfolio updated exchange rate assumptions including divestment noncore assets viiv healthcare contingent consideration liability fair strategic review prescription dermatology underway valued ifrs potential impact covid prepare consumer healthcare operate standalone pandemic remains uncertain december company assumed significant impact longterm value liability position remains programme continues target delivery billion review amount liability updated future annual savings billion total quarters information impact pandemic costs estimated billion billion expected becomes available explanation accounting cash costs proceeds divestments largely noncontrolling interests viiv healthcare set covered cash costs programme transactionrelated adjustments divestments significant legal charges items transactionrelated adjustments resulted net charge divestments items also included gains number million million included net asset disposals including disposal royalty rights million accounting charge remeasurement cabozantinib disposal cephalosporins business contingent consideration liabilities related acquisitions disposal number consumer healthcare brands fair value former shionogiviiv healthcare joint venture former gains investments certain adjusting items novartis vaccines business liabilities pfizer put including impact enactment increase option pfizer shionogi preferential dividends viiv headline rate uk corporate tax discussed healthcare consumer healthcare brands disposal programme chargecredit complete delivered net proceeds billion contingent consideration former shionogiviiv net loss disposal interests associates healthcare joint venture including shionogi million primarily driven loss disposal interest preferential dividends associate innoviva inc charge million viiv healthcare put options pfizer preferential million recorded significant legal matters arising dividends period significant legal cash payments million contingent consideration former novartis million included within divestments significant vaccines business legal items deferred tax credit million release fair value uplift acquired pfizer inventory arising transfer intellectual property within group adjustments quarter deferred tax credit arises due total transactionrelated charges differences group value market value assets transferred separation costs q group started report additional costs prepare establishment consumer healthcare business independent entity separation costs total separation costs incurred million million includes million relating transaction costs including preparatory admission costs costs relating achieve listing total separation costs estimated million excluding transaction costs gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information cash generation conversion summary consolidated cash flow statement set reconciliation net cash inflow operating activities free cash flow reconciliation net cash inflow operating activities closest equivalent ifrs measure free cash flow net cash inflow operating activities shown net cash inflowoutflow investing activities net cash outflow financing activities increase cash bank overdrafts net cash inflow operating activities cash bank overdrafts beginning year purchase property plant equipment increase cash bank overdrafts purchase intangible assets exchange adjustments proceeds sale property plant equipment cash bank overdrafts end year proceeds disposal intangible assets interest paid cash bank overdrafts end year comprise interest received cash cash equivalents dividends associates joint ventures overdrafts contingent consideration paid reported investing activities contribution noncontrolling interests capital expenditure financial investment distributions noncontrolling interests cash payments tangible intangible fixed assets free cash flow amounted million million disposals realised million million future cash flow cash payments acquire equity investments amounted long term expect future cash generated million million primarily relating operations sufficient fund operating debt vir biotechnology sales equity investments realised servicing costs normal levels capital expenditure obligations million million existing licensing agreements expenditure arising restructuring programmes routine outflows including free cash flow tax pension contributions dividends subject free cash flow amount cash generated group principal risks uncertainties discussed pages meeting obligations contingent consideration may time time additional demands interest tax dividends paid noncontrolling interests finance acquisitions including potentially acquiring capital expenditure property plant equipment increased ownership interests viiv healthcare business intangible assets minority shareholder hold put options access multiple sources liquidity short longterm capital markets financial institutions needs addition free cash inflow cash flow operations total cash payments shionogi relation viiv healthcare contingent consideration liability year investment appraisal capital allocation million million million strong framework capital allocation including recognised cash flows operating activities board govern allocation capital million recognised contingent consideration paid businesses utilise consistent cash return invested within investing cash flows payments deductible capital croic methodology prioritise investment across tax purposes group whole effectively compare returns businesses allocate capital also consider impact eps credit profile relevantgroup financial review continued financial position resources property plant equipment business sciencebased technologyintensive highly assets regulated governmental authorities allocate significant noncurrent assets financial resources renewal maintenance property plant equipment property plant equipment minimise risks interruption right use assets production ensure compliance regulatory standards goodwill number processes use hazardous materials intangible assets total cost property plant equipment investments associates joint ventures december million net book value investments million land buildings represented deferred tax assets million plant equipment million assets derivative financial instruments construction million invested million noncurrent assets new property plant equipment mainly related total noncurrent assets large number projects renewal improvement current assets expansion facilities various worldwide sites support new inventories product development launches well improve efficiency existing supply chains property mainly held current tax recoverable freehold new investment financed liquid resources trade receivables december contractual commitments derivative financial instruments future capital expenditure million believe liquid investments property plant facilities adequate current needs cash cash equivalents assets held sale observe stringent procedures use specialist skills total current assets manage environmental risks activities environmental total assets issues sometimes dating operations modified discontinued reported environment pages liabilities note financial statements legal current liabilities proceedings shortterm borrowings contingent consideration liabilities right use assets trade payables right use assets amounted million december derivative financial instruments compared million january current tax payable decrease year reflected impact depreciation shortterm provisions disposals million million respectively partly total current liabilities offset additions million noncurrent liabilities goodwill longterm borrowings corporation tax payable goodwill decreased million december million deferred tax liabilities pensions postemployment benefits intangible assets provisions derivative financial instruments intangible assets include cost intangibles acquired third parties computer software net book value contingent consideration liabilities intangible assets december noncurrent liabilities million million increase primarily total noncurrent liabilities reflected additions net disposals write offs total liabilities million offset amortisation impairment losses net net assets reversals year million total equity gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued investments associates joint ventures provisions held investments associates joint ventures carried deferred tax provisions shortterm carrying value december million noncurrent provisions million december million group sold million provisions yearend shares innoviva inc back innoviva following included million million related legal divestment group held investments associates disputes million million related joint ventures listed entities see note major restructuring programmes provision made financial statements investments associates legal disputes indemnified disposal liabilities joint ventures employee related liabilities costs restructuring programme extent balance sheet date legal investments constructive obligation existed could reliably held investments carrying value estimated december million million highest value investments held december pensions postemployment benefits curevac ag book value december account pension postemployment million million vir biotechnology arrangements accordance ias net deficits book value million million million million pension arrangements investments included equity stakes companies million million unfunded research collaborations provide postemployment liabilities see note financial access biotechnology developments potential interest statements pensions postemployment benefits interests companies arise business divestments noncurrent liabilities derivative financial instruments assets noncurrent liabilities amounted million held current derivative financial assets fair value december million million million noncurrent derivative financial assets held fair value million contingent consideration liabilities million majority financial instruments related contingent consideration amounted million foreign exchange contracts designated december million designated accounting hedges million million represented estimated present value amounts payable shionogi relating inventories viiv healthcare million million inventory million decreased million represented estimated present value contingent consideration payable novartis related vaccines acquisition trade receivables liability due shionogi included million respect trade receivables million increased preferential dividends liability preferential dividends million due pfizer december nil million explanation accounting non deferred tax assets controlling interests viiv healthcare set deferred tax assets amounted million total contingent consideration payable posttax million december basis december million million expected paid within one year consideration derivative financial instruments liabilities payable expected paid number years held current noncurrent derivative financial liabilities result total estimated liabilities discounted fair value million million primarily present values posttax basis using posttax discount rates related foreign exchange contracts designated designated accounting hedges impact settlement gilead contingent consideration liability ccl increase million trade payables posttax basis q due obligation viiv healthcare pay future cash consideration shionogi december trade payables share upfront future us sales performance million compared million biktarvy products containing bictegravir including december increase primarily reflected impact impact settlement december liability higher customer return rebate accruals higher discounted stood million accruals relating collaborations see note posttax basis financial statements trade payables shionogiviiv healthcare contingent consideration liability discounted novartis vaccines contingent consideration liability discounted partly partly group financial review continued financial position resources continued maturity profile bond debt equivalent gbp bonds eur bonds usd bonds net debt cash liquid investments billion billion held centrally december analysis cash gross debt effects hedging cash cash equivalents liquid investments follows borrowings repayable within one year borrowings repayable one year net debt cash liquid investments gross debt fixed december net debt billion compared floating billion december comprising gross debt noninterest bearing billion cash liquid divestments billion net debt net debt reduced due billion free cash flow billion proceeds investments including billion movements net debt proceeds innoviva disposal billion net favourable exchange impacts translation nonsterling denominated debt exchange financing items partly offset dividends paid shareholders billion net debt beginning year additional investments billion decreaseincrease cash bank overdrafts decreaseincrease liquid investments december gsk shortterm borrowings increase longterm loans including overdrafts lease liabilities repayable within net repayment shortterm loans months billion billion repayable repayment lease liabilities subsequent year exchange movements december gsks cash liquid investments movements held follows net debt end year bank balances deposits us treasury treasury repo money market funds liquidity funds cash cash equivalents liquid investments government securities gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information financial position resources continued interest rate benchmark reform total equity interest rate benchmark reform amendments ifrs ias december total equity increased ifrs ifrs ifrs phase phase ii million december million issued iasb september august summary movements equity set adopted uk endorsement board january phase amendment modifies specific hedge accounting requirements allow hedge accounting continue affected total equity beginning year hedges period uncertainty hedged total comprehensive income year items hedging instruments affected current interest dividends shareholders rate benchmarks amended result ongoing ordinary shares issued interest rate benchmark reforms phase ii also provides changes noncontrolling interests financial instruments measured using amortised cost transaction noncontrolling interest measurement changes basis determining sharebased incentive plans contractual cash flows required interest rate benchmark tax sharebased incentive plans reform reflected adjusting effective interest contributions noncontrolling interests rate immediate gain loss recognised distributions noncontrolling interests group closely monitored market output total equity end year various industry working groups managing transition new benchmark interest rates includes share purchases announcements made libor regulators including december gsk held million shares financial conduct authority fca us commodity treasury shares million shares cost futures trading commission regarding transition away million million libor including gbp libor usd libor deducted retained earnings euribor sterling overnight index average rate ordinary shares repurchased period january sonia secured overnight financing rate sofr february company expect euro shortterm rate str respectively make ordinary share repurchases remainder december group directly exposed interest rate benchmark reform held interest rate treasury shares transferred employee derivatives floating rate debt referenced libor share ownership plan esop trusts shares held group transition material derivatives floating rate trusts satisfy future exercises options awards debt new index instruments referencing group share option award schemes libor matured december proportion shares held trusts respect awards rules scheme require gsk satisfy exercises market purchases rather issue new shares shares held trusts matched options awards granted december esop trusts held million million gsk shares future exercise share options share awards carrying value million million deducted reserves market value shares million million february million shares transferred esop trusts trusts held million shares exercise share options share rewardsgroup financial review continued financial position resources continued contractual obligations commitments reached agreement trustees financial commitments summarised note uk pension schemes make additional contributions financial statements commitments assist eliminating pension deficit identified part december actuarial funding valuation table following table sets contractual obligations includes commitment excludes normal ongoing commitments december fall due annual funding requirement uk approximately payment million information pension obligations total yr yrs yrs yrs see note financial statements pensions postemployment benefits loans interest loans contingent liabilities lease obligations contingent liabilities set note financial future finance charges statements contingent liabilities intangible assets following table sets contingent liabilities comprising property plant equipment performance guarantees letters credit items arising investments normal course business expected purchase commitments expire pensions total total yr yrs yrs yrs commitments respect loans future interest payable guarantees loans disclosed taking account effect contingent liabilities derivatives total entered number research collaborations normal course business provided various develop new compounds pharmaceutical companies indemnification guarantees respect business disposals terms arrangements include upfront fees legal disputes subsequently arisen equity investments loans commitments fund specified provision made outflow resources considered levels research addition often agree make probable reliable estimate made likely payments future milestones achieved outcome dispute included note agreements relate compounds early financial statements provisions stages development potential obligation make provide outcome tax legal disputes milestone payments continue number years outflow resources considered probable compounds move successfully development reliable estimate outflow may made december process generally closer product marketing disputes provision approval greater probability success amounts made possible make reliable estimate shown within intangible assets represent maximum potential outflow funds might required settle would paid milestones achieved disputes possibility outflow decrease commitments result reduction remote outstanding loan commitments ultimate liability matters may vary significantly amounts provided dependent upon negotiations relevant tax authorities outcome litigation proceedings relevant discussed principal risks uncertainties pages note financial statements legal proceedings gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information treasury policies report sterling pay dividends sterling cash interest rate risk management flows role treasury monitor manage gsks objective minimise effective net interest cost groups external internal funding requirements financial balance mix debt fixed floating interest rates risks support strategic objectives gsk operates time policy interest rate risk management limits global basis primarily subsidiary companies net amount floating rate debt specific cap reviewed manage capital ensure subsidiaries able agreed less annually board operate going concerns optimise returns shareholders appropriate balance debt foreign exchange risk management equity treasury activities governed policies approved objective minimise exposure overseas operating annually board directors recently subsidiaries transaction risk matching local currency october treasury management group tmg income local currency costs possible foreign meeting chaired chief financial officer takes place currency transaction exposures arising external internal regular basis review treasury activities members trade flows selectively hedged gsks internal trading receive management information relating activities transactions matched centrally manage intercompany payment terms reduce foreign currency risk treasury operations possible manage cash surpluses borrowing objective gsks treasury activities minimise requirements subsidiary companies centrally using forward posttax net cost financial operations reduce volatility contracts hedge future repayments back originating order benefit earnings cash flows gsk uses variety currency financial instruments finance operations derivative order reduce foreign currency translation exposure financial instruments manage market risks seek denominate borrowings currencies operations derivatives principally comprise foreign exchange principal assets cash flows primarily forward contracts swaps used swap denominated us dollars euros sterling borrowings liquid assets currencies required group purposes well interest rate swaps used borrowings swapped currencies required manage exposure financial risks changes interest borrowings denominated swapped foreign rates currencies match investments overseas group assets may treated hedge relevant assets forward derivatives used exclusively hedging purposes relation contracts major currencies also used reduce exposure underlying business activities trading groups investment overseas group assets tmg speculative instruments reviews ratio borrowings assets major currencies regularly capital management gsks financial strategy implemented groups commodity risk management financial architecture supports gsks strategic priorities objective minimise income statement volatility arising regularly reviewed board manage capital fluctuations commodity prices practical cost structure group appropriate mix debt effective tmg authorised approve equity continue manage financial policies credit execution certain financial derivatives hedge commodity profile particularly targets shortterm credit ratings price exposures p maintaining single longterm ratings consistent targets counterparty risk management gsks longterm credit rating standard poors set global counterparty limits banking stable outlook moodys investor services moodys investment counterparties based longterm credit ratings stable outlook shortterm credit ratings moodys standard poors usage limits p standard poors moodys respectively actively monitored breach limits would reported cfo immediately liquidity risk management addition relationship banks credit ratings gsks policy borrow centrally order meet anticipated reviewed regularly changes ratings occur funding requirements cash flow forecasts funding changes made investment levels authority limits requirements monitored tmg regular basis appropriate banking counterparty limits reviewed strategy diversify liquidity sources using range facilities least annually maintain broad access financial markets day sweep cash number global subsidiaries central treasury accounts liquidity management purposesgroup financial review continued critical accounting policies group consolidated financial statements us medicaid programme stateadministered prepared accordance international accounting standards programme providing assistance certain poor conformity requirements companies act vulnerable patients medicaid drug rebate international financial reporting standards ifrs program established reduce state federal issued international accounting standard board iasb expenditure prescription drugs patient protection affordable care act became law required make estimates assumptions participate providing rebates states accruals affect amounts assets liabilities revenue expenses medicaid rebates calculated based specific reported financial statements actual amounts terms relevant regulations patient protection results could differ estimates affordable care act critical accounting policies relate following areas cash discounts offered customers encourage turnover prompt payment accrued time taxation note invoicing adjusted subsequently reflect actual experience legal disputes notes record accrual estimated sales returns applying contingent liabilities note historical experience customer returns amounts pensions postemployment benefits note invoiced together marketrelated information information judgements estimates made stock levels wholesalers anticipated price increases areas given note financial statements critical competitor activity accounting judgements key sources estimation reconciliation gross turnover net turnover us uncertainty pharmaceuticals business follows turnover margin margin margin respect turnover accounting policy largest business us pharmaceuticals us market gross turnover complex arrangements rebates discounts marketdriven allowances following briefly describes nature segments arrangements existence us pharmaceuticals business government mandated arrangements certain indirect customers state programmes whereby customer able buy products cash discounts wholesalers reduced prices chargeback represents customer returns difference invoice price wholesaler prior year adjustments indirect customers contractual discounted price items accruals estimating chargebacks calculated based total deductions terms agreement historical experience net turnover product growth rates customer rebates offered key managed care marketdriven segments consist primarily managed care group purchasing organisations direct indirect medicare plans negotiate contract pricing customers arrangements require customer honoured via rebates chargebacks mandated segments achieve certain performance targets relating value consist primarily medicaid federal government product purchased formulary status predetermined market programmes receive governmentmandated pricing via shares relative competitors accrual customer rebates chargebacks rebates estimated based specific terms agreement historical experience product growth rates gsk annual report group financial review continued gsk annual report strategic report governance remuneration financial statements investor information critical accounting policies continued decreased deductions government mandated may become involved significant legal proceedings state programmes gross turnover net turnover respect possible meaningfully assess reconciliation primarily reflected lower rebates chargebacks whether outcome result probable outflow respiratory products advair particular quantify reliably estimate liability could result ultimate resolution proceedings cases year advair accounted us appropriate disclosure cases would included pharmaceuticals turnover approximately annual report provision would made total deduction rebates returns position could change time therefore respiratory portfolio whole including established assurance losses result outcome respiratory products accounted approximately legal proceedings exceed material amount total deduction year amount provisions reported groups financial balance sheet accruals rebates discounts allowances statements returns us pharmaceuticals vaccines like many pharmaceutical companies faced businesses managed combined basis december various complex product liability antitrust patent litigation total accrual amounted million well investigations operations conducted various million governmental regulatory agencies throughout year monthly process operated monitor inventory levels general counsel group head groups legal wholesalers abnormal movements process uses function senior vice president head global gross sales volumes prescription volumes based third party litigation group responsible litigation data sources information received key wholesalers government investigations routinely brief chief executive aim maintain inventories consistent level officer chief financial officer board directors year year based pattern consumption significant litigation pending group basis us pharmaceuticals vaccines inventory governmental investigations group levels wholesalers distribution channels meetings appropriate detail status significant december estimated amount litigation government investigations review matters approximately four weeks turnover calculation uses number claims notified us information third party information accuracy totally potential claims yet notified assessment validity verified believed sufficiently reliable claims progress made settling claims recent settlement purpose levels potential reimbursement insurers meetings also include assessment whether legal disputes sufficient information available us able make respect accounting policy legal disputes reliable estimate potential outcomes disputes following briefly describes process often external counsel assisting us various litigation determine level provision necessary matters investigations also assist briefing accordance requirements ias provisions board senior management following discussions contingent liabilities contingent assets provide matters possible make reliable estimate anticipated settlement costs outflow resources amount provision may required considered probable reliable estimate may made level provision legal disputes reviewed likely outcome dispute legal expenses adjusted appropriate matters discussed arising claims group note financial statements legal proceedings strategic report strategic report approved board directors february iain mackay chief financial officer february corporate governance section board gsk leadership team chairs governance statement board roles responsibilities board committee information board architecture board activity board progress boards approach continuous engagement boardled purpose culture board performance board committee reports section statement directors report ggsskk aannnnuuaall rreeppoorrtt gsk annual report strategic report governance remuneration financial statements investor information board board composition board diversity international experience composition gender executive male global nonexecutive female us europe tenure nonexecutive ethnicity emap years ethnically diverse years white years years see information sir jonathan symonds cbe skills experience nonexecutive chair jon extensive international financial life sciences governance experience jon served independent nonexecutive director hsbc holdings plc april deputy age group chairman august retirement board february previously nationality british chairman hsbc bank plc chief financial officer novartis ag partner managing director goldman appointed september sachs chief financial officer astrazeneca plc partner kpmg governance experience includes roles nonexecutive director chair audit committees diageo plc qinetiq group plc n nonexecutive chair proteus digital health inc jon fellow institute chartered accountants england wales external appointments nonexecutive director rubius therapeutics inc nonexecutive director genomics england limited previously served chairman member european round table industry senior advisor chatham house dame emma walmsley skills experience chief executive officer prior appointment gsks ceo emma ceo gsk consumer healthcare joint venture gsk novartis creation march emma joined gsk loreal age worked years variety roles paris london new york shanghai emma previously nationality british nonexecutive director diageo plc appointed january emma holds classics modern languages oxford university chief executive officer external appointments april independent director microsoft inc iain mackay skills experience chief financial officer prior joining gsk iain group finance director hsbc holdings plc position held eight years chartered accountant iain lived worked asia us europe hsbc general age electric schlumberger dowell price waterhouse iain previously trustee british heart nationality british foundation chair audit risk committee appointed january iain holds business studies accounting holds honorary doctorate aberdeen university chief financial officer scotland april iain member institute chartered accountants scotland external appointments member court university aberdeen chair remuneration committee member group chair stakeholder communications reporting committee dr hal barron skills experience chief scientific officer prior joining gsk hal president rd calico llc california life company alphabetfunded company uses advanced technologies increase understanding lifespan biology prior hal president rd executive vice president head global product development chief medical officer roche responsible age products combined portfolio roche genentech genentech senior vice nationality american president development chief medical officer hal nonexecutive director chair science appointed january technology committee juno therapeutics inc march acquired celgene chief scientific officer corporation hal previously served nonexecutive board director grail inc advisory board president rd april member verily life sciences llc announced january tony wood succeed hal cso head rd effect august date hal transition nonindependent nonexecutive director additional responsibilities support rd external appointments nonexecutive director altos labs inc associate adjunct professor epidemiology biostatistics university california san francisco key committee chair n nominations corporate governance audit risk r remuneration science c corporate responsibilitythe board continued charles bancroft skills experience independent nonexecutive charlie wealth financial management experience global biopharma director charlie retired successful career bristol myers squibb bms march held number leadership roles commercial strategy finance beginning career bms held positions age increasing responsibility within finance organisation commercial operational responsibility latin nationality american america middle east africa canada japan several pacific rim countries appointed chief appointed may financial officer chief financial officer executive vice president global business operations executive vice president head integration strategy business development n charlie successfully steered bms period strategic transformation including recent billion acquisition celgene charlie also served member board colgatepalmolive company march external appointments board member kodiaksciences inc board member biovector inc advisory board member drexel universitys lebow college business board determined charlie recent relevant financial experience agreed appropriate qualifications background audit committee financial expert manvinder singh vindi banga skills experience senior independent nonexecutive vindi many years commercial experience track record delivering outstanding performance highly competitive global consumerfocused businesses director prior joining gsk vindi spent years unilever plc last role amongst several senior positions age president global foods home personal care businesses member unilever nationality british executive board vindi sat prime minister indias council trade industry appointed september board governors indian institute management iim ahmedabad vindi also senior independent nonexecutive recipient padma bhushan one indias highest civilian honours vindi nonexecutive director director may confederation british industry cbi thomson reuters corp chairman supervisory board mauser group chairman kalle gmbh director high ridge brands llc member indo uk ceo n r forum senior independent director marks spencer group plc external appointments partner clayton dubilier rice nonexecutive director economist newspaper limited member holdingham international advisory board board member international chamber commerce united kingdom member governing board indian school business hyderabad member global leadership council sad business school oxford chair board trustees marie curie chairman uk government investments dr anne beal skills experience independent nonexecutive anne brings extensive healthcare experience board physician entrepreneur combined passion patient advocacy recognised health policy expert development global national director programmes improving healthcare access patient groups ensuring voice patients age reflected research programmes nationality american prior current roles anne spent six years harvard medical school massachusetts general hospital appointed may instructor paediatrics also held leadership roles commonwealth fund aetna foundation anne previously deputy executive director chief engagement officer c patientcentered outcomes research institute us chief patient officer global head patient solutions sanofi external appointments founder ceo absolutejoi skincare board member academyhealth board member prolacta bioscience dame vivienne cox skills experience independent nonexecutive vivienne wide experience business gained energy natural resources publishing sectors also deep understanding regulatory organisations government director workforce vivienne worked bp plc years britain continental europe posts including executive vice engagement director president chief executive bps gas power renewable business alternative energy unit age vivienne previously nonexecutive director bg group plc rio tinto plc senior independent nationality british director pearson plc chairman supervisory board vallourec lead independent director appointed july uk governments department international development vivienne made dame commander order british empire dbe uk new years honours list services sustainability diversity inclusion business r c external appointments chair designate victrex plc nonexecutive director stena ab advisory board member african leadership institute vice president energy institute advisory board member montrose associates investment advisor qantx ventures chair rosalind franklin institute vice chair sad business school oxford member global leadership council patron hospice st francis key committee chair n nominations corporate governance audit risk r remuneration science c corporate responsibility gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board continued dr harry hal c dietz skills experience independent nonexecutive hal brings extensive experience field human genetics central gsks approach rd former president american society human genetics recognised worlds leading director scientific authority genetic disorder known marfan syndrome also brings experience development novel medical expert therapies role founder scientific adviser blade therapeutics biopharmaceutical age company focused diseasemodifying treatments fibrotic neurodegenerative diseases total hal authored original publications peerreviewed journals across career nationality american appointed january physician scientist dedicated entire career care study individuals heritable connective tissue disorders primary perturbations extracellular matrix homeostasis function lab identified genes many conditions uses model systems elucidate disease mechanisms hal received multiple prestigious awards including curt stern award american society human genetics colonel harland sanders lifetime achievement award medical genetics taubman prize excellence translational medical science harrington prize american society clinical investigation harrington discovery institute pasarow award cardiovascular research inbevbaillet latour health prize country belgium research achievement award american heart association inductee american society clinical investigation american association advancement science association american physicians national academy medicine national academy sciences external appointments victor mckusick professor paediatrics medicine molecular biology genetics department genetic medicine johns hopkins university school medicine investigator howard hughes medical institute founder scientific advisor blade therapeutics consultant chair scientific advisory board aytu biopharma independent chair gsks human genetics scientific advisory board lynn elsenhans skills experience independent nonexecutive lynn wealth experience running global business significant knowledge global markets gsk operates director lynn served chair president chief executive officer sunoco inc prior joining age sunoco president chief executive officer lynn worked royal dutch shell joined nationality american held number senior roles including executive vice president global appointed july manufacturing lynn previously nonexecutive director first tee greater houston flowserve corporation texas medical center trustee united way greater c n houston external appointments nonexecutive director chair governance corporate responsibility committee baker hughes company board director chair audit committee saudi aramco advisory board member johns hopkins university whiting school engineering member audit committee leadership network dr laurie glimcher skills experience independent nonexecutive laurie brings scientific public health expertise boards deliberations wealth global publicly listed pharmaceutical business experience director scientific medical expert addition number senior leadership positions held harvard medical school harvard school public health laurie also served stephen suzanne weiss dean professor medicine age weill cornell medical college attending physician new york presbyterian hospitalweill nationality american cornell medical center laurie stepped board bristolmyers squibb bms appointed september serving years board laurie previously nonexecutive director waters corporation cofounder chair scientific advisory board quentis therapeutics inc external appointments professor medicine harvard medical school ceo president attending physician danafarber cancer institute member us national academy sciences national academy medicine member scientific steering committee parker institute cancer immunotherapy independent director analog devices inc director member executive committee breakthrough cancer member scientific advisory boards repare therapeutics inc abpro therapeutics kaleido biosciences inc biocentury inc stand cancer judy lewent joined board april retired board may key committee chair n nominations corporate governance audit risk r remuneration science c corporate responsibilitythe board continued dr jesse goodman skills experience independent nonexecutive jesse brings scientific public health expertise boards deliberations wealth experience spanning science medicine vaccines regulation public health proven record addressing pressing director scientific public health needs academic federal sectors medical expert jesse previously served senior leadership positions us food drug administration fda including age recently fdas chief scientist previously deputy commissioner science public health nationality american director center biologics evaluation research cber appointed january jesse played leadership role developing fdas regulatory science medical countermeasures initiatives worked collaboratively industry academia government global public health regulatory c partners prepare respond major public health threats including emerging infectious diseases disasters terrorism led fdas response west nile virus hn influenza pandemic served senior leadership team white house medical countermeasure review jesse previously member scientific advisory committee regulatory legal working group coalition epidemic preparedness innovations cepi external appointments professor medicine attending physician infectious diseases georgetown university directs georgetown university center medical product access safety stewardship compass board member formerly president united states pharmacopeia usp board member scientific counselors infectious diseases centers disease control prevention cdc board member intellia therapeutics inc member us national academy medicine board member adaptive phage therapeutics inc urs rohner skills experience independent nonexecutive urs broad business banking legal background extensive senior level experience multinational companies director urs served chairman number boards recently credit suisse group age april prior joining credit suisse urs served chairman executive board ceo nationality swiss prosieben prosiebensat media ag followed number years private practice major law appointed january firms switzerland us admitted bars canton zurich switzerland state new york us r n external appointments member international advisory board investcorp chair vega cyber associates ag key committee chair n nominations corporate governance audit risk r remuneration science c corporate responsibility gsk annual report gsk annual report strategic report governance remuneration financial statements investor information gsk leadership team skills experience dr hal barron hal joined gsk gsk leadership team glt see board biographies pages chief scientific officer president rd roger connor roger joined glt appointed president gsk vaccines addition president vaccines global health leadership vaccines business leads gsks global health organisation since also responsible gsks global procurement organisation roger member board gavi vaccine alliance chair international federation pharmaceutical manufacturers associations ifpma ceo vaccines committee previously president global manufacturing supply vice president office ceo corporate strategy roger joined gsk astrazeneca roger holds degree mechanical manufacturing engineering queens university belfast masters manufacturing leadership cambridge university chartered accountant diana conrad diana appointed chief people officer member glt april chief people officer previously senior vice president hr pharmaceuticals rd played key strategic role leader rd people culture agenda support transformation diana joined gsk canadas hr team held several roles increasing responsibility becoming senior vice president hr consumer healthcare prior joining gsk held hr roles companies including ge capital gennum corporation zenon environmental laboratories diana honours bachelor arts mcmaster university canada james ford james joined glt appointed senior vice president group general svp group general counsel counsel legal compliance joined gsk served general counsel consumer healthcare general counsel global pharmaceuticals vice president corporate legal compliance legal acting head global ethics compliance prior gsk james solicitor clifford chance dla holds law degree university east anglia diploma competition law king 's college qualified solicitor england wales attorney new york state bar james based london practised law lived us singapore hong kong james cochair usbased civil justice reform group director european general counsel association sally jackson sally joined glt march senior vice president global communications ceo svp global communications office leads communications government affairs function globally also ceos chief staff prior sally senior vice president office ceo cfo ceo office previously served head investor relations joined gsk sally holds degree natural sciences university cambridge iain mackay iain joined gsk glt see board biographies pages chief financial officer brian mcnamara brian ceo gsk consumer healthcare ceo designate new consumer healthcare ceo gsk consumer healthcare company haleon joined gsk head europe americas consumer healthcare led two successful joint ventures first gsk novartis recently pfizer previously head novartis otc division brian began career pg brian board member consumer goods forum former chairman board member global selfcare federation gscf earned undergraduate degree electrical engineering union college new york mba finance university cincinnati n august hal barron transition current role become nonexecutive director tony wood join glt chief scientific officergsk leadership team continued skills experience luke miels luke joined gsk glt chief commercial officer responsible chief commercial officer commercial portfolio medicines vaccines luke also cochairs portfolio investment board hal previously worked astrazeneca executive vice president european business prior executive vice president global product portfolio strategy global medical affairs corporate affairs head asia roche based shanghai singapore prior held roles increasing seniority roche sanofiaventis us europe asia luke holds bachelor science degree biology flinders university adelaide mba macquarie university sydney shobie ramakrishnan shobie joined glt appointed chief digital technology officer chief digital technology officer joined gsk deep broad experience biotech hitech companies recently led digital technology gsks global commercial organisation transforming companys capabilities digital data analytics playing pivotal role establishing agile commercial operating model joining gsk shobie held senior technology leadership roles organisations including astrazeneca salesforce genentech roche board member remediant advisory board pistoia alliance shobie holds bachelors degree electronics engineering vellore institute technology university madras india david redfern david joined glt chief strategy officer responsible corporate development chief strategy officer strategic planning previously senior vice president northern europe responsibility gsks pharmaceutical businesses region senior vice president central eastern europe joined gsk david appointed chairman board viiv healthcare limited nonexecutive director aspen pharmacare holdings limited board bachelor science degree bristol university chartered accountant regis simard regis joined glt became president pharmaceuticals supply chain president pharmaceuticals responsible manufacturing supply gsks pharmaceutical products also leads quality environment health safety sustainability corporate level regis joined supply chain gsk site director france rising become senior vice president global pharmaceuticals manufacturing current role previously held senior positions sony konica minolta tyco healthcare member board viiv healthcare mechanical engineer holds mba phil thomson phil joined glt appointed president global affairs president global affairs responsibility groups strategic approach stakeholder engagement reputation policy development previously phil senior vice president communications government affairs phil chair whitehall industry group board member chinabritain business council earned degree english history russian studies durham university emma walmsley emma joined gsk glt see board biographies pages chief executive officer deborah waterhouse deborah appointed glt january became chief executive officer viiv ceo viiv healthcare healthcare april deborah joined gsk prior viiv senior vice president primary care within gsks us business strong track record performance specialty primary care deborah led hiv business uk heading hiv centre excellence pharma europe held roles general manager australia new zealand senior vice president central eastern europe deborah nonexecutive director schroders plc holds degree economic history english literature liverpool university nick hirons member glt senior vice president global ethics compliance july karenann terrell member glt chief digital technology officer december gsk annual report gsk annual report strategic report governance remuneration financial statements investor information chairs governance statement board priorities governance delivery october vindi banga sid attended meeting last three years significant change members investor forum shared progress gsk highly dynamic operating environment preparing creation new gsk pure biopharma progresses towards formation two independent company separation ch business included companies middle supporting discussion plans timings create two boards separation consumer healthcare ch creation new continuing oversight biopharma ch businesses gsk three stages oversight work december annual governance meeting board first ensure clarity board colleagues pleased share specifics management gsks strategy execution therefore investors priorities focus oversight well key priorities focused articulating ambitions progress made presentation slides transformed gsk completed biopharma meetings available website information business investor update iu june urs rohner chair remuneration committee also ch business end february ambitions consulted extensively new compensation proposals provide foundation enhanced performance biopharma business statement seeks summarise management highly transparent way track progress governance work undertaken board committees final stage ensure companys another exceptionally busy year compensation system reinforces performance culture board maintained continues build esg seeking embed rewards delivery leadership benefits company shareholders beyond iu ambitions compensation system stakeholders ch determined new board current board accountability priorities focus work also focused creating best platform ch business demerged grow sustainably ahead start year following annual evaluation board categories years come mechanism reconfirmed priorities namely separation ch valuebased process times remain objective act best interests company board regard best longterm interests shareholders shareholders put sustained value creation heart agenda never important board operate align board agenda strategy performance highest standards corporate governance supporting pipeline priorities overseeing delivery gsks transformation separation ch board continues focus work ensure management performance succession key priorities taking important decisions necessary assessed delivery progress held accountable use iu targets provide foundation enhanced shareholders key stakeholders performance management throughout board significantly stepped ensure separation ch valuebased process engagement shareholders held meetings range investors make around nearly explicit boards priorities meant companys share register prime importance able maximise time focus meeting board clear understanding views strengthening fundamentals gsk companys performance strategy boards support value creation concentrated oversight effectiveness oversight transformation separation commercial execution cost base capital allocation pipeline processes share shareholders perspectives board culture ensure delivery transformation gsk continue improve alignment clarity also helped underpin increased agility way board operated see board combination chairs ' committee met times sought improve ability respond quickly adapt events occur whilst continuing deliver plans chairs committee comprised sid committee chairs authorised necessary engage take decisions urgent matters arise scheduled board meetings agile important improving sustaining competitiveness despite challenging environment continue compete deliver patients shareholderschair 's governance statement continued set strategy board challenged proposed completed work board wellpositioned new ambitions targets biopharma business consider unsolicited conditional nonbinding proposals agreed published iu new growth received acquire ch business exercising fiduciary outlooks ambitions seek clear step change duties proposals considered rejected board performance expected new gsk board best interests shareholders oversee hold management account delivery fundamentally undervalued business public ambitions future prospects board confident haleon deliver sustained organic annual sales growth range board adopted process maximising value cer medium term gsk shareholders considering creation ch independent listed company haleon focused carefully considered best present worldleading ensuring business wellpositioned grow sustainably ch business management team shareholders ahead categories years come highly analysts prospective investors ch capital markets skilled management team lead day february management continues make good progress towards target separate ch business middle year creating publicly listed worldleading consumer health company board 's attention directed overseeing smooth execution demerger current board accountability board transformation separation priorities focus mandate separate unlock maximise longterm shareholder value remain objective act best devolved committee architecture december interests company shareholders nominations corporate governance commitment drive sustained value mandate gsk board design transition haleon board creation management team formation board agenda aligned strategy performance pipeline priorities science management performance mandate pipeline progress board strategic collaborations key succession assessed delivery priorities science innovation investor update targets provides foundation enhanced performance corporate responsibility management mandate gsk trust priority responsible sustainable business separation consumer healthcare create haleon valuebased process audit risk continuous engagement mandate financial reporting risk controls plus public shareholders documents delivering separation remuneration mandate alignment gsk remuneration investor update targets haleon 's remuneration policy separation impact gsk annual report gsk annual report strategic report governance remuneration financial statements investor information chair 's governance statement continued board committee mandates committee recommended appointment sir dave board committees never pivotal lewis haleon chair designate december supporting board activities set extensive search process followed appointment later report would like highlight key brian mcnamara haleon ceo designate july sir dave contributions discharging mandates allocated responsible building full haleon board mr last year mcnamara pleased introduce management team investors ch capital markets day february transformation separation committee dealt fundamentals separation technical requirements science committee continued focus pipeline best release maximise longterm shareholder progress strategic collaborations key priorities value considered best separate ch science innovation business principal value achieved corporate responsibility committee focused oversight option capital structures required two companies key aspects trust priorities main areas focus competitive distribute shares haleon safety culture inclusion diversity charitable shareholders exchanges haleon list giving community involvement esg performance comprehensive programme work new gsk development esg framework supported independent advisers process independent ch company haleon well execution phase given remaining work remuneration committee revisited remuneration plans clear oversight devolved relevant policy focus reinforcing fundamental change committees appropriate fulfilled mandate performance culture support delivery iu committee decommissioned ambitions esg priorities biopharma company audit risk committee particular considering committee chair consulted extensively financial implications separation including shareholders policy subject binding progressive dividend policy adopted vote years agm preparation demerger documents shareholders details board committees work consider approving separation ch business set following pages also overseeing establishment chs financial controls look forward connecting annual general meeting year may updating time nominations corporate governance committee transformation gsk progress ch demerger overseeing key board appointments transition thank continued support company pure biopharma business included succession planning especially cso subsequent appointment dr tony wood cso designate sir jonathan symonds appointment dr anne beal dr hal dietz board chair independent nonexecutive directors february board asked committee take opportunity reevaluate determine optimal biopharma board composition including skills diversity capabilities experience separation middle year expected two members current gsk board join haleon board ensure new haleon board continuity history knowledge experiences board haleon board establishes early yearsboard roles responsibilities leadership independent oversight rigorous challenge chair nonexecutive directors jonathan symonds provide strong independent element board leads manages business board constructively support challenge management provides direction focus scrutinise performance meeting agreed ensures clear structure effective operation deliverables board committees shape proposals strategy offer specialist advice maintains dialogue shareholders management governance company letter appointment setting terms sets board agenda ensures sufficient time conditions directorship allocated promote effective debate support sound devote time necessary proper decision making performance duties ensures board receives accurate timely clear expected attend meetings required information independence statement meets continuously nonexecutive director discuss individual contributions performance board considers nonexecutive directors together training development needs identified pages independent shares peer feedback provided part assessed provision financial board evaluation process reporting council 's frc uk corporate governance meets regularly nonexecutive directors code code review continuing independence independently executive directors commitment lynn elsenhans served board nine years described chairs role description available gskcom independence commitment vindi banga dame vivienne cox dr jesse goodman urs chief executive officer rohner served board six emma walmsley years course subjected responsible management group rigorous review three businesses ned 's role description available gskcom develops groups strategic direction consideration approval board senior independent director implements agreed strategy vindi banga supported members glt acts sounding board chair trusted maintains continual active dialogue intermediary directors shareholders respect companys performance together nonexecutive directors leads chief executive officers role description available gskcom annual review chairs performance taking account views executive directors discusses results chairs effectiveness review chair leads search appointment process makes recommendation board new chair acts additional point contact shareholders maintains understanding issues concerns major shareholders briefings company secretary investor relations senior independent nonexecutive directors role description available gskcom company secretary secretary board board committees victoria whyte supports board committee chairs annual agenda planning ensures information made available board members timely fashion supports chair designing delivering board inductions coordinates continuing business awareness training requirements nonexecutive directors undertakes internal board committee evaluations request chair advises directors board practice procedures corporate governance matters chairs groups disclosure committee operates boardapproved appointments policy reflects board external appointment requirements current code point contact shareholders corporate governance matters gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board committee information board established following committees board committee board committee role membership comprises report science supports board understanding key strategic dr jesse goodman chair themes upon companys rd strategy based dr hal dietz january external transactions performing indepth dr laurie glimcher reviews underlying scientific assumptions give charles bancroft may board technical assurance also undertakes indepth february risk oversight rdrelated risks judy lewent may corporate responsibility considers gsks trust priority oversight progress lynn elsenhans chair associated trust commitments reflect dr anne beal may important issues responsible sustainable dame vivienne cox business growth oversight views interests dr jesse goodman internal external stakeholders reviews issues potential serious impact upon gsks business reputation transformation advises assists board transformation sir jonathan symonds chair separation separation company oversees associated risks charles bancroft devolved committee separating group biopharma consumer vindi banga architecture disbanded healthcare companies dame vivienne cox december lynn elsenhans urs rohner judy lewent may nominations reviews structure size composition board sir jonathan symonds chair corporate governance appointment members board committees charles bancroft may appointment corporate officers makes vindi banga recommendations board appropriate plans lynn elsenhans assesses orderly succession executive nonexecutive urs rohner directors reviews management 's succession plan judy lewent may ensure adequacy responsible reporting board overseeing monitoring corporate governance arrangements making recommendations board ensure companys standards arrangements consistent existing corporate governance standards emerging best practice also reviews companys conflicts interest audit risk reviews financial reporting process integrity charles bancroft chair march companys financial statements external internal audit vindi banga process system internal control identification dr anne beal july management risks companys process lynn elsenhans monitoring compliance laws regulations ethical dr laurie glimcher codes practice judy lewent chair march initiates audit tenders selection appointment member may external auditor setting remuneration exercising oversight work remuneration sets companys remuneration policy regard urs rohner chair gsks workforce remuneration gsk able recruit vindi banga retain motivate executives dame vivienne cox remuneration policy regularly reviewed ensure consistent companys scale scope operations supports business strategy growth plans aligned wider workforce helps drive creation shareholder value chair ceo responsible evaluating making recommendations board remuneration nonexecutive directors board committee written terms reference approved board reviewed least annually ensure comply latest legal regulatory requirements reflect best practice developments current full terms reference board committee available gskcom number committee meetings held committee members ' attendance described details committee members skills experience included biographies board pages accordance frc 's code board determined charles bancroft recent relevant financial experience also agreed appropriate qualifications background audit committee financial expert defined sarbanesoxley act determined independent within meaning securities exchange act amendedboard architecture corporate governance framework designed improve effectiveness board support gsk leadership team glt continues evolve support delivery strategy priorities alignment board architecture boards agenda support demerger illustrated gsks internal control risk management arrangements described pages integral part corporate governance framework board chief science committee corporate responsibility audit risk committee executive committee officer r ead read read gsk nominations corporate remuneration committee transformation leadership governance committee separation committee team r ead read read see roles membership board committee attendance scheduled board committee meetings nominations corporate corporate transformation board governance audit risk remuneration science responsibility separation total number scheduled meetings members attended attended attended attended attended attended attended sir jonathan symonds emma walmsley iain mackay dr hal barron charles bancroft vindi banga dr anne beal dame vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman urs rohner judy lewent number adhoc meetings charles bancroft dr anne beal judy lewent numbers brackets denote number meetings individuals eligible attend dr beal joined board corporate responsibility committee may audit risk committee july charles bancroft joined science nominations corporate governance committees may judy lewent retired board following agm may addition adhoc meetings included table chairs ' committee established end met occasions consider various items business transformation separation committee devolved committee architecture disbanded december board pleased report full compliance provisions frc 's code exception code provision requires alignment pension rates executive directors available local workforce january current executive directors still role pension rates aligned wider workforce local replicate pension arrangements new executive directors appointed gsk transition set annual reports addition provision requires base salary pensionable however us pension arrangements employees allow basic salary bonus pensionable following dr barrons transition nonexecutive director effect august requirement met board also pleased report consistently applied principles frc 's code set pages remuneration reports copy code available frcs website wwwfrcorguk gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board activity board discharges responsibilities annual programme meetings papers presentations given board committees focus oversight strengthening fundamental elements business growthbased performance ambitions transformation separation gsk create two worldleading companies esg leadership priorities pursuit companys strategy information helps board facilitate effective decision making input aid boards oversight awareness business performance routine good governance practices operated company details selection principal decisions taken board committees interests relevant stakeholders taken account arriving decisions set pages items business considered critical gsks longterm success achievement key priorities highlighted areas focus boards oversight fundamentals commercial execution cost base capital allocation pipeline culture included strengthening gsks receiving regular progress updates providing input companys vaccines mrna strategy plan fundamentals receiving discussing commercial strategy performance reports pharmaceuticals vaccines viiv healthcare businesses reviewing approving objectives ambitions company patients announced investor update june approving gsk 's progressive new dividend policy approving boards priorities approving business development transactions strategic partnerships third parties including vir biotechnology curevac iteos alector receiving updates rd strategy progress company 's pipeline receiving quarterly reports ceo cfo cso scrutinising groups financial performance setting companys new purpose simplified culture oversight projects collaborations third parties develop vaccines treatments covid reviewing risks impacts covid groups business performance approving terms global settlement licensing agreement gilead separation boards preparation demerger valuebased process included consumer regularly discussing scrutinising transformation plans consumer healthcare business healthcare receiving discussing commercial strategy performance reports consumer healthcare business discussing plans consumer healthcare beyond separation haleon annual board glt strategy day approving appointment haleon chair ceo designates planning haleon board composition reviewing rejecting unsolicited proposals consumer healthcare business new gsk boards oversight creation gsk pure biopharma business delivering step change performance included regularly discussing scrutinising transformation plans new gsk discussing plans company beyond separation new gsk pure biopharma company annual board glt strategy day reviewing approving objectives ambitions company patients announced investor update receiving updates rd strategy progress company 's pipeline succession planning new gsk board including approval appointments new nonexecutive director corporate responsibility committee chair successor new nonexecutive director designated scientific medical expert maintaining boards oversight trust esg agenda included esg leadership approving trust section annual report approving task force climaterelated financial disclosures annual report delegating specific responsibility corporate responsibility committee oversight human rights companys operations regular boards focus routine programme good governance activities included governance reviewing quarterly financial results dividend proposal earnings guidance investor materials results announcements oversight receiving reports external auditor approving annual report form f setting annual budget plan forwardlooking threeyear forecast conducting annual review boards enterprise risk responsibility framework enterprisewide risks considering observations agreeing actions boards external evaluation reviewing continuing evolve boards governance architecture evaluating ceos performance setting objectives reviewing annual talent succession plan receiving reports board committees workforce engagement director discussing employee pulse survey results receiving reports corporate governance regulatory developments company secretarys report approving company 's modern slavery statement gender pay gap positioning reviewing stakeholder perception researchboard progress board committees highly focused key priorities ensuring gsk 's fundamentals continue enhanced board members decision making significant matters included consideration interests gsks key stakeholders decisions could potentially affect papers considered board committees sought highlight relevant stakeholder impacts perspective matters whether positive negative selected examples principal decisions taken board board considered relevant stakeholders perspectives described stakeholder groups progress area principal decision boardcommittee regarded stakeholder interests section duties considered commercial china committee reviewed gsk chinas implementation stakeholders execution audit risk committee healthcare professionals hcp speaker hcps medical experts recommended incremental changes engagements sales force incentive sfi policy employees investors commercial model china changes date noted tangible improvements governments regulators board approval observed people customer engagement patients consumers details available context committee considered duties incremental changes hcp engagement sfi longterm results workforce programme china included plan business relationships increase number citylevel healthcare reputation organisations hcos increase reach improvement hcp coverage across country enables innovative specialty care products ultimately reach patients continue safeguard key stakeholder interests including patients committee reviewed risk assessment training approach proposed implementation controls new potential hcos recommending change cost base transformation programme board agreed acceleration stakeholders board concluded oversight programme generate additional savings could investors patients savings made invested rd pipeline potential benefit employees transformation programme patients deliver shareholder returns duties achieve cost base competitive longterm business peers performance workforce business relationships capital allocation dividend policy change board support audit risk stakeholders committee carefully considered matter investors patients board reviewed approved concluding move progressive dividend policy people implementation new progressive dividend policy consideration duties directors duties implementation examined importance predictable returns longterm results workforce particularly uncertain times business relationships details available part deliberations board carefully balanced reputation fairness impact tradeoffs reducing shareholders dividend importance setting new gsk right capital structure resources invest grow improve shareholder returns longer term ultimately board determined setting progressive dividend policy way would support investment needed deliver growth unlock shareholder value develop even stronger pipeline innovative products capable transforming lives patients pipeline business development science committee board reviewed many stakeholders collaborations business development opportunities year patients employees deals leading concluded transactions included investors science committee considered collaboration iteos therapeutics enable duties scientific merits next generation immuneoncology combinations longterm results workforce opportunities prior boards expansion collaboration vir business relationships review approval biotechnology advance new therapeutics details available influenza respiratory viruses collaboration alector codevelop anti bodies neurodegenerative diseases deals considered context potential help gsk deliver transformational medicines patients gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board progress continued stakeholder groups section progress area principal decision boardcommittee regarded stakeholder interests duties considered new growth investor update board drew comprehensive investor feedback stakeholders ambitions board approved june investor key stakeholder research outreach patients consumers people update iu objectives ambitions help inform shape agreed ambitions shared investors governments focus gsk 's growth outlook iu event new gsk patients regulators nongovernmental maximising shareholder value shareholders impacting health organisations multilateral creation including billion people next ten years audit organisations risk committee also reviewed proposals duties competitive growth margin outlook details stakeholder interests longterm business performance taken account remuneration committee workforce business competitive sustainable returns incorporating key iu ambitions updated relationships community value creation remuneration policy gsk environment reputation new ambitions shareholders described remuneration policy review fairness shareholders society principal decision details available separation rejection unsolicited proposals completed foundational work board stakeholders consumer ch business wellpositioned consider unsolicited patients consumers people healthcare conditional nonbinding proposals received investors governments board ensured ch acquire ch business regulators nongovernmental business wellpositioned sustainably grow ahead proposals rejected organisations multilateral categories years come best interests shareholders since organisations highly skilled management fundamentally undervalued business duties team lead future prospects longterm business performance workforce business confident ch relationships community business could sustainably deliver environment reputation organic sales growth range fairness shareholders cer medium term demerger ch board supported transformation stakeholders separation committee considered best way patients consumers people board approved release maximum shareholder value two investors governments retention stake companies set firm foundations able regulators nongovernmental consumer healthcare company effectively serve patients customers organisations multilateral haleon post demerger respectively organisations haleon 's opening capital structure included appropriate capital duties structures required two companies longterm business performance competitive distribute shares haleon workforce business separation ch create gsks shareholders whether retain stake relationships community haleon mid haleon exchanges haleon environment reputation details available list fairness shareholders remuneration remuneration policy review prior developing new remuneration stakeholders policy new policy behalf people investors patients remuneration committee approved remuneration committee remuneration consumers governments new remuneration policy committee chair chair regulators proxy advisers measures biopharma company subject binding considered investor feedback key duties shareholder vote ambitions set iu event engaged longterm results workforce annual general meeting major investors proxy advisers community environment incorporates new long proposed changes reputation shortterm incentives including consulted corporate responsibility sales adjusted operating profit committee gsks esg commitments growth measures aligned iu trust priorities ambitions listened views esg expert outlined esg measures reflecting esg leadership principal decisions companys work regard concerning views stakeholders linkage esg remuneration incentives met chief people officer hr leads area business hear views remuneration arrangements gsk wider workforce pay alignment opportunities new gsk also consulted investors proxy advisers new policy proposals following engagement committee carefully considered feedback finalising design new policy details available pages board progress continued stakeholder groups section progress area principal decision boardcommittee regarded stakeholder interests duties considered esg leadership leading esg expert view esg expert stakeholders insights gsk provided overview esg investor investors patients employees following wideranging expectations governments regulators nongovernmental organisations comprehensive briefing debate described major trends esg causal multilateral organisations recognised esg expert drivers corporate responsibility duties covered gsk sector specific issues committee agreed programme longterm results business including culture net zero intangibles actions improve relationships community esg communications ir shared developments around esg links environment reputation engagement remuneration fairness shareholders providing evidence committee considered positive negative metrics data investors historical stakeholder perceptions together companys culture gsks focus purpose mission culture transformed companys new environmental sustainability goals proactively targeting announced previous year longterm investor base companys approach could enhanced strengthening alignment remuneration increasing availability incentives delivery esg ambitions board committee chairs help experts insights considered part strengthen understanding development remuneration committee committees approach work esg remuneration measures explained details available remuneration report new gsk board succession planning committee considered optimal future stakeholders composition new gsk board future patients consumers people nominations corporate governance committee agreed appropriately reflect stakeholder interests investors board wished constituted duties set key guiding principles new gsk board diverse broadest sense longterm business performance workforce optimal board skills matrix appropriate operational depth across business relationships life science value chain general supported development reputation commercial perspective roadmap future appointments medium term help deliver experience major customer markets stated ambitions patients shareholders needed skills insights members details available could continue ensure companys leadership position esg settle significant gilead dolutegravir global decision settle global litigation stakeholders litigation settlement taken careful consideration context investors patients governments bringing certainty investors support regulators board approved terms global settlement licensing additional investment business future duties agreement gilead would thereby benefiting patients investors longterm results business details available relationships reputation make upfront payment billion viiv healthcare pay royalty future us sales biktarvy respect bictegravir component bictegravircontaining products sold us gsk annual report gsk annual report strategic report governance remuneration financial statements investor information boards approach continuous engagement engage main stakeholder groups including board also learns stakeholder views patients shareholders consumers customers employees engagement feedback events quarterly across company summarised pages investor results calls annual general meeting employee strategic report survey reports workforce engagement board considered interests stakeholders directors reports experts presenting board discussions decision making set committee meetings particular investor update chair sids meeting investor forum section statement sections members provided additional sources investor feedback references annual report opportunities gain wider stakeholder views principal decisions board committees made provided annual strategy meeting glt pages part annual budget planning process stakeholders rightly high expectations us reviewing specific aspects companys policies dynamic operating environment presents many challenges strategy opportunities board aims make sure remaining addition board members encouraged meet individually commercially successful balanced aligned meeting employees shareholders key stakeholders stakeholders expectations upholding reputation induction ongoing basis maintaining licence operate building trust board encouraged report board experiences engages many stakeholders ensure identifies relevant material responds expectations effectively influence importance different stakeholder groups vary depending matter considered certain people stakeholders interests conflict meaning board needs make balanced judgements wellestablished strong engagement mechanisms stakeholder engagement feedback helps us identify colleagues described pages emerging issues also enables board make decisions two key governance channels help communicate context relevant important people thinking boardroom principal board committees glt undertake feedback global well smaller targeted engagement boards behalf accordance pulse employee surveys remit means build detailed understanding work workforce engagement director dame actions plans areor may impact stakeholders vivienne cox regularly gathers explains colleagues insights shared board appropriate views board outlines particular board receives substantial amount chair nonexecutive directors also regularly information stakeholders perspectives work meet people around group report back corporate responsibility committee discussed board covid restrictions permitted year pages pleased meet employees person board members regularly receive individually small groups well continuing meet virtually ceos board report chair workforce engagement director corporate specific external stakeholders report provides responsibility committee chair designate met leaders strategic insights based analysis key developments employee resource groups ergs example part achievements risks impacting reputation continuing dialogue progress inclusion perceptions external stakeholders diversity agenda well issues mattered monthly investor relations report summarises investor erg members employees perceptions significant year change people regular corporate governance litigation regulatory future ready transformation programme intensified updates increased anticipation around demerger consumer healthcare shape gsk ahead pulse surveys smaller groups employees meant board glt could check sentiment quickly frequently could provide valuable insights impact major initiatives events communicationsboards approach continuous engagement continued year board glt spent time listening postevent surveys show good progress made sessions leaders small groups employees explaining new gsk building confidence less positive frontline roles across company helped better sentiment around employees feeling board understand future build peoples confidence gsk acutely aware pandemic increased fatigue well testing listening feedback new reduced resilience many people reinforced purpose strategy culture emma held importance prioritising caring people small group sessions workforce glt cumulatively providing support need successful board held sessions specifically focused new gsk monitors employee engagement also provided rich feedback helped shape internal quarterly monitoring many employees taking communications achieve record engagement levels support many absent many leaving employees joining two live events company board pleased glt chose recognise every employee weeks thank pay award recognition resilience strong delivery extraordinary circumstances workforce engagement director third year workforce engagement director engagement programme highlights time appreciated chance meet different joined site directors site quality leaders meeting people across company listen carefully comprising group employees recently views perspectives year engagements appointed roles meeting part attended continued virtual however longer induction programme undertake took part pleased prevented people session discussed impact new culture open transparent discussions roles stressed importance ensuring continuous improvement sites purpose strategy culture midpoint met hr leaders established programme visits start impressed energy commitment conscious would year significant change beyond separation clear focus people transformation programme restructure group culture leadership capability would key supporting advance separation launched continued environment people thrive additionally throughout naturally important new simplified hr systems operating model uncertainty people therefore keen use would ensuring quality support people role understand impact changes organisation additionally separation getting ahead together session ambitious well closer raised questions minds people received twoday digital event brought together future shape new gsk consumer healthcare employees around world objective share business new listed company particular wanted thinking progress launch two new companies understand work done board glt exchange ideas opportunities lie ahead define new purpose strategy embed new simplified finally spent time group high potential commercial culture discussed elsewhere annual report employees greater china intercontinental region experienced completing virtual development programme probably consistent message heard year discussed key learnings importance value people attach working company developing resilience building trust strong sense purpose clear strategy additionally meeting employee group share people met supportive new culture thoughts observations leaders board appreciate simplicity clarity brings nonattributable basis perhaps valuable aspect continued jon chair engage ongoing basis views perspectives diversity employee resource groups ergs specifically factored board glt discussions decision impact announcement companys public making aspirations improving ethnicity gender representation workforce leadership positions overall dame vivienne cox responses positive continuing encourage workforce engagement director board glt intensify efforts support february promote diverse talent gsk annual report gsk annual report strategic report governance remuneration financial statements investor information boards approach continuous engagement continued shareholders annual governance meeting years event virtual institutional shareholders key board seeks directly engage private retail investment industry bodies proxy advisory firms chair institutional shareholders several ways include regular joined senior independent director workforce communications annual general meeting annual engagement director committee chairs gsks external governance meeting work investor audit partner relations team chair sir jonathan symonds shared investors priorities focus board company secretary victoria whyte committees progress made included year ceo emma walmsley cfo iain continued focus strengthening fundamentals mackay gave quarterly results presentations institutional business maintaining esg leadership strong oversight investors analysts media webcast teleconference progress towards separation create worldleading also regularly joined cso chief consumer healthcare company new growth outlooks commercial officer ceo viiv healthcare president global ambitions set gsk deliver stepchange vaccines ceo gsk consumer healthcare performance available provide detailed insights areas remuneration committee chair shared details responsibility committees review executive remuneration arrangements regular meetings emma iain ongoing gsk ahead separation included updated gsk active dialogue institutional shareholders policy focused reinforcing delivery public performance plans objectives ceo held performance ambitions set iu june individual meetings major shareholders hosted delivery public esg commitments submitted group meetings actual potential major shareholders binding shareholder vote agm cfo held individual meetings group meetings workforce engagement director discussed programme chair always maintained active dialogue engagements gather help board shareholders including fund portfolio managers understand peoples perspectives new purpose well seeing governance professionals strategy new simplified culture ch demerger chair held meetings range investors make meeting well received shareholder feedback nearly companys share register enables shared subsequently rest board current understanding investor views insights perspectives company also covers investors annual general meeting board succession planning arrangements capacity due restrictions public gatherings light covid chair nominations corporate governance committee situation time shareholders unable physically chair ceo rest board particular focus attend agm held registered office brentford communicating plans demerger therefore priority seek provide live electronic shareholders future ambitions gsk biopharma access agm many shareholders possible business part extensive outreach june ceo aim promote similar type meaningful engagement members glt hosted virtual investor update board would occur conventional agm provide clear view strategy gsk outlook pleasingly shareholders joined meeting electronically growth ambitions watch listen updates chair ceo ask questions vote proposed resolutions october investor forumhosted event december approved shareholders majorities ranging annual governance meeting chair provided update board committees aligned work drive demerger establish key governance intended agm may held workstreams support delivering focus gsks future sofitel london heathrow hotel use hybrid format biopharma business allow shareholders flexibility attend ask questions vote either person electronically see details investor materials events available gskcom boardled purpose culture boards role promote gsks sustainable success clearly identify making progress drive longterm growth shareholders value need make changes board glt stakeholders strategic report pages changed track measure culture change demonstrates work achieve goals using insights measuring frequently corporate governance report pages explains responsive making information easier access governance arrangements support oversight help drive progress shortterm make significant strategic transformation two separate businesses well change longterm details see new ambitions patients shareholders work board also briefed proposed new mission supported renewed company culture strategy culture haleon culture focused board responsible setting groups overall three behaviours purpose culture fundamental conducting go beyond business highest standards promoting longterm success unlocking protecting maximising value matters shareholders keep human four years emma walmsley ceo board described detail worked change culture always guided launched formally haleon chair ceo designates purpose values culture moving one works capital markets day february effectively towards longterm strategic priorities board also support gsk 's new culture appointing innovation performance trust board saw momentum promoting right people upholding incentivising ambition around two new businesses right behaviours strong governance controls thorough unique opportunity unify people behind one purpose processes training developing employees one strategy one culture board recognises tone top drives new purpose unite science talent technology companys culture board glt must role models get ahead disease clear ambition make lead example using words actions behaviours even meaningful impact human health create set template people like people members better sustainable returns want board take following key training awareness environment allows outstanding people thrive modules board getting ahead means preventing disease well living values expectations explores values treating means innovating combining ideas expectations culture apply capabilities knowhow inside outside gsk focus operations ways working rd deliver new vaccines medicines using science immune system human genetics advanced antibribery corruption technologies making deep commitment inclusion diversity stakeholders operate responsibly detail new single definition culture essential plans embedding new simplified culture invest reward people see pages one board also remains committed getting ahead issues ambitious patients delivering matters better matter sustainability company pricing faster access environment stronger diversity inclusion accountable impact clear ownership progress areas set pages support succeed strategic report esg performance report available gskcom right thing working integrity care understanding people count us code conduct embodies values board reviews refreshes regularly available gskcom boards discussions year focused new purpose culture centred corporate standards employee policies aligned values include longstanding speak rationale change system enables people raise matters confidentially review employee engagement feedback anonymously without fear reprisal board trialling change audit risk committee reviews speak reports provided next steps board glt needed take make legal compliance team speak channels change real people reports managed independent third party cases investigated legal compliance gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board performance board evaluates performance board agreed updated priorities year ahead committees every year facilitated externally least encapsulated actions identified stage every three years external evaluations facilitated evaluation process addition agreed use annual jan hall business advisory company strategy meeting board glt autumn reset recalibrate board future new gsk board committee evaluation process composite three key assessments first korn ferry board committees conducted interviews board director elicit review board committees involved questionnaires views ideal future composition board directors completed committee members committee provided advance information peer company considered operate effectively enhance performance board composition committees input following improvement points agreed discussions conversations board directors covered range topics including corporate responsibility continue bring direct external stakeholder perspectives committees key challenges opportunities gsk next discussions provoke quality debate respect five years eg science china areas management companys trust priority strength support audit risk continue balance committees work culture gsk current issues longer term perspectives skills experience prioritise recruiting new committee would also continue seek focused nonexecutive directors board imperatives materials enhance oversight desirable attributes considered strategic remuneration bring external perspectives opportunities lie ahead changing remuneration practice trends committees workings board committees obtained attention ensure remained contemporary thinking external input nominations corporate governance focus delivery findings formed basis transition plan transition plan create optimal composition optimal composition new gsk board nominations new gsk board corporate governance committee report explains science continue support cso leadership results work taken forward next team whilst providing perspectives opinions rds step followed annual board glt strategy meeting work nonexecutive directors formed three groups discuss thoughts days discussions agreed key insights chair priorities debated board next sid sought feedback directors day conclusions reached incorporated boards performance board chair unanimous view priorities action finally nonexecutive directors board functioning effectively completed short questionnaire performance continually strengthened chair provided excellent board committees year responses leadership throughout important eventful year board collated summarised considered board culture inclusive purposeful focusing really important issues strategy performance talent progress board evaluation progress conclusions board evaluation review set areas focus progressachievements consideration would continue given stop unnecessary board priorities agreed adhered structuring board discussions tasks free time focus priorities precondition key priorities key driver examining performance transactions creating shareholder value prime importance would remain key focus consideration would also given making best use boards increased use breakout sessions focus bring different time virtual meetings incorporating opportunities unstructured perspectives particular issues october facilitate greater person discussions possible interaction despite ongoing covid restrictions board committee annual strategy meetings held dual sites uk us chair led meeting uk ukeuropeanbased directors ceo led meeting usbased directors addition specific time set aside glt members meet board members without set objective agenda discussions greatly appreciated welcome opportunity connect science committee would look deepen understanding board science committee meeting agendas designed rds resources allocated facilitate deeper dives line boards agreed key priorities see desire enhance root cause analysis enhanced approach foundation global safety review undertaken incidents issues occurred ensure could avoided future part groups approach improving performanceboard committee reports inclusion diversity id committee continued corporate responsibility committee assess progress gsks id strategy commitments report included particular implementation changes hr processes monitoring arrangements needed support delivery aspirational diversity targets announced lynn elsenhans last years annual report committee considered key corporate responsibility committee requirements strengthening succession planning pleased present report sixth arrangements diverse talent application final one chair corporate responsibility committee broad concept equity workplace evolve committee id strategy id incredibly important part culture gsk committee reviews supports role committee comprehensive annual id training awareness session committee oversees gsks trust priority undertaken board people companys progress trust commitments charitable giving gsk tremendous reflect important areas responsible sustainable longstanding commitment charitable giving community business growth trust priority covers managements work involvement committee reviewed existing approach across esg factors integral gsks overall strategy gsk compares peers considered committee oversight views interests leverage approach align gsks core purpose strategy internal external stakeholders reviews issues could culture encouraged impact measured terms seriously impact gsks business reputation contribution commitment announced investor update june positively impact health billion committee continued oversee people next ten years progress trust commitments regular reports esg performance new gsk committee reviewed glt members senior managers management plans six areas esg focus new gsk gsks approach managing risks opportunities outlined investors company june working associated esg factors help create value audit risk remuneration committees shareholders society committee reviewed managements proposals specific metrics measure progress six areas management understanding key issues stakeholder recommendation creation single esg performance perspectives listening directly key independent expert rating assessment kpi gsk demerger also voices reviewed approach risk management governance principal risks relevant area expertise oversight arrangements measure report esg responsibility namely product quality nonpromotional performance committee pleased support engagement supply continuity environmental sustainability changes help retain develop gsks esg health safety leadership position key activities consumer healthcare ch preparation demerger committee reviewed discussed ch safety culture committee reviewed progress management progress developing distinctive delivery global safety improvement plan across gsks holistic responsible business esg framework would businesses developed comprehensive farreaching support purpose strategy culture becoming listed external evaluation safety culture reviewing actions company focus key responsible business issues embedding sustaining plans safety improvements new company committee scrutinised future committee encouraged strong focus framework proposed targets including environmental sustainability targets incorporated education training build capabilities key insights expectations gathered investors analysts ensuring clear accountability leaders safety external stakeholders heightened awareness application gsks stakeholder insights benchmarking simplified culture right thing integrity care people count us committee pays close attention evolving views expectations companys broad range key stakeholders receives regular report stakeholder insights meeting ensure considers issues may bearing gsks reputation delivery responsible business agenda employee insights feedback discussed relation progression companys modern employer agenda gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued keeping desire continually bring external science committee report perspectives committee room committee benefited direct engagement insights dr jesse goodman expectations sector company specifically two science committee areas firstly receiving expert 's insights investor pleased present fifth report science views esg trends expectations outcomes committees committee activities reported secondly gathering expert views rising expectations governments investors key activities businesses understand human rights impacts risks since committees inception continued committee monitors investor expectations esg refine focus provide greater value boards reporting disclosure ongoing basis gsk continues deliberations particular committee focused align best practice reporting accordance ensuring validity key scientific assumptions sustainability accounting standards board see esg drive companys rd strategy well providing performance report task force climaterelated technical assurance particularly relation potential financial disclosures see transactions addition committee monitors companys esg performance various indices relation peers pipeline progress respect particularly pleased gsk ranked start year committee closely reviewed first dow jones sustainability index pharmaceutical objectives biopharma business including industry group improved carbon cdp rating b relating pipeline progression delivering pipeline help rated top sustainalytics patients heart gsk committee pharmaceuticals sub group external monitors progression closely terms strategy benchmarks help evidence gsks acknowledged leadership performance committee held number discussions esg continues key driver goal dr hal barron cso rd leaders throughout deliver health impact shareholder returns year encouraged progress made approach separation committee aims since separation announced rds strategy committee continue scrutinise monitor progress delivered strong pipeline assets potential gsks material trust topics relevant enterprise risks bring transformational vaccines medicines patients company demerges focus oversight gsk notable approvals last year include embedding new approach esg performance jemperli dostarlimab treatment endometrial measurement cancer common female reproductive cancer another major milestone gsks oncology pipeline corporate responsibility committee chair succession potential transform lives women previously delighted welcome dr anne beal brought limited treatment options extensive healthcare experience board committee physician public health expert may cabenuva cabotegravir rilpivirine first longacting since anne working smooth injectable treatment hiv cabenuva potential transition handover succeeds committee transform hiv care patients reducing treatment dosing chair conclusion agm may continue days per year addition apretude received serve committee member provide continuity fda approval december first longacting support retire step board injectable option hiv prevention conclusion demerger later year november company announced positive phase iii privilege serve member board chair data daprodustat potential new oral treatment patients committee help shape oversee particular anaemia chronic kidney disease development embedding framework focused set commitments support companys trust priority covid approach responsible business listening carefully regarding pipeline covid solutions xevudy views stakeholders helped inform positive sotrovimab monoclonal antibody developed collaboration steps taken reinforcing position leader vir biotechnology approved europe received esg emergency use authorisation us treatment patients covid studies show xevudy also retains lynn elsenhans activity omicron variant terms vaccines gsk corporate responsibility committee chair announced positive phase iii results plantbased february covid vaccine candidate developed medicago vaccine covifenz approved canada february february also announced intention seek regulatory authorisation covid vaccine developed sanofi based data booster phase iii efficacy trialsour board committee reports continued february also reported collaboration enhanced rd governance curevac jointly develop next generation mrna vaccines committee particularly impressed covid potential address emerging variants developments rd governance since dr barron appointed vaccines pharma rd scientific deepdives fully united single organisation enabled innovation remains key priority gsk therefore rd effective terms efficiencies committee continued meet cso also sharing technical scientific expertise talented rd leadership undertake deepdives benefits governance enhancements already exciting complex areas science strategic become apparent improvements made cycle times importance gsk including across clinical development probability success immunology pivotal studies oncology focus synthetic lethality three half years ago management set new approach rd dr barrons leadership pipeline vaccines mrna strategy stands advanced notably science immune system key pillar rd committee emphasise need continue momentum strategy leveraged develop novel therapeutics beyond separation well potentially revolutionise drug discovery development gsks partnership andme provides board committee changes company exclusive insights field represents welcomed dr hal dietz committee january enormous opportunity rd build strong existing experience field human genetics add portfolio committee pleased see immunology significant value committees discussions already embedded across gsk rd including within appointment also means committee well oncology vaccines viiv infectious diseases rounded areas expertise required evaluate gsks strategy pipeline potential business development targets business development judy lewent left committee upon retirement addition oversight companys organic rd board agm charles bancroft joined innovation committee continued review potential committee may february following business development transactions committee receives appointment dr dietz regular previews potential business development opportunities explored undertakes indepth technical committee participated cso succession planning reviews transactions prior presentation board fully supportive tony wood 's appointment transactions added new programmes aim pleased dr barron join committee august differentiate gsks pipeline competitors support transitions nonexecutive director organic development within company dr jesse goodman key transactions reviewed committee science committee chair year include february iteos collaboration iteos codevelop antitigit monoclonal antibody collaboration gsk well positioned produce nextgeneration immunooncology therapies especially targeting cd axis alector collaboration develop two potential firstinclass monoclonal antibodies range neurodegenerative diseases including parkinsons disease alzheimers disease arrowhead pharmaceuticals exclusive licence agreement arrowhead pharmaceuticals gsk develop commercialise arrowheads investigational rnai therapeutic developed treatment patients chronic liver disease halozyme therapeutics global collaboration license agreement viiv healthcare halozyme granting exclusive access halozymes enhanze drug delivery technology enable development ultra longacting medicines hiv shionogi exclusive license agreement viiv healthcare shionogi develop thirdgeneration hiv integrase inhibitor potential use ultra longacting hiv regimens gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued nominations corporate governance cpo ceo cso dr wood established transition plan approved committee ensure committee report smooth transition become necessary jonathan symonds january board activated succession plan nominations corporate governance committee following dr barrons decision accept position ceo cochair altos labs august since dr wood pleased present third report chair key partner dr barron delivering gsks rd nominations corporate governance committee approach wide experience expertise across committee science data new technologies perfectly placed build dr barrons outstanding progress deliver value key activities pipeline board therefore agreed appoint dr committee played important role delivering key tony wood cso designate succeed dr barron priorities transform gsk separate ch business cso become member glt august committee met times year report sets details background found work company 's announcement issued january key priorities status available gskcom succession planning cso cso succession candidate committee also recommended part cso rd leadership team identified subsequently appointed cso designate transition plan dr barron appointed nonindependent nonexecutive director member science committee appoint chair corporate dr anne beal joined board responsibility committee succeed may effect august initially threeyear term lynn elsenhans would support cso transition process appoint third scientific medical expert dr hal dietz joined board corporate responsibility committee chair sme january report described search lynns successor design target gsk board composition target gsk board composition chair corporate responsibility committee crc recruit high calibre nonexecutives agreed search new resulted dr anne beals appointment board complete new gsk biopharma board nonexecutive directors may anne brought extensive healthcare experience gsk progress physician entrepreneur combined passion patient appoint haleon ceo assemble brian mcnamara appointed advocacy details experience rationale appropriately seasoned management haleon ceo designate july appointment included companys announcement team haleon management team announced december april available gskcom transition process underway enable anne succeed lynn crc appoint chair haleon support sir dave lewis appointed chair close agm despite serving composition haleon board haleon chair designate nine years lynns experience ceo sitting december selection boards means continues demonstrate remaining haleon board characteristics independence expected board progress carrying role board shaping gsk board future third scientific medical expert sme pleased confirm search third sme management succession planning successfully concluded continued finetune committee nonexecutive directors present selection criteria process evolved considered continuously assess succession plans management following executive directors ensure appropriate succession plans diverse pipeline potential successors outlook future direction rd innovation place treatment management human health given importance cso leadership experience people leadership management scale rd committee collaboration ceo either academic industry setting appropriate cso intensified planning identify interested deep understanding breadth potential cso succession candidate committee scientific therapeutic areas particularly immunology supported chief people officer cpo science well genomics genetics perspectives committee committee followed comprehensive process ability harness digital technologies including artificial making recommendation described intelligence enhance research development replicated assessing succession candidates new medicines committee science committee reviewed diverse able deliver complex science broad audience highly long list internal external potential successor candidates collaborative willingness engage proactively short list candidates compiled topics beyond immediate realm expertise interviewed science committee members chair ceo cpo cso committee joined non executive directors review final candidates following extensive process nonexecutive directors agreed identify dr tony wood csos successorour board committee reports continued committee pleased recommend appointment committee reviewed brians proposed leadership team dr hal dietz board effect january haleon particular proposed cfo chief people dr dietz brings extensive experience field human officer announced december following genetics central gsks approach rd extensive internal external searches role add strength science committee board shortlisted candidates interviewed relevant panel discussions details hals experience rationale nonexecutive directors agreed role criteria appointment included companys announcement committee approved final appointees haleon october available gskcom management team introduced investors ch capital markets day february transition new gsk board haleon chair committee followed search process planning structure new gsk board select haleon chair search focused candidates independent biopharma company committee following knowledge experience commitment commissioned korn ferry meet board member significant listed board experience understanding gather views optimal board design future investors analysts banks regulators governments details process given skills matrix developed mapped current board members high degree financial acumen successful business skills capabilities succession planning needs track record creating shareholder value growing board discussed nonexecutive directors businesses key capabilities refined final target strong emphasis coaching skills ability create skills matrix agreed committee agreed briefs highperformance environment initiate search three new nonexecutive directors appointed board next months deep experience consumer facing businesses high committee following search process recruit degree customercentricity international experience roles long lists candidates roles preferably us china considered strong strategic skills track record innovative thinking coaching development haleon board appointments well respected high credibility committee appointed subcommittee comprising stakeholders including investors capital market participants chair vindi banga dame vivienne cox dr beal regulators governments mr rohner progress haleon board appointments reported progress scheduled committee meeting high integrity strong values driven strong final decisions reached committee sense purpose nonexecutive directors invited participate understand role chair ftse haleon ceo cfo committee conducted possession humility subdued ego strong extensive global search selection process appoint emotional commitment passion ch business haleon ceo cfo designates work followed committed diversity forms resilient open committees search process particular ceo role profile minded strong judgement well natural team builder contained key selection criteria responsibilities successful candidate would need fulfil especially committee agreed sir dave lewis highly demerger emphasised importance experienced respected global business leader consumer establishing new haleon board deliver growth goods retail suitable candidate lead strategy drive significant shareholder value would haleon board noted time selection require relentless focus innovation promoting high deemed meet independence requirements performance inclusive culture whilst also operating code committees recommendation subsequently exacting standards corporate governance endorsed full board details sir daves experience rationale appointment included following interviews board members internal companys announcement december external candidates board pleased endorse available gskcom committees recommendation appoint brian mcnamara haleon ceo designate board noted particular brians sir dave progressing search high calibre non strong track record success building ch business executive directors build haleon board ensure considerable experience fmcg consumer health continuity expected two nonexecutive members meant uniquely suited right choice gsk board transfer haleon board completion unlock growth potential haleon independent listed demerger companys ch joint venture partner company details brians experience pfizer right appoint two nonexecutive rationale appointment included companys directors new haleon board announced publicly announcement july available gskcom later year part demerger arrangements gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued ways working committee worked number executive search firms committee seeks follow best practice provided additional consultancy services appointments recommends agreeing criteria role company outlined appropriate interview panel considering korn ferry general recruitment executive search comprehensive diverse long list candidates shortlisted assessment services coaching hrrelated services candidates interviewed assessed chosen egon zehnder executive search assessment coaching criteria due diligence undertaken committee services specific senior executives makes final recommendation executive search firms appointed accordance companys procurement heidrick struggles executive search services policy based expertise relative role spencer stuart executive search assessment services committee agreed search firms signatories voluntary code conduct executive committee reviewed potential conflicts interest search firms gender diversity best practice would judged appropriate safeguards engaged conflicts board committee chair glt membership changes year date report committee approved following changes membership board committees glt director membership appointment date retirement date charles bancroft chair audit risk committee chair march member nominations corporate governance science committees may february stepped science committee dr hal dietz joined committee dr anne beal member corporate responsibility may audit risk committees july dr hal dietz member science committee january judy lewent chair audit risk committee chair march member audit risk nominations corporate governance remuneration may science transformation separation committees lynn elsenhans chair corporate responsibility committee may member audit risk corporate responsibility nominations corporate ch governance committees demerger dr anne beal chair corporate responsibility committee may shobie ramakrishnan chief digital technology officer member glt december board composition tenure diversity committed diversity boardroom board seeks balance composition tenure gsk committed equal opportunities employees committees refresh time levels organisation board management enables board benefit experience longer seek encourage diverse inclusive culture throughout serving directors fresh perspectives insights company effective board needs range balance newer appointees nonexecutive directors drawn skills experience knowledge ethnicity gender social wide range industries backgrounds including economic backgrounds independence individuals pharmaceuticals industry rd vaccines consumer prepared challenge work products healthcare medical research academia collaboratively mix needs complemented insurance financial services collectively diversity personal attributes including character intellect wealth experience complex organisations global judgement honesty courage reach many board members also experience longercycle industries great assistance understanding sectorour board committee reports continued board glt diversity targets transformation separation committee responsible developing measurable committee report objectives monitoring progress towards achievement assist implementation boards diversity policy jonathan symonds including gender ethnic diversity progress transformation separation committee targets set consistency diversity metrics january shown line gender pleased present second final report chair diversity submission ftse women leaders review transformation separation committee committee review given fulfilled purpose mandate committee established may charged two progress achieved principal functions diversity objectives status performance least board positions exceed exercising oversight future ready transformation held women objective programme particularly delivery targeted cost savings least glt positions met objective separation companys infrastructure prior held women delivery team moving project design implementation least combined glt exceed direct report positions held objective considering optimal form separation also women included implications separation least one board director exceed two directors appropriate listing location haleon ethnically diverse objective committee pleased future ready committee particularly intent increasing gender transformation programme completed schedule especially ethnically diverse representation board end exceeded cost savings identified glt developing pipeline direct reports derived programme glt ethnically diverse backgrounds committee undertook programme work committee supportive new gender diversity targets understand consider key fundamentals separation review published late february including technical requirements considered women boards pleased many best unlock release maximise longterm shareholder years boards gender representation target value work supported guidance advice comfortably exceeded normally board positions external experts appropriate committee began held women transitional period considering separate principal value company separates ch business demerged achieve option available discussions committee working transition target board profile progressed capital structures required resulting new biopharma company result composition two companies competitive independent entities diversity board transition inevitably following decision demerge ch business subject fluctuation look forward confirming completion important determine distribute shares haleon work next years report reporting progress shareholders exchanges haleon list review 's increased gender diversity targets committee also considered whether retain stake representation women ethnically diverse leaders haleon big stake retain covered part diversity gsks global intensive detailed programme work workforce progress inclusion diversity committee addressed major questions commitments including gender ethnicity illustrated impact stakeholders reported board esg performance report gskcom accordingly conclusions recommendations process well execution phase oversight sir jonathan symonds remaining work appropriately rests nominations corporate governance committee chair specialist board committees devolved february appropriate reviewed overseen directly board fulfilled mandate agreed committee decommissioned would like thank board colleagues commitment diligence supporting committees work respect sir jonathan symonds transformation separation committee chair february gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued audit risk committee report processes systems fundamental appropriate financial reporting charles bancroft controls managing risks well positioned audit risk committee respect companys main accounting reporting systems centralised two global instances sap pleased present report first chair also wellestablished one finance model audit risk committee committee centralised transactional controller activities embedded joined committee back may succeeded judy gsks four regional hubs frees inmarket finance lewent chair march comprehensive people focus core business operations decision transition drawing business background making committee continues exercise regular oversight including ten years served cfo major monitoring activities critical financial systems pharmaceutical company bristol myers squibb integrity financial statements including annual always viewed people processes systems report quarterly results announcements enduring key importantly culture critical foundation successfully focus committee since joining board managing financial reporting audit compliance risks committee impressed clarity rigour time serving committee observations around processes committees position always generally board member confident gsk aim clear transparent financial disclosure controls score highly areas would therefore like gsk 's financial reporting share initial impressions key aspects previous committee chair highlighted report last culture people year continued ensure companys financial gsk strong compliance culture consistent tone reporting controls framework remains robust engagement top regularly considered require fundamental changes important emphasised committee discussions zero despite ongoing impact covid companys ways tolerance approach unethical behaviour risk working addition external auditor regularly tests management internal control framework mature well financial systems controls challenges management embedded organisation demonstrated pages reports results committee includes areas annual report enables committee deficiencies external auditor identified progress evaluate oversee gsk manages principal remediation issues discussed evaluated emerging risks key activities committee also routinely exercises oversights key decisions usual busy year improvements compliance culture everything committee working regular programme gsk underpinned great people right skill activities making important decisions support sets indeed corporate governance framework requires boards progression key priorities included good people make quality decisions right thing reviewing support board committee chair unfettered access senior incremental changes companys commercial leadership key members teams regularly model china throughout year met individually key committee attendees management including cfo general companys new growth ambitions counsel chief compliance officer head audit shared investor update june assurance group financial controller company move progressive dividend policy secretary external auditor additionally committee matters considered outcomes reported members opportunity speak end pages meeting external auditor without management present crucially also ability speak key preparation demerger members management private sessions alone required committee also key ch governance delivery workstream increasingly reviewing technical aspects delivery demerger committee specifically accountable reviewing recommending board approval key transaction documents related mattersour board committee reports continued board ultimately responsible decision principal risk assigned risk owner drawn demerge respect timing final terms senior management accountable managing hisher demerger make recommendation transaction principal risk oversight glt member including setting shareholders publication gsk shareholder implementing risk mitigation plans risk owners report circular committees role scrutinise documents quarterly respective risk management approach prior boards review process progress rocc appropriate board committee committee board continue intensify first compliance function assists rocc rmcbs half year formal point separation approaches compliance responsible advancing enterprisewide risk management developing riskbased ethically sound committee assisting ch management working practices also actively promotes ethical behaviours establishing robust internal control risk management enabling employees operate line values framework ready separation overarching principle comply applicable laws regulations replicate gsks current internal governance controls finance systems necessary adapt existing audit assurance aa function provides independent framework processes committee pleased assurance senior management board ch business currently well advanced setting effectiveness risk management groupwide line governance processes organisations managing agreed assurance plan helps senior management processes business usual environment q board meet oversight advisory responsibilities fulfilling gsks strategic objectives building trust internal control framework patients stakeholders aa dual reporting line board recognises obligation present fair balanced cfo committee understandable assessment gsks current position committee receives regular reports business units prospects reflecting responsibility accountable principal risk owners compliance aa areas evaluating approving effectiveness gsks internal significant risk group related internal controls controls including financial operational compliance reports assess internal control environment within controls risk management processes principal risk area including enhancements strengthen ensure reliability financial reporting controls following consideration reports compliance laws regulations internal committee reports annually board effectiveness control framework comprehensive enterprisewide risk gsks internal controls management model supports boards continuous authority delegated committee identification evaluation management groups board conducted robust assessment groups principal principal risks required frcs code framework risks assessment line frcs designed manage risk us achieving business code included consideration nature extent risk objectives board willing take achieving gsks strategic objectives fitforpurpose framework complemented corporate board via committee also oversaw effectiveness values culture expectations speak processes internal control environment risk management ensures risks associated business activities processes across group whole year actively effectively controlled line agreed risk approval date annual report appetite believe gsks framework provides reasonable review groups risk management approach absolute assurance material misstatement loss discussed risk management section strategic board mandates groups risk oversight compliance report pages council rocc senior leaders assist committee management principal risk explained principal overseeing risk management internal control activities risks uncertainties pages groups also provides business framework risk viability discussed group risk management section management upward escalation significant risks risk strategic report management compliance boards rmcbs across group promote tone top establish risk culture well ensuring effective oversight internal controls risk management processes gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued significant issues relating financial statements considering gsks quarterly financial results announcements financial results annual report committee reviewed significant issues management judgements determining results reviewed management papers setting key areas risk actions taken quantify effects relevant issues judgements made management appropriate accounting required address issues financial statements significant issues considered relation financial statements year ended december set following table summary financial outcomes appropriate committee external auditor discussed significant issues addressed committee year areas particular audit focus described independent auditors report pages significant issues considered committee relation financial statements issue addressed committee going concern basis preparation committee considered outcome managements halfyearly year end reviews current financial statements forecast net debt positions various financing facilities options available group committee also considered managements review current longerterm impacts covid pandemic outbreak pandemic year end following consideration assessments included stress testing viability scenarios sources liquidity funding forecasts estimates committee confirmed application going concern basis preparation financial statements continued appropriate revenue recognition including returns committee reviewed managements approach timing recognition revenue accruals rebates rar accruals customer returns rebates us pharmaceuticals vaccines accrual returns rebates billion december committee reviewed basis accrual made concurred managements judgements amounts involved fuller description process operated us pharmaceuticals vaccines business determining level accrual necessary set critical accounting policies provisions legal matters including committee received detailed reports actual potential litigation internal external legal investigations groups counsel together number detailed updates investigations groups commercial practices commercial practices management outlined levels provision corresponding disclosure considered necessary respect potential adverse litigation outcomes also areas yet possible determine provision necessary amount december provision legal matters billion set note financial statements provisions provisions uncertain tax positions committee considered current tax disputes areas potential risk concurred managements judgement levels tax contingencies required december tax payable liability billion including provisions uncertain tax positions recognised groups balance sheet impairments intangible assets committee reviewed managements process reviewing testing goodwill intangible assets potential impairment committee accepted managements judgements intangible assets required writing resulting impairment million see note financial statements intangible assets details valuation contingent consideration committee considered managements judgement necessary increase liability pay relation viiv healthcare contingent consideration result increases sales forecasts well unwind discount updated exchange rate assumptions cash payments approximately billion year december groups balance sheet included contingent consideration liability billion relation viiv healthcare settlement gilead resulted remeasurement existing liabilities contingent consideration year end included closing balance viiv healthcare put option committee reviewed agreed accounting pfizer put option concurred managements judgement valuation put option billion december settlement gilead resulted remeasurement pfizer put option year end included closing balanceour board committee reports continued auditors reappointment committee chair regularly meets independently external auditor audit partners committee also meets auditor end meeting discuss progress appropriate external auditor appointment reviewed feedback noted areas last tender may december improvement implemented audit team transition year committee satisfied first shareholder approval current auditor may effectiveness auditor external audit process first audited annual report f year ending december next audit tender required regulations auditors independence qualifications objectivity expertise contractual similar obligations restricting resources groups choice external auditor committee considers committee therefore agreed recommend company complied mandatory reappointment deloitte board forthcoming agm audit processes audit committee responsibility provisions making recommendation committee free competition markets authority statutory audit influence third party services order effectiveness quality external audit process nonaudit services committee committed ensuring gsk receives management operates presumption highquality effective external audit evaluating deloittes accountancy firms provide nonaudit services gsk performance prior making recommendation however external auditors skills experience reappointment early committee reviewed make suitable supplier nonaudit support effectiveness performance criteria auditrelated matters tax services may agreed management beginning used best interests company line gsks detailed criteria used judging effectiveness deloitte nonaudit services policy committee must ensure external auditor based audit approach auditor objectivity independence safeguarded strategy highquality independent audit effective partnership reviewing preapproving external auditors provision value money overriding responsibility deliver services company policy complies frcs smooth thorough efficientlyexecuted audit revised ethical standard sarbanesoxley act available gskcom undertaking review committee observes following core policy features considered engaging external auditor nonaudit services overall quality audit gsk nonaudit services policy key features independence deloitte process nonaudit services put competitive tender financial services providers line whether deloitte exhibited appropriate level challenge groups procurement process unless skills experience scepticism work external auditor make suitable supplier deloittes length tenure taken account safeguards adequate safeguards established objectivity assessing independence objectivity independence group audit threatened recently appointed gsks auditor however committee compromised consider effectively assumed role auditor fee cap total fee payable nonaudit services committee also considered feedback external exceed annual audit fee except special audit survey committee members financial circumstances would clear advantage auditor undertaking additional work management team corporate business unit level survey covered prohibitions gsks policy includes whitelist permitted nonaudit services line relevant regulations service effectiveness auditors challenge list prohibited integrity deloitte preapproval nonaudit services require preapproval set table ensure services approved consistent transparency reporting management gsks nonaudit policy permissible services process committee ensures services fall within scope services permitted preapproved committee represent clarity auditors communication ways working delegation authority preapproval alignment audit groups investment value preapprover systems applications products sap committee chair cfo quality audit teams leadership group financial controller skills experience audit team designate group financial controller fees paid company 's auditor associates set overleaf details given note financial statements operating profit gsk annual report gsk annual report strategic report governance remuneration financial statements investor information board committee reports continued fair balanced understandable assessment audit services comparison need annual report fair balanced understandable one key compliance requirements companys financial statements ensure gsks annual report meets requirement wellestablished documented process governing coordination review groupwide contributions publication runs parallel process followed external auditor committee received summary managements approach gsks annual report ensure met requirements frcs code enabled committee board confirm gsks annual report whole fair balanced understandable provides necessary information shareholders assess companys position audit assurance services services including tax regulatory compliance treasuryrelated performance business model strategy services services relating consumer healthcare demerger preparation code conduct reporting lines note financial statements provides details fees payable number wellestablished policies including company 's auditor code conduct available gskcom together details confidential speak lines reporting year fees audit related assurance investigating unlawful conduct services million increased million compared increase due work associated charles bancroft deloittes reporting accountant role preparing audit risk committee chair demerger consumer healthcare business including february audit fees respect gsk pension schemes million fees audit related assurance services represent annual audit service fee excluding demerger work fees audit related assurance services would represented annual audit fee committee considered hiring deloitte undertake reporting accountant role demerger best interests shareholders deloitte possessed type expertise experience size international scope required handle major demerger scale complexity company benefited specifically deloittes indepth knowledge understanding ch business processes compliance environment management time would otherwise devoted educating another firm companys business operations could instead spent delivering demerger creation haleon committee considered level nonaudit services incurred part annual review deloittes independence set satisfied auditor continued independent exercise objectivity throughout section statement company directors required law promote success allows build trust fully understand potential organisation benefit shareholders impacts decisions makes stakeholders wider stakeholders including employees suppliers engagement gsks main stakeholder groups including community patients shareholders consumers customers employees levels across organisation summarised statement aligns requirements set pages strategic report section section cza companies act act indicates year directors companys governance architecture processes addressed matters set section f summarised pages corporate governance act performing duties avoid duplication report summary explores board considers incorporates information areas annual report relevant matters making principal decisions contribute board considers statement focuses risks delivery gsks longterm priorities innovation opportunities strategically important gsk performance trust consistent groups size complexity information issues factors stakeholders board considers relevant complying section f act found locations outlined board regard following matters longterm results b workforce c business relationships likely consequences decision interests groups employees importance developing groups business longterm relationships suppliers customers others strategic report strategic report business model strategic report business model culture business model chairs statement modern employer external environment ceos statement stakeholder engagement stakeholder engagement key performance indicators innovation corporate governance report risk management performance board activity viability statement reliable supply board progress working third parties boards approach continuous corporate governance report risk management engagement chair 's governance statement boardled purpose culture corporate governance report board activity audit risk committee report board activity board progress nominations corporate governance board progress boards approach continuous committee report boards approach continuous engagement engagement boardled purpose culture remuneration report audit risk committee report audit risk committee report remuneration committee chairs corporate responsibility committee report statement directors pay wider setting gskcom gender pay gap report community environment e reputation f fairness shareholders impact groups operations desire maintain reputation high aim act fairly members community environment standards business conduct group strategic report strategic report corporate governance report trust section including culture chair 's governance statement environment trust boards approach continuous environment health safety ethics values engagement environmental sustainability risks human rights transformation separation committee climaterelated financial disclosure reporting investigating concerns report antibribery corruption risk pages investor information corporate governance report nonfinancial information statement corporate responsibility committee report approach tax corporate governance report gskcom corporate responsibility committee esg performance report report gskcom modern slavery statement gsk annual report gsk annual report strategic report governance remuneration financial statements investor information directors report directors powers determined uk legislation nominations corporate governance committee articles association contain rules reviewed register potential conflict authorisations appointment replacement directors provide register conflicts january committee reported directors may appointed ordinary resolution board conflicts appropriately members resolution board provided authorised process authorisation continued appointed board director retires next annual operate effectively committee recommended general meeting following appointment approval register conflicts board subsequently approved except described note articles also provide directors required seek financial statements related party transactions reelection annually annual general meeting end financial year director person closely accordance frc 's code associated material interest contract director cease director significance group company becomes bankrupt articles prohibit director voting resolution ceases director virtue companies act concerning appointment terms termination articles appointment suffers mental physical ill health board resolves independent advice shall cease director company agreed procedure directors take missed directors meetings continuous period independent legal andor financial advice companys six months without permission board resolves expense deem necessary shall cease director indemnification directors prohibited director law qualifying third party indemnity provisions defined resigns offers resign board accepts offer companies act force benefit directors required resign board former directors held office approval signature annual report directors conflicts interest directors duty companies act change control essential contracts avoid situation could direct contracts arrangements indirect conflict interest possible conflict individually fundamental ability business company articles provide general power board operate effectively neither company party material authorise conflicts agreements would take effect altered terminate upon board reviews new potential actual conflict change control following takeover bid recorded company secretary directors counted agreements director would provide compensation quorum authorisation actual loss office employment resulting takeover potential conflicts nominations corporate governance except provisions companys share plans may cause committee reviews register conflicts annual basis options awards granted plans vest board subsequently approves takeover continuing basis directors responsible details termination provisions executive directors informing company secretary new actual service contracts given full version companys potential conflicts may arise changes remuneration policy available wwwgskcom circumstances may affect authorisation previously given investors section even provided authorisation director absolved statutory duty promote success company actual conflict arises postauthorisation board may choose exclude director receipt relevant information participation debate suspend director board last resort require director resigndirectors report continued following information also incorporated directors content directors report report purposes uk companies act location annual report directors report glaxosmithkline plc year ended interest capitalised financial statements december comprises notes publication unaudited financial information group financial review directors report details longterm incentive schemes remuneration report waiver emoluments director applicable section pages waiver future emoluments director applicable corporate governance report non preemptive issues equity cash applicable employee engagement non preemptive issues equity cash applicable directors statements responsibilities unlisted major subsidiary undertaking investor information parent company participation placing applicable strategic report sets matters required listed subsidiary disclosed directors report considered provision services controlling applicable strategic importance shareholder shareholder waiver dividends financial statements strategic report notes shareholder waiver future dividends financial statements section pages notes risk management objectives policies agreements controlling shareholders applicable directors report likely future developments company drawn presented accordance research development activities reliance upon english company law liabilities business relationships directors connection report shall subject diversity limitations restrictions provided law provision information consultations employees approved board directors february carbon emissions signed behalf section statement sir jonathan symonds chair february gsk annual report gsk annual report strategic report governance remuneration financial statements investor information remuneration section committee chairs annual statement annual report remuneration remuneration policy summary remuneration policy report gsk annual report strategic report governance remuneration financial statements investor informationremuneration report committee chairs annual statement dear shareholder vesting lti awards performance share plan psp award vested preagreed measures behalf remuneration committee committee award rd new product performance adjusted pleased present remuneration report free cash flow relative tsr equally includes annual statement explaining committees work weighted performance measured three years year annual report remuneration december rd new product updated remuneration policy report explaining measure vested reflected delivery strengthening change proposed align compensation arrangements pipeline successful commercialisation newly new gsk details propose operate policy launched products continued strong focus cash year management generation resulted full delivery adjusted free cash flow measure disappointingly review ipt outcomes companys relative tsr performance last three years would like set decisions taken committee resulted part award lapsing full course context overall performance vested shares deferred two years see innovation terms innovation made significant base salary following review executive directors progress strengthening rd biopharma performance committee agreed receive pipeline comprises vaccines specialty medicines annual increase line increases exciting new developments hiv covid provided wider workforce uk us solutions committee also agreed award dr barron increase performance overall year strong sales august reflect creation one rd performance strategic progress gsk saw group new organisation brought together scientists sales growth cer driven growth across governance across pharmaceuticals vaccines ensure pharmaceuticals vaccines consumer healthcare together focus invest matters excluding brands divestedunder review total earnings across group whole see declined cer reflecting profit disposal details horlicks business however achieved adjusted bonus awards relation made eps growth including covid solutions cer accordance remuneration policy determining ahead updated guidance pipeline remains outcomes committee carefully considered robust continued progress pharma vaccines executive directors performance deem necessary trust company continues build esg leadership exercise discretion address anomaly position year ranked first performance outcomes review included assessment access medicines index eighth time row gsk performance relevant measures wider also first pharmaceutical industry group dow context especially companys culture trust priority jones sustainability index received gold recognition sps gsk access covid government support job sustainability yearbook cdp climate change retention schemes dividend policy maintained year company delivered remuneration outcomes upgraded financial guidance year performance delivery resulted higher total remuneration respect emma walmsley ceo dr hal barron gsks remuneration policy cso iain mackay cfo due would like set committee seeking update increase variable performance related pay remuneration policy time annual bonus achievement adjusted group pbit past four years seen period significant financial measure addition cfos remuneration increase transformation gsk results becoming also reflected vesting first psp award since joining evident seek fundamentally address long standing company issues prolonged total shareholder return key decisions made committee follows performance committee agreed therefore essential bonus outcomes ceo cfo cso review remuneration policy ahead usual threeyear cycle define biopharma business new approach determined reference performance remuneration agreed financial measure adjusted group pbit committees assessment individual performance financial performance resulted bonus payment financial target committees assessment executives performance personal objectives set start year set committee believes bonus outcomes appropriately reflect overall underlying performance achieved full details provided gsk annual report gsk annual report strategic report governance remuneration financial statements investor information policy review sought ensure remuneration support increased alignment shareholders arrangements reward delivery bold new proposing bonus earned excess salary performance ambitions key focus investor update ie maximum current remuneration policy iu ambitions next five years deliver sales growth salary proposed maximum would delivered cagr adjusted operating profit growth fully shares deferred three years half bonus earned cagr ambitions exclude salary continue deferred shares contributions early stage assets future business three years means event managements development covid solutions significantly performance iu ambitions significantly changed performance pay curves end focus exceeded increased maximum bonus earned expectations delivery going forward achievement base salary would delivered cash ambitions deliver top quartile performance balance deferred gsk shares three years sector developing new remuneration policy engaged following comprehensive review committee concluded extensively shareholders gain views feedback main policy framework remained fit purpose given committee grateful result driving long term performance consistent year made adjustments approach quantum clarity year short term improvement main aim changing performance measurement feature final annual bonus plan support deliver determined proposed policy pleased process allowed key imperative us develop remuneration structure works company shareholders enter new phase careful consideration committee concluded business post demerger changes required operation annual bonus important note achieve new maximum annual raise target performance level align delivery sales growth adjusted operating profit growth would iu ambitions required least percentage points reduce reward previously available lower respective targets acknowledged performance target performance expected frequent occurrence however achieved change financial bonus measure adjusted group committee believe appropriately rewarded pbit sales growth adjusted operating profit growth given additional value would delivered investors line key iu ambitions patients people strengthen focus strategic operational measures event annual bonus financial measures executive directors stretch personal achieved committee would consider appropriateness objectives aligned quantifiable iu ambitions reflecting measures paying personal areas accountability would also reinforce terms competitiveness ceo emma walmsley culture trust priority maximum opportunity earned result delivering given fundamental esg dna success exceptional performance required reach overall important recognise specific performance compensation package would bottom quartile versus condition incentivise incremental year year global pharmaceutical comparator group assumes improvements public ambitions peers group achieve target bonus group includes companies listed uk europe significantly reduced pay opportunity less target performance committee therefore agreed post demerger ftse company new gsk important incentivise reward truly exceptional pursue ambitious growth strategy focused purely performance occasions achieved reinforce biopharmaceuticals compete talent highly step change performance culture result one key policy competitive global pharmaceutical biopharmaceutical change annual bonus proposed sector remuneration levels significantly exceed seen uk proposed change annual bonus current bonus maximum salary paid designed strike pragmatic balance cash shares deferred three years shareholder expectations uk listed business maintained commercial imperative duty committee change proposing additional opportunity ensure company secure retain best talent material outperformance iu ambitions additional proposed annual bonus opportunity salary means maximum potential annual awarded exceptional outperformance underpin bonus opportunity salary however delivery significant growth shareholder value additional element could achieved public remuneration arrangements enhanced annual ambitions sales growth bonus opportunity still remain overwhelmingly weighted adjusted operating profit growth significantly exceeded delivery longterm performance committee therefore bringing significant shareholder value confident change annual bonus best longterm interests company shareholdersremuneration policy implementation targets set year new gsk therefore require adjustment following demerger board annual bonus lti performance measures committee believe proposals represent proposing implement changes annual bonus right approach appropriately focus reward executives lti measures going forward align iu deliver public ambitions secure strong performance ambitions trust priority metrics give greater stakeholders linkage long shortterm measures also ensure focus top line bottom line growth salary critical achieving iu ambitions well committee agreed following review performance ensuring sharp focus strategic priorities executive directors receive salary including pipeline culture esg increase aligned provided wider workforce respective geographies annual bonus measures annual total sales growth following companys announcement january annual adjusted operating profit growth dr hal barron transition cso nonindependent strategic operational esg human capital nonexecutive director july committee management inclusion diversity id determined given dr barron agreed remain director treated good leaver receive lti measures relative tsr total sales existing salary july prorated bonus growth years adjusted operating profit growth retain existing longterm incentive awards years pipeline progress esg vest subject performance prorated basis environment composite scorecard august receive fees nonexecutive committee agree key stretch strategic director subject shareholder approval per operational objectives executive director annum respect additional responsibilities focus particularly individual areas accountability undertake gsk rd underpin delivery fundamentals strategy support recoupment ultimate financial success example ceo cso clear pipeline delivery objectives allegations notified group february executives objectives also require demonstration respect dr moncef slaoui former executive director culture trust priority committee also ensure company committee exercised discretion measures quantifiable suitably stretching align applied claw back provisions recoupment policy delivery public ambitions provide disclosure respect past stock incentives received dr slaoui performance objectives reassure december dr slaoui agreed return group shareholders stretching form cash recoupment policy corporate responsibility committee supported consumer healthcare demerger committee key considerations design making strong progress towards separation development adoption aligned approach key company new gsk haleon new listed consumer esg commitments fundamental operate healthcare company mid new haleon board introducing esg measure initially short engage shareholders proposed remuneration longterm plans reward delivery external ambitions arrangements new company trust priority specifically respect human capital management id nature net positive climate agm net zero ambitions finally would like take opportunity thank shareholders input engagement remuneration policy chose focus element human capital review help shape new policy presented report management first annual bonus esg measure consultation pleased able engage reinforce delivery public id targets access approximately companys shareholder register medicines measure considered however agreed welcome shareholders feedback report ahead given success area would suitably agm look forward receiving support new stretching target whereas id important business remuneration policy annual report remuneration imperative suitably stretching targets could set annual general meeting may warrant additional reward urs rohner remuneration committee chair february gsk annual report gsk annual report strategic report governance remuneration financial statements investor information glance total remuneration following shows composition total remuneration paid executive directors office december respect emma walmsley iain mackay dr hal barron usm usm usm usm usm usm usm fixed pay salary benefits pension performance pay annual bonus ltis earned respect three year performance period ending december pay performance annual bonus financial performance lti outcome performance period ended december overall vesting maximum target relative rd new target tsr product threshold target adjusted group pbit performance achieved vested adjusted maximum performance target lapsed free cash flow executive directors shareholdings audited align interests executive directors share ownership vs sor multiples base salary shareholders required build maintain significant holdings shares gsk time executive emma walmsley x x directors required continue satisfy share ownership requirements sor holding iain mackay x x sor first months leaving gsk less sor months leaving gsk dr hal barron x x executive directors glt sor salary x x x x x sor december shareholding ceo executive directors appointed effect january gsk leadership team members glance key change stronger link short longterm performance annual bonus lti performance measures directly target payout annual bonus salary aligned investor update iu ambitions align iu ambitions ie increase delivering core ambitions measures complementary design ensure inyear performance delivers longterm sustained results reward incremental exceptional performance opportunity delivered fully shares deferred annual bonus lti performance calibration three years align shareholder experience toughened meaning reduced reward target performance maximum reward exceptional annual bonus lti measures alignment performance iu ambitions cascaded glt wider organisation maximum annual bonus opportunity increased salary salary enable recognition exceptional outperformance achieved incentive measures align strategy ab lti performance measures alignment strategy weighting weighting relative total alignment shareholders participants rewarded strong ab lti shareholder return shareholder returns total sales growth top line growth deliver iu ambition sales growth ab lti adjusted operating bottom line growth deliver iu ambition ab lti profit growth profit growth pipeline increases emphasis innovation rewards acceleration ab lti strengthening pipeline esg ambitions focus key esg ambitions including human capital management ab lti id priorities nature net positive climate net zero ambitions strategic focus key areas individual accountability underpin delivery ab operational strategy public ambitions key ab annual bonus lti longterm incentives executive director remuneration emma walmsley iain mackay fixed remuneration salary pension reduce align wider workforce january salary annual bonus maximum opportunity half bonus paid shares salary deferred three years incremental exceptional performance additional salary paid shares deferred three years lti salary share ownership requirement salary dr hal barron transition nonexecutive director effect august gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration total remuneration audited fixed pay pay performance annual bonus vested lti awards maximum opportunity vested psp awards salary measures measures adjusted group pbit rd new product total benefits individual objectives afcf remuneration three year deferral relative tsr could b pension gsk shares read pages read pages read read total remuneration audited emma walmsley iain mackay dr hal barron fixed pay salary benefits pension total fixed pay pay performance annual bonus vesting lti awards psp total pay performance total remuneration notes details mandatory bonus deferrals deferred annual bonus plan dabp set f rom august dr barrons base salary increased reflect creation one rd organisation brought scientists governance across pharmaceuticals vaccines together focus invest matters across group psp valued based closing share price february closing ads price vested amounts executive directors amount attributable share price appreciation performance period ceo cfo cso committee exercise discretion relation vesting awards share price changes committee may specific circumstances line stated principles apply clawbackmalus determines appropriate following due consideration committee recovery sums paid clawback reduction outstanding awards vesting levels malus applied respect current executive directorsannual report remuneration continued total remuneration audited continued following sections provide details element total remuneration including committee implemented approved remuneration policy year fixed pay audited salary table provides analysis total benefits grossed table sets base salaries executive tax received executive directors directors last two years compared increases benefits benefits uk us workforce change base salary emma walmsley effective date benefits available employees emma walmsley business related services iain mackay january business travel dr hal barron benefits dr hal barron august total benefits uk us employees april iain mackay b ase salary increased august reflect creation benefits available employees one rd organisation brought scientists governance across business related services pharmaceuticals vaccines together focus invest matters across group business travel details salary levels provided benefits total benefits benefits dr hal barron uk remuneration reporting regulations require company benefits available employees add executive directors total benefits calculation business related services items deemed tax authorities taxable business travel benefit accommodation whilst business travel comprise benefits employee benefits line policy total benefits employees may vary location role notes business related services provided employees assist b usiness related services tax regulations deem taxable benefit enable carry role tax authority uk andor us mackays benefits increased year year mainly due deemed taxable benefit individual membership global business organisation supports work cfo business expenses company meets recognised uk hm revenue customs therefore deemed taxable benefit incurred tax arises therefore items ncreased travel costs compared following changes covid shown grossed tax split three areas restrictions neoff refund accommodation costs relating prior year business travel includes travel costs executive director appropriate spousepartner associated accompanying executive director gsk business deemed taxable benefits executive director accommodation whilst business travel benefits gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued fixed pay audited continued pensions please see details changes pensions policy future policy table implementation addition committee previously determined current future uk us executive directors pension arrangements aligned wider uk us workforce appropriate january executive director member since pension arrangements emma walmsley pension contributions base salary matching contributions first salary cash iain mackay supplement base salary lieu pension salary excess dr hal barron cso member k plan open us employees executive supplemental savings plan essp savings scheme open us executives accrue benefits k plan limits receives base salary less contribution k essp equivalent total base salary bonus net bonus deferred dabp addition line wider us workforce january combined contribution rate k essp plans core contribution plus match total base salary bonus net bonus deferred dabp member defined contribution plan emma walmsley iain mackay eligible receive matching award first salaries accordance terms plan emma walmsley iain mackay receive cash payments lieu pension base salary excess line gsks defined contribution pension plan rates following table shows breakdown pension values set pension remuneration figures calculated accordance methodology set large mediumsized companies group accounts reports amendment regulations remuneration regulations emma walmsley iain mackay dr hal barron pension remuneration values uk defined contribution us defined benefit employer cash contributions total pension remuneration value details regarding pension values dr hal barron set table pensions figures disclosed dr hal barron member us style defined benefit plans accordance paragraph eii schedule remuneration regulations table shows accrued benefit ie annual pension accrued date accordance remuneration regulations pension remuneration calculated increase accrued benefit adjusted inflation multiplied reflect fact benefit received number years normal retirement age cash balance pension plan age additional benefit retiring early accrued pension pension remuneration december december value dr hal barron pension values us funded us unfunded total annual report remuneration continued pay performance audited annual bonus individual annual bonus adjusted group pbit objectives performance targets performance measures weightings follows weighting adjusted group pbit performance positioning performance measure executive directors target outcome target adjusted group pbit individual objectives threshold maximum performance targets set target respectively adjusted group pbit target outcome purposes annual bonus calculation differ adjusted group pbit disclosed elsewhere annual report primarily target outcome numbers calculated applying gsks budget exchange rates actual exchange rates following table shows actual bonuses earned compared bonus opportunity bonus opportunity bonus outcome financial individual total total target maximum performance objectives bonus bonus bonus salary salary base salary salary salary salary emma walmsley iain mackay dr hal barron details mandatory deferral executive directors deferred annual bonus plan annual bonus earned set table provides detail delivery adjusted group pbit financial performance overall encouraging performance exceeding updated guidance despite uncertainties covid pandemic delivered fullyear reported group sales billion stable aer cer strong commercial execution driving cer growth across pharmaceuticals vaccines consumer healthcare excluding brands divestedunder review including covid solutions sales billion adjusted group pbit million target driven higher sales effective cost control outcome adjusted exclude commercial benefit covid solutions adjusted eps p aer cer ahead guidance including covid solutions delivery driven higher sales effective cost control gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pay performance audited continued following table summarises performance scorecard individual objectives agreed committee executive director addition contribution financial performance individual objectives achievements emma walmsley committee determined ceo clearly exceeded met individual objectives highly successful year focus acceleration gsks longterm ipt priorities company exceeded financial targets gsk track separation unlock potential two new growth companies landmark year company strengthen pipeline continued progress strengthening advancing pharmaceuticals vaccines pipeline potential new build gsks reputation medicines vaccine candidates development innovation covid solutions focussed prevention treatment including xevudy sotrovimab launched treatment positive data omicron drive growth return delivered eps ahead initial updated guidance sales growth driven commercial execution excellence investment pharmaceuticals sales billion vaccines billion consumer healthcare billion demonstrate continued transformed specialty medicine commercial capabilities effectiveness across key markets commercial execution exceptional supply chain reliability continued covid disruption continued network strengthening excellence simplification deliver separation demerger milestones track programme milestones new ambitions set new gsk deliver step change growth performance health impact scale demonstrate strong sustained leading esg performance delivery global health environment inclusion diversity environmental social commitments maintained sectorleading rankings key esg indices well progress deliver climate governance esg credentials nature commitments build trust future delivery demonstrate strong culture culture talent deliver success new companies strong progress build stronger diverse leadership workforce senior female representation track gender race ethnicity aspirations continued development succession planning leadership team roles internal candidates appointed chief scientific officer designate chief digital technology officer iain mackay committee determined cfo successfully met individual objectives demonstrate financial strong financial leadership key role delivery investor update setting competitive growth profile new gsk leadership delivered full year reported group sales billion stable aer cer demonstrate financial adjusted eps p aer cer ahead updated guidance delivery supported cost discipline oversight cost discipline initial savings scale transformation programme deliver separation separation preparations track including corporate finance capital market readiness programme milestones demonstrate strong culture strong oversight across finance tech transformation including appointment new head investor relations leadership chief digital technology officer dr hal barron committee determined cso successfully met individual objectives strengthen pipeline continued rd momentum rd delivery strengthening pipeline pipeline progress targets exceeded build gsks reputation approvals phase iii starts phase ii starts potential new medicines vaccine candidates innovation development business development augment pipeline including vir iteos alector halozyme drive growth return continued progress improve rd productivity success rates including achieving us fda emergency use investment authorisation xevudy months deal signing vir preclinical phase medicine proven effective multiple covid variants including omicron creation one rd organisation bringing scientists governance across pharmaceuticals vaccines together focus invest matters demonstrate strong culture continuing focus top talent key roles rd new talent key roles external hires robust leadership succession planning including appointment new global head vaccines rd global head oncology development malus clawback policy details existing policy malus clawback please resolved legally permissible disclose refer companys remuneration policy report made without unduly prejudicing company annual report available gskcom therefore shareholders committee reviews discloses whether line disclosure guidelines committee recoupment committee exercised malus clawback exercised one instance clawback disclosure made matter subject details recoupment committee please see public reports misconduct fully annual report remuneration continued pay performance audited continued policies details existing policies recruitment remuneration loss office termination payments please refer remuneration policy report pages annual report available gskcom changes loss office policy proposed remuneration policy value earned longterm incentives ltis following tables set performance achieved targets set companys lti plans also includes update performance outstanding awards line committees agreed principles measure applicable lti awards actual performance targets reviewed adjustments made appropriate ensure vesting outcome reflects genuine underlying business performance results delivered line culture trust business priority psp awards performance period ended december committee reviewed performance psp awards granted executive directors targets set adjusted free cash flow afcf target revised line disclosure annual report restated take account revised phasing future ready programme restructuring cash payments separation costs revised timing divestments based detailed programme separation planning undertaken result target increased billion billion psp valued based closing share price february closing ads price vested amounts executive directors amount attributable share price appreciation performance period ceo cfo cso committee exercise discretion relation vesting awards share price changes performance achieved three years december vesting levels set table outcome vesting level performance measures relative weighting performance targets outcome maximum award rd new product rd new product sales performance measures aggregate threeyear sales new bn performance products launched threeyear performance period preceding two rd years ie target vesting maximum bn bn bn threshold bn adjusted free line companys agreed principles afcf figures included adjustments bn cash flow number material distorting items including legal settlements exchange rate performance movements special pension contributions rd original revised target target vesting maximum bn bn bn bn bn bn threshold bn bn revised target adjusted since annual report noted relative tsr ranked th tsr ranking within comparator group vesting performance maximum st nd rd rd th th threshold median th th sr comparator group astrazeneca bristolmyers squibb eli lilly gsk johnson johnson merck co novartis pfizer roche holdings sanofi vesting schedule based delivering vesting median performance comparator group ten companies median falls two companies total vesting respect awards gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued pay performance audited continued update performance ongoing lti awards committee also reviewed performance psp awards granted executive directors following charts provide estimate vesting levels taking account performance december actual vesting levels determined based performance full threeyear performance periods indications therefore regarded predictions final vesting levels afcf threshold associated vesting scales psp awards adjusted net overall impact increase billion billion award increase billion billion award adjustments take account following items revised phasing future ready programme restructuring cash payments based detailed programme planning undertaken revised dividends noncontrolling interests viiv shionogi pfizer changes targets set innovation sales previously named rd new product relative tsr performance measures awards psp award psp award ranked rd ranked rd bn threshold bn threshold maximum commercially commercially commercially commercially median bn sensitive sensitive median bn sensitive sensitive threshold relative adjusted free innovation pivotal trial major relative adjusted free innovation pivotal trial major tsr cash flow sales starts regulatory tsr cash flow sales starts regulatory approval approval milestones milestones estimated vesting level estimated lapsing level pipeline progress pipeline progress threshold performance award vest respect performance measure individual lti award levels appear annual report set lti awards historical vesting lti plans vesting year adjusted free rd new business lapsed total vested grant relative tsr cash flow product diversification lti awards dabp awards respect deferral bonus psp awards shown table dabp awards psp awards total bonus number face value award level number face value deferred shares award base salary shares award emma walmsley shares shares iain mackay shares shares dr hal barron ads ads face values dabp awards calculated based share price ads price closing prices february day grant nilcost options uk executive directors restricted shares us executive director performance conditions attached dabp awards reflect mandatory year deferrals respect annual bonus earned face values psp awards calculated based share price ads price closing prices february day grant conditional shares based performance measures outlined performance period psp awards january december awards vest maximum threshold performanceannual report remuneration continued directors pay wider setting internal context setting executive pay important committee good understanding wider workforce pay end annual basis meet human resources business leaders global support functions pharmaceuticals viiv healthcare vaccines consumer healthcare understand perspectives pay gsks remuneration package wider workforce year third annual meeting held pleased discuss progress groups human capital management id agenda attract retain diverse talent lies heart companys fundamental commitment equity employment reward practices meeting covered current reward environment employees across enterprise notable global competitive challenges facing company namely competitive pressures inhigh demand skills businesses actions taken attract retain key talent areas handling different pay levels across group different geographies included company experiencing particular pay challenges currently anticipated experience future mitigatory steps taken address preparation competitive reward strategy programmes consumer company implementation demerger progress companys publicly disclosed gender ethnically diverse leader aspirations discussed countrybased reviews clear guidance tools support provided markets ensure pay equity finally dame vivienne cox workforce engagement director member committee ensures employee views perspectives pay reward reflected committees discussions urs rohner remuneration committee chair remuneration structure employees element wider workforce pay comparison executive director glt pay salary market competitiveness salaries across company executive directors glt ordinarily assessed local market level competitiveness following performance review increases base salaries roles measured external market line average wider employee internal peers kept regular review population unless change scope individuals role responsibilities experience pensions company seeks provide appropriate pensions executive directors glt eligible benefits package aligned competitive receive benefits broadly line policy benefits market practices countries employees may vary location company operates employees based pension arrangements structured accordance executive director glt member expected retire current future uk us executive directors pension arrangements aligned wider uk us workforce january annual exception sales force participate executive directors glt participate plan bonus separate arrangements wider workforce participates based assessment combination stretching plan based performance four business financial business personal objectives financial measures three measures consumer executive directors required defer healthcare structured reflect priorities glt bonus earned shares specific business area adss appropriate three years plan designed reward employees collective clawback andor malus provisions apply contribution business achievement separate mechanisms place recognise outstanding individual performance address underperformance lti plans employees senior vice president svp vice executive directors glt granted annual president vp level participate psp psp awards performance targets executive directors glt periods performance targets periods executive directors required hold vested clawback andor malus provisions apply awards additional twoyear period svp vp employees together directors clawback andor malus provisions apply managers glt receive annual share value executive directors glt receive share plan awards restricted shares value plan awards following appointment gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors pay wider setting continued ceo pay ratios supplementaladditional ratios lower upper gsks ceo pay ratio likely vary potentially significantly quartile median quartile time since driven largely ceo variable pay outcomes financial year methodology p p p line reward principles ceo larger portion pay based performance individuals p p option p means depending gsks performance ratio could increase decrease significantly committee pay ratios calculated using actual earnings believes senior executives significant ceo uk employees ceo total single figure proportion pay directly linked performance remuneration light also provided supplemental ratios detailed report lti compensation excluded believe total remuneration uk fulltime equivalent employees provides additional view ltis formed substantial company december calculated line percentage ceos total remuneration highly single figure methodology except employer pension variable dependent business performance ceo contributions employees defined benefit pension due total remuneration excluding lti compensation cost complexity calculations instead future service rate agreed recent actuarial funding financial year methodology p p p valuation used employees otherwise reflects actual earnings received excluding option business expenses used produce percentile calculation option remuneration regulations business expenses excluded reimbursed total remuneration less vesting longterm incentive awards employees sufficiently substantial value historic ceo remuneration significantly impact ratios emma walmsley gsk continues choose option robust statistically accurate way company total remuneration calculate three ratios options available annual bonus award maximum remuneration regulations increase pay ratio vesting lti awards maximum due higher level bonus received compared sir andrew witty reflecting higher business individual performance set table base salary total pay total remuneration benefits percentiles annual bonus award maximum vesting lti awards maximum p p p emma walmsleys total remuneration includes pay period january salary march became ceo total sir andrew witty received prorata payment lieu variable bonus opportunity accordance remuneration policy pay benefits psp dabp awards sir andrew witty granted vest april accordance terms executive financial recoupment policy committee believes median pay ratio consistent companys pay reward progression policies base salaries employees including executive directors set reference range factors including market practice experience performance roleannual report remuneration continued directors pay wider setting continued percentage change remuneration directors percentage change percentage change salaryfee benefits bonus salaryfee benefits bonus uk employees executive directors emma walmsley iain mackay dr hal barron nonexecutive directors sir jonathan symonds charles bancroft vindi banga dr anne beal dame vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman urs rohner judy lewent uk employee population considered relevant comparison closely reflects economic environment encountered majority executive directors percentage changes calculated based total remuneration table executive directors total fees table nonexecutive directors information salary benefits executive directors found information annual bonus executive directors found fees nonexecutive directors include fees received cash form shares ads terms nonexecutive directors share allocation plan charles bancroft dr anne beal appointed board may may respectively judy lewent retired board may relative importance spend pay participants companys share save plan may save table shows total employee pay groups dividends month three years end period paid shareholders option buy gsk shares discount share change price start savings contract participants share reward plan contribute month purchase total employee pay gsk shares company matches dividends paid year details see figures table reflect payments made year impact movements exchange dilution limits rates set pages however dividends awards made plans incorporate dilution declared respect million limits consistent guidelines published investment million increase association limits rolling tenyear period total employee pay based employees average plans rolling tenyear period executive number people employed share plans granted senior executives estimated dilution existing awards made last ten years share repurchases made company december follows allemployee share plans uk executive directors may participate hmrc approved gsk employee share plans allemployee share plans wider uk workforce ie share save share reward plans executive share plans actual limit gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors pay wider setting continued external context comparator groups pay relative tsr performance graph committee used two pay comparator groups following graph sets performance company considering executive pay global pharmaceutical relative ftse index pharmaceutical comparator group also used measure relative tsr performance comparator group tenyear period performance primary groups used executive december indices selected comparison director follows purposes reflect primary index gsk constituent industry operates european crossindustry comparator group emma walmsley roche holding ag linde deutsche telekom iain mackay novartis sanofi kering lvmh astrazeneca heineken anheuserbusch inbev diageo basf unilever siemens vinci sap christian dior adidas loreal inditex bayer novo nordisk bat safran airbus volkswagen reckitt benckiser global pharmaceutical comparator group dr hal barron france us sanofi abbvie switzerland amgen novartis bristolmyers squibb roche holdings eli lilly johnson johnson uk merck co astrazeneca pfizer gsk total return gsk pharma peers ftse total return index total return index bbvie amgen included remuneration benchmarking included relative tsr comparator group index comprises astrazeneca bristolmyers squibb eli lilly johnson johnson merck co novartis pfizer roche holdings sanofi ceo total remuneration positioning reviewing ceos remuneration committee also referenced pay global pharmaceutical group european global crossindustry pharmaceutical group group lower quartile median upper emma walmsleys median quartile current position remuneration includes salary expected value incentives based committees agreed benchmarking methodologyannual report remuneration continued implementation remuneration policy fixed pay pay performance salary annual bonus committee considered average increases annual bonus plan redesigned better align awarded employees level executive directors iu ambitions trust priority full details proposed uk us due consideration performance changes annual bonus plan please refer agreed appropriate award increases line glance proposed remuneration wider workforce ceo cfo cso ensure policy report pages competitiveness remuneration could maintained bonus opportunity salary base salary change exceptional target maximum performance wider workforce emma walmsley emma walmsley iain mackay iain mackay dr hal barron dr hal barron exceptional performance additional salary fully paid shares based average increase budget employees level glt deferred three years uk us weighting performance measures dr barron transition nonexecutive director effect august adjusted strategic benefits total sales operating operational esg inclusion significant changes provision benefits proposed growth profit growth measures diversity emma walmsley full details policy relation benefits please refer proposed new remuneration policy iain mackay report dr hal barron pension reduced payout target performance table provides overview pension compared current policy proposed increase arrangements ongoing executive director payout opportunity target performance incentivise exceptional outperformance excess iu committee previously committed reduce existing ambitions trust priority goals uk executive directors pensions align wider uk workforce january increasing importance trust business priority esg commitments led us propose inclusion new ukbased usbased executive directors pension diversity human capital management measure annual aligned appropriate wider workforce bonus based upon progress towards aspirational appointment targets gender ethnically diverse representation senior pension contribution roles see emma walmsley base salary matching contributions iain mackay first salary accordance terms inevitably targets linked directly financial strategic plan open employees base plan commercially sensitive committee salary lieu pension salary excess consider appropriate disclose annual bonus targets dr hal barron base salary less contribution k year may result competitive harm however details essp equivalent total base salary bonus performance targets usual disclosed net bonus deferred dabp addition retrospective basis annual report line wider us workforce january combined contribution rate k deferred annual bonus plan dabp awards essp plans core contribution plus match total base salary bonus net table provides details mandatory deferral bonus deferred dabp dabp annual bonus payments associated awards granted shares awarded dr barron transition nonexecutive director effect august performance conditions must held three years regardless continued employment total bonus deferred dabp awards shares shares ads emma walmsley iain mackay dr hal barron gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued implementation remuneration policy continued performance share plan psp awards performance table provides details awards granted relative tsr continue measured gsks psp global pharmaceutical comparator group see total sales growth adjusted operating profit growth salary shares emma walmsley measures recognise importance commercial iain mackay ambitions iu committee set targets align ambitions dr barron receive psp award given transition nonexecutive director august trust business priority proposing new esg environment measure based lti performance measures upon trust priority goal nature net positive proposing changes measures weighting climate net zero impact see lti awards better align iu ambitions targets esg environment measure grant trust priority details please refer based upon series nature goals relating water remuneration policy report new proposed waste materials reduction biodiversity impact climate lti measures weighting goals incorporate scope emission reduction targets carbon offsetting industrialisation green ventolin lti measure measure weighting innovation pipeline progress shareholdings versus share ownership requirement performance relative tsr sor audited total sales growth adjusted operating profit growth align interests executive directors trust esg environment shareholders required build maintain significant holdings shares gsk time executive composite scorecard incorporating scope targets assessment performance metric determined line world resources directors required continue satisfy share instituteworld business council sustainable development ghg protocol ownership requirements sor holding sor methodology accounting reporting emissions footprint first months leaving gsk less innovation sor months leaving gsk pipeline progress measure seeks reward acceleration strengthening pipeline based two equally value holdings salary sor weighted elements key assets indications measured salary february december threeyear performance period emma walmsley points allocated successful assets submeasure iain mackay based upon forecast commercial value peak year sales dr hal barron end performance period shares subject performance conditions excluded submeasures award vest follows executive directors sor calculation end pivotal trial starts performance period vested shares included focuses mainly phase iii registrational trial starts may part directors sor extent performance also include phase ii starts eg oncology conditions met value holdings calculated posttax basis performance level points payout threshold nil dr hal barron ads contributing sor include threshold investments gsk k plan essp emma walmsley dr barron currently exceed sor iain mackay joined board early currently maximum working towards satisfying sor company processes place ensure major regulatory approvals executive directors sor continue satisfied performance level points payout leaving gsk including monitoring nominee accounts threshold nil executive director also agrees terms sor threshold included within service contract maximum pipeline progress measure commercially sensitive time grant end performance period provide full disclosure achievedannual report remuneration continued remuneration governance committee role membership subject election subsequent annual reelection details available incorporated subject mutual agreement expected serve reference report chair ceo chief people three years nine years appointment line officer head reward group financial controller provisions code subject annual company secretary assisted committee year reelection adviser committee committee focus pricewaterhousecoopers llp pwc independent remuneration policy adviser committee since appointed committee sets broad structure remuneration policy initial period three years full commercial tender determines remuneration executive directors exercise concluded company prior expiry chair corporate officers initial period committee reviewed quality items discussed services pwc provided result agreed extend proposed remuneration policy pwcs term end would allow remuneration impact major group restructuring ch full market review undertaken summer demerger followed full commercial tender appropriate prior engagement shareholders consideration feedback presenting recommendations committee adviser salary review support january pwc member committee periodically reviews considers remuneration remuneration consultants group voluntarily environment executive directors glt approving annual operates code conduct relation executive adjustments necessary regard performance remuneration consulting uk code conduct remuneration wider workforce found wwwremunerationconsultantsgroupcom items discussed review remuneration environment wider employee trends year addition providing consultancy services executive director glt benchmarking competitiveness committee pwc provided consulting assurance gsk comparator groups services company line protocols agreed set glt company secretary salary review recommendations committee chair pwc provided advice committee satisfied advice objective executive director salary review recommendations independent pwc provided independent commentary annual bonus matters consideration committee updates committee responsible setting specific performance market practice legislative requirements also reviewed measures annual bonus assessments performance potential conflicts interest judged items discussed appropriate safeguards conflicts pwcs fees ceo executive directors glt bonus recommendations advice year charged fixed ceo executive directors bonus objectives time materials basis willis towers watson provided additional market data committee lti plans committee responsible approving lti plan rule changes shareholder votes remuneration matters grants assessments performance vesting lti awards votes executive directors glt including interim awards total votes total votes total votes withheld cast billion million items discussed remuneration report lti performance outcomes vesting lti awards glt agm remuneration policy confirmation lti grants glt agm governance areas focus committee adheres robust remuneration governance service contracts letters appointment framework ensuring alignment internal actions external table sets dates executive directors reportingcompliance requirements service contracts available review companys items discussed registered office gskcom executive directors remuneration considerations committee programme service contract contains month notice period review terms reference date contract effective date expiry date committee evaluation annual review emma walmsley remuneration report iain mackay na confirmation group budget remuneration purposes agm remuneration report feedback external dr hal barron remuneration environment performance target disclosure dr barron transition nonexecutive director letter appointment incentive plans effect august remuneration report disclosures including ceo pay ratio nonexecutive directors ned letters appointment annual governance meeting key committee messages available view companys registered office committee chair consultation employee representatives ned expected serve board end setting pay wider workforce pay practices agm following third anniversary appointment gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued nonexecutive directors fees chair nonexecutive directors nonexecutive directors fees company aims provide chair non nonexecutive directors fees applied executive directors fees competitive set table paid companies equivalent size complexity per annum subject limits contained articles association standard annual fee supplemental fees chairs fees chair audit risk committee chair paid fee per annum senior independent director takes gsk shares chairs fees reviewed scientific medical experts appointment reviewed annually since chairs remuneration corporate responsibility science committees concluded remained appropriate workforce engagement director nonexecutive director undertaking intercontinental per meeting travel meetings implementation nonexecutive directors policy nonexecutive directors standard supplemental fees last increased effect january following review subject shareholder approval agreed authorise payment fees january science committee members per annum would paid respect additional responsibilities undertaken behalf gsk support rd would reflect time commitment responsibilities expect make increases fees payable nonexecutive directors new policy period total fees audited audited table sets value fees benefits received nonexecutive directors form cash shares ads details nonexecutive directors share allocation plan set nonexecutive directors fees paid currency sterling converted using average exchange rate reviewed time time average exchange rates updated nonexecutive directors fees converted us dollars using exchange rate benefits comprise grossed cash value travel subsistence costs incurred normal course business relation attendance board committee meetings overseasbased directors includes travel meetings uk nonexecutive directors fixed fees fixed fees emoluments audited cash sharesads benefits total pay cash sharesads benefits total pay sir jonathan symonds vindi banga charles bancroft dr anne beal dame vivienne cox lynn elsenhans dr laurie glimcher dr jesse goodman urs rohner judy lewent r etired board may annual report remuneration continued directors interests shares audited executive directors interests shares interests executive directors company office persons closely associated pca shown table december unvested share plan interests beneficial subject total directors interests interests subject performance performance february december sharesads sharesads options sharesads shares emma walmsley iain mackay ads dr hal barron total directors interests include beneficial interests unvested share plan interests subject performance balance february includes sharesads awarded performance share plan psp deferred annual bonus plan dabp vested february less sold satisfy tax liabilities vested amounts executive directors shareholdings versus sor outlined b eneficial interests include sharesads held executive directors pcas emma walmsley includes shares purchased glaxosmithkline share reward plan iain mackay currently participate share reward plan us employee dr hal barron eligible participate share reward plan open uk employees dr barrons beneficial interests include ads notional ads held way investments gsk k plan executive supplemental savings plan essp details dr barrons membership plans found u nvested sharesads subject performance represent psp sharesads vested subject additional twoyear holding period emma walmsley dr barron unvested ads subject performance dr barron also represent bonus deferrals described note unvested options subject performance represent bonus deferrals dabp awarded nilcost options described note unvested sharesads subject performance represent unvested psp awards vested unexercised options none directors hold vested unexercised options abp table shows bonus deferrals subsequent reinvestment dividends dabp amounts represent gross sharesads balances prior sale sharesads satisfy tax liabilities vesting deferred annual bonus plan bonus deferrals february december january shares emma walmsley iain mackay ads dr hal barron uk employees bonus deferrals dabp granted nilcost options emma walmsley iain mackay following table sets details nilcost options exercised number shares date market price gain exercise dabp date grant option exercise grant price exercise emma walmsley deferral award respect nilcost options awarded dabp bonus deferred executive director recorded remuneration annual bonus total remuneration table respect number shares option includes initial award amount together reinvested dividends accrued date exercise gsk annual report gsk annual report strategic report governance remuneration financial statements investor information annual report remuneration continued directors interests shares audited continued nonexecutive directors interests shares interests nonexecutive directors company office persons closely associated pca shown table share allocation plan nonexecutive directors total directors interests number sharesads beneficial dividends elected december interests reinvested december allocated february december year end year january shares sir jonathan symonds vindi banga dame vivienne cox urs rohner ads charles bancroft dr anne beal dr hal dietz lynn elsenhans dr laurie glimcher dr jesse goodman judy lewent otal directors interests include beneficial interests sharesads received part fees nonexecutive directors share allocation plan dividends received sharesads plan year january converted sharesads january beneficial interests includes sharesads held nonexecutive directors pcas haresads allocated year nonexecutive directors share allocation plan cover five quarters allocations period october december due change timing allocations sharesads allocated also includes dividends reinvested year j udy lewent retired board may time holding ads nonexecutive directors share allocation plan released terms plan holding subject uk income tax directors senior management information provided compensation interests directors senior management group group purpose group defined executive nonexecutive directors members glt company secretary financial year following table sets aggregate remuneration group periods served capacity remuneration total compensation paid aggregate increase accrued pension benefits net inflation aggregate payments defined contribution schemes members group awarded shares ads companys various lti plans set table align interests senior management shareholders executive directors glt members required build maintain significant holdings shares gsk time glt members required hold shares equivalent multiple two times base salary must continue satisfy share ownership requirements minimum months leaving gsk awards dividend reinvestment awards awarded shares ads shares ads performance share plan deferred investment awards share value plan n otional shares ads executive directors eligible receive deferred investment awards participate share value planannual report remuneration continued directors senior management continued february group pcas following interests shares ads company interests awarded various lti plans described note financial statements employee share schemes interests february shares ads owned unexercised options deferred annual bonus plan performance share plan deferred investment awards share value plan n otional shares e xecutive directors eligible receive deferred investment awards participate share value plan fees respect executive directors external appointments ceo emma walmsley independent nonexecutive director microsoft corporation received delivered cash stock options microsoft corporations deferred compensation plan nonemployee directors cso dr hal barron nonexecutive director grail inc private company august earned fees payments past directors audited simon dingemans left board may voluntary leaver vesting dabp awards governed remuneration policy prevailing time mr dingemans left board table reflects value deferred bonus accrued dividends point release number date vesting shares vested dabp february payments loss office audited loss office payments made remuneration policy continues reflect provision uk corporate governance code code clarity simplicity remuneration arrangements executive directors set clear simple way remuneration policy prior finalising remuneration policy committee consulted extensively shareholders ensure transparency clarity regarding implementation fixed remuneration elements salary benefits pension closely aligned wider workforce arrangements pay performance plans annual bonus longterm incentive reward delivery financial strategic esg objectives short longterm risk line code operate deferral postvesting holding periods addition malus clawback provisions committee retains discretion adjust award outcomes zero appropriate considers payout determined appropriately reflect overall position performance company predictability proportionality remuneration policy defines maximum limits total annual bonus longterm incentive opportunities payouts elements linked fulfilment performance conditions support companys publicly stated ambitions implementation maximum reward short longterm plans achievable material outperformance stated ambitions alignment culture gsks purpose values strategy directly reflected performance conditions set annual bonus longterm incentive particular introducing esg measure short longterm plans given external ambitions trust priority nature net positive climate net zero ambition share ownership requirements strengthen focus strategic aims ensure alignment interests experiences shareholders employment remuneration policy operated intended terms company performance quantum gsk annual report gsk annual report strategic report governance remuneration financial statements investor information remuneration policy summary remuneration policy review current remuneration policy policy approved create longterm shareholder value shareholders annual general meeting may drive success company benefit received vote favour shareholders shareholders patients people key stakeholders asked approve new policy annual general meeting may intended apply next three years addition changes policy made ensure implementation support delivery business strategy committee considered policy define whilst delivering clear understandable appropriately biopharma business new approach remuneration competitive package attract retain motivate executive decisionmaking process committee followed talent determination review implementation proposed new policy set committee chairs statement pages committee developed new policy executive nonexecutive directors context oversight wider workforce pay however consult directly employees committees review policy sought ensure new policy consulted largest shareholders continues respect proposed changes took shareholders align companys business priorities culture wider feedback account finalising new policy workforce pay policies emerging best practice table provides overview main changes support bold performance ambitions announced proposed respect new policy full policy investors june companys key esg commitments shareholders asked approve set pages remuneration element proposed changes policy rationale change pension description policy updated reflects commitment given reflect pension arrangements current uk remuneration report pension us executive directors aligned new arrangements us executive directors executive directors arrangements january would also aligned new us contribution rates updated executive directors january us references updated reflect latest contribution rates us wider workforce came effect january annual bonus maximum bonus opportunity executive directors additional opportunity salary target performance introduced annual bonus bonus payout salary appropriately focus reward executives bonus equivalent salary deliver exceed public ambitions executive directors required defer secure strong performance bonus earned shares ads appropriate stakeholders three years portion bonus earned excess additional opportunity would salary must deferred deferred full ensure alignment basis shareholders interests nonexecutive authority sought nonexecutive director appropriately remunerate nonexecutive directors fees member science committee directors work remunerated per annum undertaking additional responsibilities behalf gsk support rd current requirement nonexecutive directors company chooses replace chair invest net basic fees current investment requirement shares ads company retained minimum ownership requirement would company may choose replace chair continue maintain meaningful one nonexecutive directors minimum prudent level investment align non share ads ownership requirement least one executive directors interests times gross annual standard fee shareholders retirement board shares ads previously ability replace current investment acquired investment fees would continue requirement would facilitate greater flexibility held arrangements would operation arrangements delivered released following retirement board shares ads would count towards expected minimum ownership requirement remuneration policy report subject shareholder approval may gsks annual general meeting remuneration policy remuneration element outlined table future policy table salary provide core reward role set level appropriate secure retain high calibre change individuals needed deliver groups strategic priorities operation opportunity individuals role experience performance independently formal maximum limit ordinarily salary increases sourced data relevant comparator groups considered broadly line average increases wider determining salary levels gsk workforce salary increases typically take effect first quarter however increases may higher reflect change year scope individuals role responsibilities experience salary adjustments may also reflect wider market conditions salaries normally paid currency executive geography individual operates directors home country details current salary levels set annual report remuneration performance measures overall performance individual key consideration determining salary increases benefits levels set recruit retain high calibre individuals execute business strategy change operation executive director based outside uk executive directors eligible receive benefits line required travel uk fulfil responsibilities policy employees may vary location role attend board meetings may subject tax include limited car allowances healthcare business travel expenses uk life assurancedeath service provided part provision accommodation uk although reality individuals pension arrangements personal financial advice represents business expense tax treatment requires contractual postretirement benefits line policy travel accommodation expenses included employees executive directors may eligible benefits business context tax liabilities receive overseas relocation allowances international covered company grossedup basis transferrelated benefits required executive directors benefit provision tailored reflect market practice uk also eligible participate allemployee share geography executive director based schemes eg share save share reward plan different policies may apply current future executive subject terms directors based different country employees opportunity order recognise high business travel requirements formal maximum limit benefits costs fluctuate role executive directors also entitled car travel depending changes provider cost individual exceptionally may accompanied spousepartner circumstances business trips benefits include expenses incurred ordinary course business deemed taxable details current benefits costs set annual benefits individual report remuneration performance measure none gsk annual report gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued future policy table continued pension pension arrangements provide competitive level retirement income change pension arrangements provide competitive level retirement new executive directors uk receive date income appointment base salary contribution defined contribution plan operation matched contributions subject pension arrangements structured accordance relevant cap line implementation principles plans operated country individual likely members plan retire individual chooses become member base salary cash payment lieu pension pension plan cash lieu relevant pension contribution portion relevant cap contribution paid instead executive directors uk entitled either join defined contribution pension plan base salary cash payment lieu pension receive cash payment lieu pension contribution contribution individual member gsk legacy defined us benefit plan defined contribution plan alternative supplemental cash balance pension plan providing annual pension plan arrangement subsequently appointed contribution base salary less total base salary board may remain member plan bonus net bonus deferred dabp gsk k plan essp core contributions opportunity salary bonus matched contributions policy current executive directors salary bonus uk january current us executive directors base salary contribution defined contribution plan still role pension arrangements aligned matched contributions subject new executive directors arrangements follows relevant cap line implementation principles new executive directors us receive date members plan appointment base salary cash payment lieu pension gsk k plan essp core contributions contribution portion relevant cap salary bonus matched contributions salary bonus base salary cash payment lieu pension global contribution eligible appropriate equivalent arrangement excess january current uk directors still usuk arrangements role pension arrangements aligned new performance measures executive directors arrangements follows none n event change plans operated us similar treatment would provided successor arrangements introduced within market l ess bonus deferred dabp offset equal contribution k essp moved pension plans line wider us workforce january annual bonus incentivise recognise execution business strategy annual basis rewards change achievement stretching annual financial strategic operational measures operation committee may adjust formulaic vesting outcome either financial operational business targets set start ensure overall outcome reflects underlying year committee bonus levels determined business performance vesting period clawback andor committee based performance targets malus provisions apply described strategic operational measures set start opportunity year committee performance maximum bonus opportunity executive directors measures assessed committee salary target performance bonus executive directors required defer part bonus earned payout financial measures nil target shares ads appropriate three years performance bonus payout salary equivalent first salary deferred portion excess deferred full deferred bonus shares eligible dividend equivalents date vesting remuneration policy report continued future policy table continued performance measures based combination financial targets individual reason majority annual bonus opportunity strategic esg performance objectives majority based formal review performance stretching bonus assessed financial measures financial targets remainder bonus subject weighting different measures determined assessment individual performance key strategic year according business priorities details including operational measures aligned companys measures used financial year provided key objectives financial year andor assessment annual report remuneration performance esg targets selection annual bonus measures annual bonus financial targets set reference annual bonus designed drive achievement internal budget external consensus targets gsks annual financial strategic operational measures performance incentivise recognise delivery longer term business priorities financial growth share plan psp increases shareholder value compared pharmaceutical companies addition provide alignment shareholder interests retention element encourage longterm change shareholding discourage excessive risk taking operation opportunity conditional awards made annually vesting dependent normal maximum award limits may granted achievement performance conditions three years psp individual one year set table subject additional twoyear holding period psp targets set reference internal budget external salary consensus targets ceo awards eligible dividend equivalents date cfo vesting release executive directors committee may adjust formulaic vesting outcome performance measures either ensure overall outcome reflects based combination financial share price related underlying business performance vesting period strategic esg performance conditions aligned clawback andor malus provisions apply described companys strategic plan measures awards vest threshold performance details including performance targets attached psp respect year weightings targets psp awards provided annual report remuneration selection longterm incentive measures major adjustment calculation performance committee selects performance measures focus measures disclosed shareholders vesting executive directors longterm remuneration delivery audit risk committee chair members gsks key strategic priorities longer term addition also members remuneration committee provide input setting robust targets committee implemented number audit risk committees review groups safeguards ensure targets met sustainable way performance oversight risk factors relevant performance reflects genuine achievement targets remuneration decisions therefore represents delivery value shareholders details rationale behind performance measures performance measure impact acquisition selected calculated set annual divestment quantified adjusted event report remuneration share ownership requirements change align interests executive directors minimum executive directors required maintain shareholders required build maintain share ownership requirements end significant holdings shares gsk time first year following retirement company requirements executive director follows end second year salary ceo executive directors gsk annual report gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued future policy table continued clawback malus change event triggering event ie significant misconduct respect financial year remuneration committee way violation regulation law significant gsk policy disclose whether recoupment committee code conduct material misstatement results exercised clawback malus disclosure made serious reputational damage company matter subject public reports ability claw back three years annual deferred misconduct fully resolved legally bonuses well vested unvested ltis addition permissible disclose made without respect psp awards made participant unduly prejudicing company therefore shareholders subject investigation vesting awards additionally continuity responsibility may delayed outcome investigation initiation adverse event emergence separate recoupment committee established problem adverse event taken account investigate relevant claims misconduct recoupment assessing annual bonus awards lti vesting levels committee exercises authority wider employee base year problem identified future periods comprises senior executives relevant oversight remuneration committee recoupment committee may appropriate experience including senior vice president make appropriate adjustments individual annual bonuses chief compliance officer senior vice president well grant vesting levels lti awards reflect group general counsel legal compliance approach recruitment remuneration change committee determines remuneration package new internal appointments entitlements existing executive directors casebycase basis depending remuneration elements continue including pension role market operate entitlements outstanding awards however experience total remuneration levels set reference already case internal appointments required relevant pay comparator group appropriate move executive director contractual terms including allow future development role termination provisions expected new executive directors participate committee mindful sensitivity relating short longterm incentive plans basis recruitment packages particular buying existing directors however exceptional circumstances rights relating previous employment therefore seek committee reserves flexibility set incentive limit minimise arrangements however certain new executive director additional circumstances enable recruitment exceptional talent existing limits committee may determine arrangements best interests company shareholders committee retains flexibility recognition high arrangements possible likeforlike basis levels variable pay gsks global pharmaceutical forfeited remuneration terms arrangements competitors however committee use flexibility therefore vary depending plans arrangements put considered best interests company place previous employer may form investors cash shares may may subject performance pension arrangements external recruit executive conditions explanations provided payments director set remuneration policy table made compensation previous remuneration forfeited remuneration arrangements newly appointed benefits provided line policy existing executive director disclosed soon practicable executive directors appointment required meet business needs relocation support provided line company policy remuneration policy report continued future policy table continued loss office payment policy change company policy fixed term contracts notice period termination employing company generally contracts new appointments expire line executive director calendar months applicable policy retirement age since ability impose month noncompete period nonsolicitation restriction executive director contracts existing executive directors expire considered important company ability dates shown protect groups intellectual property staff light committee believes would appropriate provide mitigation contracts termination employment event executive directors employment company terminates following policies payments apply element remuneration loss office payment policy termination termination notice months annual salary payable termination company prorated part notice period worked payment termination payment made respect part notice period extends beyond contract expiry date bonus element normally included termination payment however terms contracts seek balance commercial imperatives best practice redundancy termination notice uk statutory redundancy pay apply us general severance policy apply retirement death illhealth injury disability termination payment lti awards psp awards governed plan rules approved shareholders following provisions normally apply termination notice unvested awards lapse redundancy retirement death illhealth injury disability reason generally awards continue vest original timescales subject performance prorated time event change control psp awards vest taking account performance date normally taking account proportion performance period elapsed alternatively awards may exchanged new awards annual bonus termination notice individual individual serves notice termination date falls december bonus forfeited termination notice company redundancy retirement death illhealth injury disability termination date falls financial year eligible prorated ontarget bonus employed december bonus payable based actual results mandatorily dabp deferred bonus awards respect mandatorily deferred bonus amounts governed plan rules approved shareholders deferred following provisions normally apply bonus termination gross misconduct generally unvested awards lapse dabp reason generally awards vest full original vesting date event change control awards vest may exchanged new awards pensions pension scheme contributions individual company pension scheme benefit accruals generally cease termination date accordance pension scheme rules access pension scheme benefits governed pension scheme rules country legislation benefits generally benefits continue apply termination date committee may make payments connection existing legal obligation respect claim related cessation employment may include fees outplacement assistance legal andor professional advice termination notice company retirement us executives line policy applicable us senior executives may become eligible future date receive continuing medical dental insurance terminationretirement termination mutual agreement certain circumstances best interests company board manage proactively succession planning development senior talent pipeline circumstances board may therefore agree executives departure mutual agreement order apply committee need satisfied executive demonstrated performance line expectations required contributed orderly succession case executive director would treated good leaver purposes gsks longterm incentive plans termination date falls financial year would eligible prorated ontarget bonus employed december bonus payable would based actual results gsk annual report gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued loss office payment policy continued committee anticipate exercise discretion executive director leaves company provided psp dabp plan rules respect committee carry assessment individuals termination payments manner would benefit performance conduct time role executive director however may unforeseen determined individuals performance conduct circumstances best interests company contrary legitimate expectations company shareholders necessary exercise committee reserves right apply appropriate mechanisms discretion explanations provided clawback reduction lapsing outstanding incentive awards malus ensure termination payments best interests company shareholders see differences remuneration policy executive directors employees setting remuneration executive directors employees directly consulted respect committee considers companys strategic priorities remuneration policy urs rohner committee chair prevailing market conditions global talent competitive meets senior hr representatives across business environment comparison remuneration review employee feedback dame vivienne cox executives companies similar size complexity independent nonexecutive director engages employees international reach positioning relativities pay various topics including remuneration role employment conditions across broader gsk workforce workforce engagement director board members engage employees around board meetings particular committee considers range base encouraged share views company management salary rises workforces parts gsk remuneration executive directors employed considered relevant comparison populations reflect wider organisation aligned performance closely economic environments encountered reward systems innovation performance trust individuals priorities culture anchored purpose performance performance system evaluates employees principles apply remuneration policy need also senior executive directors employees although people disincentivise unethical working practices using remuneration offered executive directors clawback mechanism allows us recover performance policy stronger emphasis performancerelated pay related pay offered employees group salary benefits including pension tailored local market annual bonus plan applies wider employee population based business performance combination performancerelated restricted share plans apply wider employee population allemployee share plans available employees uk including hm revenue customs approved uk share save share reward plans remuneration policy report continued scenarios future total remuneration charts opposite provide illustrations future total remuneration executive directors respect emma walmsley remuneration opportunity granted proposed remuneration policy range potential outcomes provided executive director underlying assumptions set scenarios base salary used benefits figures used ie based actual amounts received pensions emma walmsley iain mackay based upon salaries amounts shown value psp awards based upon relevant multiples include amounts respect dividends reinvested factor changes share price vesting period except fixed expected maximum maximum share price described increase fixed includes base salary pension benefits excludes pay iain mackay performance ie annual bonus would paid psp awards would vest expected includes fixed pay annual bonus assumed target performance achieved psp awards amounts reflect vesting levels maximum fixed expected maximum maximum share price assumed annual bonus would payable increase maximum level ie awards psp would vest full fixed pay annual bonus psp share price increase maximum share price increase elements maximum assuming increase share price gsk annual report gsk annual report strategic report governance remuneration financial statements investor information remuneration policy report continued nonexecutive director remuneration policy nonexecutive directors fees change element purpose link strategy operation chairs fees provide inclusive flat rate formal maximum however fees reviewed annually set reference fee competitive review chairs performance independently sourced market data paid companies committee responsible evaluating making recommendations board equivalent size fees payable chair chair participate discussions respect fees complexity subject limits contained gsks articles association basic fees formal maximum chair fees reviewed annually set reference independently sourced data chair ceo responsible evaluating making recommendations board fees payable companys nonexecutive directors fee payment alignment shareholders fees paid cash nonexecutive directors including chair required invest least total net fees shares ads company company may choose replace ownership requirement hold shares ads aggregate value one times gross annual standard fee retirement board current investment requirement replaced ownership requirement shares ads previously acquired investment fees would continue held arrangements would delivered released following retirement board shares ads would count towards minimum ownership requirement supplemental compensate nonexecutive additional fees senior independent director committee chairs science medical experts fees directors workforce engagement director role intercontinental travel chair taking additional company authority pay additional fee equivalent committee chair board responsibilities supplement nonexecutive director company require significant additional time undertaking intercontinental commitment exceptional unforeseen circumstances travel company authority pay additional fee nonexecutive directors excluding chair members science committee undertaking additional responsibilities behalf gsk support rd benefits facilitate execution travel subsistence costs nonexecutive directors incurred normal course business responsibilities duties relation meetings board committee matters gskhosted events overseas required role based nonexecutive directors includes travel meetings uk event necessary business purposes whilst normal practice nonexecutive directors may accompanied spouse partner meetings events costs associated met company instances deemed taxable therefore treated benefits nonexecutive director approach recruitment remuneration change following policy principles apply roles chair nonexecutive directors nonexecutive director seeks ensure alignment fee levels new nonexecutive directors set shareholders requirement invest company basis existing nonexecutive directors shares ads company subject local laws regulations event nonexecutive director different role chair responsibilities appointed fee levels benchmarked fees set level competitive paid set reference comparable roles companies companies equivalent size complexity fees equivalent size complexity paid partly shares loss office change chair nonexecutive directors entitled receive payments respect fees loss office retire step board remuneration policy report continued operation scope remuneration policy remuneration policy policy set pages ii policy came effect provided terms annual report intended policy payment consistent shareholderapproved gsks executive nonexecutive directors operate remuneration policy force time agreed period three years date approval companys iii time relevant individual director annual general meeting may company opinion committee payment committee wrote policy principally relation consideration individual becoming director remuneration arrangements executive directors whilst company purposes payments includes taking account possible recruitment replacement committee satisfying awards variable remuneration additional executive director operation relation award shares ads terms policy committee intends policy operate payment agreed time award granted period set entirety however may due performance share plan psp awards subject consideration seek change policy period terms psp plan rules award believes appropriate longterm granted committee may adjust amend awards success company consultation shareholders accordance provisions plan rules includes sought shareholder approval general meeting making adjustments reflect oneoff corporate events committee reserves right make remuneration change companys capital structure payments andor payments loss office including committee may also make minor amendments policy exercising discretions available connection regulatory exchange control tax administrative purposes payments notwithstanding line take account change legislation without obtaining policy terms payment agreed shareholder approval amendments agm may date companys first shareholderapproved directors remuneration policy came statement consideration shareholder views effect committee engages regular dialogue shareholders holds annual meetings gsks largest investors discuss take feedback remuneration policy practices governance matters basis preparation annual report remuneration prepared annual report remuneration approved accordance companies act large board directors signed behalf mediumsized companies groups accounts reports amendment regulations regulations accordance regulations following parts urs rohner annual report remuneration subject audit total remuneration committee chair remuneration figures executive directors including february details element remuneration salary benefits pension annual bonus longterm incentive awards nonexecutive directors fees emoluments received year directors interests shares including interests gsk share plans payments past directors payments loss office share ownership requirements holdings opinion thereon expressed remaining sections annual report remuneration subject audit pages referred within audited sections gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial statements section directors statement responsibilities independent auditors report financial statements notes financial statements financial statements glaxosmithkline plc prepared uk gaap gsk annual report strategic report governance remuneration financial statements investor informationdirectors statement responsibilities directors responsible preparing annual report directors responsible keeping adequate accounting remuneration report group parent company records sufficient show explain companys financial statements accordance applicable law transactions disclose reasonable accuracy time regulations financial position group enable ensure group financial statements remuneration uk company law requires directors prepare financial report comply companies act article statements financial year directors required ias regulation also responsible safeguarding prepare group consolidated financial statements assets group hence taking reasonable steps accordance international accounting standards prevention detection fraud irregularities conformity requirements companies act international financial reporting standards ifrs group financial statements year ended issued international accounting standards board iasb december comprising principal statements directors elected prepare parent company supporting notes set financial statements financial statements accordance united kingdom pages report parent company accounting standards applicable law united kingdom financial statements year ended december generally accepted accounting practice company law comprising balance sheet statement changes directors must approve financial statements unless equity year ended december supporting satisfied give true fair view state notes set pages affairs group profit loss period responsibilities auditor relation financial preparing financial statements directors statements set independent auditors report required pages select suitable accounting policies apply financial statements year ended december consistently included annual report published printed form made available website directors make judgements accounting estimates responsible maintenance integrity annual reasonable prudent report website accordance uk legislation state group financial statements comply governing preparation dissemination financial ifrs issued iasb conformity statements access website available outside requirements companies act uk comparable legislation may different state regard parent company financial statements current directors whose names functions applicable uk accounting standards listed corporate governance section annual followed subject material departures disclosed report confirms best knowledge explained parent company financial statements group financial statements prepared prepare financial statements going concern basis accordance ifrs issued iasb unless inappropriate presume group conformity requirements companies act parent company continue business give true fair view assets liabilities financial position profit group strategic report risk sections annual report represent management report include fair review development performance business position company group taken whole together description principal risks uncertainties faces gsk annual report gsk annual report strategic report governance remuneration financial statements investor information directors statement responsibilities continued disclosure information auditor uk corporate governance code directors office date annual report board considers glaxosmithkline plc applies confirmed principles complies provisions uk corporate governance code maintained financial reporting far aware relevant audit council described corporate governance section information companys auditor unaware pages board considers taken steps ought annual report taken whole fair balanced taken director make aware understandable provides information necessary relevant audit information establish companys shareholders assess groups position performance auditor aware information business model strategy confirmation given interpreted required financial conduct authoritys listing rules accordance provisions section auditor considered directors statement companies act compliance relation points uk corporate governance code specified review going concern basis pages contain information performance annual report group financial position cash flows net debt position annual report year ended december borrowing facilities information including treasury comprising report directors remuneration risk management policies exposures market credit risk report financial statements additional information hedging activities given note financial investors approved board directors statements financial instruments related disclosures signed behalf assessed principal risks matters considered connection viability statement sir jonathan symonds directors considered appropriate adopt going concern chairman basis accounting preparing financial statements february internal control board audit risk committee reviewed assessment risks internal control framework operates gsk considered effectiveness system internal control operation group year covered annual report date approval board directors detail review internal controls set governance report independent auditors report members glaxosmithkline plc report audit financial statements opinion basis opinion opinion conducted audit accordance international standards auditing uk isas uk applicable law financial statements glaxosmithkline plc parent responsibilities standards company subsidiaries group give true described auditors responsibilities audit fair view state groups parent financial statements section report companys affairs december groups profit year ended independent group parent company accordance ethical requirements relevant group financial statements properly prepared audit financial statements uk including accordance united kingdom adopted international financial reporting councils frcs ethical standard accounting standards international financial reporting applied listed public interest entities fulfilled standards ifrss issued international accounting ethical responsibilities accordance standards board iasb requirements confirm provided parent company financial statements properly nonaudit services prohibited frcs ethical standard prepared accordance united kingdom generally group parent company noted audit risk accepted accounting practice including frs reduced committee report within corporate governance section disclosure framework annual report financial statements prepared accordance believe audit evidence obtained requirements companies act sufficient appropriate provide basis opinion audited financial statements comprise audit scope execution group structured approach audit reflect consolidated balance sheet december group organised well ensuring audit consolidated income statement year ended effective risk focused audit approach consolidated statement comprehensive income summarised following areas enabled us obtain year ended evidence required form opinion group consolidated statement changes equity year parent company financial statements ended risk assessment audit planning group level consolidated cash flow statement year ended central control common systems throughout group enabled us structure audit centrally use notes financial statements includes data analytic tools allowed detailed understanding accounting principles policies flow transactions enabling us focus risk assessment design targeted audit testing procedures parent company risk assessment procedures considered amongst balance sheet december factors impact global pandemic climate change account balances disclosures company statement changes equity year ended practices appointed partners group audit team notes l financial statements includes lead global audit three business units accounting principles policies pharmaceuticals vaccines consumer healthcare addition partners responsible component legal financial reporting framework applied entity audits country global business unit preparation group financial statements applicable law partners met regularly senior business unit management united kingdom adopted international accounting standards understand strategy performance matters ifrss issued iasb financial reporting arose throughout year could impacted framework applied preparation financial reporting addition held regular meetings parent company financial statements applicable law members internal audit internal legal counsel united kingdom accounting standards including frs global ethics compliance teams understand reduced disclosure framework united kingdom generally work review reports enhance risk accepted accounting practice assessment audit work performed global shared service centres significant amount groups operational processes cover financial reporting undertaken shared service centres group audit team included senior individuals responsible global processes coordinated audit work shared service centres gsk annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued inscope group audit ensure developed good impact climate change audit understanding endtoend processes supported climate change potential impact group material account balances classes transactions number ways set strategic report pages disclosures within group financial statements annual report notes evaluated effectiveness internal controls financial financial statements group set environmental reporting processes considered goals paris climate accord net zero impact implications remainder audit work climate net positive impact nature audit work executed component level individual planning audit considered potential legal entities following components subject impact climate change groups business audit procedures well assessment financial statements effectiveness internal controls financial reporting sought understand groups identification australia belgium canada china france germany italy assessment potential impacts climate change japan spain switzerland united kingdom united risks influence groups strategy implications states group audit team active dialogue financial statements throughout audit component audit teams responsible audit work direction groups assessment focused impacts supervision group audit team included frequent extreme weather conditions water scarcity changes determining whether work planned performed political landscape media focus accordance overall group audit strategy propensity cause changes consumer market requirements group audit instructions behaviour volatility costs availability materials components due restrictions overseas travel resources could impact future financial performance visit components year consistent prior asset valuations year satisfy oversight supervision consultation climate change specialists appropriate performed remote reviews audit working papers using videoconferencing technology conducted detailed risk assessment procedures across increased frequency length reviews inscope balances transactions determine risks depending significance risk component material misstatement financial statements applying continued attend planning clearance meetings expected impact climate change understanding components business audit procedures undertaken group level challenged appropriateness groups assessment parent company addition also performed potential impact climate change impact audit work group parent company financial financial statements including area statements including limited consolidation intangible assets described section report groups results preparation financial used assessment impact climate change statements certain disclosures within directors challenge groups assessment going concern remuneration report litigation provisions exposures including considering potential impact future addition entity level oversight controls relevant performance availability financing financial reporting components legal entities engaged provide assurance annual revenue greater total group revenue accuracy climate change disclosures set pages included audit scope components legal annual report part audit procedures entities covered audit scope subject required read consider disclosures analytical procedures confirm conclusion consider whether materially inconsistent significant risks material misstatement financial statements knowledge obtained audit aggregated financial information identify material inconsistencies result internal controls testing approach tested procedures effectiveness internal controls financial reporting across inscope entities entity level controls application materiality group level common systems allowed relevant define materiality magnitude misstatement controls tested centrally across components financial statements makes probable economic able place reliance controls planned decisions reasonably knowledgeable person would efficient notwithstanding controls changed influenced use materiality planning deficiencies disclosed key audit matters section scope audit work evaluating results report mitigating controls existed allowed us work continue take reliance controls planned audit scope addressed groups revenue groups profit tax groups total assetsindependent auditors report continued report audit financial statements continued based professional judgement determined agreed audit risk committee would materiality financial statements whole follows report committee audit differences excess million million well differences parent company group financial statements financial statements threshold view warranted reporting materiality million million qualitative grounds also report audit risk million million committee disclosure matters identified basis determining benchmark materiality assessing overall presentation financial statements determining materiality considered determined using materiality metrics used investors total assets benchmark conclusions relating going concern readers financial statements capped particular considered group materiality auditing financial statements concluded statutory profit tax adjusted materiality represents directors use going concern basis accounting profit tax revenue net total assets preparation financial statements appropriate cash flows operations using professional judgement evaluation directors assessment groups determined materiality parent companys ability continue adopt going concern million basis accounting included metric enquiries group directors management regarding statutory profit tax assumptions used going concern models including adjusted profit tax potential impact climate change revenue net cash inflow evaluating groups existing access sources operating activities financing including undrawn committed bank facilities reconciliation statutory reading analyst reports industry data external profit tax adjusted profit tax detailed adjusting information determine provided corroborative items section strategic report contradictory evidence relation assumptions used comparing forecasted sales recent historical financial rationale given importance parent company information metrics used investors holds groups benchmark readers financial statements investments testing underlying data generated prepare forecast applied concluded statutory profit profitoriented scenarios determined whether adequate tax primary strength benchmark adjusted profit balance sheet key support assumptions underlying forecast tax revenue net cash measure financial evaluating groups disclosures going concern inflow operating activities health important supporting benchmarks shareholders since requirements ias component materiality primary concern based work performed identified allocated inscope parent company material uncertainties relating events conditions components ranged payment million million dividends using individually collectively may cast significant doubt benchmark total groups parent companys ability continue going range materiality allocated assets therefore concern period least twelve months across components audit appropriate metric prior years group financial financial statements authorised issue statements relation reporting group applied million million uk corporate governance code nothing material set performance materiality level lower materiality add draw attention relation directors statement reduce probability aggregate uncorrected financial statements whether directors considered undetected misstatements exceed materiality appropriate adopt going concern basis accounting financial statements whole group parent company responsibilities responsibilities directors performance materiality set group parent respect going concern described relevant sections materiality respectively audit report determining performance materiality considered factors including risk assessment including assessment groups overall control environment consider appropriate rely controls number business processes past experience audit indicated low number corrected uncorrected misstatements identified prior periods gsk annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matters key audit matters matters professional judgement significance audit financial statements current period include significant assessed risks material misstatement whether due fraud identified matters included greatest effect overall audit strategy allocation resources audit directing efforts engagement team matters addressed context audit financial statements whole forming opinion financial statements whole provide separate opinion matters key audit matter description scope audit responded key audit matter valuation viiv healthcare shionogi contingent audit procedures performed consideration liability performed following audit procedures amongst others group completed number significant transactions related sales forecasts resulted recognition material contingent obtained groups assessment key inputs consideration liabilities key source estimation assumptions used forecasts evaluated uncertainty significant liabilities appropriateness including enquiries key individuals viiv healthcare shionogi contingent consideration liability senior leadership team commercial strategy team viiv ccl key personnel involved budgeting forecasting process group completed acquisition remaining inspection supporting evidence interest shionogiviiv healthcare joint venture challenged us volume assumptions made group upon completion group recognised contingent estimate sales forecasts involved benchmarking forecast consideration liability fair value expected future market share data external data total payments made shionogi december prescription volumes new patient prescription volumes liability valued million order assess sources contradictory evidence identified viiv ccl key audit matter evaluated reasonableness us pricing assumptions significant management estimates assumptions relating group comparing forecasted returns rebates rate sales forecasts used valuing viiv ccl product current rate assessing forecasted sensitivity valuation inputs significant returns rebates comparable products relate sales forecasts united states us expected changes payer policy certain products treatment portfolio forecasts based assessment expected launch dates considered results clinical studies undertaken year ability shift market practice prescriber behaviour towards group key competitors order assess whether longacting injectable treatments drug regimens corroborative contradictory assumptions used continuing impact covid related restrictions hiv product portfolio sales forecasts us prescriptions subsequent sales volumes pricing benchmarked groups sales forecasts forecasts also required significant audit effort perform included reports analysts considered sales appropriate audit procedures challenge evaluate forecasts total viiv basis individual product reasonableness forecasts basis assessing identified contradictory data set note post balance sheet events group inspected agreement gilead evaluated financial statements agreement reached gilead managements approach ensure meets relevant accounting settle global patent infringement litigation relating standards requirements inputs used estimating commercialisation gileads biktarvy increases future impact fair value viiv ccl consistent consideration payable shionogi therefore impacts fair agreement external data value viiv ccl result audit assessed managements estimate impact tested controls key inputs assumptions used valuation contingent consideration liability including contingent consideration liabilities including viiv ccl review controls sales forecasts treatment product disclosed key source estimation uncertainty note portfolio used value viiv ccl group financial statements disclosures provided notes matter also discussed key observations communicated audit risk committee audit risk committee report within corporate sales forecasts used valuation reasonable line governance section annual report relevant supporting information satisfied sales forecasts reasonable appropriately reflect trends overall hiv treatment market including changes competitive environment shifts towards longacting injectable treatments drug regimens approach valuing viiv ccl consistent prior periods overall satisfied valuation liability reasonable consistent ifrsindependent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation us returns rebates rar accruals audit procedures performed us group sells customers various commercial performed following audit procedures amongst others government mandated contracts reimbursement related estimates rar accruals arrangements include rebates chargebacks right challenged assumptions selection utilisation rates return certain pharmaceutical products revenue focusing certain products concluded accrual recognition reflects grosstonet sales adjustments sensitive assumptions challenge included adjustments known returns rebates rar comparison historical utilisation rates consideration accruals source significant estimation uncertainty historical accuracy drivers market changes could material impact reported revenue impact ongoing generic competition macroeconomic us pharmaceuticals business million impacts covid pandemic rar deductions made gross revenue million supplemented substantive analytical procedures resulting net revenue million balance sheet developing independent expectation accrual balance accrual december combined us key segments based historical claims received pharmaceuticals vaccines businesses amounted adjusted reflect market changes period including million assessment time lag initial point sale three significant payer channels also referred claim receipt compared independent buying groups rar accrual relates managed expectation recorded evaluate appropriateness healthcare organisations medicaid ryan white medicare year ending accrual position part considered historical accuracy estimates evaluated two main causes significant estimation uncertainty whether forecast assumptions appropriately updated selection cases actual rebate claims differed utilisation rate portion total sales amount accrued made payer channel estimated group recording accruals utilisation assumption challenged appropriateness completeness challenging key assumptions used derive accrual periodend adjustments liability made part given influenced market demand factors ongoing review estimated accrual outside control group tested key controls estimation rar accruals time lag point sale point including controls associated forecasting exact rebate amounts known group upon receipt utilisation rates process monthend accrual review claim payer channels longest time lag result controls greater accrued period therefore greater level key observations communicated audit risk committee estimation uncertainty estimating period end accrual satisfied estimated liability rar accruals level estimation uncertainty also impacted significant yearend appropriate observed level prudence shifts channel mix driven changes competitive estimate assessing independent landscape including competitor generic product launches expectations accordance requirements ifrs macroeconomic factors focus revenue contracts customers limit risk utilisation assumptions products deem significant reversal revenue level estimation uncertainty significant furthermore auditing standards presume significant fraud risk exists revenue recognition line presumption also focus periodend adjustments made rar accruals adjustments reflected updates made initial assumptions included within forecasted rar rates view present greatest opportunity fraud revenue recognition notwithstanding existence internal controls us pharmaceuticals returns rebates disclosed key source estimation uncertainty note group financial statements disclosures provided note matter also discussed audit risk committee report within corporate governance section annual report gsk annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation intangible assets audit procedures performed december group held million performed following audit procedures amongst others intangible assets including licences patents trademarks related future sales growth likelihood successful new brand names excluding goodwill computer product innovations profit margin levels used assessment software recoverable amount intangible intangible assets impairment assets relies certain assumptions estimates future met key individuals senior leadership team trading performance create estimation uncertainty product category leads key personnel involved assets risk material impairment identified forecasting process discuss evaluate groups using sensitivity analysis key assumptions review evidence support future sales growth rates profitability potential triggering events could indicative assumptions impairment carrying value associated assets evaluated groups risk assessment impact climate result analysis performed additional audit procedures change long term forecasts focused largest certain indefinite life consumer healthcare intangible assets products material carrying values least headroom key assumptions applied determining recoverable amount comparing external data points include future sales growth rates profit margin levels evaluated business assumptions applied estimating sales well likelihood successful new product innovations gross profit margin forecasts including benchmarking changes assumptions could lead impairment forecasts external market data actual trading carrying value intangible assets performance costs included independent market research identified valuation intangible assets key expected category growth assessment sources audit matter due inherent judgements involved contradictory evidence estimating future cash flows year compared forecast sales gross profit margins increased uncertainty brought covid plan data asset asset internal forecasts approved pandemic associated lockdowns auditing estimates gsk leadership team board directors required extensive audit effort challenge evaluate reasonableness forecasts assessed historical accuracy forecasts including consumption data estimates new sales innovation disclosures relating intangible assets included note group financial statements matter considered whether events transactions occurred also discussed audit risk committee report within balance sheet date reporting date affect corporate governance section annual report conclusions reached carrying values assets associated disclosures tested review controls key inputs assumptions used valuation intangible assets controls encompass review valuation models contain number assumptions revenue growth rates profit margins key observations communicated audit risk committee audit challenged future forecast performance consumer healthcare products concluded assumptions underpinning impairment review intangible assets reasonable accordance ifrsindependent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter valuation uncertain tax positions including transfer audit procedures performed pricing support tax specialists assessed group operates numerous jurisdictions appropriateness uncertain tax provisions performing open tax transfer pricing matters exposures uk following audit procedures amongst others us overseas tax authorities give rise uncertain tax assessed challenged provisions uncertain tax positions positions wide range possible outcomes evaluation possible outcomes procedures provisions contingencies certain judgements respect focused jurisdictions group estimates tax exposures contingencies required greatest potential exposure highest level order assess adequacy tax provisions judgement required sometimes complex result considerations required multiple tax laws regulations assessed assumptions judgements required determine range possible outcomes recognition december group recorded provisions measurement uncertain tax positions compliance million respect uncertain tax positions requirements ifric valuation uncertain tax positions disclosed key source involved transfer pricing specialists evaluate transfer estimation uncertainty note group financial pricing methodology group associated approach statements disclosures included note provision recognition measurement matter also discussed audit risk committee report within corporate governance section annual report considered evidence actual results recent tax authority audits enquiries thirdparty tax advice obtained group tax specialists knowledge market practice relevant jurisdictions tested key controls preparation review reporting judgmental tax balances transactions include provisions uncertain tax provisions key observations communicated audit risk committee satisfied estimates relation uncertain tax positions related disclosures accordance ifrs work concluded consistent approach applied estimating uncertain tax provisions whilst continuing prudent required ifric appropriate supportable gsk annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued key audit matter description scope audit responded key audit matter systems impact financial reporting audit procedures performed systems within group form critical component audit scope driven level reliance placed groups financial reporting activities impact account technology obtain sufficient audit evidence within business balances process technology deemed relevant audit based financial data system configured automated controls andor key identified systems impact financial reporting financial reports reside within used specialists key audit matter support evaluation risks associated technology pervasive reliance complex technology integral testing design operation controls operation key business processes financial testing technology deemed relevant audit included reporting following areas reliance technology continues increase line general controls including user access change business strategy increase use management controls automation across group key financial reports system configured automated controls importance controls maintaining effective control environment key interdependency exists controls provide assurance completeness ability rely controls ability rely accuracy relevant data migrations financial data system configured automated controls testing remediation previously identified deficiencies system reports risk assessment procedures included assessment continued remediation controls supporting impact unremediated control deficiencies determine application systems relevant groups financial impact audit plan relevant audit plan reporting activities adjusted include testing additional manual business implementation application systems key business process controls mitigate unaddressed risk areas year key observations communicated audit risk committee systems impact financial reporting discussed satisfied controls impacting groups financial audit risk committee report within corporate reporting activities designed operating effectively control governance section annual report deficiencies identified remediated year end mitigated compensating controls significant progress made year remediating control deficiencies relating user access change management group many layers business process controls mitigate risk associated remaining control deficienciesindependent auditors report continued report audit financial statements continued information information comprises information included annual report financial statements auditors report thereon directors responsible information contained within annual report opinion financial statements cover information except extent otherwise explicitly stated report express form assurance conclusion thereon responsibility read information consider whether information materially inconsistent financial statements knowledge obtained course audit otherwise appears materially misstated identify material inconsistencies apparent material misstatements required determine whether gives rise material misstatement financial statements based work performed conclude material misstatement information required report fact summarise work relation areas information including areas upon specifically required report matters specifically required report responsibility reporting principal risks viability statement review confirmation description light knowledge set corporate governance statement gathered audit considering directors section nothing material report add draw processes support statements made challenging key judgements attention respect matters estimates consideration historical forecasting accuracy evaluating macroeconomic assumptions consider statements aligned relevant provisions code directors remuneration report report whether part directors remuneration report audited set opinions matters prescribed properly prepared disclosures specified companies act companies act section opinion part made directors remuneration report audited prepared accordance companies act strategic report directors report report whether consistent audited financial statements set opinions matters prescribed prepared accordance applicable legal requirements companies act section opinion based work undertaken course audit report identified material misstatements either report information reports consistent light knowledge understanding group parent audited financial statements prepared company environment obtained course audit accordance applicable legal requirements gsk annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued reporting information responsibility reporting alternative performance measures apms apms measures defined generally accepted accounting opinion practice gaap therefore typically included financial use calculation disclosure apms statement part annual report group use apms adjusted consistent groups published definitions profit free cash flow constant currency growth rates reporting policies financial performance use apms groups reporting results reviewed assessed calculation reporting consistent guidelines produced esma metrics assess consistency groups published definitions frc policies items appropriate balance use also considered assessed whether use apms statutory metrics apms together clear groups reporting results consistent guidelines produced definitions reconciliation apms used financial regulators european securities markets authority esma reporting guidelines use apms frc alternative performance measures thematic review published october also considered whether appropriate balance use statutory metrics apms addition whether clear definitions reconciliation apms used financial reporting provided dividends distribution policy consider whether dividends policy transparent dividends paid opinion dividends policy appropriately consistent policy outlined strategic report disclosed dividends paid consistent policy responsibilities directors auditors responsibilities audit financial statements explained fully directors responsibilities statement directors responsible preparation objectives obtain reasonable assurance financial statements satisfied give whether financial statements whole free true fair view internal control directors material misstatement whether due fraud error determine necessary enable preparation financial issue auditors report includes opinion reasonable statements free material misstatement whether assurance high level assurance guarantee due fraud error audit conducted accordance isas uk always detect material misstatement exists preparing financial statements directors misstatements arise fraud error considered responsible assessing groups parent material individually aggregate could reasonably companys ability continue going concern disclosing expected influence economic decisions users taken applicable matters related going concern using basis financial statements going concern basis accounting unless directors either intend liquidate group parent company cease description responsibilities audit operations realistic alternative financial statements located frcs website wwwfrcorgukauditorsresponsibilities description forms part auditors reportindependent auditors report continued report audit financial statements continued audit response risks identified extent audit considered result performing identified valuation capable detecting irregularities including us returns rebates accruals key audit matter fraud related potential risk fraud key audit matters irregularities including fraud instances noncompliance section report explains matter detail also laws regulations design procedures line describes specific procedures response key audit responsibilities outlined detect material matter common audits isas uk also misstatements respect irregularities including fraud required perform specific procedures respond risk extent procedures capable detecting management override irregularities including fraud detailed addition procedures respond risks identified included following identifying assessing potential risks related irregularities reviewing financial statement disclosures testing identifying assessing risks material misstatement supporting documentation assess compliance respect irregularities including fraud noncompliance provisions relevant laws regulations described laws regulations considered following direct effect financial statements nature industry sector control environment enquiring senior leadership team audit risk business performance including design groups committee inhouse external legal counsel remuneration policies key drivers directors remuneration concerning actual potential litigation claims bonus levels performance targets performing analytical procedures identify unusual results enquiries senior leadership team internal unexpected relationships may indicate risks material audit audit risk committee including obtaining misstatement due fraud reviewing supporting documentation concerning reading minutes meetings charged groups policies procedures relating governance reviewing internal audit reports identifying evaluating complying laws correspondence regulators regulations whether aware instances addressing risk fraud management override noncompliance controls testing appropriateness journal entries detecting responding risks fraud whether adjustments assessing whether judgements made knowledge actual suspected alleged making accounting estimates indicative potential fraud bias evaluating business rationale significant transactions unusual outside normal course internal controls established mitigate risks related business fraud noncompliance laws regulations also communicated relevant identified laws regulations matters discussed among engagement team including potential fraud risks engagement team members significant component audit teams involving relevant significant component audit teams remained alert internal specialists including tax valuations pensions indications fraud noncompliance laws industry specialists regarding fraud might regulations throughout audit occur financial statements potential indicators fraud report legal regulatory requirements obtained understanding legal regulatory frameworks group operates focusing provisions opinions matters prescribed laws regulations direct effect companies act determination material amounts disclosures financial statements key laws regulations opinion part directors remuneration report considered context included provisions uk audited properly prepared accordance companies act pensions legislation tax legislation companies act also considered key laws regulations opinion based work undertaken course fundamental effect operations group including audit good clinical practice fda regulations general data protection requirements antibribery corruption policy information given strategic report directors foreign corrupt practices act report financial year financial statements prepared consistent financial statements strategic report directors report prepared accordance applicable legal requirements gsk annual report gsk annual report strategic report governance remuneration financial statements investor information independent auditors report continued report audit financial statements continued light knowledge understanding group directors remuneration parent company environment obtained companies act also required report course audit identified material opinion certain disclosures directors remuneration misstatements strategic report directors report made part directors remuneration report audited agreement accounting corporate governance statement records returns listing rules require us review directors statement nothing report respect matters relation going concern longerterm viability part corporate governance statement relating groups matters required compliance provisions uk corporate address governance code specified review auditor tenure based work undertaken part audit following recommendation audit risk committee concluded following elements corporate effect january appointed governance statement materially consistent financial board directors audit financial statements year statements knowledge obtained audit ended december subsequent financial periods directors statement regards appropriateness period total uninterrupted engagement firm four adopting going concern basis accounting years material uncertainties identified set consistency audit report additional report directors explanation assessment groups audit risk committee prospects period assessment covers audit opinion consistent additional report period appropriate set audit risk committee required provide directors statement fair balanced understandable accordance isas uk annual report set use report boards confirmation carried robust assessment emerging principal risks set report made solely parent companys members pages body accordance chapter part companies act audit work undertaken section annual report describes review might state parent companys members effectiveness risk management internal control matters required state auditors report systems set pages purpose fullest extent permitted law section describing work audit risk accept assume responsibility anyone committee set pages parent company parent companys members body audit work report opinions matters required report formed exception due course required financial conduct authority adequacy explanations received accounting records fca disclosure guidance transparency rule dtr companies act required report r financial statements form part opinion european single electronic format esefprepared annual financial report filed national storage mechanism received information explanations uk fca accordance esef regulatory technical require audit standard esef rts auditors report provides adequate accounting records kept assurance whether annual financial report parent company returns adequate audit prepared using single electronic format specified received branches visited us esef rts parent company financial statements agreement parent company passed resolution accordance accounting records returns section companies act senior statutory auditors name stated nothing report respect matters deloitte llp statutory auditor london united kingdom february consolidated income statement year ended december notes turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit finance income finance expense share tax profits associates joint ventures loss disposal interest associates profit taxation taxation profit taxation year profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p diluted earnings per share pence p p p consolidated statement comprehensive income year ended december notes profit year comprehensive incomeexpense year items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates fair value movements cash flow hedges tax fair value movements cash flow hedges reclassification cash flow hedges income statement items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement gainslosses defined benefit plans tax remeasurement defined benefit plans comprehensive expenseincome year total comprehensive income year total comprehensive income year attributable shareholders noncontrolling interests total comprehensive income year gsk annual report gsk annual report strategic report governance remuneration financial statements investor information consolidated balance sheet december notes noncurrent assets property plant equipment right use assets goodwill intangible assets investments associates joint ventures investments deferred tax assets derivative financial instruments noncurrent assets total noncurrent assets current assets inventories current tax recoverable trade receivables derivative financial instruments liquid investments cash cash equivalents assets held sale total current assets total assets current liabilities shortterm borrowings contingent consideration liabilities trade payables derivative financial instruments current tax payable shortterm provisions total current liabilities noncurrent liabilities longterm borrowings corporation tax payable deferred tax liabilities pensions postemployment benefits provisions derivative financial instruments contingent consideration liabilities noncurrent liabilities total noncurrent liabilities total liabilities net assets equity share capital share premium account retained earnings reserves shareholders equity noncontrolling interests total equity financial statements pages approved board february signed behalf sir jonathan symonds chairmanconsolidated statement changes equity year ended december shareholders equity share share retained noncontrolling total capital premium earnings reserves total interests equity december revised implementation ifrs december adjusted profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests changes noncontrolling interests dividends shareholders recognition interest consumer healthcare jv realised losses disposal equity investments shares issued shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests contributions noncontrolling interests changes noncontrolling interests dividends shareholders shares issued realised profits disposal equity investments share associates joint ventures realised profits disposal equity investments shares acquired esop trusts writedown shares held esop trusts sharebased incentive plans tax sharebased incentive plans december profit year comprehensive expenseincome year total comprehensive income year distributions noncontrolling interests contributions noncontrolling interests dividends shareholders realised profits disposal equity investments share associates joint ventures realised profits disposal equity investments shares issued writedown shares held esop trusts sharebased incentive plans transactions noncontrolling interests tax sharebased incentive plans december analysis reserves presented part note movements equity gsk annual report gsk annual report strategic report governance remuneration financial statements investor information consolidated cash flow statement year ended december notes cash flow operating activities profit taxation year adjustments reconciling profit tax operating cash flows cash generated operations taxation paid net cash inflow operating activities cash flow investing activities purchase property plant equipment proceeds sale property plant equipment purchase intangible assets proceeds sale intangible assets purchase equity investments proceeds sale equity investments contingent consideration paid purchase businesses net cash acquired disposal businesses net cash disposed investments associates joint ventures increasedecrease liquid investments interest received proceeds disposal associates joint ventures dividends associates joint ventures equity investments net cash inflowoutflow investing activities cash flow financing activities issue share capital purchase noncontrolling interests increase longterm loans repayment shortterm notes repayment ofincrease shortterm loans repayment lease liabilities interest paid dividends paid shareholders distributions noncontrolling interests contributions noncontrolling interests financing cash flows net cash outflow financing activities decreaseincrease cash bank overdrafts cash bank overdrafts beginning year exchange adjustments decreaseincrease cash bank overdrafts cash bank overdrafts end year cash bank overdrafts end year comprise cash cash equivalents cash cash equivalents reported assets held sale overdrafts notes financial statements presentation financial statements description business financial period gsk major global healthcare group engaged financial statements cover financial year creation discovery development manufacture january december comparative figures marketing pharmaceutical products vaccines overthe financial years january december counter otc medicines healthrelated consumer appropriate january december products gsks principal pharmaceutical products include accounting principles policies medicines following therapeutic areas respiratory hiv immunoinflammation oncology well metabolic financial statements prepared using antibacterials dermatology historical cost convention modified revaluation certain items stated accounting policies going compliance applicable law ifrs concern basis financial statements prepared accordance financial statements prepared accordance international accounting standards conformity groups accounting policies approved board requirements companies act international described note accounting principles policies financial reporting standards issued iasb information application accounting policies including areas estimation judgement given note composition financial statements critical accounting judgements key sources estimation consolidated financial statements drawn sterling uncertainty functional currency glaxosmithkline plc accordance ifrs accounting presentation financial preparation financial statements conformity statements comprise generally accepted accounting principles requires management make estimates assumptions affect reported consolidated income statement amounts assets liabilities disclosure contingent consolidated statement comprehensive income assets liabilities date financial statements consolidated balance sheet reported amounts revenues expenses reporting period actual results could differ estimates consolidated statement changes equity parent company financial statements consolidated cash flow statement financial statements parent company notes financial statements glaxosmithkline plc prepared accordance composition group uk gaap uk accounting presentation company list subsidiaries associates opinion balance sheet presented accounting directors principally affected amount profit net policies given pages assets group given note principal group companies accounting principles policies consolidation group ability exercise joint control consolidated financial statements include rights net assets entities entities accounted joint ventures group ability assets liabilities results cash flows exercise joint control arrangement rights company subsidiaries including esop trusts specified assets obligations specified liabilities groups share results net assets associates arrangement arrangement accounted joint joint ventures operation group ability exercise significant influence entities accounted groups share assets liabilities revenue expenses associates results assets liabilities associates joint operations joint ventures incorporated consolidated financial statements entities consolidated made financial statements using equity method accounting december year groups rights assets liabilities revenue expenses entities group power direct joint operations included consolidated financial relevant activities affect returns group statements accordance rights obligations generally control financial operating interests acquired entities consolidated date policies accounted subsidiaries group acquires control interests sold deconsolidated date control ceases gsk annual report gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued transactions balances subsidiaries eliminated exchange adjustments arising opening net assets profit tax taken sales subsidiaries profits year retained overseas subsidiaries products sold customers outside group associates joint ventures translated sterling less relevant proportion profits transactions joint exchange differences arising related foreign currency ventures joint operations associates also deferred borrowings hedge groups net investment products sold third parties transactions non operations taken separate component equity within controlling interests recorded directly equity deferred retained earnings tax relief unrealised intragroup profit accounted translating sterling assets liabilities results extent considered recoverable cash flows overseas subsidiaries associates joint business combinations ventures reported currencies hyperinflationary economies adjustments made material reflect business combinations accounted using acquisition current price levels loss net monetary assets charged accounting method identifiable assets liabilities contingent consolidated income statement liabilities acquired measured fair value acquisition date consideration transferred measured fair value revenue includes fair value contingent consideration turnover fair value contingent consideration liabilities group receives revenue supply goods external reassessed balance sheet date changes customers orders received majority contracts recognised income statement payments contingent gsk enters relate sales orders containing single consideration reduce balance sheet liability result performance obligations delivery pharmaceutical recorded income statement vaccine consumer healthcare products average part payment relating original estimate duration sales order less months fair value contingent consideration acquisition product revenue recognised control goods reported within investing activities cash flow statement passed customer point control passes part payment relating increase liability determined customer arrangement generally occurs since acquisition date reported within operating cash flows delivery customer consideration transferred together non product revenue represents net invoice value including fixed controlling interest exceeds fair value net assets variable consideration variable consideration arises sale liabilities contingent liabilities acquired excess goods result discounts allowances given accruals recorded goodwill costs effecting acquisition estimated future returns rebates revenue charged income statement period recognised full highly probable significant reversal incurred amount cumulative revenue recognised occur goodwill capitalised separate item case methodology assumptions used estimate rebates subsidiaries part cost investment case returns monitored adjusted regularly light joint ventures associates goodwill denominated contractual legal obligations historical trends past experience currency operation acquired projected market conditions estimates associated returns rebates revisited reporting date cost acquisition fair value net resolved revenue adjusted accordingly please refer assets acquired difference recognised directly note details rebates discounts allowances income statement group entered collaborative agreements typically equity subsidiary acquired pharmaceuticals biotechnology companies noncontrolling interest recognised either fair value develop produce market drug candidates vaccines noncontrolling interests share net assets subsidiary qualify joint arrangements gsk control casebycase basis changes groups ownership commercialisation activities group recognises turnover percentage subsidiaries accounted within equity cost sales gross basis profit sharing amounts foreign currency translation royalties due counterparty recorded within cost sales foreign currency transactions booked functional cost sales includes profit sharing costs million currency group company exchange rate ruling million million counterparty controls date transaction foreign currency monetary assets commercialisation activities records sale group liabilities retranslated functional currency deemed principal customer contract instead records rates exchange ruling balance sheet date exchange share gross profit copromotion income net basis differences included income statement within turnover nature copromotion activities group records costs sales pharmaceutical turnover consolidation assets liabilities including related includes copromotion revenue million million goodwill overseas subsidiaries associates joint million reimbursements counterparty ventures translated sterling rates exchange collaborations selling general administration ruling balance sheet date results cash flows research development costs recorded net overseas subsidiaries associates joint ventures respective lines consolidated income statement translated sterling using average rates exchangenotes financial statements continued accounting principles policies continued operating income royalty income liability includes groups portion total costs gsk enters development marketing collaborations also portion potentially responsible parties costs outlicences groups compounds products probable able satisfy parties contracts give rise fixed variable respective shares cleanup obligation recoveries consideration upfront payments development milestones reimbursements recorded assets virtually certain salesbased milestones royalties legal disputes income dependent achievement development provision made anticipated settlement costs legal milestone recognised highly probable disputes group outflow resources significant reversal amount cumulative revenue considered probable reliable estimate made recognised occur usually related event likely outcome respect product liability claims related occurs salesbased milestone income recognised certain products provision made sufficient highly probable sales threshold reached history claims made settlements enable management salesbased royalties licence intellectual property make reliable estimate provision required cover recognised relevant product sale occurs unasserted claims revenue time recognition revenue certain cases incurred reported ibnr actuarial payment customer expected technique used determine estimate addition one year impact material amount consideration provision made legal expenses arising discounted using appropriate discount rates claims received disputes value added tax sales taxes excluded revenue group may become involved legal proceedings respect possible meaningfully assess expenditure whether outcome result probable outflow expenditure recognised respect goods services quantify reliably estimate liability cases received supplied accordance contractual terms appropriate disclosure cases would included provision made obligation exists future liability provision would made respect past event amount costs associated claims made group third obligation reliably estimated manufacturing startup parties charged income statement incurred costs validation achievement normal production expensed incurred pensions postemployment benefits advertising promotion expenditure charged income costs providing pensions defined benefit schemes statement incurred calculated using projected unit credit method spread period benefit expected derived shipment costs intercompany transfers charged cost employees services consistent advice qualified sales distribution costs sales customers included actuaries selling general administrative expenditure pension obligations measured present value restructuring costs recognised provided estimated future cash flows discounted rates reflecting appropriate respect direct expenditure business yields highquality corporate bonds pension scheme assets reorganisation plans sufficiently detailed well measured fair value balance sheet date advanced appropriate communication affected undertaken costs postemployment liabilities calculated similar way defined benefit pension schemes spread research development period benefit expected derived research development expenditure charged employees services accordance advice income statement period incurred qualified actuaries service cost providing retirement development expenditure capitalised criteria benefits employees year together cost recognising asset met usually regulatory filing curtailment charged operating profit year made major market approval considered actuarial gains losses effect changes actuarial highly probable property plant equipment used assumptions recognised statement comprehensive research development capitalised depreciated income year arise accordance groups policy groups contributions defined contribution plans environmental expenditure charged income statement incurred environmental expenditure related existing conditions resulting past current operations employee share plans current future benefit discernible charged income incentives form shares provided employees statement group recognises liability sitebysite share option share award schemes basis reliably estimated fair values options awards calculated grant dates using blackscholes option pricing model charged income statement relevant vesting periods gsk annual report gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued group provides finance esop trusts purchase nonlease components accounted separately company shares meet obligation provide shares lease components plant equipment leases employees exercise options awards costs running separately accounted land buildings vehicle leases esop trusts charged income statement modifications reassessments lease obligations occur shares held esop trusts deducted lease liability right use asset remeasured reserves transfer made reserves retained right use assets title expected pass gsk earnings vesting periods related share options point future depreciated basis consistent awards reflect ultimate proceeds receivable similar owned assets cases right use assets employees exercise depreciated shorter useful life asset property plant equipment lease term property plant equipment ppe stated cost goodwill purchase construction less provisions depreciation goodwill stated cost less impairments goodwill impairment financing costs capitalised within cost deemed indefinite useful life tested qualifying assets construction impairment least annually depreciation calculated write cost less residual fair value interest acquired entitys value ppe excluding freehold land using straightline assets liabilities contingent liabilities exceeds basis expected useful life residual values lives consideration paid excess recognised immediately reviewed appropriate adjusted annually normal gain income statement expected useful lives major categories ppe intangible assets freehold buildings years intangible assets stated cost less provisions leasehold land buildings lease term years amortisation impairments plant machinery years equipment vehicles years licences patents knowhow marketing rights separately acquired acquired part business combination disposal ppe cost related accumulated amortised estimated useful lives generally depreciation impairments removed financial exceeding years using straightline basis statements net amount less proceeds taken time available use estimated useful lives income statement determining amortisation charge take account patent leases lives exclusivity period applicable well value group recognises right use assets lease obtained periods nonexclusivity pharmaceutical arrangements lessee except shortterm intangible assets depending characteristics competitive leases defined leases lease term months environment estimated longterm profits asset less leases low value assets rights use assets book value amortised owned third parties lease agreements capitalised exclusivity period straightline basis remaining inception lease recognised consolidated book value amortised nonexclusivity period balance sheet years straightline basis vaccines intangible assets cost usually amortised exclusivity period plus corresponding liability lessor recognised lease years years exclusivity period granted obligation within short longterm borrowings carrying straightline basis asset lives reviewed amount subsequently increased reflect interest appropriate adjusted annually lease liability reduced lease payments made contingent milestone payments recognised point calculating discounted lease liability leases annual contingent event becomes probable development payments million implicit rate lease costs incurred group associated acquired used available incremental borrowing rate licences patents knowhow marketing rights written lease specific adjustment used neither available income statement incurred unless criteria leases annual payments less million recognition internallygenerated intangible asset met incremental borrowing rate used incremental borrowing usually regulatory filing made major market rate calculated rate interest gsk would approval considered highly probable able borrow similar term similar security funds necessary obtain similar asset similar market acquired brands valued independently part fair value businesses acquired third parties brand finance costs charged income statement value substantial longterm brands produce constant periodic rate charge remaining either contractual legal nature sold separately balance obligations accounting period rest businesses acquired brands amortised variable rents part lease liability right use estimated useful lives years using asset payments charged income statement straightline basis except considered useful incurred shortterm lowvalue leases capitalised economic life indefinite lease rentals also charged income statement incurrednotes financial statements continued accounting principles policies continued costs acquiring developing computer software expected credit losses recognised income statement internal use internet sites external use capitalised financial assets measured amortised cost fair value intangible fixed assets software site supports comprehensive income apart equity significant business system expenditure leads investments creation durable asset erp systems software amortised investments seven ten years computer software three investments comprise equity investments five years using straightline basis investments limited life funds group elected impairment noncurrent assets designate majority equity investments measured carrying values noncurrent assets reviewed fvtoci initially recorded fair value plus transaction impairment either standalone basis part larger costs remeasured subsequent reporting dates cash generating unit indication assets fair value unrealised gains losses recognised might impaired additionally goodwill intangible assets comprehensive income indefinite useful lives intangible assets yet disposal equity investment gains losses available use tested impairment annually deferred comprehensive income transferred provision impairment charged income statement directly retained earnings investments limited life funds year concerned measured fvtpl initially recorded fair value impairments goodwill reversed impairment losses remeasured subsequent reporting dates fair value noncurrent assets reversed unrealised gains losses recognised income change estimates used determine recoverable amounts statement extent revised recoverable amounts dividends equity investments distributions funds exceed carrying values would existed net recognised income statement groups right depreciation amortisation impairments receive payment established recognised purchases sales investments accounted investments associates joint ventures joint trade date operations trade receivables investments associates joint ventures carried trade receivables measured accordance consolidated balance sheet groups share net business model portfolio trade receivables assets date acquisition postacquisition held group portfolios three business retained profits losses comprehensive income models ifrs collect contractual cash flows together goodwill arising acquisition group factoring agreement place measured recognises rights assets liabilities revenue expenses amortised cost sell contractual cash flows joint operations trade receivables sold factoring agreement inventories measured fvtpl collect sell inventories included financial statements lower contractual cash flows trade receivables may sold cost including raw materials direct labour direct costs factoring arrangement measured fvtoci trade related production overheads net realisable value receivables measured amortised cost carried cost generally determined first first basis original invoice amount less allowances expected credit prelaunch inventory held asset high losses probability regulatory approval product expected credit losses calculated accordance point provision made carrying value simplified approach permitted ifrs using provision matrix recoverable amount provision reversed point applying lifetime historical credit loss experience trade high probability regulatory approval determined receivables expected credit loss rate varies depending whether extent settlement trade financial instruments receivables overdue also adjusted appropriate financial assets reflect current economic conditions estimates future financial assets measured amortised cost fair value conditions purpose determining credit loss rates comprehensive income fvtoci fair value customers classified groupings similar loss profit loss fvtpl measurement basis patterns key drivers loss rate nature determined reference business model business unit location type customer managing financial asset contractual cash flow trade receivable determined reasonable characteristics financial asset financial assets expectation recovery written firstly trade receivables month expected credit loss expected credit loss allowance available ecl allowance recorded initial recognition income statement subsequent evidence significant increase credit risk asset allowance increased reflect full lifetime subsequent recoveries amounts previously provided ecl realistic prospect recovery asset written credited income statement longterm written receivables discounted effect material gsk annual report gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued accounting principles policies continued cash cash equivalents changes fair value derivatives designated fair value cash held deposit accounts measured amortised cost hedges recorded income statement together investments money market funds held fair value changes fair value hedged asset liability profit loss funds fail solely payments taxation principal interest sppi test current tax provided amounts expected paid borrowings applying tax rates enacted substantively borrowings initially recorded amount proceeds enacted balance sheet date received net transaction costs borrowings subsequently deferred tax provided full temporary differences arising carried amortised cost difference tax bases assets liabilities carrying proceeds net transaction costs amount due amounts financial statements deferred tax assets redemption recognised charge income recognised extent probable future taxable statement period relevant borrowing profits available temporary differences derivative financial instruments utilised deferred tax provided temporary derivative financial instruments used manage exposure differences arising investments subsidiaries associates market risks principal derivative instruments used joint ventures except timing reversal gsk foreign currency swaps interest rate swaps foreign temporary difference controlled probable exchange forward contracts options group temporary difference reverse foreseeable hold issue derivative financial instruments trading future deferred tax provided using rates tax speculative purposes enacted substantively enacted balance sheet date derivative financial assets liabilities including derivatives uncertain tax position identified management embedded host contracts separated make judgement probable outcome host contract classified heldfortrading assuming relevant tax authority full knowledge measured fair value changes fair value derivative situation assessed economic outflow instruments qualify hedge accounting probable arise provision made best estimate recognised immediately income statement liability estimating liability gsk applies riskbased approach takes account appropriate hedge accounting probability group would able obtain derivatives designated hedging instruments classified compensatory adjustments international tax treaties inception hedge relationship cash flow hedges net estimates take account specific circumstances investment hedges fair value hedges dispute relevant external advice changes fair value derivatives designated cash flow discounting hedges recognised comprehensive income time value money material balances extent hedges effective ineffective portions discounted current values using appropriate discount rates recognised profit loss immediately amounts deferred unwinding discounts recorded finance income comprehensive income reclassified income finance expense statement hedged item affects profit loss net investment hedges accounted similar way cash flow hedges critical accounting judgements key sources estimation uncertainty preparing financial statements management required estimates make judgements items gross turnover reduced rebates discounts allowances recognised financial statements estimates product returns given expected given assumptions affect amounts assets liabilities vary product arrangements buying groups revenue expenses reported financial statements arrangements purchasing organisations dependent actual amounts results could differ estimates upon submission claims time initial following considered critical accounting recognition sale accruals made time sale judgements key sources estimation uncertainty estimated rebates discounts allowances payable returns made based available market information turnover historical experience reported group turnover million millionnotes financial statements continued critical accounting judgements key sources estimation uncertainty continued us pharmaceuticals business largest estimates complex arrangements rebates discounts allowances group open tax issues number revenue us pharmaceuticals turnover million authorities management makes judgement whether million recording deductions sufficient information able make reliable estimate million million rebates discounts outcome dispute insufficient information available allowances returns balance sheet accruals rebates provision made discounts allowances returns us pharmaceuticals sufficient information available estimating potential tax vaccines businesses managed combined basis liability gsk applies riskbased approach takes december total accrual amounted account appropriate probability group would million million nature able obtain compensatory adjustments international accruals practicable give meaningful tax treaties estimates take account specific sensitivity estimates due large volume variables circumstances dispute relevant external advice contribute overall rebates chargebacks returns inherently judgemental could change substantially revenue accruals time dispute progresses new facts emerge significant variability final outcomes december group recognised provisions group applies constraint measuring variable element million respect uncertain tax positions within revenue revenue recognised suitably million due number uncertain tax positions held cautious amount objective constraint ensure number jurisdictions relate highly probable significant reversal revenue practicable give meaningful sensitivity estimates occur uncertainties resolved constraint uncertain tax position individually significant group applied making suitably cautious estimates inputs assumptions used estimating variable consideration factors affecting tax charge future years set amounts estimated may fully reflect note taxation gsk continues believe made final outcome amounts subject change adequate provision liabilities likely arise open dependent upon amongst things types buying assessments open issues exist ultimate liability group product sales mix constraints applied matters may vary amounts provided recognising revenue mean risk material downward dependent upon outcome negotiations relevant adjustment revenue next financial year low tax authorities necessary litigation proceedings level accrual rebates returns reviewed legal disputes adjusted regularly light contractual legal legal costs year million million obligations historical trends past experience projected december provisions legal disputes market conditions market conditions evaluated using amounted million million wholesaler thirdparty analyses market research data internallygenerated information reasonably possible estimates could significant adjustment within next management makes judgement whether sufficient months recognise additional revenue actual outcomes information able make reliable estimate likely better cautious constrained estimates revenue outcome dispute legal expenses arising recognised full highly probable significant claims group insufficient information reversal amount cumulative revenue recognised available provision made disclosure claim occur amount turnover recognised year given performance obligations satisfied previous periods set estimated provisions take account specific note turnover segment information circumstances dispute relevant external advice indication level sensitivity estimate inherently judgemental could change substantially time future events could cause assumptions dispute progresses new facts emerge details accruals based change could materially affect status various uncertainties involved significant future results group unresolved disputes set note legal proceedings companys directors taken legal advice taxation established provisions taking account relevant tax charge year million facts circumstances matter accordance million december current tax payable accounting requirements respect product liability claims million million noncurrent corporation related certain products sufficient history claims tax payable million million current made settlements enable management make reliable tax recoverable million million estimate provision required cover unasserted claims gsk annual report gsk annual report strategic report governance remuneration financial statements investor information notes financial statements continued critical accounting judgements key sources estimation uncertainty continued group may become involved legal proceedings respect pensions postemployment benefits possible meaningfully assess whether judgement outcome result probable outflow quantify reliably surplus defined benefit scheme arises estimate liability cases appropriate disclosure potential surplus arise committed future cases would provided provision would made contributions rights trustees prevent group contingent liability quantified obtaining refund surplus future considered ultimate liability legal claims may vary amounts determining whether necessary restrict amount provided dependent upon outcome litigation surplus recognised three uk schemes surplus proceedings investigations possible settlement negotiations combined surplus million december position could change time therefore million recognised pension surpluses assurance losses result outcome totalling million spread across countries legal proceedings exceed amount provisions million across countries gsk made judgement reported groups financial statements material amount amounts meet requirements recoverability contingent consideration estimates income statement charge contingent costs providing pensions postemployment consideration million million benefits assessed basis assumptions selected management assumptions include future earnings december liability contingent consideration pension increases discount rates expected longterm rates amounted million million return assets mortality rates disclosed note amount million million related pensions postemployment benefits acquisition former shionogiviiv healthcare joint venture discount rates derived aa rated corporate bond yields except countries deep market corporate estimates bonds government bond yields used sensitivity contingent consideration included consideration analysis provided note pensions post payable business combination recorded fair value employment benefits reduction discount rate date acquisition fair values generally based would lead increase net pension deficit riskadjusted future cash flows discounted using appropriate approximately million increase annual pension posttax discount rates fair values reviewed cost approximately million similarly increase regular basis least annually changes reflected discount rate would lead decrease net pension income statement see note contingent consideration deficit approximately million decrease annual liabilities pension cost approximately million selection different assumptions could affect future results group new accounting requirements group previously accounted saas software year group implemented interest rate service configuration customisation costs intangible benchmark reform phase amendments ifrs ias assets following ifrs ic interpretation committee ifrs ifrs ifrs issued august agenda decision saas april group adopted adopted uk endorsement board january treatment set ifrs ic agenda decision amendments address issues arise implementation expensed configuration customisation costs reforms including replacement one benchmark entity control software configured alternative one practical expedient provided impacts change impairment million change contractual cash flows financial assets previously capitalised intangible assets increase liabilities including lease liabilities accounted expenses million presented selling general prospectively revising effective interest rate addition administration research development hedge accounting discontinued solely ibor reform information provided note retirement benefit employee entitled capped specified number consecutive years group certain new accounting standards amendments accounting previously accounted employee benefits standards interpretations published employment commencement date following ifrs ic mandatory december reporting periods agenda decision attributing benefit periods service early adopted group standards may group adopted treatment set amendments interpretations expected ifrs ic agenda decision account employee benefits material impact group current future reporting last specified number years employee periods earn benefit impact change reduction expenses million presented cost sales selling general administration research developmentnotes financial statements continued exchange rates group uses average exchange rates prevailing period translate results cash flows overseas subsidiaries joint ventures associates sterling period end rates translate net assets entities currencies influence translations relevant exchange rates average rates period end rates us us euro euro yen yen turnover segment information operating segments reported based financial information provided chief executive officer responsibilities gsk leadership team glt gsk reports results four segments pharmaceuticals pharmaceuticals rd vaccines consumer healthcare individual members glt responsible segment groups management reporting process allocates intragroup profit product sale market sale recorded profit analyses presented basis corporate unallocated turnover costs includes results certain consumer healthcare products held sale number markets order meet antitrust approval requirements together costs corporate functions revenue recognised year performance obligations satisfied previous periods totalled million million included million million impacting turnover arising changes prior year estimates rar returns rebates accruals million million milestone income million million royalty income recognised current year turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover gsk reviewed presentation pharmaceuticals products january moved sales arnuity ellipta incruse ellipta relvarbreo ellipta respiratory therapeutic area established pharmaceuticals therapeutic area comparative information revised consistent basis revised revised pharmaceuticals turnover therapeutic area respiratory hiv immunoinflammation oncology pandemic new specialty established pharmaceuticals vaccines turnover category meningitis influenza shingles established vaccines pandemic vaccines gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information turnover segment information continued us operations pharmaceuticals vaccines businesses made sales three wholesalers million million million million million million million million million respectively allocating finalcustomer discounts wholesalers consumer healthcare turnover category oral health pain relief vitamins minerals supplements respiratory health digestive health brands divestedunder review segment profit pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment profit corporate unallocated costs reconciling items segment profit operating profit operating profit finance income finance costs loss disposal interest associates share aftertax profits associates joint ventures profit taxation taxation profit taxation year reconciling items segment profit operating profit comprise items specifically allocated segment profit include impairment amortisation intangible assets major restructuring costs include impairments tangible assets computer software transactionrelated adjustments related significant acquisitions proceeds costs disposals associates products businesses significant legal charges expenses settlement litigation government investigations operating income royalty income items separation costs please refer detail reconciling items segment profit operating profit analysis adjusting items group financial review depreciation amortisation segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment depreciation amortisation corporate unallocated depreciation amortisation reconciling items segment depreciation amortisation total depreciation amortisation total depreciation amortisation notes financial statements continued turnover segment information continued ppe intangible asset goodwill impairment segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment corporate unallocated impairment reconciling items segment impairment total impairment total impairment ppe intangible asset impairment reversals segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment impairment reversals corporate unallocated impairment reversals reconciling items segment impairment reversals total impairment reversals total impairment reversals net operating assets segment pharmaceuticals pharmaceuticals rd pharmaceuticals including rd vaccines consumer healthcare segment net operating assets corporate unallocated net operating assets net operating assets net debt investments associates joint ventures derivative financial instruments current deferred taxation assets held sale excluding cash cash equivalents net assets pharmaceuticals segment includes shionogiviiv healthcare contingent consideration liability million million pfizer put option million million gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information turnover segment information continued geographical information uk regarded groups country domicile turnover location customer uk us rest world external turnover revised noncurrent assets location subsidiary uk us belgium switzerland rest world noncurrent assets noncurrent assets location excludes amounts relating investments deferred tax assets derivative financial instruments pension assets amounts receivable insurance contracts certain noncurrent receivables countries individually material external revenue noncurrent assets gsk revised presentation noncurrent assets location include belgium switzerland independently rest world operating incomeexpense fair value remeasurements equity investments disposal businesses assets fair value remeasurements contingent consideration recognised business combinations remeasurement viiv healthcare put option liabilities preferential dividends fair value adjustments derivative financial instruments income disposal businesses assets included net gain disposal rights royalty stream cabozantinib net gain disposal cephalosporin antibiotic brands sandoz disposal businesses assets included net profit disposal horlicks consumer healthcare nutritional brands two subsidiaries india bangladesh million reflected reversal million embedded derivative gains value shares taken prior years partly offset related million loss shares hindustan unilever limited including fair value remeasurement losses acquisition consideration divestment gsk consumer healthcare limited india subsequent disposal operating income also included increase profit milestone income number asset disposals fair value remeasurements contingent consideration recognised business combinations included million related acquisition former shionogiviiv healthcare joint venture million payable novartis related vaccines acquisition together fair value movements related hedging contractsnotes financial statements continued operating profit following items included operating profit employee costs note advertising distribution costs depreciation property plant equipment impairment property plant equipment net reversals depreciation right use assets impairment right use assets amortisation intangible assets impairment intangible assets net reversals impairment property plant equipment held sale net reversals impairment intangible assets held sale net reversals impairment goodwill allocated disposal group net reversals net foreign exchange gainslosses inventories cost inventories included cost sales writedown inventories reversal prior year writedown inventories shortterm lease charge lowvalue lease charge variable lease payments fees payable companys auditor associates relation group see reversals prior year writedowns inventories principally arise reassessment usage demand expectations prior inventory expiration net foreign exchange gainslosses include net gain million million loss million gain arising recycling exchange liquidation disposal overseas subsidiaries recycling exchange disposal overseas associates loss million nil reported loss disposal interest associates included within operating profit major restructuring charges million million million see note major restructuring costs fees payable companys auditor associates audit parent company consolidated financial statements including attestation sarbanesoxley act audit companys subsidiaries total audit services audit related assurance services services total auditrelated nonaudit services assurance services provided auditor related agreed upon procedures assurance services outside statutory audit requirements addition fees paid auditor respect gsk pension schemes audit services material fee paid auditors respect audits certain companys subsidiaries acquired year million million audit fees include million relation incremental audit work performed audit opinions issued compliant pcaob auditing standards preparation consumer healthcare demerger audit related assurance services include million due reporting accountant work performed preparation consumer healthcare demerger gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information employee costs wages salaries social security costs pension postemployment costs including augmentations note cost sharebased incentive plans severance costs integration restructuring activities group provides benefits employees commensurate local practice individual countries including markets healthcare insurance subsidised car schemes personal life assurance cost sharebased incentive plans analysed follows share value plan performance share plan share option plans cash settled plans average monthly number persons employed group including directors year number number number manufacturing selling general administration research development average monthly number group employees excludes temporary contract staff numbers group employees end financial year given financial record compensation directors senior management members glt aggregate follows wages salaries social security costs pension postemployment costs cost sharebased incentive plans information remuneration directors given sections annual report remuneration labelled audited within pages notes financial statements continued major restructuring costs within pharmaceuticals sector highly regulated manufacturing operations supply chains long lifecycle business mean restructuring programmes particularly involve rationalisation closure manufacturing rd sites likely take several years complete major restructuring costs related specific boardapproved major restructuring programmes including integration costs following material acquisitions structural significant scale costs individual related projects exceed million existing combined restructuring integration programme incorporates previous major change programme pharmaceuticals restructuring programme restructuring integration programme following novartis transaction programme substantially complete july board approved major restructuring programme designed significantly improve competitiveness efficiency groups cost base savings delivered primarily supply chain optimisation reductions administrative costs programme substantially complete february board approved major restructuring plan generate synergies integration pfizer consumer healthcare business gsks consumer healthcare business january board approved twoyear separation preparation programme prepare separation gsk two companies total restructuring costs million incurred following areas restructuring costs prepare separation gsk two companies restructuring following integration pfizer consumer healthcare business gsk consumer healthcare continued implementation restructuring programme started july simplify operating models improve resource allocation pharmaceutical consumer healthcare supply chains continued transformation central functions including gsk technology platforms interfaces deliver greater digital synergies simplification applications staff reductions analysis costs charged operating profit programmes follows increase provision major restructuring programmes see note amount provision reversed unused see note impairment losses recognised noncash charges cash costs provision reversals million million million reflected provision releases mainly separation preparation programme major restructuring programme asset impairments million noncash charges million principally comprised fixed asset writedowns manufacturing facilities accelerated depreciation asset lives shortened supply chain manufacturing network result major restructuring programmes charges settled cash include site closure costs consultancy project management costs analysis major restructuring charges programme follows cash noncash total separation preparation programme consumer healthcare joint venture integration programme major restructuring programme including tesaro combined restructuring integration programme cash noncash total separation preparation programme consumer healthcare joint venture integration programme major restructuring programme including tesaro combined restructuring integration programme gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information major restructuring costs continued analysis major restructuring charges income statement line follows cost sales selling general administration research development operating expense finance income finance income arising financial assets measured amortised cost financial assets measured fair value profit loss net gains arising forward element forward contracts net investment hedge relationships finance income finance expense finance expense arising financial liabilities amortised cost derivatives fair value profit loss net losses arising financial instruments mandatorily measured fair value profit loss retranslation loans reclassification hedges comprehensive income unwinding discounts provisions finance expense arising lease liabilities finance expense finance expense arising derivatives fair value profit loss relates swap interest expensenotes financial statements continued associates joint ventures groups share aftertax profits losses associates joint ventures set share aftertax profits associates share aftertax losses joint ventures following disposal innoviva inc may see details note december group held significant individual associates december group held one significant associate innoviva inc summarised income statement information respect innoviva may set groups share aftertax profits associates comprehensive income includes profit million comprehensive income nil respect innoviva results innoviva included summarised income statement information represent estimated earnings innoviva relevant periods based publicly available information balance sheet date figures include share innovivas turnover profit total comprehensive income date disposal turnover profit taxation total comprehensive income aggregated financial information respect gsks share associated undertakings joint ventures set share turnover share aftertax losses share comprehensive income share total comprehensive incomeexpense groups sales associates joint ventures nil nil million please refer balance sheet information associates joint ventures note gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information taxation groups tax charge sum total current deferred tax expense taxation charge based profits year uk current year charge rest world current year charge chargecredit respect prior periods current taxation deferred taxation gsk made payments million uk corporation tax hmrc amounts uk corporation tax include various business taxes borne uk gsk year deferred tax credits period reflect origination current year expenses offset taxable profits future periods probable relates primarily unwind deferred tax liabilities intangible assets recognition current year tax losses reversal temporary differences deferred tax credit also reflected impact revaluation deferred tax assets liabilities following enactment increase headline rate uk corporation tax significant prior year credits reflected impact settlement number open issues tax authorities following table reconciles tax charge calculated uk statutory rate group profit tax actual tax charge year reconciliation taxation group profits profit tax uk statutory rate taxation differences overseas taxation rates benefit intellectual property incentives rd credits fair value remeasurement nontaxable put options tax losses benefit recognised permanent differences disposals acquisitions transfers permanent differences reassessments prior year estimates changes tax rates tax chargetax rate global healthcare company substantial business employment presence many countries around world impact differences overseas taxation rates arose profits earned countries tax rates higher uk statutory rate significant us belgium germany italy japan adverse impact partly offset benefit intellectual property incentives uk patent box belgian patent income deduction regimes provide reduced rate corporation tax profits earned qualifying patents claim incentives manner intended relevant statutory regulatory framework changes tax rates included credits relation enactment increase headline rate uk corporation tax effective changes tax rates included credits relation uk previously proposed reduction corporation tax rate cancelled india tax treatment dividends changed effect april uk credit partly reversed expense future benefit provided formerly enacted corporation tax rate permanent differences disposals acquisitions transfers reflects tax credits arising transfer intellectual property within group reflected tax impact disposal horlicks consumer healthcare brands subsequent disposal shares received hindustan unilever groups tax rate also influenced closure open issues tax authorities various jurisdictions reassessment prior year estimates includes current deferred tax future tax charges therefore effective tax rate may affected factors acquisitions disposals restructurings location research development activity tax regime reforms resolution open matters continue bring tax affairs date around world continued focus tax reform expected future years driven oecds project address tax challenges arising digitalisation economy may result significant changes established tax principles increase tax authority disputes turn could adversely affect gsks effective tax rate could result higher cash tax liabilitiesnotes financial statements continued taxation continued tax items charged equity statement comprehensive income current taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments deferred taxation sharebased payments defined benefit plans fair value movements cash flow hedges fair value movements equity investments total credit equity statement comprehensive income items charged statement comprehensive income except tax sharebased payments issues relating taxation integrated nature groups worldwide operations involves significant investment research strategic manufacture limited number locations consequential crossborder supply routes numerous endmarkets line current oecd guidelines base transfer pricing policy arms length principle support transfer prices economic analysis reports however different tax authorities may seek attribute profit activities undertaken jurisdiction potentially resulting double taxation group also open items several jurisdictions concerning matters deductibility particular expenses tax treatment certain business transactions gsk applies risk based approach determine transactions likely subject challenge probability group would able obtain compensatory adjustments international tax treaties calculation groups total tax charge therefore necessarily involves degree estimation judgement respect certain items whose tax treatment finally determined resolution reached relevant tax authority appropriate formal legal process december group recognised provisions million respect uncertain tax positions million presented current tax payables reductions current tax recoverable assets net increase recognised provisions driven reassessment estimates utilisation provisions uncertain tax positions following settlement number open issues tax authorities various jurisdictions whilst ultimate liability matters may vary amounts provided dependent upon outcome agreements relevant tax authorities litigation appropriate group continues consider made appropriate provision periods open yet agreed tax authorities provision deferred tax liabilities million december million made respect taxation would payable remittance profits certain overseas subsidiaries whilst aggregate amount unremitted profits balance sheet date approximately billion billion majority unremitted profits would subject tax including withholding tax repatriation uk legislation relating company distributions provides exemption tax overseas profits subject certain exceptions deferred tax provided temporary differences million million arising unremitted profits management ability control future reversal consider reversal probable gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information taxation continued movement deferred tax assets liabilities pensions share accelerated post option net capital intangible contingent intragroup employment tax award temporary allowances assets consideration profit benefits losses schemes differences total january exchange adjustments creditcharge income statement creditcharge statement comprehensive income acquisitions disposals rd credits utilisation december exchange adjustments creditcharge income statement creditcharge statement comprehensive income acquisitions disposals rd credits utilisation december deferred tax liabilities provided relation intangible assets predominately relate temporary differences arising assets liabilities acquired part historic business combinations group continues recognise deferred tax assets future obligations respect contingent consideration amounts payable minority shareholders payments tax deductible point time payment made deferred tax asset recognised intragroup profits arising intercompany inventory eliminated within consolidated accounts intragroup profits eliminated individual entities tax returns temporary difference arises reverse point time inventory sold externally deferred tax asset recognised tax losses million million relates trading losses deferred tax assets recognised probable future taxable profit available utilise losses supported product level forecasts net temporary differences included accrued expenses tax deduction available paid basis deferred tax assets liabilities recognised balance sheet follows deferred tax assets deferred tax liabilities unrecognised unrecognised deferred tax deferred tax tax losses asset tax losses asset unrecognised tax losses trading losses expiring within years years available indefinitely december capital losses expiring available indefinitely december deferred tax assets recognised probable future taxable profit available utilise lossesnotes financial statements continued earnings per share pence pence pence basic earnings per share diluted earnings per share basic earnings per share calculated dividing profit attributable shareholders weighted average number shares issue period deducting shares held esop trusts treasury shares trustees waived rights dividends shares held esop trusts diluted earnings per share calculated adjusting weighted average number shares used basic calculation assume conversion potentially dilutive shares potentially dilutive share forms part employee share schemes exercise price average market price gsk shares period performance conditions attaching scheme met balance sheet date numbers shares used calculating basic diluted earnings per share reconciled weighted average number shares issue millions millions millions basic dilution share options awards diluted dividends dividend total dividend total dividend total per share dividend per share dividend per share dividend paidpayable pence paid pence paid pence first interim july july july second interim october october october third interim january january january fourth interim april april april total estimate fourth interim dividend disclosed annual report accounts million million less dividend ultimately paid ifrs interim dividends recognised financial statements paid declared gsk normally pays dividend two quarters quarter relates one quarter declared financial statements recognise dividends paid namely third fourth interim dividends first second interim dividends amounts recognised year follows dividends shareholders gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information property plant equipment plant land equipment assets buildings vehicles construction total cost january exchange adjustments additions business combinations additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december exchange adjustments additions capitalised borrowing costs disposals writeoffs reclassifications transfer assets held sale cost december depreciation january exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december exchange adjustments charge year disposals writeoffs transfer assets held sale depreciation december impairment january exchange adjustments disposals writeoffs impairment losses reversal impairments transfer assets held sale impairment december exchange adjustments disposals writeoffs impairment losses reversal impairments impairment december total depreciation impairment december total depreciation impairment december net book value january net book value december net book value december notes financial statements continued property plant equipment continued weighted average interest rate capitalised borrowing costs year disposals writeoffs year included number assets nil net book value longer use business impairment losses principally arose decisions rationalise facilities calculated based fair value less costs disposal fair value less costs disposal valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy calculations determine net present value projected riskadjusted posttax cash flows relevant asset cash generating unit applying discount rate group posttax weighted average cost capital wacc adjusted appropriate specific segment country currency risk assets continue used group generally assessed part associated cash generating unit value use basis value use calculations posttax cash flows include impact future uncommitted restructuring plans improvements impairment indicated pretax cash flow calculation expected give materially different result test would reperformed using pretax cash flows pretax discount rate group wacc equivalent pretax discount rate approximately net impairment losses charged cost sales million million rd million million sga million million included million million arising major restructuring programmes reversals impairment arose subsequent reviews impaired assets conditions gave rise original impairments deemed longer apply reversals credited cost sales million million computer software reclassified assets construction intangible assets becoming ready use assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded impact cause material impairments right use assets land plant buildings equipment vehicles total net book value january exchange adjustments additions depreciation disposals impairments reclassifications net book value december exchange adjustments additions depreciation disposals impairments net book value december total cash outflow leases amounted million group entered lease contracts yet commenced nominal value estimated future lease payments lease contracts approximates million december contracts mainly concern relocation us corporate headquarters lease period analysis lease liabilities set note net debt gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information goodwill cost january exchange adjustments additions business combinations note movements transfer assets held sale cost december net book value january net book value december million increase goodwill corresponds immaterial payment pension liabilities consumer healthcare subgroup required sale purchase agreement increase noncontrolling interest subgroup result transaction goodwill allocated groups segments follows pharmaceuticals vaccines consumer healthcare net book value december recoverable amounts cash generating units assessed using fair value less costs disposal model fair value less costs disposal calculated using discounted cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate used based group wacc cash generating units integrated operations across large parts group discount rate adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy details relating discounted cash flow models used impairment tests pharmaceuticals vaccines consumer healthcare cash generating units follows valuation basis fair value less costs disposal key assumptions sales growth rates profit margins terminal growth rate discount rate taxation rate determination assumptions growth rates internal forecasts based internal external market information margins reflect past experience adjusted expected changes terminal growth rates based managements estimate future longterm average growth rates discount rates based group wacc adjusted appropriate taxation rates based appropriate rates jurisdiction period specific projected cash flows five years terminal growth rate discount rate terminal growth rate discount rate pharmaceuticals pa pa pa vaccines pa pa pa consumer healthcare pa pa pa terminal growth rates exceed longterm projected growth rates relevant markets reflect impact future generic competition take account new product launches goodwill monitored impairment segmental level case valuations indicated sufficient headroom reasonably possible change key assumptions unlikely result impairment related goodwill consumer healthcare cash generating unit also comprises collection smaller cash generating units including brands indefinite lives carrying value billion billion details indefinite life brands given note intangible assets assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded impact cause material impairmentsnotes financial statements continued intangible assets licences patents computer amortised indefinite life software brands etc brands total cost january exchange adjustments capitalised development costs additions business combinations additions disposals asset writeoffs transfer assets held sale reclassifications cost december exchange adjustments capitalised development costs additions disposals asset writeoffs transfer assets held sale reclassifications cost december amortisation january exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december exchange adjustments charge year disposals asset writeoffs transfer assets held sale amortisation december impairment january exchange adjustments impairment losses reversal impairments disposals asset writeoffs transfer assets held sale reclassification impairment december exchange adjustments impairment losses reversal impairments disposals asset writeoffs impairment december total amortisation impairment december total amortisation impairment december net book value january net book value december net book value december weighted average interest rate capitalised borrowing costs year net book value computer software included million million internally generated costs carrying value december intangible assets impairments charged year following impairments million million carrying value december intangible assets impairment reversals charged year following impairment reversals million million patent expiry dates groups significant assets relevant set pages please refer note groups accounting policy estimate useful life intangible assets exclusivity nonexclusivity periods gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information intangible assets continued amortisation impairment losses net reversals charged income statement follows amortisation net impairment losses cost sales selling general administration research development licences patents amortised brands etc includes large number acquired licences patents knowhow agreements marketing rights either marketed use still development note acquisitions disposals gives details additions business combinations year book values largest individual items follows tesaro assets meningitis portfolio dolutegravir benlysta alector assets iteos assets lamisil merck assets vir assets bms assets fluarixflulaval okairos curevac assets stiefel trade name others july gsk signed agreement global codevelopment cocommercialisation collaboration immunoneurology alector two clinical stage firstinclass monoclonal antibodies neurodegenerative diseases total upfront payment recognised intangible asset million total million paid total million paid june gsk signed codevelopment cocommercialisation collaboration iteos therapeutics eos antitigit monoclonal antibody recognising intangible asset million tesaro assets comprise zejula jemperli well combination therapies meningitis portfolio includes menveo bexsero men abcwy menjugate lamisil moved licences patents amortised brands etc following decision start amortisation gsk divested breathe right brand indefinite life brands comprise portfolio consumer healthcare products primarily acquired acquisitions sterling winthrop inc block drug company inc novartis consumer healthcare business pfizer consumer healthcare business book values major brands follows advil voltaren centrum caltrate otrivin preparation h robitussin nexium fenistil chapstick emergenc theraflu panadol sensodyne others notes financial statements continued intangible assets continued brands considered indefinite life given strength durability brand level marketing support brands relatively similar stable profitable market sectors similar risk profiles size diversification market shares mean risk marketrelated factors causing reduction lives brands considered relatively low group aware material legal regulatory contractual competitive economic factors could limit useful lives accordingly amortised brand tested annually impairment amortised intangible assets tested indicators impairment arise testing applies fair value less costs disposal methodology generally using year posttax cash flow forecasts terminal value calculation discount rate equal group posttax wacc adjusted appropriate specific segment country currency risks valuation methodology uses significant inputs based observable market data therefore valuation technique classified level fair value hierarchy main assumptions include future sales price volume growth product contribution future expenditure required maintain products marketability registration relevant jurisdictions exchange rates assumptions based past experience reviewed part managements budgeting strategic planning cycle changes market conditions sales erosion competition terminal growth rates applied managements estimates future longterm average growth rates relevant markets year ended december robitussin preparation h affected lower cold flu incidence resulting covid social distancing measures supply chain issues respectively resulted reduced level headroom group performed sensitivity analysis based changes key assumptions considered reasonably possible management leaving assumptions unchanged sensitivity analysis year ended december identified two brands sensitive reasonably possible changes key assumptions order recoverable amount equal carrying values robitussin preparation h either discount rate would increased operating margin decreased long term growth rate decreased respectively group consider changes key assumptions magnitude reasonably possible current environment described group consider reasonably possible changes key assumptions would cause fair value less cost sale brands disclosed fall carrying values assessed qualitative quantitative impact climate related risks asset recoverable amounts concluded impact cause material impairments investments associates joint ventures joint joint ventures associates total ventures associates total january exchange adjustments additions disposals distributions received net fair value movements comprehensive income impairment interest associates profitloss tax recognised consolidated income statement december group held one significant associate december innoviva inc december group owned million shares innoviva biopharmaceutical company listed nasdaq innoviva partnered gsk development longacting beta agonist vilanterol currently receives royalty income sales products contain component namely relvarbreo ellipta anoro ellipta also economic interest royalties paid gsk sales trelegy ellipta remaining economic interest royalties held theravance biopharma inc group holds investment see note may group agreed innoviva inc sell shares innoviva back innoviva million following settlement transaction gsk longer held innoviva stock loss million including million recycling exchange differences innoviva presented loss disposal interest associates consolidated income statement transaction include changes innovivas commercial interest royalties paid gsk loss disposal interest associates also includes million gain disposal another immaterial associate please refer income statement information associates joint ventures note gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information investments associates joint ventures continued disposals include book values innoviva million million another investment gsk received noncash consideration summarised balance sheet information december respect innoviva set december noncurrent assets current assets current liabilities noncurrent liabilities net assets carrying value groups investment innoviva analysed follows interest net assets associate goodwill fair value adjustments carrying value december investment innoviva market value million december investments investments investments designated investments designated investments measured measured measured measured fvtoci fvtpl fvtoci fvtpl january additions net fair value movements comprehensive income net fair value movements profit loss disposals settlements december investments comprise noncurrent equity investments recorded fair value balance sheet date investments traded active market fair value determined reference relevant stock exchange quoted bid price investments fair value estimated management reference relevant available information including current market value similar instruments recent financing rounds discounted cash flows underlying net assets net fair value movements include impact exchange gains million comprehensive income million profit loss losses million nil respectively investments include listed investments million million gsk elected designate majority equity investments measured fair value comprehensive income fvtoci significant investments held december curevac ag group held vir biotechnology group held investments fair value december million million million million respectively investments include equity stakes companies gsk research collaborations companies provide access biotechnology developments potential interest june gsk issued us us notes exchangeable option note holders time maturity notes june shares held gsk theravance biopharma inc notes exchanged gsk expects deliver shares may option certain circumstances deliver cash combination theravance biopharma shares cash theravance biopharma shares measured fvtoci fair value december million million disposal equity investments measured fvtoci accumulated fair value movements reclassified fair value reserve retained earnings investments fair value million million disposed year cumulative gain investments tax million million certain investments investments funds limited lives investments acquired intention sell measured fair value profit loss fvtpl additions disposals investments measured fvtpl included acquisition shares hindustan unilever limited merger gsks indian listed consumer healthcare entity hindustan unilever subsequent divestment sharesnotes financial statements continued noncurrent assets amounts receivable insurance contracts pension schemes surplus receivables amounts receivable insurance contacts held cash surrender value movements profit loss within receivables million million million million classified financial assets million million classified fair value profit loss remaining balance million million expected credit loss allowance immaterial december inventories raw materials consumables work progress finished goods trade receivables trade receivables net loss allowance accrued income prepayments interest receivable employee loans advances receivables trade receivables included nil nil due associates joint ventures receivables included nil nil due associates joint ventures loss allowance trade receivables january exchange adjustments charge year subsequent recoveries amounts provided utilised december total trade receivables balance million million considered credit impaired million million expected credit loss allowance applied amount purchased originated credit impaired within receivables million million million million classified financial assets nil nil classified fair value profit loss remaining balance million million expected credit loss allowance million million recognised december charge reported profit loss year discussion credit risk practices please refer note gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information cash cash equivalents cash bank hand shortterm deposits cash cash equivalents included billion billion available general use due restrictions applying subsidiaries held restrictions include exchange controls taxes repatriation assets held sale property plant equipment intangibles inventory noncurrent assets disposal groups transferred assets held sale expected carrying amounts recovered principally disposal sale considered highly probable held lower carrying amount fair value less costs sell inventory written fair value less costs sell included assets held sale million valuation methodology used significant inputs based observable market data therefore valuation classified level fair value hierarchy intangible assets million transferred intangibles year million intangible assets held sale impairments exchange movements assets divested year remaining december millionnotes financial statements continued trade payables trade payables wages salaries social security viiv healthcare put option payables deferred income customer return rebate accruals accruals trade payables included nil million due associates joint ventures group provides limited supplier financing arrangements certain customers amounts involved december material revenue recognised year included deferred income january million million customer return rebate accruals provided group point sale respect estimated rebates discounts allowances payable customers included million million respect us pharmaceuticals vaccines fully described group financial review accruals made time sale actual amounts paid based claims made time initial recognition sale amounts estimated may fully reflect final outcome subject change dependent upon amongst things types buying group product sales mix level accrual reviewed adjusted quarterly light historical experience actual amounts paid changes arrangements future events could cause assumptions accruals based change could affect future results group pfizers put option shareholding viiv healthcare currently exercisable pfizer may request ipo viiv healthcare time either gsk consent ipo offering completed within nine months pfizer could require gsk acquire shareholding amount liability put option held gross redemption basis derived internal valuation viiv healthcare business utilising discounted forecast future cash flow multiplesbased methodologies table shows indicative basis income statement balance sheet sensitivity pfizer put option reasonably possible changes key assumptions increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts basis points increase discount rate basis points decrease discount rate cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro sales forecast viiv healthcare sales respect viiv healthcare put option explanation accounting viiv healthcare set gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information net debt listing exchange current assets liquid investments cash cash equivalents shortterm borrowings commercial paper bank loans overdrafts libor us us medium term note new york stock exchange euribor euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange lease liabilities longterm borrowings us us medium term note new york stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange exchangeable us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange euro medium term note london stock exchange us us medium term note new york stock exchange euro medium term note london stock exchange longterm borrowings lease liabilities net debt notes financial statements continued net debt continued current assets liquid investments classified financial assets amortised cost december included us treasury notes government bonds effective interest rate liquid investments december approximately approximately liquid investment balances december earning interest floating rates amount million million liquid investment balances december earning interest fixed rates amount million nil balances reported within cash cash equivalents original maturity three months less effective interest rate cash cash equivalents december approximately approximately cash cash equivalents december earning interest floating fixed rates amounted million million respectively million million noninterest bearing holdings amounted million million gsks policy regarding credit quality cash cash equivalents set note financial instruments related disclosures shortterm borrowings gsk billion billion us commercial paper programme nil issue december million million gsk billion euro commercial paper programme million million issue december nil gsk billion threeyear committed facility billion billion day committed facility threeyear committed facility agreed september extended one year september extended one year august day committed facility agreed august facilities undrawn december preparation separation consumer healthcare business february gsk cancelled replaced three year day facilities new revolving credit facilities equivalent size agreed maturities september september weighted average interest rate commercial paper borrowings december weighted average interest rate current bank loans overdrafts december average effective preswap interest rate notes classified shortterm december rate reflected maturities libor coupon note may zero coupon euribor note september longterm borrowings yearend gsk longterm borrowings billion billion billion billion fell due five years average effective preswap interest rate notes issue december approximately approximately longterm borrowings repayable five years carry interest effective rates repayment dates ranging pledged assets group held pledged investments us treasury notes par value million million million million security irrevocable letters credit issued groups behalf respect groups selfinsurance activity provisions respect selfinsurance included within provisions legal disputes discussed note provisions lease liabilities maturity analysis discounted lease liabilities recognised group balance sheet follows rental payments due within one year rental payments due one two years rental payments due two three years rental payments due three four years rental payments due four five years rental payments due five years total lease liabilities gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits pension postemployment costs uk pension schemes us pension schemes overseas pension schemes unfunded postretirement healthcare schemes analysed funded defined benefithybrid pension schemes unfunded defined benefit pension schemes unfunded postretirement healthcare schemes defined benefit schemes defined contribution pension schemes costs defined benefit pension postretirement healthcare schemes charged income statement follows cost sales selling general administration research development gsk entities operate pension arrangements cover groups material obligations provide pensions retired employees arrangements developed accordance local practices countries concerned pension benefits provided state schemes defined contribution schemes whereby retirement benefits determined value funds arising contributions paid respect employee defined benefit schemes whereby retirement benefits based employee pensionable remuneration length service pension costs defined benefit schemes accounting purposes calculated using projected unit credit method certain countries pension benefits provided unfunded basis administered trustee companies formal independent actuarial valuations groups main plans undertaken regularly normally least every three years remeasurement movements year recognised statement comprehensive income discount rates derived aa rated corporate bond yields except countries deep market corporate bonds government bond yields used discount rates selected reflect term expected benefit payments projected inflation rates pension increases longterm predictions based yield gap longterm indexlinked fixed interest gilts uk mortality rates determined adjusting saps standard mortality tables reflect recent scheme experience rates projected reflect improvements life expectancy line cmi projections longterm rate improvement per year males females us mortality rates calculated using pri white collar table adjusted reflect recent experience rates projected using mp allow future improvements life expectancynotes financial statements continued pensions postemployment benefits continued average life expectancy assumed individual age projected apply individual age follows uk us male female male female years years years years current projected assets funded schemes generally held separately administered trusts either specific assets proportion general fund insurance contracts assets invested different classes order maintain balance risk return investments diversified limit financial effect failure individual investment physical asset allocation strategy three four uk plans returnseeking assets liabilitymatching assets buyin insurance contract purchased cover substantially obligations uk plan december value insurance contract million million asset allocation us plans currently set returnseeking assets liabilitymatching assets pension plans exposed risk arises estimated market value plans assets might decline investment returns might reduce estimated value plans liabilities might increase line agreed mix returnseeking assets generate future returns liabilitymatching assets better match future pension obligations group defined overall longterm investment strategy plans investments across broad range assets main market risks within asset hedging portfolio credit risk interest rates longterm inflation equities property currency bank counterparty risk plan liabilities series future cash flows relatively long duration ias basis cash flows sensitive changes expected longterm inflation rate discount rate aa corporate bond yield curve increase longterm inflation corresponds increase liabilities increase discount rate corresponds decrease liabilities interest rate risk credit rate risk us partially hedged targets based accounting measure plan liabilities uk plans interest rate inflation hedging strategy place targets based economic measure plan liabilities furthermore plans also currently hedge portion equity exposure staggered maturity profile uk defined benefit pension schemes operated benefit former glaxo wellcome employees former smithkline beecham employees remain separate schemes closed new entrants subsequent uk employees entitled join defined contribution scheme addition group operates number postretirement healthcare schemes principal one us following period consultation impacted employees announced december uk defined benefit plans would closed future accrual effective march result post closure accrued benefits active participants revalued line inflation rpi legacy glaxo wellcome plans cpi legacy smithkline beecham plans subject relevant caps arrangement rather capped pay increases addition defined benefit plan participants still active april receive defined pension contribution effect closure defined contribution enhancement together resulted oneoff cost million announced september us cash balance pension plans would closed future accrual january change resulted credit million june september two amendments made retiree healthcare plans us resulting credit million group applied following financial assumptions assessing defined benefit liabilities uk us rest world pa pa pa pa pa pa pa pa pa rate increase future earnings na na discount rate expected pension increases na na na cash balance creditconversion rate na na na inflation rate sensitivity analysis detailing effect changes assumptions provided analysis provided reflects assumption changes material impact results group gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued amounts recorded income statement statement comprehensive income three years ended december relation defined benefit pension postretirement healthcare schemes follows postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service cost net interest cost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement gainslosses recorded statement comprehensive income postretirement pensions benefits uk us rest world group group amounts charged operating profit current service cost past service costcredit net interest incomecost gains settlements expenses remeasurement losses recorded statement comprehensive income amounts included within past service costs uk included million million million augmentation costs arose major restructuring programmes together charge nil million relation impact closure defined benefit schemes future accrual past service credit million us reflected closure cash balance pension plans january amendments retiree healthcare plan us resulted credit million past service costs postretirement benefits notes financial statements continued pensions postemployment benefits continued summarised balance sheet presentation group defined benefit pension schemes postretirement benefits set table recognised noncurrent assets pension schemes surplus recognised assets held sale postretirement benefits recognised pensions postemployment benefits pension schemes deficit postretirement benefits event plan windup gsk believes uk pension scheme rules provide company right refund surplus assets following full settlement plan liabilities result net surplus uk defined benefit pension schemes recognised full fair values assets liabilities uk us defined benefit pension schemes together aggregated data defined benefit pension schemes group follows uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets asset ceiling restrictions present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets multiasset funds comprise investments pooled investment vehicles invested across range asset classes increasing diversification within growth portfolio value funds asset class quoted market price million million liabilitiesassets category comprises cash mark market values derivative positions indexlinked gilts held part uk repo programme included government bonds related loan million december million million deducted within assets gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets uk us rest world group december equities listed unlisted multiasset funds property listed unlisted corporate bonds listed unlisted government bonds listed insurance contracts liabilitiesassets fair value assets present value scheme obligations net surplusobligation included noncurrent assets included pensions postemployment benefits actual return plan assets notes financial statements continued pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements fair values assets assets january exchange adjustments additions business combinations interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december exchange adjustments interest income expenses settlements curtailments remeasurement employer contributions scheme participants contributions benefits paid assets december group made additional funding contributions uk pension schemes million million million nil nil nil us schemes gsk reached revised agreement trustees uk pension schemes make additional contributions eliminate pension deficits identified within schemes december actuarial funding valuation based funding agreements additional contributions eliminate pension deficit expected million included within note commitments funding commitment supersedes previous agreement made contributions based government bond yield curve approach selecting discount rate rate chosen included allowance expected investment returns reflected asset mix schemes employer contributions including special funding contributions estimated approximately million respect defined benefit pension schemes million respect postretirement benefits gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued postretirement pensions benefits uk us rest world group group movements defined benefit obligations obligations january exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments disposals service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december exchange adjustments service cost past service cost interest cost settlements curtailments remeasurement scheme participants contributions benefits paid obligations december defined benefit pension obligation analysed follows funded unfunded liability us postretirement healthcare scheme assessed using assumptions us pension scheme together assumption future medical inflation grading thereafter december us postretirement healthcare scheme obligation million million million postretirement benefits unfundednotes financial statements continued pensions postemployment benefits continued movement net defined benefit liability follows january exchange adjustments additions business combinations service cost past service cost interest cost settlements curtailments remeasurements return plan assets excluding amounts included interest lossgain change demographic assumptions gainloss change financial assumptions experience lossgain employer contributions expenses december remeasurements included within postretirement benefits detailed gain change demographic assumptions gainloss change financial assumptions experience gains defined benefit pension obligation analysed membership category follows active retired deferred postretirement benefit obligation analysed membership category follows active retired deferred weighted average duration defined benefit obligation follows years years years pension benefits postretirement benefits gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information pensions postemployment benefits continued sensitivity analysis effect changes assumptions used benefit obligations annual defined benefit pension postretirement costs detailed information determined taking account duration liabilities overall profile plan memberships increase decrease discount rate decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease decreaseincrease annual pension cost increasedecrease annual postretirement benefits cost decreaseincrease pension obligation decreaseincrease postretirement benefits obligation increase decrease inflation rate increasedecrease annual pension cost increasedecrease pension obligation year increase life expectancy increase annual pension cost increase annual postretirement benefits cost increase pension obligation increase postretirement benefits obligation increase rate future healthcare inflation increase annual postretirement benefits cost increase postretirement benefits obligation notes financial statements continued provisions legal major employee restructuring related disputes programmes provisions provisions total january exchange adjustments charge year reversed unused unwinding discount utilised reclassifications movements transfer pension obligations december settled within one year settled one year december legal disputes major restructuring programmes group involved substantial number legal group four major restructuring disputes including notification possible claims set programmes progress combined restructuring note legal proceedings provisions legal integration programme major restructuring disputes include amounts relating product liability antitrust programme substantially complete government investigations contract terminations self consumer healthcare joint venture integration programme insurance separation preparation programme programmes focused primarily simplifying supply chain processes net charge year million including reversals rationalising groups manufacturing network restructuring estimated insurance recoveries primarily related pharmaceuticals commercial operations integrating provisions product liability cases commercial disputes pfizer consumer healthcare business preparing various government investigations separation gsk two new companies discount provision nil increased restructuring provisions primarily include severance costs million discount calculated using riskadjusted management made formal decision eliminate projected cash flows riskfree rates return certain positions communicated respect product liability claims related certain products groups employees affected appropriate consultation provision made sufficient history claims procedures completed appropriate provision made settlements enable management make reliable made staff severance payments paid immediately estimate provision required cover unasserted claims discount provisions increased million ultimate liability matters may vary amounts increased million provided dependent upon outcome litigation proceedings investigations possible settlement pension augmentation includes million relating negotiations defined benefit plan arising staff redundancies shown note pensions postemployment benefits nature groups business number matters may subject negotiation litigation employee related provisions many years litigation proceedings including various employee related provisions include obligations certain appeal procedures often take many years reach resolution medical benefits disabled employees spouses outofcourt settlement discussions also often us december provision benefits protracted indemnified disputes result provision amounted million million employee charge corresponding receivable benefits reflect variety provisions severance costs group potential settlement discussions number jubilee awards longservice benefits disputes amounts provided given nature provisions amounts likely based current assessment progress settled many years disputes estimates million amount provided december settled within one year provisions december expected million included provisions provisions onerous million provision made legal contracts insurance provisions number disputes reimbursed third parties discussion provisions including vehicle insurance regulatory matters legal issues see note legal proceedings gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information contingent consideration liabilities consideration certain acquisitions includes amounts contingent future events development milestones sales performance group provided fair value contingent consideration follows shionogi viiv novartis healthcare vaccines total january remeasurement income statement cash payments operating cash flows cash payments investing activities movements december remeasurement income statement cash payments operating cash flows cash payments investing activities december remeasurement income statement cash payments operating cash flows cash payments investing activities december contingent consideration payable december million million expected paid within one year consideration payable acquisition shionogiviiv healthcare joint venture novartis vaccines business expected paid number years result total estimated liabilities discounted present values shown shionogiviiv healthcare contingent consideration liability discounted novartis vaccines contingent consideration liability discounted commercialised products pipeline assets shionogiviiv healthcare novartis vaccines contingent consideration liabilities calculated principally based forecast sales performance specified products lives products table shows indicative basis income statement balance sheet sensitivity reasonably possible changes key inputs valuations contingent consideration liabilities shionogi shionogi viiv novartis viiv novartis healthcare vaccines healthcare vaccines increasedecrease financial liability lossgain income statement increase sales forecasts decrease sales forecasts increase discount rate decrease discount rate cent appreciation us dollar cent depreciation us dollar cent appreciation euro cent depreciation euro sales forecast viiv healthcare sales respect shionogiviiv healthcare contingent consideration explanation accounting viiv healthcare set notes financial statements continued noncurrent liabilities accruals deferred income payables payables includes number employeerelated liabilities including employee savings plans contingent liabilities december contingent liabilities gsk present obligation result past event comprising guarantees items arising normal course business amounted million million contingent liabilities arise group present obligation arising past event december million million financial assets pledged collateral contingent liabilities provision made outcome tax legal disputes probable group suffer outflow funds possible make reliable estimate outflow december disputes provision made possible meaningfully assess whether outcomes result probable outflow quantify reliably estimate liability provision recorded descriptions significant legal disputes group party set note legal proceedings commitments contractual obligations commitments contracted provided financial statements intangible assets property plant equipment investments purchase commitments pensions interest loans future finance charges leases commitments related intangible assets include milestone payments dependent successful clinical development meeting specified sales targets represent maximum would paid milestones however unlikely achieved amounts riskadjusted discounted net decrease intangible asset commitments mainly attributable termination number agreements including termination agreement bintrafusp alfa merck kgaa darmstadt germany offset increase number new rd collaborations including alector iteos therapeutics lifemine therapeutics gsk reached agreement trustees uk pension schemes make additional contributions eliminate pension deficit identified december actuarial funding valuation payment million due table includes commitment excludes normal ongoing annual funding requirement uk approximately million group also commitments principally relate revenue payments made licences alliances commitments respect future interest payable loans disclosed taking account effect interest rate swaps gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information share capital share premium account share ordinary shares p premium number share capital issued fully paid january issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes ordinary shares acquired esop trusts december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes movements equity retained earnings reserves amounted million december million million million million million related associates joint ventures cumulative translation exchange equity follows net translation exchange included non total retained fair value controlling translation earnings reserve interests exchange january exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries december exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries december exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates december notes financial statements continued movements equity continued analysis comprehensive income equity category follows non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries associates fair value movements cash flow hedges reclassification cash flow hedges income expense tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement losses defined benefit plans tax remeasurement losses defined benefit plans comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries fair value movements cash flow hedges reclassification cash flow hedges income expense tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement losses defined benefit plans tax remeasurement losses defined benefit plans comprehensive expenseincome year non retained controlling earnings reserves interests total items may subsequently reclassified income statement exchange movements overseas net assets net investment hedges reclassification exchange movements liquidation disposal overseas subsidiaries fair value movements cash flow hedges reclassification cash flow hedges income expense tax fair value movements cash flow hedges items reclassified income statement exchange movements overseas net assets noncontrolling interests fair value movements equity investments tax fair value movements equity investments remeasurement gains defined benefit plans tax remeasurement gains defined benefit plans comprehensive expenseincome year information net investment hedges provided part note financial instruments related disclosures gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information movements equity continued analysis reserves follows esop trust fair value cash flow shares reserve hedge reserve reserves total january exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year ordinary shares acquired esop trusts writedown shares held esop trusts december exchange adjustments transferred retained earnings year disposal equity investments net fair value movement year transferred income expense year impairments equity investments december reserves include various nondistributable merger premerger reserves amounting million december million million reserves also include capital redemption reserve created result share buyback programme amounting million december million million noncontrolling interests total noncontrolling interests includes following individually material noncontrolling interests noncontrolling interests individually material viiv healthcare gsk holds viiv healthcare subgroup giving rise material noncontrolling interest summarised financial information respect viiv healthcare subgroup follows turnover profit taxation comprehensive incomeexpense total comprehensive income noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net liabilities net cash inflow operating activities net cash outflow investing activities net cash outflow financing activities decreaseincrease cash bank overdrafts year notes financial statements continued noncontrolling interests continued financial information relates viiv healthcare group standalone basis impact grouprelated adjustments primarily related recognition preferential dividends profit taxation million million million stated charging preferential dividends payable gsk shionogi pfizer charge million million million remeasurement contingent consideration payable consideration expected paid number years following amounts attributable viiv healthcare group included gsks financial statements share profit year attributable noncontrolling interest dividends paid noncontrolling interest noncontrolling interest consolidated balance sheet consumer healthcare joint venture gsk holds consumer healthcare subgroup giving rise material noncontrolling interest summarised financial information respect consumer healthcare subgroup follows turnover profit taxation comprehensive expenses total comprehensive incomeexpenses noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets net cash inflow operating activities net cash inflowoutflow investing activities net cash outflow financing activities increase cash bank overdraft yearperiod financial information relates consumer healthcare joint venture standalone basis period formation july december impact grouprelated adjustments classification cash pooling accounts group companies outside consumer healthcare joint venture major restructuring charges following amounts attributable consumer healthcare joint venture included gsks financial statements share profit yearperiod attributable noncontrolling interest dividends paid noncontrolling interest noncontrolling interest consolidated balance sheet gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information related party transactions year group disposed interest innoviva inc see note details disposal royalties due gsk innoviva year date disposal million million loan million million medicxi ventures lp remained due gsk december gsk increased investment kurma biofund ii fcpr million medicxi ventures lp million part joint venture agreement qura therapeutics llc group obligation fund joint venture april gsk joint venture partner committing financial support amount million december outstanding liability due qura million cash distributions received investments medicxi ventures lp million longwood founders fund lp million apollo therapeutics llp million aggregate compensation directors glt given note employee costs acquisitions disposals details acquisition disposal significant subsidiaries associates joint ventures businesses given business acquisitions gsk completed material business acquisitions business disposals gsk made number business disposals net cash consideration received year million profit disposal businesses year million calculated follows total consideration cash consideration including currency forwards purchase adjustments deferred consideration total net assets sold property plant equipment cash cash equivalents net assets total costs deal costs reclassification exchange comprehensive income gain disposals associates joint ventures may gsk agreed innoviva inc innoviva sell approximately million shares common stock innoviva back innoviva price per share raising gross proceeds approximately million following settlement transaction gsk longer hold innoviva stock see details note investment associates joint ventures cash flows associates joint business ventures disposals disposals cash consideration received net deferred consideration paid transaction costs cash cash equivalents divestedacquired cash outflowinflow notes financial statements continued acquisitions disposals continued business acquisitions gsk completed one smaller business acquisition acquired pfizer biotech corporation taiwan part pfizers consumer healthcare business previously recognised part consumer healthcare joint venture september non cash consideration million represented goodwill million cash million assets acquired million less noncontrolling interest million net liabilities million total net assets acquired intangible assets property plant equipment inventory trade receivables cash cash equivalents trade payables noncontrolling interest goodwill noncash consideration settlement promissory note total consideration business disposals april gsk completed divestment horlicks consumer healthcare nutrition products india number countries excluding bangladesh unilever merger gsks indian listed consumer healthcare entity hindustan unilever indian listed public company gsk received equity stake hindustan unilever million cash gsk disposed equity stake hindustan unilever may divestment bangladesh closed june total cash consideration received million cash divested part disposal india bangladesh consumer healthcare entities million profit disposal businesses year million calculated follows horlicks divestment total consideration cash consideration receivable including currency forwards purchase adjustments equity investment hindustan unilever limited total net assets disposed goodwill intangible assets property plant equipment inventory cash cash equivalents net liabilitiesassets total costs transaction costs derivative reclassification exchange comprehensive income total gain disposals gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued exposure share price movements embedded agreement merge gsks indian listed consumer healthcare entity hindustan unilever limited part divestment horlicks nutrition products india number countries recognised derivative signing agreement completion transaction million recorded cost table derecognition derivative asset largely reflects fair value gains recognised income statement prior periods associates joint ventures year gsk made investments associates million million paid cash cash flows associates joint business business ventures acquisitions disposals investments cash consideration receivedpaid net deferred consideration transaction costs cash cash equivalents acquireddivested cash inflowoutflow business acquisitions pfizer consumer healthcare business acquisition pfizers consumer healthcare business completed july gsk pfizer contributed respective consumer healthcare businesses new consumer healthcare joint venture noncash transaction whereby gsk acquired pfizers consumer healthcare business return shares joint venture gsk equity interest majority control joint venture pfizer equity interest group control consumer healthcare joint venture consolidated within groups financial statements number territories legal completion acquisition occurred regulatory constraints however consumer healthcare joint venture obtained control majority businesses territories july consolidated net assets businesses date cases entitled benefits trading businesses delayed territories noncontrolling interest consumer healthcare joint venture calculated applying proportionate goodwill method represents pfizers share net assets joint venture excluding goodwill goodwill billion expected deductible tax purposes recognised goodwill represents potential synergies arising combining acquired businesses gsks existing business together value workforce acquired total transaction costs recognised acquisition amounted million since acquisition july sales billion arising pfizer consumer healthcare business included group turnover business acquired beginning year estimated group turnover would approximately billion higher business integrated groups existing activities practicable identify impact group profit period tesaro inc january gsk acquired tesaro inc oncology focused biopharmaceutical company cash consideration billion billion order strengthen groups pharmaceutical pipeline transaction costs amounted million goodwill billion none expected taxdeductible recognised goodwill represents potential synergies arising combining acquired businesses gsks existing business together value workforce acquired acquisition january december sales billion arising tesaro business included group turnover business integrated groups existing activities practicable identify impact group profit periodnotes financial statements continued acquisitions disposals continued fair value assets acquired business combinations including goodwill set table amounts related pfizer consumer healthcare business acquisition provisional subject change pfizer consumer healthcare business tesaro net assets acquired intangible assets property plant equipment right use assets inventory trade receivables assets including cash cash equivalents trade payables net deferred tax liabilities liabilities term loan noncontrolling interest goodwill total consideration settled shares gsk consumer healthcare joint venture cash consideration paid fair value investment joint venture converted subsidiary total consideration noncontrolling interest million represents pfizers share fair value pfizer consumer healthcare business excluding goodwill total noncontrolling interest initially recognised consolidated statement changes equity million also includes pfizers share book value gsk consumer healthcare business disposals gsk made number business disposals net cash consideration received year million profit disposal businesses year million calculated follows total cash consideration receivable net subsidy payable net assets disposed goodwill intangible assets property plant equipment inventory cash cash equivalents net assets transaction costs reclassification exchange comprehensive income noncontrolling interest divested transaction signed yet completed gain embedded derivative transaction signed yet completed transaction costs total profit disposal gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information acquisitions disposals continued transaction signed yet completed december december gsk agreed divest horlicks consumer healthcare nutrition brands unilever plc form merger glaxosmithkline consumer healthcare limited hindustan unilever limited total consideration valued approximately billion glaxosmithkline consumer healthcare limited public company listed national stock exchange nse bombay stock exchange bse gsk held stake following merger glaxosmithkline consumer healthcare limited hindustan unilever limited public company listed nse bse gsk would million hindustan unilever limited shares group entered forward foreign exchange contracts relation transaction contracts value billion designated cash flow hedge part foreign exposure arising transaction contracts value billion designated net investment hedges inr eur assets addition exposure share price movements forward purchase shares hindustan unilever limited recognised embedded derivative embedded derivative asset position fair value million december million associates joint ventures year gsk made investments million associates joint ventures million paid cash cash flows associates joint business business venture acquisitions disposals investments cash consideration paidreceived net deferred consideration received transaction costs cash cash equivalents acquireddivested cash outflowinflow adjustments reconciling profit tax operating cash flows profit tax tax profits share aftertax profits associates joint ventures finance expense net finance income depreciation amortisation intangible assets impairment assets written profit sale businesses profit sale intangible assets loss sale investments associates profit sale equity investments business acquisition costs changes working capital decrease inventories increase trade receivables increase trade payables increase receivables contingent consideration paid see note noncash increase contingent consideration liabilities increase payables increasedecrease pension provisions sharebased incentive plans fair value adjustments cash generated operations notes financial statements continued reconciliation net cash flow movement net debt net debt previously reported implementation ifrs net debt beginning year adjusted increase cash bank overdrafts increasedecrease liquid investments increase longterm loans repayment shortterm notes repayment ofincrease shortterm loans repayment lease liabilities debt subsidiary undertakings acquired exchange adjustments noncash movements movement net debt net debt end year january interest change reclass december exchange expense fair value ifications cash flow analysis changes net debt liquid investments cash cash equivalents overdrafts debt due within one year commercial paper europeanus mtn bank facilities lease liabilities debt due one year europeanus mtn bank facilities lease liabilities net debt interest payable derivative financial instruments total liabilities financing activities excluding cash cash equivalents overdrafts liquid investments gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information adjustments net cash flow movement net debt continued january interest change reclass december exchange expense fair value ifications cash flow analysis changes net debt liquid investments cash cash equivalents cash cash equivalents ahfs overdrafts debt due within one year commercial paper europeanus mtn bank facilities lease liabilities debt due one year europeanus mtn bank facilities lease liabilities net debt interest payable derivative financial instruments total liabilities financing activities excluding cash cash equivalents overdrafts liquid investments information significant changes net debt see note net debtnotes financial statements continued financial instruments related disclosures objective gsks treasury activity minimise gsk access shortterm finance billion posttax net cost financial operations reduce volatility billion us commercial paper programme nil nil benefit earnings cash flows gsk uses variety issue december million financial instruments finance operations derivative million gsk access shortterm finance financial instruments manage market risks billion euro commercial paper programme million operations derivatives principally comprise foreign exchange million issue december nil forward contracts swaps used swap december gsk billion threeyear committed borrowings liquid assets currencies required group facility billion billion day committed purposes well interest rate swaps used facility threeyear committed facility agreed manage exposure financial risks changes interest september extended one year september rates financial instruments reduce uncertainty extended one year august foreign currency transactions interest payments day committed facility agreed august derivatives used exclusively hedging purposes committed facilities undrawn december relation underlying business activities trading gsk considers level committed facilities speculative instruments adequate given current liquidity requirements preparation separation consumer healthcare capital management business february gsk cancelled replaced gsks financial strategy supports groups strategic three year day facilities new revolving credit facilities priorities regularly reviewed board gsk manages equivalent size agreed maturities september capital structure group appropriate mix september debt equity gsk billion euro medium term note programme capital structure group consists net debt december billion notes issue billion see note net debt total equity including programme group also billion items related noncontrolling interests billion see billion notes issue december consolidated statement changes equity us shelf registration gsks borrowings mature dates total capital including provided noncontrolling interests billion put option owned pfizer viiv healthcare group continues manage financial policies credit exercisable reviewing liquidity requirements gsk considers profile particularly targets shortterm credit ratings sufficient financing options available put p maintaining single longterm ratings consistent option exercised targets groups longterm credit rating standard poors stable outlook moodys market risk investor services moodys stable outlook interest rate risk management groups shortterm credit ratings p standard objective gsks treasury activity minimise poors moodys respectively effective net interest cost balance mix debt fixed liquidity risk management floating rates time gsks policy borrow centrally order meet anticipated groups main interest rate risk arises borrowings funding requirements strategy diversify liquidity investments floating rates refinancing maturing fixed sources using range facilities maintain broad access rate debt changes interest rates affect future financial markets day sweep cash cash flows fair values financial instruments policy number global subsidiaries central treasury accounts interest rate risk management limits net amount liquidity management purposes gsk utilises physical floating rate debt specific cap reviewed agreed notional cash pool arrangements appropriate location less annually board currency notional cash pools liquidity drawn majority debt issued fixed interest rates foreign currency balances provide local funding changes floating rates interest significantly central liquidity required balances actively managed affect groups net interest charge includes maintained appropriate levels balances notional borrowings interest rate swaps place pooling arrangements settled across currencies gross removes impact associated periodic repricing cash overdraft balances reported shortterm borrowings including bank facilities exposed december gsk billion borrowings risk future changes market interest rate repayable within one year held billion cash majority cash liquid investments cash equivalents liquid investments billion held centrally gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued interest rate benchmark reform order reduce foreign currency translation exposure interest rate benchmark reform amendments ifrs ias group seeks denominate borrowings currencies ifrs ifrs ifrs phase phase ii principal assets cash flows primarily issued iasb september august denominated us dollars euros sterling borrowings adopted uk endorsement board january swapped currencies required phase amendment modifies specific hedge accounting borrowings denominated swapped foreign requirements allow hedge accounting continue currencies match investments overseas group assets affected hedges period uncertainty may treated hedge relevant assets forward hedged items hedging instruments affected current contracts major currencies also used reduce exposure interest rate benchmarks amended result groups investment overseas assets see net ongoing interest rate benchmark reforms phase ii also provides investment hedges section note details financial instruments measured using amortised cost measurement changes basis determining credit risk contractual cash flows required interest rate benchmark credit risk risk counterparty default reform reflected adjusting effective interest contractual obligations resulting financial loss group rate immediate gain loss recognised arises cash cash equivalents favourable group closely monitored market output derivative financial instruments held banks financial various industry working groups managing institutions well credit exposures wholesale retail transition new benchmark interest rates includes customers including outstanding receivables announcements made libor regulators including group considers maximum credit risk december financial conduct authority fca us commodity million december futures trading commission regarding transition away million total groups financial assets libor including gbp libor usd libor exception investments comprising equity euribor sterling overnight index average rate investments bear equity risk rather credit risk sonia secured overnight financing rate sofr see details groups total financial assets euro shortterm rate str respectively december gsks greatest concentration december group directly exposed credit risk billion wholesaler us interest rate benchmark reform held interest rate billion legal general investment derivatives floating rate debt referenced libor management class gbp liquidity fund aaaaaa group transition material derivatives floating rate see information groups credit debt new index instruments referencing risk exposure respect three largest us wholesaler libor matured december customers foreign exchange risk management change estimation techniques groups objective minimise exposure overseas significant assumptions made current reporting operating subsidiaries transaction risk matching local period assessing loss allowance financial assets currency income local currency costs possible amortised cost fvtoci since adoption ifrs foreign currency transaction exposures arising external start reporting period internal trade flows selectively hedged gsks internal treasuryrelated credit risk trading transactions matched centrally intercompany gsk sets global counterparty limits gsks banking payment terms managed reduce foreign currency risk investment counterparties based longterm credit possible gsk manages cash surpluses ratings moodys standard poors usage borrowing requirements subsidiary companies centrally limits actively monitored using forward contracts hedge future repayments back originating currency gsk actively manages exposure credit risk reducing surplus cash balances wherever possible part gsks strategy regionalise cash management concentrate cash centrally much possible table sets credit exposure counterparties rating liquid investments cash cash equivalents derivatives gross asset position derivative contract considered purpose table although isda agreements amount risk net position counterparty table e sets groups financial assets liabilities offset basisnotes financial statements continued financial instruments related disclosures continued december million million cash categorised held unrated subinvestment grade rated counterparties lower bbbbaa million million cash transit remaining exposure concentrated overseas banks used local cash management investment purposes including million nigeria held united bank africa zenith bank access bank stanbic ibtc bank million halk bank uk million btv austria million argentina held banco de la nacion banco de la provincia million j trust royal bank cambodia million produbanco ecuador million banco central de honduras honduras million bac san jos panama million banco popular puerto rico million bank balances deposits held bbbbaa rated counterparties million held bbbbaa rated counterparties including balances deposits million hdfc bank india banks used local investment purposes gsk measures expected credit losses cash cash equivalents function individual counterparty credit ratings associated month default rates expected credit losses cash cash equivalents thirdparty financial derivatives deemed immaterial loss experienced credit ratings assigned standard poors moodys respectively opinions two rating agencies differ gsk assigns lower rating two counterparty local rating agency fitch data source available ratings converted global ratings equivalent standard poors moodys using published conversion tables credit ratings form basis assessment expected credit loss treasuryrelated balances held amortised cost bank balances deposits government securities bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total bbba aaaaaa aaaa aa bbbbaa unrated total bank balances deposits us treasury treasury repo money market funds liquidity funds government securities rd party financial derivatives total gsks centrally managed cash reserves amounted december group trade receivables due billion december available within three three wholesalers totalling million months includes billion cash managed total trade receivables million group viiv healthcare owned subsidiary group exposed concentration credit risk respect billion cash managed group gsk consumer wholesalers one encounters healthcare owned subsidiary group invested financial difficulty could materially adversely affect centrally managed liquid assets bank deposits aaaaaa groups financial results rated us treasury treasury repo money market funds groups credit risk monitoring activities relating aaaaaa rated liquidity funds wholesalers include review quarterly financial wholesale retail credit risk information standard poors credit ratings development outside us customer accounts gsk internal risk ratings establishment periodic groups trade receivables balance review credit limits us line pharmaceutical companies new customers subject credit vetting process group sells products small number wholesalers existing customers subject review least annually addition hospitals pharmacies physicians vetting process subsequent reviews involve obtaining groups sales three largest wholesalers amounted information including customers status government approximately sales us private sector entity audited financial statements credit bureau pharmaceuticals vaccines businesses reports debt rating agency eg moodys standard poors reports payment performance history trade references industry credit groups bank references gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued trade receivables consist amounts due large number fair value financial assets liabilities excluding customers spread across diverse industries lease liabilities geographical areas ongoing credit evaluation performed table presents carrying amounts financial condition accounts receivable fair values groups financial assets liabilities appropriate credit insurance purchased factoring excluding lease liabilities december arrangements put place december amount information obtained proportional level fair values financial assets liabilities included exposure considered information evaluated price would received sell asset paid quantitatively ie credit score qualitatively ie judgement transfer liability orderly transaction market conjunction customers credit requirements participants measurement date determine credit limit following methods assumptions used measure trade receivables grouped customer segments fair values significant financial instruments carried fair similar loss patterns assess credit risk value balance sheet receivables financial assets assessed individually investments equity investments traded active historical forwardlooking information considered market determined reference relevant stock determine appropriate expected credit loss allowance exchange quoted bid price equity investments group believes credit risk provision determined reference current market value similar required excess allowance expected credit losses instruments recent financing rounds discounted cash see note trade receivables flows underlying net assets credit enhancements trade receivables carried fair value based invoiced group uses credit enhancements including factoring amount credit insurance minimise credit risk trade receivables group december million interest rate swaps foreign exchange forward contracts million trade receivables insured swaps options based present value order protect receivables loss due credit risks contractual cash flows option valuation models using default insolvency bankruptcy market sourced data exchange rates interest rates balance sheet date group entity assesses credit risk private customers determine credit insurance required cash cash equivalents carried fair value based net asset value funds factoring arrangements managed locally entities used mitigate risk arising large credit risk contingent consideration business acquisitions concentrations factoring arrangements nonrecourse divestments based present values expected future cash flows following methods assumptions used estimate fair values significant financial instruments measured fair value balance sheet receivables payables including put options carried amortised cost approximates carrying amount liquid investments approximates carrying amount cash cash equivalents carried amortised cost approximates carrying amount longterm loans based quoted market prices level fair value measurement case european us medium term notes approximates carrying amount case fixed rate borrowings floating rate bank loans shortterm loans overdrafts commercial paper approximates carrying amount short maturity instrumentsnotes financial statements continued financial instruments related disclosures continued carrying fair carrying fair value value value value notes financial assets measured amortised cost noncurrent assets b trade receivables b liquid investments cash cash equivalents financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables ab financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets ab trade receivables ab held trading derivatives designated effective hedging relationship ade cash cash equivalents derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial assets financial liabilities measured amortised cost borrowings excluding obligations lease liabilities bonds designated hedging relationship bonds bank loans overdrafts commercial paper borrowings total borrowings excluding lease liabilities f trade payables c provisions c noncurrent liabilities c financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities ac held trading derivatives designated effective hedging relationship ade derivatives designated effective hedging instruments fair value movements comprehensive income ade total financial liabilities excluding lease liabilities net financial assets financial liabilities excluding lease liabilities valuation methodology used measure fair value table described categorised trade receivables noncurrent assets trade payables provisions contingent consideration liabilities noncurrent liabilities reconciled relevant notes pages gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued fair value investments gsk shares december employee share ownership plan esop trusts held gsk shares carrying value million million market value million million based quoted market price shares held esop trusts satisfy future exercises options awards employee incentive schemes carrying value lower cost expected proceeds shares recognised deduction reserves december gsk held treasury shares cost million million deducted retained earnings financial instruments held fair value following tables categorise groups financial assets liabilities held fair value valuation methodology applied determining fair value possible quoted prices active markets used level prices available asset liability classified level provided significant inputs valuation model used based observable market data one significant inputs valuation model based observable market data instrument classified level investments classified level tables comprise equity investments unlisted entities group entered research collaborations also investments emerging life science companies level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci level level level total december financial assets fair value financial assets measured fair value comprehensive income fvtoci investments designated fvtoci trade receivables financial assets mandatorily measured fair value profit loss fvtpl investments noncurrent assets trade receivables held trading derivatives designated effective hedging relationship cash cash equivalents derivatives designated effective hedging instruments fair value movements oci financial liabilities fair value financial liabilities mandatorily measured fair value profit loss fvtpl contingent consideration liabilities held trading derivatives designated effective hedging relationship derivatives designated effective hedging instruments fair value movements oci notes financial statements continued financial instruments related disclosures continued movements year financial instruments measured using level valuation methods presented january net losses recognised income statement net gains recognised comprehensive income settlement contingent consideration liabilities additions disposals settlements transfers level december net losses million million attributable level financial instruments recognised income statement respect financial instruments held end year reported operating income charges million million arose remeasurement contingent consideration payable acquisition former shionogiviiv healthcare joint venture million million arose remeasurement contingent consideration payable acquisition novartis vaccines business net gains million net gains million attributable level financial instruments reported comprehensive income fair value movements equity investments arose prior transfer level equity investments transferred level valuation methodology result listing recognised stock exchange year net gains losses include impact exchange movements financial liabilities measured using level valuation methods december included million million respect contingent consideration payable acquisition former shionogiviiv healthcare joint venture consideration expected paid number years vary line future performance specified products movements certain foreign currencies also included million million respect contingent consideration acquisition novartis vaccines business consideration expected paid number years vary line future performance specified products achievement certain milestone targets movements certain foreign currencies sensitivity analysis balances provided note contingent consideration liabilities b trade receivables noncurrent assets scope ifrs following table reconciles financial instruments within trade receivables noncurrent assets fall within scope ifrs relevant balance sheet amounts financial assets predominantly noninterest earning nonfinancial instruments include tax receivables pension surplus balances prepayments outside scope ifrs non non amortised financial financial amortised financial financial fvtpl fvtoci cost instruments instruments total fvtpl fvtoci cost instruments instruments total trade receivables note noncurrent assets note trade receivables include trade receivables million million group portfolios three business models ifrs million million measured fvtpl held sell contractual cash flows receivables sold factoring arrangement million million measured fvtoci held either collect sell contractual cash flows receivables may sold factoring agreement million million measured amortised cost held collect contractual cash flows factoring agreement place gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued c trade payables provisions contingent consideration liabilities noncurrent liabilities scope ifrs following table reconciles financial instruments within trade payables provisions contingent consideration liabilities noncurrent liabilities fall within scope ifrs relevant balance sheet amounts financial liabilities predominantly noninterest bearing nonfinancial instruments include payments account tax social security payables provisions arise contractual obligations deliver cash another financial asset outside scope ifrs non non amortised financial financial amortised financial financial fvtpl cost instruments instruments total fvtpl cost instruments instruments total trade payables note provisions note contingent consideration liabilities note noncurrent liabilities note derivative financial instruments hedging programmes derivatives used economic hedging purposes speculative investments classified held trading designated effective hedging instruments presented current assets liabilities expected settled within months end reporting period otherwise classified noncurrent group following derivative financial instruments fair value fair value assets liabilities assets liabilities noncurrent cash flow hedges interest rate swap contracts principal amount million nil current cash flow hedges interest rate swap contracts principal amount nil million net investment hedges cross currency swaps principal amount nil million cash flow hedges foreign exchange contracts principal amount million million net investment hedges foreign exchange contracts principal amount million million derivatives designated effective hedging instruments noncurrent embedded derivatives current foreign exchange contracts principal amount million million embedded derivatives derivatives classified held trading total derivative instruments fair value hedges december december group designated fair value hedgesnotes financial statements continued financial instruments related disclosures continued net investment hedges december certain foreign exchange contracts designated net investment hedges respect foreign currency translation risk arising consolidation groups net investment european euro japanese jpy foreign operations shown table carrying value bonds included million million designated hedging instruments net investment hedges cash flow hedges group entered forward foreign exchange contracts designated cash flow hedges entered hedge foreign exchange exposure arising cash flows euro denominated coupon payments relating notes issued groups european medium term note programme buyout novartis noncontrolling interest consumer healthcare joint venture divestment horlicks nutrition brands took place refinancing existing debt maturities group manages cash flow interest rate risk using floatingtofixed interest rate swaps addition group carries balance reserves arose prehedging fluctuations longterm interest rates pricing bonds issued prior years current year future balance reclassified finance costs life bonds foreign exchange risk current year group designated certain foreign exchange forward contracts swaps cash flow net investment hedges foreign exchange derivative financial assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet following tables detail foreign exchange forward contracts swaps outstanding end reporting period well information related hedged items hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments ensure economic relationship exists hedged item hedging instrument group enters hedge relationships critical terms hedging instrument match exactly terms hedged item qualitative assessment effectiveness performed changes circumstances affect terms hedged item critical terms longer match exactly critical terms hedging instrument group uses hypothetical derivative method assess effectiveness main source hedge ineffectiveness hedging relationships effect counterparty groups credit risk fair value foreign exchange forward contracts swaps reflected fair value hedged item attributable changes foreign exchange rates ineffectiveness rolling cash flow hedges divestments mentioned sources ineffectiveness emerged hedging relationships ineffectiveness recorded cash flow hedges amounted nil gain million ineffectiveness recorded net investment hedges nil included table borrowings bonds notional value us million swapped fixed interest rate eur debt cross currency interest rate swap periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments cash flow hedges foreign exchange contracts buy foreign currency less months usd months eur months eur gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments net investment hedges foreign exchange contracts sell foreign currency less months eur sgd jpy borrowings less months eur months eur cumulative balance cash periodic change value flow hedge reserveforeign calculating hedge currency translation reserve ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment foreign operations periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments cash flow hedges foreign exchange contracts buy foreign currency months eur periodic change value calculating average foreign notional carrying hedge exchange rate currency value value ineffectiveness hedging instruments net investment hedges foreign exchange contracts sell foreign currency less months eur less months sgd less months jpy borrowings including cross currency interest rate swaps months eur months eur notes financial statements continued financial instruments related disclosures continued cumulative balance cash periodic change value flow hedge reserveforeign calculating hedge currency translation reserve ineffectiveness continuing hedges hedged items cash flow hedges variability cash flows highly probable forecast transaction variability cash flows foreign exchange exposure arising euro denominated coupon payments relating debt issued net investment hedges net investment foreign operations million million balances cash flow hedge reserve arise hedging relationships hedge accounting longer applied following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss amount line item hedged hedge profit future cash line item hedging ineffectiveness loss flows gainslosses gainslosses hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows highly probable forecast transaction operating operating income income expense expense variability cash flows foreign exchange exposure arising finance finance euro denominated coupon payments relating debt issued income income expense expense net investment hedges net investment foreign operations finance finance income income expense expense following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss amount line item hedged hedge profit future cash line item hedging ineffectiveness loss flows gainslosses gainslosses hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows highly probable forecast transaction operating operating income income expense expense variability cash flows foreign exchange exposure arising finance finance euro denominated coupon payments relating debt issued income income expense expense net investment hedges net investment foreign operations finance finance income income expense expense gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued interest rate risk group manages cash flow interest rate risk using floatingtofixed interest rate swaps quarterly intervals difference fixed contract rates floating rate interest amounts calculated reference agreed notional principal amounts exchanged none swaps outstanding december however interest rate risk element future debt issuance managed entering forward starting interest rate swaps effectively lock interest rates debt advance closed time issuing debt resulting gain loss held oci recycled income statement interest payments debt impact income statement forward starting interest rate swaps forward starting interest rate contracts exchanging floating interest fixed interest designated cash flow hedges hedge interest variability interest cash flows associated future fixed rate debt interest rate swaps interest rate swap contracts exchanging floating rate interest fixed interest designated cash flow hedges hedge variability interest cash flows associated floating rate debt relating notes issued groups european medium term note programme interest rate swaps interest payments loan occur simultaneously amount accumulated equity reclassified profit loss period floating rate interest payments affect profit loss critical terms interest rate swap forward starting interest rate swap contracts corresponding hedged items materially qualitative assessment effectiveness performed expected value interest rate swap contracts value corresponding hedged items systematically change opposite directions response movements underlying interest rates main sources ineffectiveness hedge relationships effects groups credit risk fair value interest rate swap contracts reflected fair value hedged item attributable change interest rates material sources ineffectiveness emerged hedging relationships following tables provide information regarding interest rate swap forward starting interest rate swap contracts outstanding related hedged items december december interest rate swap contract assets liabilities presented line derivative financial instruments either assets liabilities consolidated balance sheet change fair value average notional recognising fair value contracted fixed principal hedge assets rate value ineffectiveness liabilities hedging instruments years years years balance cash change value flow hedge used reserve calculating continuing hedge hedges ineffectiveness tax hedged items prehedging longterm interest rate million million balances cash flow hedge reserve arise hedge relationships hedge accounting longer applied change fair value average notional recognising fair value contracted fixed principal hedge assets rate value ineffectiveness liabilities hedging instruments less year years balance cash change value flow hedge used reserve calculating continuing hedge hedges ineffectiveness tax hedged items variable rate borrowings notes financial statements continued financial instruments related disclosures continued following table details effectiveness hedging relationships amounts reclassified hedging reserve profit loss amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates matured past finance finance years income income expense expense years years amount reclassified profit loss line item hedged amount profit future cash line item hedging hedge loss flows gainslosses ineffectiveness hedge longer hedged reclassification recognised recognised ineffectiveness expected item affects adjustment reserves profit loss included occur profit loss included cash flow hedges variability cash flows finance finance income income expense expense prehedging longterm interest rates finance finance income income expense expense e offsetting financial assets liabilities financial assets liabilities offset net amount reported balance sheet legally enforceable right offset recognised amounts intention settle net basis realise asset settle liability simultaneously also arrangements meet criteria offsetting still allow related amounts offset certain circumstances bankruptcy termination contract following tables set financial assets liabilities offset subject enforceable master netting arrangements similar agreements offset december december column net amount shows impact groups balance sheet offset rights exercised gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset amount december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued gross financial financial liabilities net financial related assets assets assets amounts net liabilities offset liabilities offset balance december financial assets trade receivables derivative financial instruments financial liabilities trade payables derivative financial instruments amounts meet criteria offsetting balance sheet could settled net certain circumstances principally relate derivative transactions isda international swaps derivatives association agreements party option settle amounts net basis event default party presently legally enforceable right offset amounts offset balance sheet presented separately table f debt interest rate repricing table following table sets exposure group interest rates debt including commercial paper maturity analysis fixed rate debt stated contractual maturity floating rate debt interest rate repricing dates purpose table debt defined classes borrowings lease liabilities total debt total floating fixed rate debt less one year one two years two three years three four years four five years five ten years greater ten years total original issuance profile fixed rate interest floating rate interest addition forward starting interest rate swaps entered affect pricing debt raised future see section interest rate risk detailsnotes financial statements continued financial instruments related disclosures continued g sensitivity analysis tables illustrate estimated impact income statement equity result hypothetical market movements foreign exchange interest rates relation groups financial instruments range variables chosen sensitivity analysis reflects managements view changes reasonably possible oneyear period foreign exchange sensitivity group operates internationally primarily exposed foreign exchange risk relation sterling movements us dollar euro japanese yen foreign exchange risk arises translation financial assets liabilities functional currency entity holds based groups net financial assets liabilities december weakening strengthening sterling currencies variables held constant illustrated tables tables exclude financial instruments expose group foreign exchange risk risk fully hedged another financial instrument increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease income income income statement impact nonfunctional currency foreign exchange exposures cent depreciation us dollar cent depreciation euro yen depreciation yen equity impact shown foreign exchange sensitivity relates derivative nonderivative financial instruments hedging groups net investments european euro foreign operations cash flow hedges foreign exchange exposure arising euro denominated coupon payments relating notes issued groups european medium term note programme increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent appreciation euro increasedecrease increasedecrease equity equity equity impact nonfunctional currency foreign exchange exposures cent depreciation euro gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information financial instruments related disclosures continued tables present groups sensitivity weakening strengthening sterling relevant currency based composition net debt shown note adjusted effects foreign exchange derivatives part net debt affect future foreign currency cash flows increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent appreciation us dollar cent appreciation euro yen appreciation yen increasedecrease increasedecrease net debt net debt impact foreign exchange movements net debt cent depreciation us dollar cent depreciation euro yen depreciation yen interest rate sensitivity group exposed interest rate risk outstanding borrowings investments changes interest rates affect future cash flows fair values financial instruments majority debt issued fixed interest rates changes floating rates interest significantly affect groups net interest charge although majority cash liquid investments earn floating rates interest table hypothetically shows groups sensitivity changes interest rates relation sterling us dollar euro floating rate financial assets liabilities interest rates applicable floating rate financial assets liabilities increased basis points assuming variables remained constant estimated groups finance income would decreased approximately million million increase basis points movement usd interest rates would cause increase million equity nil basis points movement interest rates eur sterling deemed material effect equity increasedecrease increasedecrease income income income statement impact interest rate movements basis points increase sterling interest rates basis points increase us dollar interest rates basis points increase euro interest rates notes financial statements continued financial instruments related disclosures continued h contractual cash flows nonderivative financial liabilities derivative instruments following tables provide analysis anticipated contractual cash flows including interest payable groups non derivative financial liabilities undiscounted basis purpose table debt defined classes borrowings except lease liabilities interest calculated based debt held december without taking account future issuance floating rate interest estimated using prevailing interest rate balance sheet date cash flows foreign currencies translated using spot rates december finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows finance trade payables charge interest lease lease liabilities debt debt liabilities liabilities net debt total december due less one year one two years two three years three four years four five years five ten years greater ten years gross contractual cash flows table provides analysis anticipated contractual cash flows groups derivative instruments excluding equity options give rise cash flows embedded derivatives material using undiscounted cash flows cash flows foreign currencies translated using spot rates december gross cash flows foreign exchange contracts presented purpose table although practice group uses standard settlement arrangements reduce liquidity requirements instruments gross cash inflows gross cash ouflows gross cash inflows gross cash outflows foreign foreign foreign foreign forward exchange forward exchange cross exchange cross exchange starting forward starting forward currency forward currency forward interest rate contracts interest rate contracts interest rate contracts interest rate contracts swaps swaps swaps swaps swaps swaps swaps swaps less one year one two years two three years three four years four five years greater five years gross contractual cash flows gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information employee share schemes gsk operates several employee share schemes including share value plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost threeyear vesting period performance share plan whereby awards granted employees acquire shares ads glaxosmithkline plc cost subject achievement group specified performance targets granting restricted share awards replaced granting options employees cost schemes readily equates potential gain made employee group also operates savings related share option schemes whereby options granted employees acquire shares glaxosmithkline plc discounted price grants restricted share awards normally exercisable end threeyear vesting performance period awards normally granted employees acquire shares ads glaxosmithkline plc circumstances may settled cash grants savingsrelated share option schemes normally exercisable three years saving accordance uk practice majority options savingsrelated share option schemes granted price market price ruling date grant options historical share option schemes granted market price ruling date grant total charge sharebased incentive plans million million million amount million million million arose share value plan see note employee costs details glaxosmithkline share award schemes share value plan share value plan share awards granted certain employees cost awards vest two half three years performance criteria attached fair value awards determined based closing share price day grant deducting expected future dividend yield duration award shares weighted ads weighted number shares ads issuable number fair value number fair value january awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december awards granted awards exercised awards cancelled december performance share plan performance share plan share awards granted directors senior executives cost percentage award vests based upon performance group defined measurement period dividends reinvested period awards granted performance conditions based three equally weighted measures threeyear performance period adjusted free cash flow tsr rd new product performance awards granted performance conditions based four measures threeyear performance period adjusted free cash flow tsr rd new product performance pipeline progress fair value awards determined based closing share price day grant tsr performance elements adjusted likelihood condition met assessed time grant awards made million shares weighted fair value million ads weighted fair value december outstanding awards million shares million adsnotes financial statements continued employee share schemes continued share options savingsrelated options purposes valuing savingsrelated options arrive sharebased payment charge blackscholes option pricing model used assumptions used model follows grant grant grant riskfree interest rate dividend yield volatility expected life years years years savingsrelated options grant price including discount savingsrelated options outstanding share option schemes weighted number exercise price december range exercise prices options outstanding year end weighted average market price exercise year weighted average remaining contractual life years options million shares granted year savingsrelated share option scheme weighted average fair value december million savingsrelated share options exercisable change effective exercise price outstanding options year employee share ownership plan trusts group sponsors employee share ownership plan esop trusts acquire hold shares glaxosmithkline plc satisfy awards made employee incentive plans options granted employee share option schemes trustees esop trusts purchase shares finance provided group way loans contributions costs running esop trusts charged income statement shares held esop trusts deducted reserves amortised value proceeds receivable employees exercise transfer retained earnings trustees waived rights dividends shares held esop trusts february million treasury shares transferred esop trusts trusts held million shares exercise share options share rewards shares held share award schemes number shares nominal value carrying value market value shares held share option schemes number shares nominal value carrying value market value gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information principal group companies following represent principal subsidiaries countries incorporation group december equity share capital entities shown percentage columns companies incorporated principal country operation except stated england us glaxo group limited alacer corp glaxo operations uk limited block drug company inc glaxosmithkline capital plc corixa corporation glaxosmithkline consumer healthcare holdings limited glaxosmithkline capital inc glaxosmithkline consumer healthcare uk trading limited glaxosmithkline consumer healthcare holdings us llc glaxosmithkline consumer trading services limited glaxosmithkline consumer healthcare lp glaxosmithkline export limited glaxosmithkline holdings americas inc glaxosmithkline finance plc glaxosmithkline llc glaxosmithkline holdings limited human genome sciences inc glaxosmithkline research development limited gsk consumer health inc glaxosmithkline services unlimited gsk equity investments limited glaxosmithkline uk limited stiefel laboratories inc glaxosmithkline us trading limited tesaro inc glaxo wellcome uk limited viiv healthcare company setfirst limited smithkline beecham limited viiv healthcare finance limited viiv healthcare limited viiv healthcare uk limited europe others glaxosmithkline biologicals sa belgium glaxosmithkline australia pty ltd australia glaxosmithkline sant grand public france glaxosmithkline consumer healthcare australia pty ltd australia laboratoire glaxosmithkline france glaxosmithkline brasil limitada brazil viiv healthcare sas france glaxosmithkline consumer healthcare ulcglaxosmithkline soins glaxosmithkline consumer healthcare gmbh co kg germany de sante aux consommateurs sri canada glaxosmithkline gmbh co kg germany glaxosmithkline inc canada gsk vaccines gmbh germany id biomedical corporation quebec canada glaxosmithkline consumer healthcare srl italy pf consumer healthcare canada ulcpf soins de sante glaxosmithkline spa italy sri canada gsk vaccines srl italy glaxosmithkline limited china hong kong viiv healthcare srl italy sinoamerican tianjin smith kline french laboratories ltd china pfizer consumer manufacturing italy srl italy wyeth pharmaceutical co ltd china gsk services sp z oo poland glaxosmithkline asia private limited india glaxosmithkline trading services limited republic ireland glaxosmithkline pharmaceuticals limited india glaxosmithkline healthcare ao russia glaxosmithkline consumer healthcare japan kk japan jsc glaxosmithkline trading russia glaxosmithkline kk japan glaxosmithkline sa spain glaxosmithkline pakistan limited pakistan laboratorios viiv healthcare sl spain glaxo wellcome manufacturing pte ltd singapore gsk consumer healthcare sarl switzerland glaxosmithkline korea limited republic korea directly held whollyowned subsidiary glaxosmithkline plc head office england subsidiaries associates listed principally affect figures groups financial statements glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc whollyowned finance subsidiary company company fully unconditionally guaranteed securities issued glaxosmithkline capital inc glaxosmithkline capital plc glaxosmithkline llc see pages complete list subsidiary undertakings associates joint ventures form part financial statementsnotes financial statements continued legal proceedings group involved significant legal administrative dolutegravir proceedings proceedings principally product liability intellectual property tivicaytriumeq tax antitrust consumer fraud governmental investigations viiv healthcare received patent challenge letters significant matters tax matters hatchwaxman act cipla dr reddys labs apotex described group makes provision triumeq tivicay letters lupin mylan triumeq proceedings regular basis summarised note letter sandoz tivicay viiv healthcare lists two accounting principles policies note patents fda orange book tivicay triumeq provisions note also describes disclosure made one patent covers molecule dolutegravir expires proceedings provision legal expenses october second patent claims crystal form incurred provisions related legal claims charged dolutegravir expires december letters selling general administration costs group challenged laterexpiring crystal form patent several believe information amount sought plaintiffs generic companies allege crystal form patent known would meaningful respect invalid others claim crystal form patent invalid legal proceedings due number factors including infringed proposed products viiv limited stage proceedings entitlement healthcare filed patent infringement suits six generic parties appeal decision clarity theories liability companies settlements reached litigations damages governing law september viiv healthcare received paragraph iv december groups aggregate provision legal letter lupin relating tivicay mg dosage oral disputes including tax matters described note suspension challenging crystal form patent taxation million assurance november viiv healthcare filed suit lupin losses result outcome legal proceedings us district court district delaware trial date exceed material amount amount provisions yet set reported groups financial statements dovato happen could material adverse impact results september viiv healthcare received paragraph iv operations group reporting period letter cipla relating dovato challenging judgements incurred settlements entered crystal form patent november viiv healthcare filed intellectual property suit cipla us district court district delaware trial date yet set intellectual property claims include challenges validity enforceability groups patents various products juluca processes well assertions noninfringement january viiv healthcare received paragraph iv letter patents loss cases could result loss lupin relating juluca challenging crystal form patent protection product issue consequences patent well patent relating combination loss could significant decrease sales dolutegravir rilpivirine expires january product could materially affect future results operations february viiv healthcare filed suit lupin group patents additionally june cipla sent viiv healthcare paragraph iv letter related juluca july coreg viiv healthcare filed suit cipla federal court gsk initiated suit teva inducing delaware court yet set trial date either matter infringement patent relating use carvedilol coreg decreasing mortality caused congestive heart litigation gilead sciences inc failure june case proceeded jury trial february viiv healthcare filed patent infringement us district court district delaware jury returned litigation regarding bictegravir gilead sciences inc verdict gsks favour awarding gsk lost profits gilead us district court district delaware reasonable royalties total award million canadian federal court viiv healthcare alleged march trial judge ruled posttrial motions filed gileads triple combination hiv drug containing hiv teva found substantial evidence trial support integrase inhibitor bictegravir infringes viiv healthcares patent jurys finding induced infringement overturning jury covering dolutegravir compounds include award gsk appealed october divided panel dolutegravirs unique chemical scaffold viiv healthcare also court appeals federal circuit reversed commenced actions uk france germany japan ireland district courts ruling reinstated jury award gsks south korea australia gilead alleging gileads favour december teva filed petition rehearing biktarvy infringes certain viiv healthcares hiv integrase en banc court granted tevas petition inhibitor patents viiv healthcare agreed settle global rehearing threemember panel issued original patent infringement litigation gsk shionogi decision august original panel issued shareholder viiv healthcare gilead concerning viiv rehearing opinion majority reinstated jurys healthcares patents relating dolutegravir details regarding damages award million gsks favour teva global settlement licensing agreement found filed petition rehearing en banc rejected note post balance sheet events court appeals federal circuit february gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information legal proceedings continued product liability group named defendant approximately group currently defendant number product us personal injury claims numerous unfiled claims liability lawsuits registered census required court presiding zantac multidistrict litigation mdl proceeding class actions avandia alleging economic injury thirdparty payer class action two pending us class actions brought thirdparty also filed federal court outside us payers assert claims racketeer influenced three class actions pending group canada corrupt organizations act rico state consumer along class action israel among state court cases protection laws december third circuit court naming group first bellwether trial california appeals reversed summary judgements granted favour currently scheduled begin october trial group remanded thirdparty payer cases back scheduled madison county illinois proceed district court discovery underway district court august trial dates yet set possible class certification hearing held early february us product liability litigation assigned mdl status southern district florida ppi litigation group filed several rounds motions dismiss certain members group defendants ongoing mdl resulting following position court ruled proton pump inhibitor ppi litigation plaintiffs allege favour groups motion innovator liability issue use ppis caused serious bodily injuries including appeal court ruled favour defendants acute kidney injury chronic kidney disease endstage respect third party payor class action plaintiffs opted renal failure january approximately replead action issues appeal prevacid hr personal injury lawsuits approximately court dismissed rico claims economic loss nexium hr cases pending group nearly class action allowed class move forward plaintiffs pending multidistrict litigation mdl misbranding theory medical monitoring proceeding district new jersey manufacturers economic loss class actions allowed move forward ppis including prescription otc products also generics retailers packagers dismissed named codefendants mdl group filed cases motions dismiss several hundred cases mdl court yet ruled motions first ppi bellwether mdl plaintiffs required identify types trial delayed due ongoing covid pandemic cancer wished pursue identified different set october involve group types november plaintiffs withdrew consideration addition mdl cases small number cases breast cancer kidney cancer reducing number types pending state courts cancer january plaintiffs withdrew consideration colorectal prostate lung proceed zantac following five types cancer bladder group contacted several regulatory esophageal gastric liver pancreatic authorities regarding detection nnitrosodimethylamine ndma zantac ranitidine products based information addition class action litigation march available time correspondence regulators department justice doj sent group notice civil group made decision suspend release distribution investigation opened allegations false claims act supply dose forms zantac markets pending violations group related zantac june outcome ongoing tests investigations also doj served civil investigative demand group precautionary action group made decision initiate formalizing request documents day voluntary pharmacyretail level recall zantac products new mexico attorney general filed lawsuit multiple globally defendants including group alleging violations state consumer protection false advertising statutes among april european medicines agency ema claims recommended suspension ranitidine medicines following publication emas recommendation company communicated decision reenter market us fda requested manufacturers withdraw ranitidine products marketnotes financial statements continued legal proceedings continued zofran antitrustcompetition group defendant product liability cases certain governmental actions private lawsuits involving zofran pending multidistrict litigation mdl brought group alleging violation competition proceeding district massachusetts cases alleged antitrust laws children suffered birth defects due mothers uk competition markets authority investigation ingestion zofran andor generic ondansetron pregnancy february uk competition markets related nausea vomiting plaintiffs asserted group authority cma issued decision fining group sold zofran knowing unsafe pregnant women failed million infringement competition act connection warn risks illegally marketed zofran offlabel agreements settle patent disputes group entered use pregnant women potential suppliers generic june mdl court granted groups motion paroxetine formulations summary judgment federal preemption grounds court group appealed competition appeal tribunal cat found fda fully informed relevant safety delivered initial judgement march information regarding zofran repeatedly rejected referred certain questions law european union court attempt add birth defect warning label court justice ecj january ecj issued granted judgment group cases pending mdl judgement endorsing general approach undertaken closed mdl proceeding july plaintiffs filed cma original decision may cat appeal preemption decision united states delivered final judgement held gsk infringed court appeals first circuit appeal pending applicable competition law reduced fine imposed group also defendant two state court cases group million million litigation four proposed class actions canada closed sales marketing regulation lamictal purported classes direct purchasers filed suit us groups marketing promotion pharmaceutical district court district new jersey alleging vaccine products subject certain governmental group teva pharmaceuticals unlawfully conspired delay investigations private lawsuits brought litigants generic competition lamictal resulting overcharges various theories law purchasers entering allegedly anticompetitive gsk korea proceedings fair trade laws reverse payment settlement resolve patent infringement august gsk korea indicted koreas litigation separate count accuses group monopolising monopoly regulation fair trade laws relation market government tenders hpv cervarix pcv synflorix december trial judge granted plaintiffs class vaccines prosecutor alleged certification motion certifying class direct purchasers gsk korea actions least one group filed rule f motion court appeals employees interfered tender process third circuit challenging class certification decision national immunisation programme using straw bidders april court appeals vacated lower courts one employee also charged individual capacity grant class certification remanded issue back prosecutor relation matter lower court analysis number wholesalers codefendants proceedings october district court heard argument korea fair trade commission also commenced plaintiffs renewed motion class certification remand investigation gsk korea regarding matter gsk april district court denied plaintiffs motion korea cooperating authorities matters class certification putative direct purchaser class leaving proceedings ongoing potential class brandonly purchasers plaintiffs moved supplement expert report seek additional discovery support addition certain generic purchasers january district court denied plaintiffs motion supplement expert report seek additional discovery held issue generic purchasers already decided denied courts ruling decertification parties move briefing class certification remaining brandonly purchasers gsk annual report notes financial statements continued gsk annual report strategic report governance remuneration financial statements investor information post balance sheet events february viiv healthcare reached agreement gilead settle global patent infringement litigation relating commercialisation gileads biktarvy concerning viiv healthcares patents relating dolutegravir antiretroviral medication used together medicines treat human immunodeficiency virus hiv terms global settlement licensing agreement gilead made upfront payment billion viiv healthcare february addition gilead also pay royalty future us sales biktarvy respect bictegravir component future bictegravircontaining products sold us royalties payable gilead viiv healthcare february expiry viiv healthcares us patent october gileads obligation pay royalties extend period regulatory paediatric exclusivity awarded settlement resulted remeasurement existing liabilities contingent consideration pfizer put option year end upfront payment contingent asset balance sheet date receipt considered virtually certain date therefore recognised q operating income result settlement patent infringement cases us uk france ireland germany japan south korea australia canada discontinued company balance sheet uk gaap including frs reduced disclosure framework december notes fixed assets investments e current assets trade receivables f cash bank total current assets trade payables g total current liabilities net current assets total assets less current liabilities provisions liabilities h noncurrent liabilities net assets capital reserves share capital j share premium account j reserves k retained earnings january profitloss year changes retained earnings k equity shareholders funds financial statements pages approved board february signed behalf sir jonathan symonds chairman glaxosmithkline plc registered number company statement changes equity year ended december share share premium retained total capital account reserves earnings equity january profit total comprehensive income attributable shareholders dividends shareholders shares issued employee share schemes treasury shares transferred esop trusts december profit total comprehensive income attributable shareholders dividends shareholders shares issued employee share schemes december gsk annual report gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework presentation financial statements balance sheet prepared accordance companys accounting policies approved board description business described note b policies consistently glaxosmithkline plc parent company gsk major applied unless otherwise stated global healthcare group engaged creation discovery development manufacture marketing key accounting judgements estimates pharmaceutical products including vaccines overthecounter key accounting judgements estimates required otc medicines healthrelated consumer products current year preparation financial statements b accounting policies financial statements prepared using foreign currency transactions historical cost convention modified include revaluation certain financial instruments going concern basis foreign currency transactions recorded exchange prepared accordance financial reporting standard rate ruling date transaction foreign currency assets reduced disclosure framework uk accounting liabilities translated rates exchange ruling presentation companies act december balance sheet date comparative figures december dividends paid received permitted section companies act dividends paid received included financial income statement company presented statements period related dividends annual report actually paid received expenditure company included group financial statements glaxosmithkline plc publicly available expenditure recognised respect goods services received supplied accordance contractual terms following exemptions requirements ifrs provision made obligation exists future liability applied preparation financial statements respect past event amount accordance frs obligation reliably estimated paragraphs b ifrs sharebased investments subsidiary companies payment investments subsidiary companies held cost less ifrs financial instruments disclosures provision impairment also includes capital contribution relation movements contingent consideration paragraphs ifrs fair value measurement impairment investments paragraph ias presentation financial statements carrying value investments reviewed impairment comparative information requirements respect indication investment might paragraph iv ias impaired one assessment methods used compare paragraphs f b carrying value investment share ias presentation financial net assets value investment share statements valuation subsidiary based expected discounted cash ias statement cash flows flows total amount investments also evaluated groups valuation basis overall market paragraph ias accounting policies changes capitalisation impairment charge recognised accounting estimates errors income statement year concerned paragraph ias related party disclosures sharebased payments requirement ias disclose related party issuance company subsidiaries grant transactions entered two members companys shares represents additional capital group contributions company subsidiaries additional accounting convention standards investment subsidiaries results corresponding increase balance sheet prepared using historical shareholders equity additional capital contribution cost convention complies applicable uk accounting based fair value grant issued allocated standards underlying grants vesting period accounting principles policies preparation balance sheet conformity generally accepted accounting principles requires management make estimates assumptions affect reported amounts assets liabilities disclosure contingent assets liabilities date balance sheet actual amounts could differ estimatesnotes company balance sheet uk gaap including frs reduced disclosure framework continued taxation financial guarantees current tax provided amounts expected paid liabilities relating guarantees issued company applying tax rates enacted substantively behalf subsidiaries initially recognised fair value enacted balance sheet date amortised life guarantee deferred tax provided full using liability method c perating profit temporary differences arising tax bases assets fee relating audit liabilities carrying amounts financial company charged operating profit statements deferred tax assets recognised extent considered recoverable future dividends taxable profits directors declared four interim dividends resulting deferred tax measured average tax rates dividend year pence line dividend expected apply periods temporary details see note group financial differences expected realised settled deferred statements dividends tax liabilities assets discounted e fixed assets investments shares glaxosmithkline services unlimited shares glaxosmithkline holdings one limited shares glaxosmithkline holdings limited shares glaxosmithkline consumer healthcare holdings limited shares glaxosmithkline mercury limited capital contribution relating sharebased payments contribution relating contingent consideration f trade receivables amounts due within one year uk corporation tax recoverable amounts owed group undertakings amounts due one year amounts owed group undertakings movement amounts owed group undertakings period reflected within notes primarily reflects receipt dividend income subsidiaries utilisation companys current account fund payment third fourth interim dividends well first second interim dividends gsk annual report gsk annual report strategic report governance remuneration financial statements investor information notes company balance sheet uk gaap including frs reduced disclosure framework continued g trade payables amounts due within one year creditors contingent consideration payable amounts owed group undertakings company guaranteed debt issued subsidiary companies one receives fees aggregate company outstanding guarantees billion debt instruments billion amounts due subsidiary company relation guarantee fees recovered life bonds disclosed within trade receivables see note f h provisions liabilities january charge year utilised december provisions relate number legal disputes company currently involved noncurrent liabilities contingent consideration payable contingent consideration relates amount payable acquisition novartis vaccines portfolio current year liability included within trade payables details see note group financial statements contingent consideration liabilitiesnotes company balance sheet uk gaap including frs reduced disclosure framework continued j share capital share premium account share premium ordinary shares p account number share capital issued fully paid january issued employee share schemes ordinary shares acquired esop trusts december issued employee share schemes december december december number shares issuable employee share schemes number unissued shares option december issued share capital shares held esop trusts shares held treasury shares shares free issue issued shares fully paid nominal carrying market values shares held esop trusts disclosed note employee share schemes february million treasury shares transferred esop trusts trusts held million shares exercise share options share rewards k retained earnings reserves profit glaxosmithkline plc year million million profit dividends paid million million effect nil treasury shares transferred subsidiary company million retained earnings december stood million million million unrealised million dividends shareholders paid realised profits company december amounted million million reserves includes capital redemption reserve reserve reflecting historical contributions shares company issued satisfy share option awards granted employees subsidiary companies l group companies see pages complete list subsidiaries associates joint ventures significant shareholdings forms part financial statements gsk annual report gsk annual report strategic report governance remuneration financial statements investor information investor information section quarterly trend pharmaceuticals turnover vaccines turnover five year record product development pipeline products competition intellectual property principal risks uncertainties share capital control dividends financial calendar annual general meeting tax information shareholders shareholder services contacts us law regulation group companies glossary terms gsk annual report strategic report governance remuneration financial statements investor informationfinancial record quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs loss disposal interest associates share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial record continued quarterly trend continued quarterly trend unaudited analysis group results provided quarter sterling financial year income statement total months q q q q reported reported reported reported reported cer cer cer cer cer turnover pharmaceuticals vaccines consumer healthcare total turnover cost sales selling general administration research development royalty income operating incomeexpense operating profit net finance costs loss disposal interest associates share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders basic earnings per share pence p p p p p diluted earnings per share pence p p p p p income statement adjusted total turnover cost sales selling general administration research development royalty income operating profit net finance costs share aftertax profitslosses associates joint ventures profit taxation taxation tax rate profit taxation period profit attributable noncontrolling interests profit attributable shareholders adjusted earnings per share pence p p p p p calculation adjusted results described financial record continued pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory anoro ellipta trelegy ellipta nucala hiv dolutegravir products tivicay triumeq juluca dovato rukobia cabenuva immunoinflammation benlysta oncology zejula blenrep jemperli pandemic xevudy new specialty pharmaceuticals established pharmaceuticals established respiratory arnuity ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair ventolin respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial record continued pharmaceutical turnover therapeutic area total us europe international growth growth growth growth therapeutic areamajor products cer cer cer cer respiratory anoro ellipta trelegy ellipta nucala hiv dolutegravir products tivicay triumeq juluca dovato rukobia cabenuva immunoinflammation benlysta oncology zejula blenrep new specialty pharmaceuticals established pharmaceuticals established respiratory arnuity ellipta avamysveramyst flixotideflovent incruse ellipta relvarbreo ellipta seretideadvair ventolin respiratory dermatology augmentin avodart imigranimitrex lamictal seroxatpaxil valtrex pharmaceuticals financial record continued vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix vaccines excluding pandemic pandemic vaccines pandemic adjuvant total vaccines represents growth actual exchange rates cer represents growth constant exchange rates vaccines turnover total us europe international growth growth growth growth major products cer cer cer cer meningitis bexsero menveo influenza fluarix flulaval shingles shingrix established vaccines infanrix pediarix boostrix hepatitis rotarix synflorix priorix priorix tetra varilrix cervarix total vaccines represents growth actual exchange rates cer represents growth constant exchange rates gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record record financial performance provided analysed accordance current reporting practice information included five year record prepared accordance ifrs adopted european union also ifrs issued international accounting standards board group turnover geographic region us europe international group turnover segment pharmaceuticals vaccines consumer healthcare segment turnover corporate unallocated turnover revised revised revised revised pharmaceuticals turnover respiratory hiv immunoinflammation oncology pandemic new specialty established pharmaceuticals vaccines turnover meningitis influenza shingles established vaccines pandemic vaccines consumer healthcare turnover oral health pain relief vitamins minerals supplements respiratory health digestive health subtotal brands divestedunder review financial record continued five year record continued financial results total turnover operating profit profit taxation profit taxation pence pence pence pence pence basic earnings per share diluted earnings per share millions millions millions millions millions weighted average number shares issue basic diluted financial results adjusted turnover operating profit profit taxation profit taxation pence pence pence pence pence adjusted earnings per share return capital employed return capital employed calculated total profit taxation percentage average net assets year gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued balance sheet noncurrent assets current assets total assets current liabilities noncurrent liabilities total liabilities net assets shareholders equity noncontrolling interests total equity number employees us europe international manufacturing selling administration research development geographic distribution employees table based location gsks subsidiary companies number employees number permanent employed staff end financial period excludes employees employed managed gsk contract basis exchange rates guide holders ads following tables set periods indicated information exchange rate us dollars sterling reported bank england pm buying rate average rate year calculated average pm buying rates day year average feb jan dec nov oct sep high low pm buying rate february usfinancial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal separation adjusted results amortisation impairment restructuring related items costs results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs loss disposal interest associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal separation adjusted results amortisation impairment restructuring related items costs results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report gsk annual report strategic report governance remuneration financial statements investor information financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal adjusted results amortisation impairment restructuring related items results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p weighted average number shares millions financial record continued five year record continued divestments intangible intangible significant adjusted results reconciliation total asset asset major transaction legal us tax adjusted results amortisation impairment restructuring related items reform results december turnover cost sales gross profit selling general administration research development royalty income operating expenseincome operating profit net finance costs profit disposal associates share aftertax profits associates joint ventures profit taxation taxation tax rate profit taxation profit attributable noncontrolling interests profit attributable shareholders earnings per share p p p p p p p p weighted average number shares millions gsk annual report gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition pharmaceuticals vaccines product development pipeline key nlicense alliance relationship third party eua emergency use authorisation v iiv healthcare global specialist hiv company phase e valuation clinical pharmacology usually conducted gsk pfizer inc shionogi limited shareholders volunteers responsible developing delivering hiv medicines phase ii etermination dose initial evaluation efficacy bla biological licence application conducted small number patients maa marketing authorisation application europe phase iii l arge comparative study compound versus placebo nda new drug application us andor established treatment patients establish approved clinical benefit safety submitted maa ndabla regulatory review milestones shown table achieved future filing dates included list achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla oncology jemperli antiprogrammed cell death protein receptor l dmmrmsih endometrial cancer approved jun apr dostarlimab pd antibody l dmmr solid tumours approved aug l endometrial cancer iii l endometrial cancer combination niraparib iii nonsmall cell lung cancer ii zejula poly adpribose polymerase parp inhibitor l maintenance ovarian cancer combination iii niraparib dostarlimab l maintenance non small cell lung cancer iii nsclc combination pembrolizumab premetastatic select biomarker population iii breast cancer blenrep adc targeting bcell maturation antigen l multiple myeloma iii belantamab l multiple myeloma combination pomalyst iii mafodotin dexamethasone l multiple myeloma combination velcade iii dexamethasone multiple myeloma combination anticancer ii treatments platform study l multiple myeloma combination velcade revlimid dexamethasone letetresgene engineered tcr tcells targeting nyeso l synovial sarcoma myxoidround cell ii pivotal autoleucel liposarcoma l nonsmall cell lung cancer ii cobolimab antitcell immunoglobulin mucin domain nonsmall cell lung cancer combination ii tim antibody jemperli dostarlimab docetaxel antilymphocyte activation gene lag cancer antibody sting cytosolic dna pathway agonist cancer cd antagonist cancer engineered tcr tcells coexpressing cda cancer cell surface receptor targeting nyeso engineered tcr tcells coexpressing cancer dntgfrii cell surface receptor targeting nyeso methionine adenosyltransferase mata cancer inhibitor tigit antagonist cancer eos footnotes nonregistrational transition activities underway enable progression partner gsk exclusive option codevelop post ph ph trial patients progranulin gene mutation gsk contributing pandemic adjuvant covid vaccines collaborations submitted canada enrolment vaccination stopped february analysis better understand safety data trials ongoingpipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla hiv apretude hiv integrase strand transfer inhibitor hiv preexposure prophylaxis approved dec cabotegravir longacting hiv mgml formulation hiv maturation inhibitor hiv infection ii hiv broadly neutralising antibody hiv infection ii hiv maturation inhibitor hiv infection hiv capsid protein inhibitor hiv infection infectious diseases xevudy sotrovimab antispike protein antibody covid approved adec eua may gepotidacin triazaacenaphthylene bacterial type ii uncomplicated urinary tract infection uuti iii topoisomerase inhibitor gonorrhea gc leucyl trna synthetase inhibitor tuberculosis ii bepirovirsen hbv antisense hepatitis b ii fimh antagonist uncomplicated urinary tract infection uuti crk inhibitor visceral leishmaniasis proteasome inhibitor visceral leishmaniasis mtb cholesterol dependent inhibitor tuberculosis bvlgsk ethionamide booster tuberculosis vir antispike protein antibody covid vir neutralizing monoclonal antibody influenza pik beta inhibitor viral copd exacerbations priorix mmr vaccine live attenuated measles mumps rubella prophylaxis us registration jun menveo vaccine conjugatedliquid formulation meningococcal acw disease prophylaxis registration sep adolescents rotarix vaccine live attenuated pcv porcine circovirus rotavirus prophylaxis us registration dec free bexsero vaccine recombinant protein meningococcal b disease prophylaxis infants us iii men abcwy vaccine recombinant protein conjugated meningococcal abcw disease prophylaxis iii adolescents rsv vaccine recombinant protein respiratory syncytial virus prophylaxis pregnant iii woman population prevent respiratory syncitial virus lower respiratory tract illness infants first months life transfer maternal antibodies recombinant protein adjuvanted respiratory syncytial virus prophylaxis older adult iii population covid plant recombinant proteinadjuvanted vaccine covid registration derived viruslike particles vaccine medicago covid vaccine recombinant proteinadjuvanted vaccine covid iii sanofi covid vaccine recombinant protein nanoparticle covid iii sk bioscience adjuvanted vaccine sam vaccine selfamplifying mrna vaccine covid covid model footnotes nonregistrational transition activities underway enable progression partner gsk exclusive option codevelop post ph ph trial patients progranulin gene mutation gsk contributing pandemic adjuvant covid vaccines collaborations submitted canada enrolment vaccination stopped february analysis better understand safety data trials ongoing gsk annual report gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceuticals vaccines product development pipeline continued achieved regulatory review milestones compound mechanism actionvaccine type indication phase maa ndabla infectious diseases continued malaria next recombinant protein adjuvanted malaria prophylaxis plasmodium falciparum ii generation vaccine vaccine fractional dose shigella vaccine bioconjugated tetravalent vaccine shigella diarrhea prophylaxis ii therapeutic hbv primeboost viral vector vaccines treatment chronic hepatitis b infections aims ii vaccine co sequentially administrated functional cure controlling resolving adjuvanted recombinant proteins infection reducing need treatment aureus vaccine recombinant protein bioconjugated active immunization prevention primary ii adjuvanted vaccine recurrent softskintissue infections caused aureus men abcwy recombinant protein conjugated meningococcal b c wy disease prophylaxis ii vaccine nd gen vaccine adolescents infants varicella new strain live attenuated vaccine active immunization prevention varicella ii individuals months age older c difficile vaccine recombinant protein adjuvanted vaccine active immunization prevention primary c diff diseases prevention recurrences sam vaccine selfamplifying mrna rabies prophylaxis rabies model klebsiella recombinant protein bioconjugated klebsiella pneumoniae prophylaxis pneumoniae adjuvanted vaccine cmv recombinant subunit adjuvanted cytomegalovirus cmv infection prophylaxis vaccine females years age immunology respiratory nucala interleukin il antagonist hypereosinophilic syndrome approved nov mepolizumab nasal polyposis approved nov jul egpa approved nov copd iii otilimab granulocyte macrophage colony rheumatoid arthritis iii stimulating factor inhibitor depemokimab interleukin il antagonist longacting asthma iii al antisortilin monoclonal antibody frontotemporal dementia ftd iii amyotrophic lateral sclerosis als ii anticcl antibody osteoarthritis pain transglutaminase tg inhibitor celiac disease al antisortilin monoclonal antibody neurodegenerative disease antiil antibody atopic dermatitis antiil antibody multiple sclerosis ms hsdb silencer nonalcoholic steatohepatitis nash opportunity driven daprodustat hif prolyl hydroxylase inhibitor anaemia chronic kidney disease iii row linerixibat ileal bile acid transporter ibat inhibitor cholestatic pruritus pbc primary biliary cholangitis iii trpv channel blocker diabetic macular edema dme novel mechanism heart failure brand names appearing italics trade marks owned licensed gsk group companies footnotes nonregistrational transition activities underway enable progression partner gsk exclusive option codevelop post ph ph trial patients progranulin gene mutation gsk contributing pandemic adjuvant covid vaccines collaborations submitted canada enrolment vaccination stopped february analysis better understand safety data trials ongoingpipeline products competition continued pharmaceutical products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu respiratory anoro ellipta umeclidinium bromide copd stiolto respimat vilanterol trifenatate utibronultibro nce nce breezhaler duaklir genuair device device bevespi aerosphere brimica genuair arnuity ellipta fluticasone furoate asthma beclazone pulmicort budesonide gx nce nce asmanex alvesco device device avamysveramyst fluticasone furoate rhinitis dymista xhance nasonex expired fluticasone gx flixotideflovent fluticasone propionate asthmacopd beclazone pulmicort expired expired budesonide gx diskus device diskus device asmanex alvesco expired hfadevice hfadevice incruse ellipta umeclidinium bromide copd spiriva handihaler respimat yupelri nce nce braltus seebri breezhaler bretaris device device genuair nucala mepolizumab severe eosinophilic asthma egpa xolair cinqair expired expired hypereosinophilic syndrome chronic fasenra dupixent rhinosinusitis nasal polyps relvarbreo ellipta fluticasone furoate asthmacopd symbicort foster vilanterol trifenatate budesonideformetrol gx nce nce sirdupla dulera device device seretideadvair salmeterol xinafoate asthmacopd symbicort foster expired expired fluticasone propionate budesonideformetrol gx diskus device diskus device sirdupla dulera expired hfadevice hfadevice trelegy ellipta fluticasone furoate copd trimbow vilanterol trifenatate breztri aerosphere nce nce umeclidinium bromide trixeo aerosphere enerzair breezhaler device device ventolin hfa albuterol sulphate asthmacopd generic companies expired hfadevice hfadevice xevudy sotrovimab early treatment covid regencov na bamlanivimabetesevimab nbe evusheld antivirals valtrex valaciclovir genital herpes coldsores shingles prevymis valacyclovir gx expired expired valcyte central nervous system lamictal lamotrigine epilepsy bipolar disorder vimpat trokendi xr expired expired inovelon imigranimitrex sumatriptan migraine zomig maxalt relpax expired expired seroxatpaxil paroxetine depression various anxiety trintellix aplenzin viibryd expired expired disorders zoloft cardiovascular urogenital avodart dutasteride benign prostatic hyperplasia harnal vesomni urorec expired expired antibacterials augmentin amoxicillinclavulanate common bacterial generic products na expired potassium infections includes supplementary protection certificates granted multiple countries eu including uk patent term extensions granted us data exclusivity expires eu us gsk annual report gsk annual report strategic report governance remuneration financial statements investor information pipeline products competition continued pharmaceutical products competition intellectual property continued major patent expiry dates products compounds indications competitor brands us eu oncology zejula niraparib ovarian cancer lynparza rubraca nce nce blenrep belantamab mafodotin relapsedrefractory multiple sarclisa xpovio myeloma jemperli dostarlimab dmmr recurrent advanced keytruda endometrial cancer solid tumours nbe nbe immunoinflammation benlysta benlysta belimumab systemic lupus erythematosus lupkynis saphnelo sc iv lupus nephritis hiv apretude cabotegravir hiv prevention descovy truvada nce nce cabenuvavocabria cabotegravir rilpivirine hivaids descovy genvoya rekambys odefsey biktarvy nce nce rukobia fostemsavir hivaids trogarzo nce nce dovato dolutegravir lamivudine hivaids descovy genvoya odefsey biktarvy nce nce juluca dolutegravir rilpivirine hivaids descovy genvoya odefsey biktarvy nce nce triumeq dolutegravir lamivudine hivaids descovy genvoya abacavir odefsey biktarvy nce nce tivicay dolutegravir hivaids isentress prezista symtuza reyataz nce nce biktarvy vaccine products competition intellectual property major patent expiry dates products compounds indications competitor brands us eu bexsero meningococcal groupb vaccine meningitis group b prevention trumenba boostrix diphtheria tetanus acellular diphtheria tetanus acellular adacel expired expired pertussis pertussis booster vaccination infanrix hexapediarix diphtheria tetanus pertussis prophylaxis diphtheria pentacel pediacel expired expired polio hepatitis b haemophilus tetanus pertussis polio pentaxim pentavac influenzae type b eu hepatitis b haemophilus hexaxim hexyon influenzae type b eu vaxelis cervarix hpv virus like human papilloma virus gardasil silgard particles vlps type adjuvant mpl aluminium hydroxide fluarix tetra split inactivated influenza seasonal influenza prophylaxis intenza flumist qiv antigens virus subtypes vaxigrip qiv subtype b fluzone qiv fluzone high dose flulaval split inactivated influenza seasonal influenza prophylaxis vaxigrip mutagrip antigens virus subtypes fluzone influvac subtype b aggripal fluad intenza flumist menveo meningococcal group c w meningitis group c w nimenrix menactra conjugate vaccine prophylaxis priorix priorix tetraab live attenuated measles mumps measles mumps rubella mmr ii mmrvaxpro expired expired varilrixb rubella varicella vaccine chickenpox prophylaxis proquad varivax rotarix human rotavirus rix strain rotavirus prophylaxis rotateq synflorix conjugated pneumococcal prophylaxis invasive prevenar prevnar na polysaccharide disease pneumonia acute otitis media shingrix zoster vaccine herpes zoster zostavax recombinant adjuvanted shingles see note financial statements legal proceedings includes supplementary protection certificates granted multiple countries eu including uk patent term extensions granted us related compoundsindications measles mumps rubella vaccineprophylaxisb b related compound varicella vaccinepipeline products competition continued consumer healthcare products competition brand products application markets competition oral health sensodyne toothpastes toothbrushes relief dentinal hypersensitivity global colgate sensitive prorelief pronamel mouth rinse pronamel additionally protects colgatepalmolive acid erosion elmex colgatepalmolive oral b procter gamble parodontax toothpaste dailymedicated helps stop prevent global colgate total gum health corsodyl mouthwash gel spray bleeding gums treats colgatepalmolive prevents gingivitis oral b gum enamel repair crest gum detoxify procter gamble polident denture adhesive denture improve retention comfort global fixodent kukident poligrip cleanser wipes dentures cleans dentures procter gamble corega steradent reckitt benckiser aquafresh toothpastes toothbrushes aids prevention dental cavities global colgate colgatepalmolive mouthwashes maintains healthy teeth gums crest procter gamble fresh breath oralb procter gamble pain relief panadol tablets caplets infant paracetamolbased treatment global except us aspirin bayer syrup headache joint pain fever cold tylenol johnson johnson symptoms nurofen reckitt benckiser voltaren topical gel diclofenac nonsteroidal diclofenac based global salonpas hisamitsu tablets patches antiinflammatory aspirin bayer tylenol johnson johnson nurofen reckitt benckiser icy hot sanofi advil tablets caplets gel caplets ibuprofen based treatment us canada brazil tylenol tylenol pm tylenol childrens nonrespiratory liquid filled suspension headache toothache backache colombia mexico motrin motrin childrens johnson range drops childrens menstrual cramps muscular johnson aleve aleve pm bayer pains minor pain arthritis vitamins minerals supplements centrum tablets gummies vitamin supplement global nutralite infinitus cheongkwanjung capsules chewables byhealth nature made herbalife swisse caltrate tablets gummies calcium supplement global citracal bayer oscal nature made soft chews private label emergenc powder gummies immune support dietary us canada airborne reckitt benckiser supplement zicam church dwight nature made pharmavite sambucol healthcare brands international esterc american health respiratory health otrivin nasal spray nasal decongestant germany netherlands afrin bayer nasivin proctor gamble norway russia sweden tyzine johnson johnson theraflu hot liquids tablets syrups cold flu relief russia poland us tylenol cold flu johnson johnson mucinex reckitt benckiser lemsip reckitt benckiser advil respiratory tablets allergy relief cold flu tylenol cold flu johnson johnson cold flu advil relief lemsip mucinex reckit benckiser respiratory allergy flixonaseflonase nasal spray tablets allergy relief us china uk ireland claritin bayer allegra sanofi piriton zyrtec johnson johnson robitussin syrup tablets coughcold us canada singapore mucinex reckitt benckiser philippines australia dimetapp foundation consumer healthcare digestive health nexium hr capsules clear minis treatment frequent heartburn us canada australia prilosec prevacid tablets two days week adults years older zovirax topical cream lip care treat prevent global compeed johnson johnson abreva nonmedicated patch onset cold sores carmex carma labs blistex blistex incorporated retail label chapstick lip balm protect moisturise prevent global blistex burts bees carmex carma labs soothe chapped lips eos nivea beiersdorf vaseline unilever eno effervescent immediate relief antacid global except us estomazil hypermarca gelusil tums chewable tablets immediate relief antacid us alkaseltzer bayer gaviscon reckitt benckiser rolaids sanofi nicorette us lozenges gum treatment nicotine withdrawal global nicorette johnson johnson nicoderm nicotinell transdermal patches aid smoking reduction niquitin perrigo ex australia cessation gsk annual report gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties outline principal risks uncertainties relevant similarly global business exposes us litigation gsks business financial condition operations may government investigations including product liability litigation affect performance ability achieve objectives patent antitrust litigation sales marketing litigation risks believe could cause actual litigation government investigations related results differ materially expected historical results provisions may make unfavourable outcomes increases related costs insurance premiums operating pharmaceutical sector carries various inherent could also materially adversely affect financial results risks uncertainties may affect business detail status various uncertainties must comply broad range laws regulations significant unresolved disputes potential litigation set apply research development manufacturing note legal proceedings testing approval distribution sales marketing pharmaceutical vaccine consumer healthcare products details regarding risk management framework affect cost product development time required identify principal risks found pages reach market likelihood successfully uninterrupted basis uk regulations require description principal risks rules regulations change government interpretation uncertainties explanation managed evolves business activities develop nature mitigated description principal risks particular risk may also alter changes regulatory regimes summary activities take manage may substantial alteration failure comply risk across businesses listed order applicable laws regulations could materially adversely significance consistent principal risks detailed affect financial results pages patient safety risk definition balance routine pharmacovigilance activities potential failure appropriately collect review follow variety business change initiatives supporting report human safety information hsi including adverse events current product portfolio optimising perform potential sources act relevant findings pharmacovigilance prepared deliver future timely manner strategy including increased focus oncology vaccines specialty medicines successful separation risk impact consumer healthcare business gsk zero tolerance unfavourable benefittorisk ratio collect information safety efficacy patients use products collect review follow products humans clinical development gain report human safety information potential sources comprehensive information realworld use products use conduct robust timely safety signal market addition safety surveillance detection take appropriate measures safeguard activities external parties analyse publiclyavailable clinical trial patients consumers effectively manage risks results data new external initiatives use realworld patient safety activities serious repercussion evidence sources accessible gsk could harm patients compliant may used regulatory agencies supplement validate pharmacovigilance drug safety regulations globally evidence use support safety efficacy consequences could include inspection findings regulatory products scrutiny civil criminal sanctions either temporary permanent loss product marketing authorisation ineffective extensive news social media coverage safety management patient safety risks could also lead efficacy covid vaccines therapies increased reputational damage loss trust patients healthcare publics recognition importance pharmacovigilance providers productrelated litigation loss shareholder drug development process product marketing confidence phase rise misinformation also led distrust vaccine hesitancy environment could undermine regulatory context governmental public trust medicines treating fully accountable safeguarding patients covid could negatively influence healthcare licence operate depends compliance increasingly decisions diseases leading reputational damage complex variable global regulatory requirements product liability lawsuits include pharmacovigilance regulations also stringent privacy protections information security considerations compliance depends employees third parties acting behalf managing human safety information accordance internal processesprincipal risks uncertainties continued patient safety continued mitigating activities actions discussed beforehand regulatory chief medical officer accountable patient safety authorities include updating prescribing information enterprise risk human safety matters collaboration communicating healthcare providers restricting product head global safety crossenterprise safety governance prescribingavailability help assure safe use carrying board oversees implementation control framework clinical trials certain cases may appropriate including risk management global safety board ensures stop clinical trials withdraw product specific batch address human safety proactively throughout products market lifecycle global policy management human safety reinforced requirements human safety information requires employees immediately report issues information management across gsk range relating safety products thirdparty oversight communication efforts including improved internal mechanisms framework ensures third parties may encounter human adverse event reporting also launched initiative safety information identified trained appropriately automate adverse event case intake processing reporting manage safety information products sources consolidated governance pharmacovigilance process compliance global regulations information allows us related activities two boards single governance detect safety signals products take timely action forum launched pilot optimise delivery oversight information changes products riskbenefit profile patient safety activities globally target core patient safety processes simplification andor optimisation product quality risk definition increasingly using new technology enhance failure gsk contractors suppliers ensure manufacture testing products example use new electronic documentation systems advanced appropriate controls governance quality product laboratory information management tools development significant changes taking place gsk implement compliance good manufacturing practice good new strategy structure quality organisations distribution practice regulations commercial clinical trials assess changes make sure quality procedures manufacture distribution activities governance facilitate strategy also ensuring compliance terms gsk product licences unintended consequences increase product quality risk supporting regulatory activities industry experiencing increased regulatory onsite inspection presence resumed since onset pandemic risk impact taking steps ensure inspection readiness failure ensure product quality could farreaching implications patient consumer safety cause product mitigating activities launch delays drug shortages product recalls align extensive global network quality compliance regulatory legal financial consequences could professionals sitelevel senior management materially adversely affect gsks reputation financial business unit provide oversight assist delivery results quality performance operational compliance deliver management oversight hierarchy quality context councils independent chief product quality officer external environment product quality remains global product quality office oversees product quality risk challenging affected misinformation fuelling vaccine across company hesitancy increased cyberattacks data breaches developed implemented single quality across industry cyberattacks remain key risk management system defines quality standards integrity product quality data audit trail systems businesses associated pharmaceutical prepared meet european medicines vaccine consumer healthcare products clinical agency ema requirements licensing medical devices trial materials system broad scope applicable continue prepare vitro diagnostic medical throughout product lifecycle rd mature device regulation becomes effective may commercial supply consolidation regulatory requirements continue plan implementation new annex markets across world augments system guidance manufacture sterile medicinal products means meets external expectations product quality first half markets supply system based internationally recognised principles ich q pharmaceutical quality system framework gsk annual report gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued product quality continued routinely update quality management system qms established complaint process ensures respond keeps pace evolving external regulatory environment appropriately product quality issues raised patients new scientific understanding products customers independent functions review triage allegations processes also made policies procedures noncompliance misconduct received formal simpler understand implement adopted innovative informal speak channels global disciplinary tools make userfriendly regularly train staff enforcement procedures apply breaches regulatory expectations learnings inspections standards initiated appropriate following existing procedures maintain current good investigations use key risk indicators support risk manufacturing practice standards management activities provide gsks leadership team risk oversight compliance council implemented riskbased approach assessing integrated assessment product quality performance managing third party suppliers provide materials used finished products expect contract manufacturers make completed initial review manufacturing products comply gsk standards regularly processes products identify potential risks conduct audits provide us assurance associated nitrosamine impurities completed work accordance health authority regulatory timelines product incident committee processes place continuing product evaluations take investigate product issues make recommendations necessary risk mitigation steps remediation activities including necessary recall products protect patients consumers financial controls reporting risk definition treasury group deals daily high value transactions mostly failure comply current tax laws incurring significant foreign exchange cash management transactions losses due treasury activities failure report accurate transactions involve market volatility counterparty risk financial information compliance accounting standards groups effective tax rate reflects locations applicable legislation activities value generate determine jurisdictions profits arise applicable tax rates risk impact may higher lower uk statutory rate noncompliance existing new financial reporting may reflect regimes encourage innovation investment disclosure requirements changes recognition income rd providing tax incentives changed could expenses could expose gsk litigation regulatory affect gsks tax rate addition worldwide nature action could materially adversely affect financial operations means crossborder supply routes results current global pandemic significant necessary ensure supplies medicines result changes short notice failure comply changes conflicting claims tax authorities profits substance application laws governing transfer pricing taxed individual countries lead double taxation dividends tax credits intellectual property could also profits taxed one country complexity materially adversely affect financial results tax regulations also means may occasionally disagree inconsistent application treasury policies transactional tax authorities technical interpretation particular settlement errors counterparty defaults could lead area tax law tax charge included financial significant losses statements best estimate tax liability pending audits tax authorities context expect continued focus tax reform driven required laws various jurisdictions publicly initiatives oecd ec address tax disclose financial results events could materially challenges arising digitalisation economy together affect groups financial results regulators routinely review domestic initiatives around world may result financial statements listed companies compliance significant changes established tax principles new revised existing accounting regulatory increase tax authority disputes regardless merit requirements believe comply appropriate outcomes may costly divert management attention regulatory requirements concerning financial statements adversely impact reputation relationship key disclosure material information including stakeholders transactions relating business restructuring acquisitions divestitures however subject investigation potential noncompliance accounting disclosure requirements could lead restatements previously reported results significant penaltiesprincipal risks uncertainties continued financial controls reporting continued mitigating activities counterparty exposure subject defined limits approved financial results reviewed approved regional board credit rating individual counterparties management reviewed gsks group financial middle office within treasury monitor management controller chief financial officer cfo allows counterparty risk line agreed policy oversight financial controller cfo assess evolution corporate compliance officer operating independently business time evaluate performance plan treasury details mitigation treasury risks significant judgements reviewed confirmed senior found pages management integrate technical organisational manage tax risk robust internal policies processes transformation newly acquired activities external risks training compliance programmes maintain open covid pandemic risk assessments constructive relationships tax authorities worldwide apply appropriate controls reviews monitor government debate tax policy key jurisdictions maintain control environment designed identify material understand potential future changes tax errors financial reporting disclosure design law share informed point view relevant operating effectiveness key financial reporting controls provide pragmatic constructive business input tax policy regularly reviewed management tested external third makers either directly industry trade bodies parties minimum standard control set place includes advocating reform support economic growth finance locations irrespective size reviewed job creation well needs patients key management monitored independently gives us stakeholders submit significant tax decisions tax assurance controls key financial reporting governance board meets quarterly comprised senior disclosure processes operating effectively global gsk finance colleagues finance risk management controls frmc group tax affairs managed global basis team tax provides extra support significant transformations professionals led global head tax work closely system deployment managementstructural business daytoday basis global tax team reorganisations add operational resources adapt suitably qualified roles perform support programme timelines ensure processes controls training needs provide date technical maintained significant changes advice line responsibilities disclosure committee reporting board reviews submit tax returns according statutory time limits gsks quarterly results annual report throughout year engage proactively tax authorities ensure tax affairs consultation legal advisors disclosure committee current entering continuous audit programmes also determines whether necessary disclose publicly advance pricing agreements appropriate information group stock exchange arrangements provide longterm certainty tax announcements keep date latest authorities gsk tax treatment business developments financial reporting requirements working based full disclosure relevant facts seek resolve external auditor legal advisors differences interpretation tax legislation tax treasury management group tmg meets regularly authorities cooperative manner exceptional cases ensure liquidity interest rate counterparty foreign may resolve disputes formal proceedings currency transaction foreign currency translation risks managed line prudent approach detailed risk strategies policies adopted board gsk annual report gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued antibribery corruption abac risk definition appropriate controls place around transactions bribery corruption risk failure gsk employees payments third parties training awareness consultants third parties comply antibribery raising strong monitoring plan continue pre corruption abac principles standards well posttransaction abac due diligence increase applicable legislation capabilities business monitoring oversight red flag resolution third parties review controls risk impact accountabilities government officials continue assess failure mitigate risk could expose group understand money laundering risk exposure associated persons governmental investigation regulatory mitigate existing risk action civil criminal liability may compromise code conduct values expectations groups ability supply products certain government commitment zero tolerance towards bribery corruption contracts addition failure prevent bribery corruption integral mitigate risk light complexity could substantial implications gsks reputation geographic breadth risk constantly evolve credibility senior leaders might erode investor confidence oversight activities data reinforce workforce governance risk management could also lead gsks clear expectations regarding acceptable behaviours legal financial penalties maintain regular communications centre local context markets overall environment abac continues challenging built abac programme based best class countries holding individuals well corporations principles subject ongoing review development accountable increasing employer duty care provides us basis seek manage divergence legislation increasing political protectionism risk top bottom example social inequality pricing pressures making compliance programme includes toplevel commitment board harder society holding corporations ever higher standards leadership data analytics programme create technology providing rapid anonymous avenue embed local key risk indicators enable targeted intervention dissemination previously confidential information even risk management activities damaging false reports global abac policy written standards controls enforcement actions penalties continued across globe address business activities give rise abac focus use thirdparty intermediaries proposed risk underpins programme addition programme eu legislation would require businesses conduct due mandates enhanced controls interactions government diligence potential human rights related environmental officials business development transactions impacts operations supply chains imposing legal controls abac policy establish due diligence standard care addition ongoing impact covid requirements engagement third parties could increase risk bribery corruption dedicated team responsible implementation supportive aspects external environment include evolution abac programme abac team increase transparency collaboration among enforcement continually works groups across enterprise authorities aim reducing bribery corruption address improve controls monitoring requirements globally advances technology use data analytics audit assurance independent business monitoring teams also providing better platforms streamline processes complement teams work provide added assurance detect potential issues use issues found oversight assurance exercises investigations identify areas specific intervention mitigating activities markets drive continuous improvement enterprise wide abac programme designed programme ensure compliance abac policies mitigate risk regularly provide mandatory abac training employees bribery corruption builds business standards relevant third parties accordance roles culture form comprehensive practical approach responsibilities risks face compliance flexible evolving nature business benchmark abac programme gsks abac governance board oversees provides large multinational companies use external expertise programme governance enterprise risk management internal insights drive improvements includes representation key functional areas formal informal speak channels available report misconduct noncompliance central investigations team reviews triages allegations noncompliance allocates investigation appropriateprincipal risks uncertainties continued commercial practices risk definition approved medicine vaccine failure engage commercial activities consistent obligation provide important information healthcare letter spirit law industry regulations community various ways always responsible legal groups requirements relating sales promotion ethical manner appropriate product promotion ensures hcps medicines vaccines appropriate interactions access information need patients healthcare professionals organisations patients legitimate consumers facts medicines vaccines transparent transfers value competition antitrust require prescribed recommended used regulations commercial practices including trade channel manner provides healthcare benefit activities tendering business committed ethical responsible commercialisation products support purpose risk impact improve quality human life enabling people failure engage activities consistent feel better live longer letter spirit law industry regulations groups requirements relating sales promotion medicines mitigating activities vaccines appropriate interactions healthcare achieve strategic objectives must meet price professionals hcps organisations patients expectations payers hcps consumers community legitimate transparent transfers value pricing values behaviours provide guide lead competition antitrust regulations commercial make decisions constantly strive right thing practices including trade channel activities business deliver quality medicines vaccines sustain reliable tendering could materially adversely affect ability supply meet customer needs seek ensure deliver strategy longterm priorities additionally may actions reflect gsks values behaviours purpose result incomplete awareness riskbenefit profile understand impact data industry strive products possibly suboptimal treatment patients become organisation makes datadriven decisions consumers governmental investigation regulatory action approach aligned efforts become agile legal proceedings brought group governmental work pace gsk acted enhance improve private plaintiffs could result government policies standards application data analytics sanctions criminal andor financial penalties practices channel activities developed policies support found misaligned values expectations strong growth consumer healthcare internet channels could also result reputational harm dilute trust digital marketing activities using artificial intelligence established external stakeholders powered tools improve oversight context gsk websites operate highly regulated extremely competitive evolved policies standards stepwise approach biopharma consumer industry amongst peers make ensure commercial activities undertake significant product innovations technical advances conducted behalf executed within established intensify price competition additional external factors impacting governance train employees relevant information business operations include ongoing covid global focus interactive learning elements behavioural pandemic access limitations customers macroeconomic science commercial activities worldwide must conform inflationary dynamics pricing pressure across markets high ethical regulatory industry standards local achieve strategic objectives must continue standards differ global ones apply develop commercially viable new products deliver stringent standards acquired company joint additional uses existing products address needs venture partner differ global standards remediate patients consumers hcps payers financially new legacy policies implement revisions align productsindications carry uncertainty consumer healthcare business harmonised policies regards future success product development costly procedures guide regional global commercial timely uncertain carries potential failure practice processes clarified applicable standards stage even upon successful product development operations markets operate still face challenges launch competitors implemented specific control framework five export products pricing strategies could render assets less hubs embedded promotional code china enable competitive supporting efforts product innovation responsible business growth employee behaviour continued focus creating omnichannel way engagement continued focus patient gsk annual report gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued commercial practices continued gsks pharmaceuticals consumer healthcare vaccines implemented phased thoughtful approach businesses continue use internal control framework supported comprehensive training control monitoring support assessment management risks business framework ensure full alignment gsks valuesbased unit risk management compliance boards manage approach hcp engagement risks across global incountry business activities oversee allow fair market value payments made gsk commercial activities monitoring programmes expert practitioners speak innovative medicines recent combination legal compliance functions vaccines restricted period products lifecycle one team result stronger cohesive support global endtoend process system currently set function businesses begin deployment q improve promotional materials activities must reviewed execution activities also strengthen controls approved according policies standards automation use data permitted conducted accordance local laws regulations report payments individual hcps part commitment requirements seek ensure materials activities transparency responsible disclosure fairly represent groups products services consumer consumer healthcare key driver development healthcare deployed new copy approval tool improve ethical code global selfcare federation setting controls important promotional activity necessary principles promotion healthcare practitioners event misconduct disciplined employees pharmacy staff including termination contract clawed back remuneration senior management gsk committed complying applicable sanctions laws regulations deployed programme enable continued evolve incentive programme management sanctions risk programme led gsk pharmaceuticals vaccines sales representatives better finance made various systems controls including recognise reward individual effort mature markets limited policies procedures training capped variable pay element representatives compensation awareness screening monitoring risk reporting evaluated basis individual sales targets nonpromotional engagement risk definition context failure engage nonpromotional activities nonpromotional engagements diverse activities directed consistent local laws regulations guidance industry healthcare professionals well patients payers codes internal gsk policies standards controls external stakeholders engagements conducted gsk values including communications hcpohs improve patient care exchange provision nonhcps relating medicines andor associated disease knowledge use products related diseases areas ii appropriate conduct nonpromotional interactions nonpromotional engagement external stakeholder groups iii legitimacy transparency nonpromotional vital gsk researchbased healthcare company interactions necessary scientific medical advances expect nonpromotional activities scientifically sound risk impact accurate conducted ethically transparently compliant without controls place risk could result real applicable codes laws regulations however non perceived disguised promotion including offlabel promotional engagements largely unregulated therefore priorauthorisation promotion real perceived provision measured risktaking rooted sound values principles medical advice turn could lead criminal investigations based decisionmaking training communication penalties civil litigation competitor complaints monitoring activities key managing risk time engage fully appropriately enabling full appropriate engagement could result patient harm failure advance science innovation reputational damage financial loss mitigating activities consequences may reduce trust public patients chief medical officer cmo oversees nonpromotional healthcare professionals payers regulators governments engagement enterprise risk owner gsk code practice key internal policy nonpromotional engagement activities activities include scientific interactions support medical education advice seeking gathering insights unmet needs patients scientific communication research disease awarenessprincipal risks uncertainties continued nonpromotional engagement continued since pandemic seen continued increase enhanced internal networks foster collaboration virtual engagements eg external experts advisory best practice sharing risk management networks boards patient advocacy patient engagements scientific identify emerging risks associated nonpromotional congresses developed modernised digital activities early support staff conduct activities approach hcps insightgathering applied compliance gsks values policies local laws internal principles policies rapidly changing regulations continue build effective management growing environment monitoring systems apply key risk indicators managing nonpromotional engagement privacy risk definition countries data privacy laws require appointment failure collect secure use share destroy personal data protection officer dpo gsk appointed single dpo information pi accordance data privacy laws lead eu represented supported specific countries harm individuals eg financial stress prejudice gsk country privacy advisors eg fines operational financial reputational general counsel gsks enterprise risk owner ero ero appointed delegate risk owner global risk impact privacy officer gpo daytoday accountability noncompliance data privacy laws globally could lead designing implementing control framework gpo harm individuals gsk could also damage trust coleads crossfunctional privacy centre excellence gsk individuals communities business partners together global privacy counsel privacy officers government authorities many countries increased privacy counsel multiple country privacy advisors enforcement powers data protection authorities familiar local privacy regulations support groups allowing impose significant fines impact crossborder data flows temporarily ban data processing many new gsk evolved initial control framework implemented country laws also give individuals right bring collective eu general data protection regulation legal actions companies like gsk failure follow comprehensive privacy control framework based global data privacy laws privacy principles common across global privacy landscape global framework deployed countries showing need context comprehensive framework based factors like robust data privacy legislation diverse limited harmonisation local privacy legislation established data protection authorities simplification challenging multinationals gsk footprint beyond countries deploying standardise approach compliance data privacy proportionate control framework set minimum privacy laws governments enforcing compliance data privacy standards irrespective applicable legislation laws rigorously focus ethical use personal privacy centre excellence responsible information growing compliance data privacy laws due increase volume data operating improving centralised global privacy control processed advances technology framework workforce protection effective privacy controls research continuously assessing providing relevant covid pandemic create unique challenges proportionate controls aid nondeployed markets additionally new data privacy laws personal monitoring new changing laws adapting privacy information protection law pipl china court decisions framework accordingly like court justice european union ruling deploying comprehensive training programme drive schrems ii invalidating established international data greater awareness accountability managing personal transfer mechanisms international companies relied information across entire organisation increasing trend data sovereignty affects ability drive medical innovation effectively operate certify key gsk privacy network roles accredited internationally international privacy association mitigating activities continuously improve processes issue identification reporting handling monitoring general counsel also chair privacy privacy centre excellence engages new business governance board oversees gsks overall data privacy development opportunities early stage ensure operating model gsk business area appointed risk perform appropriate due diligence right steps taken owner accountable overseeing privacy risks supported onboarding splitting business unit privacy leaders within business gsk annual report gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued research practices risk definition use wide variety biological materials discovery research practices risk failure adequately conduct research development assets ethical sound preclinical clinical research addition convention biological diversity cbd nagoya failure engage scientific activities protocol international community established global consistent letter spirit law industry framework regulating access use genetic resources groups requirements comprises following subrisks nonhuman origin research development data governance laboratory research human subject support principles access benefitsharing research genetic resources outlined cbd nagoya protocol also recognise importance appropriate risk impact effective proportionate implementation measures potential impacts risk include harm human subjects national regional levels reputational damage failure obtain necessary regulatory mitigating activities approvals products governmental investigation legal proceedings brought gsk governmental research practices risk overseen enterprise private plaintiffs product liability suits claims damages framework seeks strengthen governance across rd loss revenue due inadequate patent protection inability pharmaceuticals vaccines consumer healthcare supply products regulatory action fines businesses penalties loss product authorisation poor data integrity leadership research practices enterprise risk governance could compromise gsks rd efforts owner management risk takes pragmatic approach negatively impact reputation could materially information sharing streamlining risk identification adversely affect financial results damage trust escalation ensuring ownership risk mitigation stays patients customers business context established office animal welfare ethics research involving animals raise ethical concerns strategy risk oawesr led chief veterinary many cases however research animals way officer supports humane responsible care investigate effects potential new medicine living animals carries ethical reviews independent scientific body humans animal research provides critical reviews animal studies shares knowledge advocates information causes mechanisms diseases application nonanimal alternatives oawesr therefore remains vital part research continually provides framework animal welfare governance defines seek ways minimise use animals provides oversight training animal care promotes research development testing complying replacement refinement reduction animal research regulatory requirements reducing impact conducts quality assessments manages programme animals used external animal diligence develops deploys strategies human subject research critical assessing reproducing experiments translating human demonstrating safety efficacy investigational clinical end points products evaluate products ensuring implement maintain proper data governance approved research includes clinical trials healthy controls remains important priority especially volunteers patients follows regulations high ethical scientific strategy evolving take advantage breath medical scientific standards disclose results data example genomics artificial intelligence research externally regardless whether reflect machine learning focus building data integrity well positively negatively products scientific privacy usage controls internal control framework community learn outcomes research quality assurance teams conduct audits provide independent also work human biological samples business monitoring internal controls fundamental discovery development safety rd organisation maintains controls prepublication monitoring products committed managing procedures guard public disclosure patent human biological samples accordance relevant laws applications filed addition lack data regulations ethical principles manner integrity preparing patent application data information respects interests sample donors lead loss patent protection legal experts collaborate data pivotal rd strategy maximising rd support review process new patent use data serve patients governing data accordance applications rd organisation also collaborates relevant laws regulations contractual obligations legal experts throughout development assets expectations culture across privacy information take account relevant thirdparty patent rights security data integrity essentialprincipal risks uncertainties continued environment health safety risk definition mitigating activities failure management global leadership team responsible ehs governance risk oversight ensure effective execution hazardous activities control framework inplace inuse manage ehs gsks physical assets infrastructure risks impacts legal compliance issues handling processing hazardous chemicals business units includes assigning responsibility senior biological agents managers providing maintaining controls ensuring tiered monitoring governance processes control releases substances harmful environment place within business units function leaders ensure short longterm ehs control framework implemented effectively leading incidents could disrupt rd supply respective business area compliant applicable activities harm employees harm communities harm laws regulations adequately resourced local environments operate maintained communicated monitored every employee qualified contractor acting behalf gsk personally risk impact responsible ensuring follow applicable local failure manage ehs risks could lead significant harm standard operating procedures people environment communities riskbased proactive approach articulated operate fines inability meet stakeholder expectations global ehs policy detailed global ehs standards regulatory requirements litigation regulatory action audit operations ensure compliance damage companys reputation could materially ensure hazards appropriately controlled adversely affect financial results design facilities equipment systems rigorous context procedures applied correctly put effective barriers gsk subject health safety environmental laws place protect employees health safety various jurisdictions laws impose duties protect late created safety improvement plan people environment communities strengthen corporate safety programmes focusing operate life saving rules safety leadership warehouse safety significant milestones programmes delivered overall number significant incidents occurred year reduced environmental sustainability risk definition risk impact failure management recognise way respond climate change manage environmental risks affects ability supply physical climate environmental risks products patients consumers could lead harm current future regulatory requirements environmental environment reputation failure meet fastevolving policies taxes regulatory requirements stakeholder expectations could delivery performance management environmental result litigation regulatory actions may objectives material adverse impact financial results longer term loss trust undermining credibility company leading reduced supply chain resilience product life cycle management issues loss trustreputation employees context investors customers regulators stakeholders increasingly understood interconnected effects increased costs loss sales market access negative climate change nature loss societys impact impacts environment influencing human health internal external expectations companies address impact environment increasing effects climate change operational resilience regard access energy water natural resources used products along potential cost increases regulatory changes environmental taxes gsk annual report gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued environmental sustainability continued mitigating activities ensure delivery reductions carbon emissions energy november gsk announced new commitment water waste across operations mature net zero climate impact net nature positive programmes managing performance improvements goals built longterm ambition set sites include sustainability considerations design reduce impact environment products packaging strengthening engagement suppliers target key interventions gsk leadership team glt responsible support needed environmental sustainability governance risk oversight ensures effective framework place use continue monitor control antibiotic emissions manage risks across businesses manufacturing effluents gsk facilities deliver commitments glts responsibilities include suppliers following good operational practice meeting appointing dedicated senior leaders resources provide emission limits defined amr alliance manufacturing maintain risk controls ensure governance framework assess impact environment processes established effective within businesses continuously reassess business resilience climate dedicated environmental sustainability enterprise risk plan change task force climaterelated financial place supported dedicated programme team disclosures tcfd framework guidelines governance framework manage transformation activities information security risk definition covid pandemic continues another significant risk information security gsk characterised external factor affecting manage information security unauthorised disclosure theft unavailability corruption gsk covidrelated threats include increase gsks information key information systems may lead ransomware attacks healthcare sector hackers harm patients workforce customers disruption continue use opportunity disrupt critical healthcare business andor loss commercial strategic advantage operations cases seize healthcare research regulatory sanction damage reputation related covid vaccines treatments operate highly connected information network risk impact holds confidential research development manufacturing failure adequately protect information key information commercial workforce financial data means systems may cause harm patients workforce systems information continue customers disruption business andor loss commercial target cyberattacks continue consolidate information strategic advantage regulatory sanction damage systems reduce attack points enable focused reputation controls gsks strategic approach digital analytics context increase dependency digital assets distributed data continued analysis assessment overall information security environment challenging critical data assets threats assets difficulty keeping pace increasingly require continuous reevaluation emerging risks gsk sophisticated cyber threats due many factors mitigating actions already defined areas includes including complexity large regulated organisations secure deployment operation resources highrisk wellresourced nature hacking activities increasing markets risk posed gsk data cloud demands accountability data handled companies potential complexity resulting agile businessled additionally gsk separation period significant development across enterprise change increases risk requires additional vigilance continue reassess reliance interconnectivity third party contractors partners suppliersprincipal risks uncertainties continued information security continued mitigating activities optimising security architecture mitigate risk data dedicated team program activity supports loss intentionally unintentionally implementing cloud global information security policy accompanying security strategy ensuring new solution development standards processes gsk technology security includes security design also continuing risk function provides strategy direction oversight remediate improve control environment privileged mirrored functions new ch readiness elevated user rights across systems separation includes active monitoring cybersecurity transferring third party risk management managed enhancing global information security capabilities service partner organisation process critical ongoing programme investment continue sensitive information supports solution enable make significant investments mitigation activities us move third parties access resources continue advance coming year remotely via secure environment modernising cyber operations consistent evaluation enabling business performance high risk markets security solutions deployment best class cyber assessing data information originating flowing security technology ensure timely detection international markets local laws norms represent response information security incidents particular heightened risk confidentiality integrity availability focus ransomware preparation awareness operational systems modernising cyber security within manufacturing rd sites address age complexity global footprint environments supply continuity risk definition complex endtoend supply chains often involve third party failure deliver continuous supply compliant finished suppliers active pharmaceutical ingredient api product inability respond effectively crisis incident manufacturers raw material suppliers third party timely manner recover sustain critical operations logistics providers contract engineering firms embed integrated risk management sourcing day day risk impact business processes alongside thirdparty oversight recognise important continuity supply programme products patients consumers rely covid exemplar events external environment supply disruption lead result unforeseen significant supply challenges including staffing shortages essential manufacturing product shortages product recalls operations critical raw materials supply pressures eg glass regulatory intervention vials plastic tubing interruptions distribution reputational harm cybersecurity remains significant threat supply chain lost sales revenue operations global cyber threat increased global pandemic remain hypervigilant data security consequently need sophisticated endtoend supply chain breaches operational technology risks management robust crisis management business continuity plans place respond mitigating activities risk management context supply chains set ensure sustainable supply run supply chains continually evolving highly across gsk portfolio pharmaceuticals vaccines regulated environment single set global consumer healthcare products gsk internal control regulations governs manufacture distribution framework drives approach risk management designed medicines must adhere requirements identify emerging new risks support clear decision markets licence sell manufacture products making rely upon internal quality management system internal control framework ensure continue preserve licence operate gsk annual report gsk annual report strategic report governance remuneration financial statements investor information principal risks uncertainties continued supply continuity continued supply chain manages risk oversight business continuity hierarchy risk management compliance boards crisis management business continuity plans place assure risk mitigation including identifying new emerging across pharmaceuticals vaccines consumer healthcare threats include authorised response recovery strategies key areas responsibility clear communication routes supply inventory management chains regularly use business continuity plans manage supply chain governance committees within business potential supply disruptions manufacturing sites crisis unit closely monitor inventory status delivery management plans place tested annually products occurrence deployment ensure maintenance skills core commercial cycle links supply chain forecasting crisis management commercial ambition designed reduce risk demand fluctuations manage temporary shortages supply periodically review node supply chains ensure hold adequate safety stocks whilst balancing working capital particular emphasis mitigating supply risks associated medically critical highrevenue products new product launches eg using dual sourcing key products apis use monthly performance management process across supply chains monitor business activity highlight adverse trends supply operations budget workforce capability transformation separation risk definition mitigating activities failure deliver plan successful transformation future ready office fro established fourth separation gsk two new leading companies one quarter accountable monitoring progress biopharma one consumer healthcare performance risks associated creating two new companies reports monthly gsk leadership team risk impact glt ensure enterprise oversight plan using failure manage macro level risk due covid key performance risk indicators track programme highly competitive labour market relation delivery resource programme delivery talent retention recruitment separation plan could materially adversely affect onboarding address covid labour market ability deliver gsks strategy longterm priorities challenges addition gsks chief executive officer ceo chief financial officer chief strategy officer head fro context meet leaders consumer healthcare gather input february gsk announced new future ready approval key design choices new company overall programme prepare separation two companies balance transformation separation upheld new gsk pharma company rd approach focused clear governance joint coordination new gsk science related immune system use genetics consumer healthcare rigorous progress tracking new technologies new leader consumer setting clear parameters healthcare gsk increases investment rd new product launches twoyear separation programme aims gsk board regularly informed future ready drive common approach innovation improved capital programme lead indicators ceo board report allocation align improve capabilities efficiencies board meeting board level transformation global support functions support new gsk separation committee supports advises managements optimise supply chain portfolio including divesting work transforming separating group committee noncore assets prepare consumer healthcare chaired gsk chairman includes senior operate standalone company complete outlook independent director chairs audit risk companies fundamentally strengthened remuneration corporate responsibility committees making efficient modern automated skills capabilities serve futureshareholder information share capital control details issued share capital number shares interests voting rights held treasury december found stated far aware note financial statements share capital share persons significant direct indirect holdings premium account company information provided company pursuant ordinary shares listed london stock exchange financial conduct authoritys disclosure guidance lse also quoted new york stock exchange transparency rules dtr published regulatory nyse form american depositary shares ads information service companys website ads represents two ordinary shares details listed debt wwwgskcom listed refer note financial statements company received notifications accordance net debt dtr following notifiable interests voting rights holders ordinary shares ads entitled receive companys issued share capital dividends declared companys annual report december february also entitled attend speak appoint proxies percentage percentage exercise voting rights general meetings company total voting total voting voting rights rights voting rights rights restrictions transfer limitations blackrock inc holding ordinary shares ads requirements dodge cox obtain approval prior transfers ordinary shares p ercentage total voting rights date notification company ads carry special rights regard control c omprising indirect interest ordinary shares company restrictions voting rights major holding qualifying financial instruments contract shareholders voting rights per share difference shareholders known arrangements c omprising indirect interest ordinary shares financial rights held person holder american depositary shares shares known agreements restrictions share company acquired disposed interests transfers voting rights shares period review shares acquired groups employee share plans rank equally shares issue special share buyback programme rights trustees employee share ownership plan board authorised issue allot ordinary trusts waived rights dividends shares held shares article companys articles association trusts power article authority company make purchases shares subject shareholder exchange controls limitations authorities sought annual basis annual affecting holders general meeting agm shares purchased certain economic sanctions may company may cancelled held treasury shares force time time currently applicable laws used satisfying share options grants group 's decrees regulations force uk restricting import employee share plans export capital restricting remittance dividends programme covers purchases shares cancellation payments holders companys shares held treasury shares accordance nonresidents uk similarly certain economic authority renewed shareholders agm may sanctions may force time time company authorised purchase maximum limitations relating nonresidents uk english million shares details shares purchased law companys articles association right cancelled held treasury shares subsequently holder vote respect companys shares transferred treasury satisfy awards groups employee share plans disclosed note financial statements share capital share premium account determining specific share repurchase levels company considers development free cash flow year shares purchased since company confirms currently intend make market purchases company review potential future share buybacks line usual annual cycle subject return ratings criteria gsk annual report gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued share capital control continued market capitalisation share price trend three years ended market capitalisation based shares issue excluding december treasury shares gsk december billion date gsk th largest company market uk us capitalisation ftse index share price january december increasedecrease high year low year table sets middle market closing prices companys share price increased compares increase ftse index year middle market closing share price february uk share price uk us ads price us nature trading market following table sets periods indicated high low middle market closing prices companys ordinary shares lse ads nyse ordinary shares ads uk per share us per share high low high low february january december november october september quarter ended december quarter ended september quarter ended june quarter ended march quarter ended december quarter ended september quarter ended june quarter ended march year ended december year ended december year ended december year ended december february shareholder information continued analysis shareholdings december number total total number accounts accounts shares shares holding shares held institutional corporate holders individuals corporate bodies guaranty nominees limited held treasury shares glaxosmithkline jp morgan chase bank na depositary companys american depository receipt adr programme companys ads listed nyse ordinary shares representing companys adr programme managed depositary registered name guaranty nominees limited february guaranty nominees limited held ordinary shares representing issued share capital excluding treasury shares date february number holders ordinary shares us holdings ordinary shares number registered holders ads holdings ads certain ordinary shares ads held brokers nominees result number holders record registered holders us representative number beneficial holders residence beneficial holders dividends company pays dividends quarterly continues return june new gsk investor update gsk cash shareholders dividend policy dividends set progressive dividend policy remain essential component total shareholder return implemented new gsk dividend policy total gsk recognises importance dividends shareholders expected cash distribution respective dividend payout company aims distribute regular dividend payments ratios new gsk new consumer healthcare remain determined primarily reference free cash flow unchanged gsk expects declare p per share dividend generated business funding investment payable current group first half comprises necessary support groups future growth pence per share new gsk pence per share representing consumer healthcare first half whilst dividends per share part group second half new gsk table sets dividend per share per ads continues expect declare p per share dividend last five years dividend per ads translated previously communicated new gsk would expect declare us dollars applicable exchange rates dividend pence per share following separation dividend policy new consumer year pence us healthcare company responsibility board directors expected guided per cent payout ratio basis expect secondhalf dividend new consumer healthcare company equivalent payout around pence per share subject boards decisions intrayear phasing dividend q ordinary dividend receivable ads holders calculated based payments expected distribution per share second exchange rate april annual fee per ads per half year adjusted highlighted ads per quarter charged depository cumulative dividend receivable ads holders q q q gsk investor update june reflect total number shares circa billion shares new consumer healthcare company expected issue upon demerger june planning assumption investor update reflected gsk shares issue time circa billion shares gsk annual report gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued dividends continued aggregate would represent full year basis dividend calendar equivalent group dividend around p per share quarter exdividend date record date payment date dividends payable consumer healthcare q february february april receivable shareholders remain invested consumer q may may july healthcare postseparation appropriate record dates q august august october details dividends declared amounts payment q november november january dates given note financial statements q february february april dividends financial calendar results announcements event date quarter results announcement april results announcements issued lse available annual general meeting may news service also sent us securities quarter results announcement july exchange commission sec nyse issued quarter results announcement november media made available website preliminaryquarter results announcement february financial reports annual report publication februarymarch annual report distribution march company publishes annual report made available website date publication information company including share ads shareholders may elect receive notification email price available website wwwgskcom information publication annual reports registering made available website constitute part wwwshareviewcouk may also elect receive annual report printed copy annual report contacting registrar equiniti limited copies previous annual reports available website printed copies also obtained registrar see contact details annual general meeting annual general meeting agm held pm ads holders wishing attend meeting electronically uk time wednesday may sofitel london refer agm notice details request proxy heathrow terminal london heathrow airport tw gd appointment depositary jp morgan chase bank na also broadcast live join electronically enable attend ask questions vote electronically business transacted meeting agm companys principal forum communication ads holders reminded instruct private shareholders addition formal agm depositary way shares represented business presentation ceo ads voted completing returning performance group future development voting card provided depositary shares opportunity questions asked board voted chairs boards committees workforce engagement director available take questions documents display relating roles articles association company directors details access agm electronically service contracts applicable letters appointment attend person ask questions vote found directors company subsidiaries notice annual general meeting agm notice side letters relating severance terms pension available website wwwgskcom arrangements available inspection companys investors holding shares nominee service registered office made available inspection arrange nominee service appointed agm proxy respect shareholding order attend vote meeting electronicallyshareholder information continued tax information shareholders summary certain uk tax us federal income tax inheritance tax consequences holders shares ads citizens individual ukdomiciled otherwise shareholders may uk us set complete liable uk inheritance tax transfer shares ads analysis possible tax consequences purchase tax may charged amount value ownership sale securities intended shareholders estate reduced result transfer general guide holders advised consult advisers way lifetime gift disposal less full market respect tax consequences purchase ownership value case bequest death tax may charged sale shares ads consequences state value shares date shareholders death local tax laws us implications current gift disposal subject uk ukus tax conventions inheritance tax us estate gift tax estate gift tax us holders ads generally treated owners convention would generally provide tax paid us underlying shares purposes current ukus credited tax payable uk double taxation conventions relating income gains stamp duty stamp duty reserve tax income tax convention estate gift taxes estate gift tax convention purposes internal revenue uk stamp duty andor stamp duty reserve tax sdrt code amended subject certain exemptions payable transfer shares rate rounded nearest uk shareholders case stamp duty consideration transfer notwithstanding provided instrument executed summary applies uk resident shareholder pursuance agreement gave rise charge holds shares capital assets sdrt instrument stamped within six years agreement including stamped exempt sdrt taxation dividends charge cancelled sdrt already uk tax year uk resident individuals entitled paid repaid dividend tax allowance first dividends received tax year free tax us shareholders dividends excess allowance taxed basic rate taxpayers higher rate taxpayers summary applies shareholder citizen additional rate taxpayers note april tax resident us domestic corporation person dividend income increase help support otherwise subject us federal income tax net income nhs social care basis respect shares ads holds shares ads capital assets resident uk uk tax purposes uk resident shareholders corporation taxpayers hold shares purposes trade profession note dividends payable ordinary shares generally vocation carried uk branch entitled exemption corporation tax agency taxation capital gains summary also address tax treatment holders subject special tax rules banks uk resident shareholders may liable uk tax gains taxexempt entities insurance companies dealers securities disposal shares ads currencies persons hold shares ads part disposals individuals uk tax year integrated investment including straddle comprised taxable capital gain accruing disposal shares ads share ads one positions persons taxed basic rate taxpayers directly indirectly constructively allowable deductions individuals taxable income companys stock vote value address tax year exceeds basic rate income tax banding note treatment may applicable result international following use exemptions available individual income tax treaties taxpayer annual exempt amount corporation taxpayers may entitled indexation allowance applies reduce capital gains extent gains arise due inflation indexation allowance may reduce chargeable gain create allowable loss assets acquired january legislation finance act freezes level indexation allowance given calculating companys chargeable gains value would apply disposal asset december assets acquired january onwards legislation finance act removes indexation allowance disposal gsk annual report gsk annual report strategic report governance remuneration financial statements investor information shareholder information continued tax information shareholders continued taxation dividends taxation capital gains gross amount dividends received treated foreign generally us holders subject uk capital gains source dividend income us tax purposes eligible tax subject us tax capital gains realised dividend received deduction allowed us corporations sale disposal shares ads gains dividends ads payable us dollars dividends longterm capital gains subject reduced rates taxation ordinary shares payable sterling dividends paid individual holders shares ads held sterling included income us dollar amount one year date shares vestedreleased calculated reference exchange rate day shortterm capital gains subject taxation rates dividends received holder subject certain whereas longterm capital gains may subject exceptions shortterm hedged positions individual rates state local tax rates capital gains eligible us holder subject us taxation maximum may also apply federal rate plus applicable state local tax respect qualified dividends qualified dividend defined information reporting backup withholding us internal revenue service irs dividend dividends payments proceeds sale shares meets following criteria ads paid within us certain usrelated financial ust issued us corporation corporation intermediaries subject information reporting may incorporated us possession corporation subject backup withholding unless us holder eligible benefits comprehensive income tax treaty corporation exempt recipient provides taxpayer deemed satisfactory published irs identification number certifies loss exemption occurred nonus holders generally subject dividends type listed irs dividends information reporting backup withholding may qualify required provide certification nonus status required dividend holding period met connection payments received amounts withheld shares must owned days allowed refund credit holders us federal holding period defined day income tax liability provided required information furnished period begins days exdividend date irs day stock trades without dividend priced example stocks exdividend date october estate gift taxes shares must held days period estate gift tax convention us shareholder august november year order generally subject uk inheritance tax however us count qualified dividend holder may subject us federal estate gift tax dividends qualified subject taxation stamp duty us federal graduated tax rates maximum rate types dividends automatically excluded uk stamp duty andor sdrt subject certain exemptions qualified dividends even meet requirements payable transfer shares ads custodian include limited depository rate amount consideration provided transferred sale value transferred capital gains distributions consideration dividends bank deposits however stamp duty sdrt payable ividends held corporation employee stock transfer agreement transfer ads ownership plan esop dividends paid taxexempt corporations us state local tax rates qualified nonqualified dividends may vary would assessed addition federal tax rates communicated aboveother statutory disclosures shareholder services contacts registrar companys registrar equiniti limited aspect house spencer road lancing bn da wwwshareviewcouk tel uk tel outside uk equiniti provides range services shareholders service offers participate dividend reinvestment plan alternative receiving cash dividends may choose drip election form downloaded drip reinvest dividends buy gsk shares wwwshareviewcouk requested contacting equiniti dividend payment direct bank dividends paid directly bank building society dividend bank mandate form account bank mandate account receive cash dividends must provide downloaded wwwshareviewcouk equiniti bank building society account details requested contacting equiniti quick secure method payment dividend payment direct bank equiniti convert dividend local currency details service costs account overseas shareholders send direct local bank account service available involved please contact equiniti countries worldwide electronic communications shareholders may elect receive electronic notifications please register wwwshareviewcouk company communications including annual report dividend payments dividend confirmations availability online voting general meetings time gsk publishes shareholder documents receive email containing link document relevant website shareview portfolio service enables create free online portfolio view please register wwwshareviewcouk share balance movements update address dividend payment instructions register votes general meetings deduplication publications mailings receive duplicate copies mailings may please contact equiniti one account please contact equiniti arrange accounts merged one convenience avoid waste unnecessary costs share dealing service shareholders may trade shares either held certificated online transactions please log please note market trading hours form corporate sponsored nominee online wwwshareviewcoukdealing pm uk time telephone via postal dealing service provided equiniti telephone transactions please call monday friday excluding public financial services limited uk holidays england wales outside uk lines open pm uk time monday friday excluding uk public holidays postal transactions please call request dealing form corporate sponsored nominee account convenient way manage shares without requiring application form requested share certificate service provides facility hold wwwshareviewcouk shares nominee account sponsored company contacting equiniti continue receive dividend payments attend vote companys general meetings shareholders names appear publicly available share register service free join individual savings accounts isas company arranged equiniti financial services details available wwwshareviewcouk limited provide gsk corporate isa hold gsk shares requested telephoning equiniti lines open pm dealing pm enquiries monday friday excluding public holidays england wales lines open pm monday friday excluding public holidays england wales provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued shareholders services contacts continued ads depositary contacts adr programme administered jp morgan investor relations chase bank na investor relations may contacted follows regular correspondence uk eq shareowner services great west road po box brentford middlesex tw gs st paul mn tel delivery stock certificates overnight mail us eq shareowner services crescent drive centre point curve suite philadelphia pa mendota heights mn tel us toll free wwwshareowneronlinecom tel outside us general gsk response center outside us tel us toll free depository also provides global invest direct direct share scam alert ads purchasesale dividend reinvestment plan ads receive unsolicited telephone call offering sell buy holders details enrol please visit wwwadrcom shares please take extra care caller may part call helpline number obtain enrolment pack highly organised financial scam donating shares save children uk shareholder please contact financial gsk embarked ambitious global partnership conduct authority wwwfcaorgukconsumers save children share expertise resources consumer helpline aim helping save lives one million children tel uk shareholders small number shares value tel outside uk makes uneconomical sell may wish consider donating save children donated shares aggregated lines open pm uk time monday friday except uk public holidays pm saturdays sold save children use funds raised help reach goal obtain share donation form please contact registrar equiniti managing donation sale uk shares save children free charge provision share dealing details intended invitation inducement engage investment activity advice share dealing obtained stockbroker independent financial adviser stock exchange announcement notifications provide shareholders service receive automatic email notifications publish stock exchange announcement receive email notifications please sign announcements wwwgskcom investors sectionother statutory disclosures continued us law regulation number provisions us law regulation apply section corporate responsibility company shares quoted nyse financial reports form ads sarbanesoxley requires ceo cfo complete formal certifications confirming nyse rules reviewed annual report form f general nyse rules permit company follow uk corporate governance practices instead applied based knowledge annual report form f us provided explain significant variations contains material misstatements omissions explanation contained form f based knowledge financial statements accessed sec 's edgar database via website financial information fairly present material respects nyse rules require us file annual interim written financial condition results operations cash flows affirmations concerning audit risk committee arc dates periods presented annual report statement significant differences corporate form f governance responsible establishing maintaining sarbanesoxley act disclosure controls procedures ensure material information made known evaluated following number corporate accounting scandals effectiveness controls procedures year us congress passed sarbanesoxley act end results evaluation contained sarbanesoxley wideranging piece legislation annual report form f concerned largely financial reporting corporate governance responsible establishing maintaining internal control financial reporting provides reasonable recommended sec company established assurance regarding reliability financial reporting disclosure committee committee reports ceo preparation financial statements external purposes cfo arc chaired company secretary accordance generally accepted accounting principles members consist senior managers finance legal corporate communications investor relations disclosed annual report form f external legal counsel external auditors internal experts changes internal controls financial reporting invited attend disclosure committees meetings period covered annual report form f periodically committee responsibility considering materially affected reasonably likely affect materially materiality information timely basis determining companys internal control financial reporting disclosure information responsibility disclosed based recent evaluation timely filing reports sec formal review internal control financial reporting external auditor annual report form f committee met arc significant deficiencies material times weaknesses design operation internal controls sarbanesoxley requires annual report form f financial reporting reasonably likely affect contains statement whether member arc adversely companys ability record process audit committee financial expert defined rules summarise report financial information fraud sarbanesoxley statement relevant members regardless materiality involving persons arc charles bancroft included board significant role companys internal control financial committee information area corporate governance reporting report biography additional group carried evaluation supervision disclosure requirements arise section section participation management including ceo sarbanesoxley respect disclosure controls cfo effectiveness design operation procedures internal control financial reporting groups disclosure controls procedures december inherent limitations effectiveness system disclosure controls procedures including possibility human error circumvention overriding controls procedures accordingly even effective disclosure controls procedures provide reasonable assurance achieving control objectives gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued us law regulation continued ceo cfo expect complete certifications group exports certain pharmaceutical vaccine report conclusions effectiveness disclosure consumer products iran via sales nonus entities controls procedures march following subsidiaries us entity two privately held iranian certifications filed sec part groups distributors form f group regularly receive information regarding identity distributors ' downstream customers section managements annual report internal intermediaries iran possible parties control financial reporting include entities governmentowned hospitals accordance requirements section pharmacies owned directly indirectly iranian sarbanesoxley following report provided government persons entities sanctioned connection management respect companys internal control terrorism proliferation activities financial reporting defined rules af df group regularly receive information us securities exchange act amended regarding identity distributors ' downstream customers exchange act establish proportion gross revenue sales management responsible establishing maintaining potentially attributable entities affiliated iranian adequate internal control financial reporting government parties sanctioned disclosable activities group internal control financial reporting designed result group reporting entire gross revenues provide reasonable assurance regarding reliability million net profits million group 's financial reporting preparation financial statements sales iran external purposes accordance ifrs group also aware hospitals medical management conducted evaluation effectiveness facilities lebanon may affiliated controlled internal control financial reporting based hezbollah groups designated united framework internal control integrated framework states pursuant executive order group issued committee sponsoring organisations deal directly hospitals facilities treadway commission coso instead sells distributors group unable changes groups internal control establish proportion gross revenue sales potentially financial reporting materially attributable reportable activities result group affected reasonably likely materially affect reporting entire gross revenues million net groups internal control financial reporting profits million group 's sales lebanon management assessed effectiveness internal unless noted group intends continue activities control financial reporting december described conclusion filed part groups form addition section r exchange act us law f generally restricts dealings us persons dealings deloitte llp audited consolidated financial otherwise subject us jurisdiction certain countries statements group year ended december territories subject comprehensive sanctions currently also assessed effectiveness groups crimea cuba donetsk people 's republic iran luhansk internal control financial reporting auditing people 's republic north korea syria well standard public company accounting oversight government venezuela though country board united states audit report filed venezuela whole group business via nonus groups form f entities owned controlled us entities certain jurisdictions believe group complies section r exchange act applicable us sanctions material respects laws complex continue evolve rapidly section r exchange act requires issuers make specific disclosure annual reports certain types dealings iran controlled transactions dealings governmentowned entities well dealings entities sanctioned activities related terrorism proliferation weapons mass destruction even activities prohibited us law involve us personsother statutory disclosures continued donations political organisations political expenditure ensure consistent approach political contributions result definitions may cover legitimate business across group global policy introduced activities ordinary sense considered political voluntarily stop corporate political contributions donations political expenditure designed support political party independent election candidate period january december group make political donations eu therefore notwithstanding policy noneu organisations intend make donations eu political parties organisations incur eu political expenditure notwithstanding introduction policy accordance annually seek shareholder authorisation inadvertent federal election campaign act us continue expenditure support employeeoperated political action committee pac facilitates voluntary political donations eligible authority precautionary measure ensure gsk employees company subsidiaries inadvertently breach legislation pac controlled gsk decisions amounts recipients contributions governed pac board authorisation process expenditure directors contributions pac made participating year dates back agm held may following eligible employees exercising legal right pool introduction political parties elections resources make political contributions subject referendums act authority since strict limitations us law total renewed annually us us donated political organisations gsk employee pac english law requires prior shareholder approval political contributions eu political parties independent election candidates well eu political expenditure definitions political donations political expenditure political organisations used legislation however quite broad particular definition eu political organisations may extend bodies concerned policy review law reform representation business community special interest groups concerned environment company subsidiaries might wish support gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies accordance section companies act full list subsidiaries associates joint ventures joint arrangements address registered office effective percentage equity owned december disclosed unless otherwise stated share capital disclosed comprises ordinary shares indirectly held glaxosmithkline plc percentage held class share stated less unless otherwise stated subsidiary companies registered office tax resident country incorporation name security registered address wholly owned subsidiaries alberta ulc common nd street sw calgary ab tp j canada action potential venture capital limited ordinary great west road brentford middlesex tw gs england adechsa gmbh ii ordinary co prv provides treuhandgesellschaft ag dorfstrasse baar switzerland allen hanburys limited ii ordinary great west road brentford middlesex tw gs england allen hanburys pharmaceutical nigeria limited ordinary abimbola way ilasamaja isolo lagos nigeria allen farmaceutica sa ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain allen pharmazeutika gesellschaft mbh ordinary wagenseilgasse euro plaza gebude stock vienna austria beecham group plc p shares ' b ' great west road brentford middlesex tw gs england p shares ' ' beecham pharmaceuticals pte limited ordinary quality road jurong industrial estate jurong singapore beecham portuguesaprodutos farmacuticos e qumicos lda ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal beecham sa ii ordinary avenue fleming wavre belgium biovesta ilalari ltd sti ii nominative bykdere caddesi levent plaza b blok levent istanbul turkey cascan gmbh co kg partnership capital prinzregentenplatz munich germany castleton investment ltd liquidation ordinary co dtos cybercity th floor standard chartered tower ebene mauritius cellzome gmbh ordinary meyerhofstrasse heidelberg germany cellzome limited liquidation since year end ordinary baker street london wu eu united kingdom charles midgley limited liquidation since year end cumulative preference baker street london wu eu united kingdom ordinary clarges pharmaceuticals limited liquidation since year end ordinary baker street london wu eu united kingdom preference clarges pharmaceutical trustees limited ii iv ordinary great west road brentford middlesex tw gs england colleen corporation common corporation service company little falls drive wilmington de united states corixa corporation common corporation service company little falls drive wilmington de united states dealcyber limited ordinary great west road brentford middlesex tw gs england desarrollo energa solar alternativa sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain duncan flockhart australia pty limited ii iv ordinary mountain highway boronia victoria vic australia duncan pharmaceuticals philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines etex farmaceutica ltda social capital avenue andres bello piso las condes santiago cp chile genelabs technologies inc common corporation service company gateway oaks drive suite n sacramento ca united states glaxo group limited ordinary great west road brentford middlesex tw gs england glaxo kabushiki kaisha ii ordinary akasaka minatoku tokyo japan glaxo laboratories nigeria limited ii ordinary marine road apapa lagos nigeria glaxo laboratories limited liquidation ordinary baker street london wu eu united kingdom glaxo new zealand pension plan trustee limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxo operations uk limited ordinary great west road brentford middlesex tw gs england glaxo properties bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxo trustees limited ii liquidation ordinary baker street london wu eu united kingdom glaxo verwaltungs gmbh ordinary prinzregentenplatz munich germany glaxo wellcome australia pty ltd ii iv ordinary mountain highway boronia victoria vic australia glaxo wellcome farmacutica limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxo wellcome international bv ii iii ordinary huis ter heideweg lz zeist netherlands glaxo wellcome manufacturing pte ltd ordinary pioneer sector jurong industrial estate jurong singapore glaxo wellcome production ordinary rue franois jacob rueilmalmaison france glaxo wellcome vidhyasom limited ii ordinary th floor wave place wireless road lumpini pathumwan bangkok thailandother statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxo wellcome sa ordinary poligono industrial allendeduero avenida de extremadura aranda de duero burgos spain glaxo sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain glaxoallenburys nigeria limited ii ordinary creek road apapa lagos pmb nigeria glaxochem pte ltd iii ordinary rochester park singapore glaxosmithkline produtos farmacuticos limitada ordinary quota rua dr antonio loureiro borges arquiparque miraflores alges portugal glaxosmithkline cambodia co ltd liquidation ordinary th floor dksh building preah monivong boulevard co sangkat phsar deum thakov khan chamkarmon phnom penh cambodia glaxosmithkline china investment co ltd ordinary room unit floor mid th east ring road chaoyang district beijing china glaxosmithkline china rd company limited equity f building huanke road pilot free trade zone shanghai china glaxosmithkline cyprus limited ordinary arch makariou iii capital center th floor nicosia pc cyprus glaxosmithkline gsk srl ordinary costache negri street opera center one th th floors zone district bucharest romania glaxosmithkline ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline israel ltd ordinary basel street po box petachtikva israel glaxosmithkline malta limited ordinary first floor de la cruz avenue qormi qrm malta glaxosmithkline private limited ii ordinary unit anthony road msasa harare zimbabwe glaxosmithkline thailand limited ordinary th floor wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline ab ordinary hemvarnsg solna sweden glaxosmithkline ag ordinary talstrasse muenchenbuchsee switzerland glaxosmithkline angola unipessoal limitada iv quota luanda bairro petrangol estrada de cacuaco n angola glaxosmithkline argentina sa ordinary tucumn piso buenos aires caaa argentina glaxosmithkline ordinary drammensveien oslo norway glaxosmithkline asia private limited equity patiala road nabha dist patiala punjab india glaxosmithkline australia pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands glaxosmithkline beteiligungs gmbh ordinary prinzregentenplatz munchen germany glaxosmithkline biologicals shanghai ltd ordinary niudun road pilot free trade zone shanhai china glaxosmithkline biologicals kft ordinary gdll homoki nagy istvn utca hungary glaxosmithkline biologicals sas ordinary rue des aulnois saintamand les eaux france glaxosmithkline biologicals sa ordinary rue de l'institut b rixensart belgium preference glaxosmithkline brasil limitada quotas estrada dos banderiantes rio de janeiro brazil glaxosmithkline capital inc common wilmington trust sp services inc north market street suite wilmington de united states glaxosmithkline capital plc ordinary great west road brentford middlesex tw gs england glaxosmithkline caribbean limited ordinary great west road brentford middlesex tw gs england glaxosmithkline chile farmaceutica limitada social capital avenue andres bello piso las condes santiago cp chile glaxosmithkline colombia sa ordinary avenida el dorado bpiso bogot colombia glaxosmithkline consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer holding bv ii ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline doo quotas zmja od bosne broj sarajevo bosnia herzegovina glaxosmithkline doo equity capital ulica damira tomljanovica gavrana zagreb croatia glaxosmithkline doo beograd ordinary omladinskih brigada new belgrade city belgrade serbia glaxosmithkline ecuador sa ordinary av de agosto n naciones unidas edificio electroectuatoriana piso quito ecuador glaxosmithkline eesti ou ordinary ltsa tallinn estonia glaxosmithkline el salvador sa de cv ordinary municipio de san salvador departamento de san salvador el salvador glaxosmithkline eood ordinary g tsarigradsko shose blvd floor mladost region sofia bulgaria glaxosmithkline export limited ordinary great west road brentford middlesex tw gs england glaxosmithkline export panama sa ordinary panama city republic panama panama glaxosmithkline far east bv ordinary van asch van wijckstraat h lp amersfoort netherlands glaxosmithkline finance plc ordinary great west road brentford middlesex tw gs england glaxosmithkline gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline guatemala sa ordinary ra av zona torre citibank nivel guatemala city guatemala gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline holding ordinary drammensveien oslo norway glaxosmithkline holdings americas inc common wilmington trust sp services inc north market street suite wilmington de united states glaxosmithkline holdings one limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings limited ordinary great west road brentford middlesex tw gs england glaxosmithkline holdings pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline honduras sa ordinary tegucigalpa mdc honduras glaxosmithkline ihc limited ordinary great west road brentford middlesex tw gs england glaxosmithkline ilaclari sanayi ticaret nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithkline inc class common mississauga road north mississauga ontario ln l canada class c preference glaxosmithkline insurance ltd ordinary parlaville road hamilton hm bermuda glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property holdings limited ordinary great west road brentford middlesex tw gs england b ordinary glaxosmithkline intellectual property limited deferred great west road brentford middlesex tw gs england ordinary glaxosmithkline intellectual property management limited ordinary great west road brentford middlesex tw gs england glaxosmithkline investigacin desarrollo sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline investment holdings limited liquidation ordinary baker street london wu eu united kingdom glaxosmithkline investment services limited liquidation ordinary baker street london wu eu united kingdom glaxosmithkline investments pty ltd ordinary mountain highway boronia victoria vic australia glaxosmithkline kk ordinary akasaka minatoku tokyo japan glaxosmithkline korea limited ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline latin america sa ordinary panama city republic panama panama glaxosmithkline latvia sia ordinary duntes iela riga latvia glaxosmithkline lietuva uab ordinary ukmerges st vilnius lt lithuania glaxosmithkline limited ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline manufacturing spa ordinary viale dellagricoltura verona italy glaxosmithkline maroc sa ordinary angle bd rachidi et abou hamed el glaza casablanca morocco glaxosmithkline medical healthcare products limited ordinary h csorsz utca budapest hungary glaxosmithkline mercury limited ordinary great west road brentford middlesex tw gs england glaxosmithkline mexico sa de cv ordinary calzada mexicoxochimilco colonia san lorenzo huipulco ordinary b delegacion tlalpan mexico glaxosmithkline nz limited ordinary level e generator gridakl madden street wynyard quarter auckland new zealand glaxosmithkline oy ordinary piispansilta po box espoo fin finland glaxosmithkline peru sa ordinary av javier prado oeste san isidro lima peru glaxosmithkline pharma ordinary nykaer dk brondby denmark glaxosmithkline pharma gmbh ordinary wagenseilgasse euro plaza gebude stock wien glaxosmithkline pharmaceutical kenya limited ordinary likoni road nairobi kenya glaxosmithkline pharmaceutical nigeria limited ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline pharmaceutical sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia glaxosmithkline pharmaceuticals pvt ltd ordinary galle road kaldemulla moratuwa sri lanka glaxosmithkline pharmaceuticals costa rica sa ordinary autopista florencia del castillo kilmetro siete oficentro terracampus edificio uno cuarto piso san diego cartago costa rica glaxosmithkline pharmaceuticals sa ordinary ul grunwaldzka poznan poland ordinary b ordinary c ordinary glaxosmithkline pharmaceuticals sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline pharmaceuticals ukraine llc chartered capital pavla tychyny avenue v kiev ukraine glaxosmithkline philippines inc ordinary rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline pte ltd ordinary rochester park singapore glaxosmithkline puerto rico inc common prenticehall corporation system puerto rico inc co fast solutions llc ponce de leon avenue floor san juan puerto ricoother statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued glaxosmithkline republica dominicana sa ordinary blue mall tower floor ave winston churchill santo domingo dominican republic glaxosmithkline research development limited ordinary great west road brentford middlesex tw gs england glaxosmithkline sa ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline spa ordinary viale dellagricoltura verona italy glaxosmithkline sro ordinary hvezdova c prague czech republic glaxosmithkline services gmbh co kg partnership capital prinzregentenplatz munchen germany glaxosmithkline services unlimited ordinary great west road brentford middlesex tw gs england glaxosmithkline single member aebe ordinary kifissias avenue halandri athens greece glaxosmithkline sl llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline sl lp ii viii partnership great west road brentford middlesex tw gs england glaxosmithkline slovakia sro ordinary galvaniho bratislava slovakia glaxosmithkline south africa pty limited ordinary flushing meadows building campus sloane street bryanston south africa glaxosmithkline trading services limited iii ordinary riverwalk citywest business campus dublin ireland glaxosmithkline tunisia sarl ordinary immeuble regus lot b centre urbain nord tunis tunisia glaxosmithkline uk limited ordinary great west road brentford middlesex tw gs england glaxosmithkline uruguay sa registered provisory stock salto cp montevideo uruguay glaxosmithkline us trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline venezuela ca ordinary urbanizacion la trinidad calle luis de camoems edif apatado posta caracas venezuela bolivarian republic glaxosmithkline vietnam limited liability company ii iv equity capital metropolitan dong khoi street district th floor unit ho chi minh city vietnam glycovaxyn ag iv common grabenstrasse schlieren switzerland preferred preferred b preferred c groupe glaxosmithkline ordinary rue franois jacob rueilmalmaison france gsk australia nvd pty ltd ii iv ordinary mountain highway boronia victoria vic australia gsk bangladesh private limited ordinary sweden tower harinnachala konabari gazipur bangladesh gsk biopharma argentina sa nominative non endorseable ordinary tucumn piso buenos aires caaa argentina gsk business service centre sdn bhd ordinary level quill jalan prof khoo kay kim petaling jaya selangor malaysia gsk capital bv iii v ordinary great west road brentford middlesex tw gs england gsk capital kk ordinary akasaka minatoku tokyo japan gsk commercial sp z oo ordinary ul rzymowskiego warsaw poland gsk doo ljubljana ordinary amerika ulica ljubljana slovenia gsk enterprise management co ltd ordinary floor lane huanke road zhongke road shanghai china gsk equity investments limited units corporation service company interstate drive suite harrisburg pa united states gsk finance limited ordinary great west road brentford middlesex tw gs england gsk finance plc ordinary great west road brentford middlesex tw gs england gsk india global services private limited equity level luxor north tower bagmane capital business park outer ring road bangalore karnataka india gsk international holding finance bv ordinary van asch van wijckstraat h lp amersfoort netherlands gsk kazakhstan llp participation interest furmanov street almaty medeu district kazakhstan gsk limited ordinary great west road brentford middlesex tw gs england gsk pharma vietnam company limited chartered capital unit th floor metropolitan tower dong khoi street ben nghe ward district ho chi minh vietnam gsk pharmaceutical trading sa ii iv ordinary bucharest costache negri street opera center one th floor discussions room district romania gsk psc poland sp z oo equal indivisible shares ul grunwaldzka pozna pol gsk services sp z oo ordinary ul grunwaldzka poznan poland gsk vaccines bv ordinary hullenbergweg cl amsterdam netherlands gsk vaccines gmbh ordinary emilvonbehringstr marburg germany gsk vaccines institute global health srl quotas via fiorentina siena italy gsk vaccines srl quotas via fiorentina siena italy gsk vaccines vertriebs gmbh ii ordinary rudolfdieselring holzkirchen germany hgs france sarl ii iv ordinary rue de la belle feuille boulognebillancourt france human genome sciences inc common corporation service company little falls drive wilmington de united states id biomedical corporation quebec common boul du parc technologique qubec qubec gp r canada gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued instituto luso farmaco limitada ii quotas rua dr antonio loureiro borges arquiparque miraflores algs portugal interpharma dienstleistungen gmbh ii quotas wagenseilgasse euro plaza gebude stock vienna austria jj technologies lc llc interests corporation service company shockoe slip nd floor richmond va united states jsc glaxosmithkline trading ordinary leningradskiy prospect building floor premises xv room moscow russian federation laboratoire glaxosmithkline ordinary rue franois jacob rueilmalmaison france laboratoire pharmaceutique algrien lpa production spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoire pharmaceutique algrien spa ordinary zone industrielle est boudouaou boumerdes algeria laboratoires paucourt ii ordinary rue franois jacob rueilmalmaison france laboratoires saintgermain ii ordinary rue franois jacob rueilmalmaison france laboratorios dermatologicos darier sa de cv ordinary calzada mexico xochimilco san lorenzo huipulco district federal ordinary b mexico mexico laboratrios farmaceuticos stiefel portugal ltda ii ordinary rua dr antonio loureiro borges arquiparque miraflores algs portugal laboratorios stiefel de venezuela sa ordinary calle luis de camoens edificio glaxosmithkline urb la trinidad caracas venezuela bolivarian republic laboratorios stiefel ltda ordinary rua professor joao cavalheiro salem bairro de bonsucesso municipality guarulhos sao paulo cep brazil laboratorios wellcome de portugal limitada ii quota rua dr antonio loureiro borges arquiparque miraflores alges portugal mixis genetics limited liquidation ordinary bdo llp temple square temple street liverpool l rh montrose pharma company limited ii iv ordinary quota h csorsz utca budapest hungary penn labs inc ii common corporation service company little falls drive wilmington de united states setfirst limited ordinary great west road brentford middlesex tw gs england sitari pharma inc common stock corporation service company little falls drive wilmington de united states smith kline french portuguesaprodutos farmaceuticos ordinary rua dr antonio loureiro borges arquiparque miraflores lda ii alges portugal smithkline beecham bangladesh private limited ii ordinary housea roadgulshan dhaka bangladesh smithkline beecham cork limited ordinary riverwalk citywest business campus dublin ireland smithkline beecham manufacturing limited liquidation ordinary bdo beax lane house mercer street lower dh dublin dh ireland smithkline beecham swg limited liquidation ordinary bdo llp temple square temple street liverpool l rh smithkline beecham egypt llc quotas amoun street el salam city cairo egypt smithkline beecham farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain smithkline beecham limited ordinary great west road brentford middlesex tw gs england smithkline beecham pension plan trustee limited ii ordinary great west road brentford middlesex tw gs england smithkline beecham pension trustees limited liquidation ordinary baker street london wu eu united kingdom smithkline beecham pharma gmbh co kg partnership capital prinzregentenplatz munchen germany smithkline beecham pharma verwaltungs gmbh ordinary prinzregentenplatz munchen germany smithkline beecham pharmaceuticals pty limited ii iv ordinary flushing meadows building campus sloane street bryanston south africa smithkline beecham pharmaceuticals co common corporation service company little falls drive wilmington de united states smithkline beecham port louis limited liquidation ordinary co cim corporate services ltd les cascades building edith cavell street port louis mauritius smithkline beecham senior executive pension plan trustee ordinary great west road brentford middlesex tw gs england limited ii stiefel dominicana srl ii iv ordinary ave lope de vega torre novocentro local santo domingo dominican republic stiefel farma sa ordinary severo ochoa parque tecnologico de madrid tres cantos madrid spain stiefel gmbh co kg partnership capital prinzregentenplatz munchen germany stiefel india private limited equity battery house bhulabhai desai raod mumbai maharashtra india stiefel laboratories maidenhead ltd liquidation ordinary bdo llp temple square temple street liverpool l rh stiefel laboratories legacy ireland limited ordinary unit building avenue cork airport business park cork ireland stiefel laboratories limited liquidation since year end ordinary baker street london wu eu united kingdom stiefel laboratories pte limited ordinary pioneer sector singaporeother statutory disclosures continued group companies continued name security registered address wholly owned subsidiaries continued stiefel laboratories inc common corporation service company little falls drive wilmington de united states stiefel maroc sarl ii iv ordinary boulevard zerktouni casablanca morocco stiefel research australia holdings pty ltd ordinary mountain highway boronia victoria vic australia stiefel research australia pty ltd ordinary mountain highway boronia victoria vic australia stiefel west coast llc llc interests corporation service company little falls drive wilmington de united states strebor inc common corporation service company little falls drive wilmington de united states tesaro bio gmbh liquidation ordinary poststrasse zug switzerland tesaro bio netherlands bv ordinary joop geesinkweg ab amsterdamduivendrecht netherlands tesaro bio sweden ab common co bdo malardalen ab skatt box stockholm sweden tesaro development ltd ordinary clarendon house church street hamilton hm bermuda tesaro inc common corporation service company little falls drive wilmington de united states sydney ross co ii ordinary corporation service company princeton south corporate center suite charles ewing blvd ewing nj united states ucb pharma asia pacific sdn bhd ii ordinary th floor menara symphony jalan prof khoo kay kim seksyen petaling jaya malaysia wellcome consumer healthcare limited ii ordinary great west road brentford middlesex tw gs england wellcome consumer products limited liquidation ordinary bdo llp temple square temple street liverpool l rh since year end wellcome developments pty ltd ii iv ordinary mountain highway boronia victoria vic australia wellcome limited ordinary great west road brentford middlesex tw gs england wellcome operations pty ltd ii iv ordinary mountain highway boronia victoria vic australia effective name security ownership registered address subsidiaries effective interest less alacer corp common corporate service company dba csc lawyers incorporating service gateway oaks drive suite n sacramento california united states amoun pharmaceutical industries co sae new monetary shares el salam city po box cairo egypt beecham enterprises inc ii common corporation service company little falls drive wilmington de united states biddle sawyer limited equity dr annie besant road mumbai india block drug company inc common corporation service company princeton south corporate center suite charles ewing blvd ewing nj united states block drug corporation ii common corporation service company princeton south corporate center suite charles ewing blvd ewing nj united states british pharma group limited capital great west road brentford middlesex tw gs england consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england consumer healthcare intermediate holdings limited ordinary great west road brentford middlesex tw gs england duncan consumer healthcare philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines exlax inc common prentice hall corporation system puerto rico inc co citi tower ponce de leon avenue floor san juan puerto rico ferrosan aps shares delta park vallensbk strand denmark b shares ferrosan international aps ordinary delta park vallensbk strand denmark ferrosan srl registered capital c calea turzii clujnapoca cluj county romania galvani bioelectronics inc common corporation service company little falls drive wilmington de united states galvani bioelectronics limited ordinary great west road brentford middlesex tw gs england b ordinary glaxo saudi arabia limited ordinary po box area warehouse city first stage al khomrah jeddah saudi arabia glaxo wellcome ceylon limited ordinary galle road kaldemulla moratuwa sri lanka ordinary b glaxosmithkline suzhou trading co ltd registered capital gangpu road wusongjiang science technology industrial park wuzhong economic technical development zone suzhou china glaxosmithkline tianjin co ltd ordinary fifth avenue tai feng industrial park tianjin economic technolog tianjin china glaxosmithkline algrie spa ordinary zone industrielle est boudouaou wilaya de boumerdes algeria glaxosmithkline brasil produtos para consumo quotas av das americas th floor rooms rio de janeiro rj e saude ltda brazil gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline consumer healthcare china co ltd ordinary room shengang boulevard lingang special area china pilot free trade z shanghai shanghai china glaxosmithkline consumer healthcare hong kong limited ordinary f tower gateway canton road tsimshatsui kowloon hong kong glaxosmithkline consumer healthcare ireland limited ordinary riverwalk citywest business campus dublin ireland glaxosmithkline consumer healthcare overseas limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare thailand limited ordinary th floor unit wave place wireless road lumpini pathumwan bangkok thailand glaxosmithkline consumer healthcare uk ip limited iv ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare uk trading limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare us ip llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline consumer healthcare ab ordinary hemvrnsgatan po box solna sweden glaxosmithkline consumer healthcare aps ordinary delta park vallensbk strand denmark glaxosmithkline consumer healthcare australia pty ltd ordinary hughes avenue ermington new south wales nsw australia glaxosmithkline consumer healthcare bv ordinary van asch van wijckstraat g lp amersfoort netherlands glaxosmithkline consumer healthcare colombia sas ordinary carrera piso colombia glaxosmithkline consumer healthcare czech republic sro ordinary hvezdova c prague czech republic glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finance limited ordinary great west road brentford middlesex tw gs england glaxosmithkline consumer healthcare finland oy ordinary piispansilta fin espoo finland glaxosmithkline consumer healthcare gmbh ordinary wagenseilgasse euro plaza gebude stock vienna austria glaxosmithkline consumer healthcare gmbh co kg partnership capital barthstr mnchen germany glaxosmithkline consumer healthcare hellas single ordinary kifissias avenue halandri athens greece member societe anonyme glaxosmithkline consumer healthcare holdings great west road brentford middlesex tw gs england limited b preference glaxosmithkline consumer healthcare holdings us llc llc interests corporation service company little falls drive wilmington de united states glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland limited iii liquidation glaxosmithkline consumer healthcare investments ordinary knockbrack dungarvan co waterford x ry ireland ireland unlimited company iii liquidation glaxosmithkline consumer healthcare japan kk ordinary akasaka minatoku tokyo japan glaxosmithkline consumer healthcare korea co ltd ordinary f ls yongsan tower hangangdaero yongsangu seoul korea republic glaxosmithkline consumer healthcare llc llc interests corporation service company interstate drive suite harrisburg pa united states glaxosmithkline consumer healthcare mexico de rl ordinary boulevard adolfo ruiz cortines torre piso colonia de cv jardines del pedregal alcalda alvaro obregn ciudad de mxico cp mexico glaxosmithkline consumer healthcare new zealand ulc ordinary level e madden street auckland central auckland new zealand glaxosmithkline consumer healthcare norway ordinary drammensveien lysaker norway glaxosmithkline consumer healthcare pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline consumer healthcare philippines inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines glaxosmithkline consumer healthcare pte ltd ordinary rochester park singapore glaxosmithkline consumer healthcare sa ordinary site apollo avenue pascal wavre belgium glaxosmithkline consumer healthcare sa ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain glaxosmithkline consumer healthcare srl ordinary via zambeletti snc baranzate milan italy glaxosmithkline consumer healthcare saudi limited ordinary salamah tower th floor madinah road alsalamah district jeddah saudi arabia glaxosmithkline consumer healthcare sdn bhd ordinary lot jalan enggang ampang hulu kelang industrial estate selangor darul ehsan ampang malaysia glaxosmithkline consumer healthcare slovakia r ownership interest galvaniho bratislava slovakia glaxosmithkline consumer healthcare south africa pty ordinary flushing meadows building campus sloane street bryanston ltd south africa glaxosmithkline consumer healthcare spzoo ordinary ul grunwaldzka poznan poland glaxosmithkline consumer healthcare srl ordinary costache negri street opera center one th floor zone district bucharest romaniaother statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued glaxosmithkline consumer healthcare ulc class preference burrard street suite three bentall centre po box glaxosmithkline soins de sante aux consommateurs sri common vancouver bc vx l canada glaxosmithkline consumer healthcare vietnam company charter capital floor metropolitan dong khoi ben nghe ward district ho limited ii chi minh city vietnam glaxosmithkline consumer healthcare lp partnership capital corporation service company little falls drive wilmington de united states glaxosmithkline consumer healthcare produtos para ordinary quota rua dr antonio loureiro borges arquiparque miraflores saude e higiene lda algs portugal glaxosmithkline consumer nigeria plc vi ordinary industrial avenue ilupeju ikeja lagos pm b nigeria glaxosmithkline consumer private limited equity patiala road nabha dist patiala punjab india glaxosmithkline consumer trading services limited ordinary great west road brentford middlesex tw gs england glaxosmithkline costa rica sa ordinary san jos este de la rotonda betania carretera sabanilla costa rica glaxosmithkline dungarvan limited ordinary knockbrack dungarvan co waterford x ry ireland glaxosmithkline healthcare ao ordinary premises iii room floor presnenskaya nab moscow russian federation glaxosmithkline healthcare gmbh ordinary barthstr mnchen germany glaxosmithkline healthcare ukraine ooo ownership interest pavla tychyny avenue v kiev ukraine glaxosmithkline limited cumulative redeemable likoni road po box nairobi kenya preference ordinary glaxosmithkline pakistan limited ordinary sykes building dockyard road west wharf karachi pakistan glaxosmithkline panama sa nonqualified preference urbanizacion industrial juan calles b republic panama shares panama ordinary glaxosmithkline paraguay sa ordinary oficial gilberto aranda planta alta casi salvador del mundo asuncin paraguay glaxosmithkline pharmaceuticals limited equity dr annie besant road mumbai india glaxosmithkline sae ordinary boomerang office building land zone j st district town center th tagammoe new cairo city egypt glaxosmithkline sant grand public ordinary rue franois jacob rueilmalmaison france glaxosmithkline technology taizhou co ltd ordinary room building phase ii new drug innovation base taizhou jiangsu province china glaxosmithkline tuketici sagligi anonim sirketi nominative bykdere caddesi levent plaza b blok levent istanbul turkey glaxosmithklineconsumer kft membership h csorsz utca budapest hungary gsk canada holding company limited ordinary great west road brentford middlesex tw gs england gsk ch caricam sociedad de responsabilidad participation urbanizacion industrial juan calles b republic panama limitada ii panama gsk ch kazakhstan llp charter capital manasa str bostandyk district almaty kazakhstan gsk consumer health inc common corporation service company little falls drive wilmington de united states gsk consumer healthcare capital nl bv iii v shares great west road brentford middlesex tw gs england gsk consumer healthcare capital us llc llc interests corporation service company little falls drive wilmington de united states gsk consumer healthcare chile spa clp interests av andrs bello n th floor las condes chile gsk consumer healthcare egypt limited ordinary north th street boomerang building th district cairo egypt gsk consumer healthcare egypt llc quotas north th street boomerang building th district cairo egypt gsk consumer healthcare export limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holdings limited nonvoting preference great west road brentford middlesex tw gs england shares ordinary gsk consumer healthcare holdings limited nonvoting preference great west road brentford middlesex tw gs england shares ordinary gsk consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holdings us inc common corporation service company little falls drive wilmington de preference stock united states gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued gsk consumer healthcare holdings llc iii unit corporation service company little falls drive wilmington de united states gsk consumer healthcare insurance limited ordinary dorey court admiral park st peter port gy guernsey gsk consumer healthcare israel ltd iv ordinary basel street petech tikva israel gsk consumer healthcare levice sro ordinary priemyselny park gena ul e sachsa levice slovakia gsk consumer healthcare peru srl ordinary av jorge basadre piso san isidro lima w peru gsk consumer healthcare sarl ordinary route de i'etraz prangins switzerland gsk consumer healthcare schweiz ag ordinary suurstoffi rotkreuz switzerland gsk consumer healthcare services inc common corporation service company little falls drive wilmington de united states gsk consumer healthcare singapore pte ltd ordinary rochester park singapore gsk consumer healthcare trinidad tobago limited ordinary th floor algico plaza st vincent street port spain trinidad preference tobago gskgebro consumer healthcare gmbh ordinary bahnhofbichl fieberbrunn kitzbhel austria iodosan spa ordinary via zambeletti snc baranzate milan italy kuhs gmbh ordinary barthstr mnchen germany laboratorios viiv healthcare sl ordinary severo ochoa parque tecnolgico de madrid tres cantos madrid spain modern pharma trading company llc quotas amoun street po box el salam city cairo egypt nch nutrition consumer health ltd ii ordinary hamephalsim st petach tikva israel pt smithkline beecham pharmaceuticals ordinary jl pulobuaran raya kav iii dd kawasan industri pulogadung ordinary b jakarta indonesia pt sterling products indonesia shares graha paramita building th f jalan denpasar raya blok jakarta b shares indonesia panadol gmbh ordinary barthstr mnchen germany pf consumer healthcare llc membership interest corporation service company little falls drive wilmington de united states pf consumer healthcare bv class van asch van wijckstraat g lp amersfoort netherlands class b pf consumer healthcare brazil importadora e distribuidora quota barueri avenida ceci block iii part tambore district de medicamentos ltda paulo brazil pf consumer healthcare canada ulcpf soins de sante common burrard street suite three bentall centre po box sri preferred vancouver bc vx l canada pf consumer healthcare holding bv ordinary van asch van wijckstraat g lp amersfoort netherlands pf consumer healthcare uk limited liquidation ordinary great west road brentford middlesex tw gs england pf consumer ireland company limited liquidation ordinary bdo beax lane house mercer street lower dh dublin dh ireland pf consumer taiwan llc interests corporation trust company corporation trust center orange street wilmington de united states pfizer biotech corporation ordinary f sec zhong xiao w rd taipei taiwan pfizer consumer healthcare ab ordinary vetenskapsvagen se sollentuna sweden pfizer consumer healthcare gmbh ordinary linkstrasse berlin germany pfizer consumer manufacturing italy srl quota stock via nettunese aprilia prov di latin italy pfizer laboratories pfe pty ltd common flushing meadows building campus sloane street bryanston south africa pfizer pfe colombia sas common carrera piso colombia phivco llc llc interests corporation service company little falls drive wilmington de united states phivco llc llc interests corporation service company little falls drive wilmington de united states prism pch limited nonvoting shares great west road brentford middlesex tw gs england voting shares pt glaxo wellcome indonesia class jl pulobuaran raya kaviiidd kws industri pulogadung class b jatinegara cakung jakarta timur indonesia pt gsk consumer healthcare indonesia ordinary graha paramita building th f jalan denpasar raya blok kuningan jakarta selatan indonesia pt bina dentalindo liquidation ordinary gedung graha ganesha lantai jl raya bekasi km jakarta timur indonesia shionogiviiv healthcare llc ii common interests corporation service company little falls drive wilmington de united states sinoamerican tianjin smith kline french laboratories ordinary cheng lin zhuang industrial zone dong li district tianjin ltd china smithkline beecham private limited ordinary world trade center level west tower echelon square colombo sri lankaother statutory disclosures continued group companies continued effective name security ownership registered address subsidiaries effective interest less continued smithkline beecham research limited ordinary great west road brentford middlesex tw gs england smithkline beecham sa ordinary ctra de ajalvir km alcala de henares madrid spain smithkline beechambiomed ooo participation interest leningradskiy prospect building floor premises xiv room moscow russian federation staffordmiller ireland limited ordinary clocherane youghal road dungarvan co waterford ireland staffordmiller limited liquidation ordinary clocherane youghal road dungarvan co waterford dungarvan noncumulative non waterford ireland redeemable preference sterling drug malaya sdn berhad ordinary lot jalan enggang ampanghulu kelang industrial estate selangor darul ehsan ampang malaysia sterling products international incorporated ii common corporation service company little falls drive wilmington de united states stiefel consumer healthcare uk limited ordinary great west road brentford middlesex tw gs england stiefel egypt llc ii quotas amoun street po box el salam city cairo egypt stiefel laboratories ireland limited liquidation ordinary bdo beax lane house mercer street lower dh dublin dh ireland treerly health co ltd capital contribution unit room east zhujiang road tianhe district guangzhou city prc china viiv healthcare south africa proprietary limited ii iv ordinary flushing meadows building campus sloane street bryanston south africa viiv healthcare bv ordinary van asch van wijckstraat h lp amersfoort netherlands netherlands viiv healthcare company common corporation service company little falls drive wilmington de united states viiv healthcare finance limited liquidation ordinary baker street london wu eu united kingdom viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england viiv healthcare finance limited ordinary great west road brentford middlesex tw gs england redeemable preference viiv healthcare gmbh ordinary prinzregentenplatz munchen germany viiv healthcare gmbh ordinary talstrasse muenchenbuchsee switzerland viiv healthcare hong kong limited ii ordinary f tower gateway canton road harbour city tsimshatsui kowloon hong kong viiv healthcare kk ordinary akasaka minatoku tokyo japan viiv healthcare limited class great west road brentford middlesex tw gs england class b class c class class deferred class e cumulative preference viiv healthcare pty ltd ordinary mountain highway boronia victoria vic australia viiv healthcare puerto rico llc llc interests centro international de mercadeo carr torre suite guaynabo puerto rico viiv healthcare srl quota viale dellagricoltura verona italy viiv healthcare sas ordinary rue franois jacob rueilmalmaison france viiv healthcare sprl ordinary site apollo avenue pascal wavre belgium viiv healthcare trading llc ii participation interest leningradskiy prospect building floor premises xiv room moscow russian federation viiv healthcare trading services uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare uk limited ordinary great west road brentford middlesex tw gs england viiv healthcare ulc common nd street sw calgary ab tp j canada viiv healthcare venture llc llc interests corporation service company little falls drive wilmington de united states viivhiv healthcare unipessoal lda quota rua dr antonio loureiro borges arquiparque miraflores algs portugal vog au pty ltd ii ordinary hughes avenue ermington new south wales nsw australia redeemable preference winster pharmaceuticals limited ii ordinary association avenue ilupeju industrial estate lagos po box nigeria wyeth pharmaceutical co ltd registered capital baodai west road suzhou jiangsu province china wyeth pharmaceuticals company vii partnership registered address required puerto rico general partnership contact entity contact questions puerto rico gsk annual report gsk annual report strategic report governance remuneration financial statements investor information statutory disclosures continued group companies continued effective name security ownership registered address associates glaxosmithkline landholding company inc common rd floor finance centre th street corner th avenue bonifacio global city taguig city philippines index ventures life vi jersey lp partnership interest esplanade st helier jersey je wg channel islands kurma biofund ii fcpr partnership interest rue royale paris france longwood fund lp partnership interest prudential tower suite boylston street boston medicxi ventures lp partnership interest esplanade st helier jersey je wg channel islands joint ventures chiron panacea vaccines private limited equity shares th floor wing sagar tech plaza saki naka andheri east mumbai maharashtra india qualivax pte limited ordinary robinson road singapore qura therapeutics llc units corporation service company little falls drive wilmington de united states significant holdings axon therapies inc common series west th street new york delaware usa preference global farm sa shares cazadores de coquimbo piso munro argentina b shares c shares shares e shares f shares longwood fund ii lp partnership interest prudential tower suite boylston street boston sanderling ventures vii lp partnership interest el camino real suite san mateo ca sr one capital fund ib lp partnership interest corporation service company little falls drive city wilmington county new castle delaware following uk subsidiaries take advantage audit exemption set within section companies act period ended december unless otherwise stated undertakings listed owned either directly indirectly glaxosmithkline plc effective company name security ownership registered address number uk registered subsidiaries exempted audit burroughs wellcome international limited ordinary great west road brentford middlesex tw gs england domantis limited ordinary great west road brentford middlesex tw gs england edinburgh pharmaceutical industries limited ii ordinary shewalton road irvine ayrshire ka ap united kingdom sc preference eskaylab limited ordinary great west road brentford middlesex tw gs england glaxo wellcome uk limited ordinary great west road brentford middlesex tw gs england glaxochem uk unlimited ordinary great west road brentford middlesex tw gs england ordinary b ordinary c glaxosmithkline consumer healthcare uk ordinary great west road brentford middlesex tw gs england limited glaxosmithkline consumer healthcare sri lanka ordinary great west road brentford middlesex tw gs england holdings limited glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline intellectual property limited ordinary great west road brentford middlesex tw gs england glaxosmithkline international limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare capital uk plc ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england gsk consumer healthcare holdings limited ordinary great west road brentford middlesex tw gs england gsk new zealand holding company limited ordinary great west road brentford middlesex tw gs england montrose fine chemical company ltd ordinary shewalton road irvine ayrshire ka ap united kingdom sc phivco uk ii limited ordinary great west road brentford middlesex tw gs england phivco uk limited ordinary great west road brentford middlesex tw gs england smith kline french laboratories limited iv ordinary great west road brentford middlesex tw gs england smithkline beecham export limited ordinary great west road brentford middlesex tw gs england smithkline beecham h limited noncumulative great west road brentford middlesex tw gs england nonredeemable ordinaryother statutory disclosures continued group companies continued effective company name security ownership registered address number uk registered subsidiaries exempted audit continued smithkline beecham investments limited ordinary great west road brentford middlesex tw gs england smithkline beecham legacy h limited ordinary great west road brentford middlesex tw gs england smithkline beecham marketing technical ordinary great west road brentford middlesex tw gs england services limited smithkline beecham nominees limited ordinary great west road brentford middlesex tw gs england smithkline beecham overseas limited ordinary great west road brentford middlesex tw gs england stiefel laboratories uk ltd ordinary great west road brentford middlesex tw gs england tesaro uk limited ordinary great west road brentford middlesex tw gs england wellcome foundation limited ordinary great west road brentford middlesex tw gs england viiv healthcare overseas limited ordinary great west road brentford middlesex tw gs england accordance section c companies act company guarantee debts liabilities uk subsidiary undertakings december total sum debts liabilities million million key directly owned glaxosmithkline plc ii ormant entity iii ax resident uk iv entity expected disposed removed v incorporated netherlands vi consolidated subsidiary accordance section companies act grounds dominant influence vii principal business address puerto rico viii exempt provisions regulations partnership accounts regulation accordance exemptions noted regulation regulation gsk annual report gsk annual report strategic report governance remuneration financial statements investor information glossary terms terms used annual report us equivalent brief description accelerated capital allowances tax allowance excess depreciation arising purchase fixed assets delay charging payment tax equivalent tax depreciation american depositary receipt adr r eceipt evidencing title ads gsk adr represents two ordinary shares american depositary shares ads listed new york stock exchange represents two ordinary shares basic earnings per share basic income per share called share capital ordinary shares issued fully paid cer growth growth constant exchange rates company glaxosmithkline plc currency swap exchange two currencies coupled subsequent reexchange currencies agreed exchange rates dates defined benefit plan pension plan specific employee benefits often called final salary scheme defined contribution plan pension plan specific contributions level pension dependent upon growth pension fund derivative financial instrument financial instrument derives value price rate underlying item diluted earnings per share diluted income per share employee share ownership plan trusts trusts established group satisfy sharebased employee incentive plans equity shareholders funds shareholders equity finance lease capital lease freehold ownership absolute rights perpetuity group glaxosmithkline plc subsidiary undertakings gsk glaxosmithkline plc subsidiary undertakings hedging reduction risk normally relation foreign currency interest rate movements making offsetting commitments intangible fixed assets assets without physical substance computer software brands licences patents knowhow marketing rights purchased outside parties ordinary share fully paid ordinary share capital company profit income profit attributable shareholders net income share capital ordinary shares capital stock common stock issued fully paid share option stock option share premium account additional paidup capital paidin surplus distributable shares issue number shares outstanding subsidiary entity gsk exercises control treasury share treasury stock turnover revenue uk corporate governance code required uk listing authority company disclosed annual report applied best practice corporate governance provisions financial reporting councils uk corporate governance codeindex remuneration policy summary investor relations accounting principles policies key performance indicators acquisitions disposals legal proceedings adjustments reconciling profit tax operating major restructuring costs cash flows modern employer affordability availability movements equity annual general meeting net debt approach tax new accounting requirements assets held sale nominations committee report associates joint ventures noncontrolling interests audit risk committee report noncontrolling interests viiv healthcare responsible business nonexecutive directors fees business model nonfinancial information statement cash cash equivalents notes financial statements cash generation conversion operating profit ceos statement intangible assets chairmans statement investments chairmans governance statement noncurrent assets chairmans remuneration annual statement noncurrent liabilities climaterelated financial disclosure operating incomeexpense commitments provisions consolidated balance sheet culture consolidated cash flow statement external environment consolidated income statement longterm priorities consolidated statement changes equity pensions postemployment benefits consolidated statement comprehensive income performance consumer healthcare pharmaceuticals consumer healthcare products competition pharmaceutical products competition contingent consideration liabilities intellectual property contingent liabilities pipeline corporate governance post balance sheet events corporate responsibility committee report presentation financial statements critical accounting judgements key sources principal group companies estimation uncertainty principal risks uncertainties critical accounting policies property plant equipment data engagement quarterly trend directors senior management reconciliation net cash flow movement net debt directors interests shares registrar directors report related party transactions directors statement responsibilities reliable supply dividends remuneration governance donations political organisations remuneration report political expenditure reporting framework earnings per share right use assets employee costs risk management employee share schemes science technology environment science committee report ethics values section statement exchange rates share capital control finance expense share capital share premium account finance income shareholder information financial calendar shareholder services contacts financial instruments related disclosures stakeholder engagement financial performance task force climaterelated financial disclosures financial position resources taxation financial statements glaxosmithkline plc prepared tax information shareholders uk gaap board five year record trade payables glossary terms trade receivables goodwill transformation separation committee report group companies treasury policies group financial review trust gsk leadership team turnover segment information independent auditors report us law regulation innovation vaccines inventories vaccine products competition intellectual property investments associates joint ventures viability statement gsk annual report strategic report governance remuneration financial statements investor information gsk glaxosmithkline plc incorporated english brand names brand names appearing italics throughout report public limited company december trade marks either owned andor licensed gsk associated companies trade marks formed merger glaxo wellcome plc property respective owners smithkline beecham plc gsk acquired two acknowledgements printing english companies december part printed sustainably uk pureprint carbonneutral company fsc chain custody iso merger arrangements certified environmental management system recycling dry waste shares listed london stock exchange paper printed innovation premium fsc certified paper new york stock exchange pulps used totally chlorine free manufacturing mill iso environmental management certification mills energy produced biomass fuels sourced local forestry read wwwgskcom fossil fuels used carbon emissions measured offset using world land trusts carbon balanced scheme download pdfs nnual report f orm f cautionary statement regarding number nonifrs measures used report groups guidance assumes successful delivery forwardlooking statements performance business measures defined groups integration restructuring plans also groups reports filed furnished us pages reconciliation adjusted assumes separation programme deliver securities exchange commission sec including results total results set demerger consumer healthcare business r f f g f bou uh e yivt ti rl e u uw e ha r r ae et es ho r e b ed e fc ad vy u g cel nr te tr hk uo n pr g ba ts nl h e sn c eih td nua ya vt ra l dee fn e sm oomy n f e ne n orn eht h tct xe se p ra eg r nem f lw c ar ia ttr rd eaui ewt te p nt siae tt r rt nm fdo csi ttl oh loy hf yo r e e c tr fk ospm oi e nu rn ha e tb g c si tlo si ta ac n ts e r tn ce aom eh lf ne e ot n rs g e p p cn ofh e elf g ne r f fx sar oi tgt r r ro sf uo es ar inm e dn ni tl c cal ha n e et k si ro l c nan n n p e ot ni hn r tni p oe hn ol fiv r ih c n ti tii gns boa fo v ertd ie ni r ao ers e tnnc ct h lu aiit ien som se dv tanb ie utu nan pay ntt oco ud n anho iv l ae rtr ss r ie e e n p gi nt pu u r c tc se en htm ote ot ui n lfu dt u te bo u e ra e n n bh fe pe e afew e sl cti iv ie co sse p x tn ier p se de n id c sn b u tac tu h hc ei dl ec gn e u gs r tn uo igs oc iu df nhu v p aae el l ns ly n cd pa eagn p ia ai sevt ee r l gdinnr ri ia vt ed l h e ntc e nh h ep rs nv ot es u e bf ctno l e oo itr ne noa vi nn skl e v tdf sm ae e ns c mav tt ye e c l b nr ue e e tp rn r mt e ii nn en ct n yt current facts use words anticipate outlooks sales ambition estimate expect intend project plan assumptions related guidance dividend expectations read together believe target words terms similar outlining guidance group made section basis preparation assumptions meaning connection discussion future certain assumptions healthcare sector cautionary statements pages stock operating financial performance particular different markets group operates exchange announcement relating update investors include statements relating future actions prospective delivery revenues financial benefits current dated june outlook ambition statements products product approvals future performance portfolio pipeline restructuring programmes given constant currency basis use results current anticipated products sales efforts group also assumes demerger consumer actual exchange rates base expenses outcome contingencies legal healthcare business delivered mid proceedings dividend payments financial results guidance relates new gsk notice regarding limitations accordance legal regulatory director liability english law obligations including market abuse group made planning assumptions uk companies act safe harbour limits regulations uk listing rules disclosure healthcare systems approach normality year liability directors respect statements transparency rules financial conduct progresses expect sales specialty medicines omissions directors report see authority group undertakes obligation update grow approximately cer sales general strategic report remuneration report forwardlooking statements whether result medicines show slight decrease primarily reflecting english law directors would liable new information future events otherwise reader increased genericisation established respiratory company third party one however consult additional disclosures products vaccines sales expected grow low reports contained errors result recklessness group may make documents teens percentage cer year whole however knowing misstatement dishonest concealment publishes andor files sec readers governments prioritisation covid vaccination material fact would otherwise liable pages wherever located take note disclosures programmes ongoing measures contain inclusive comprise accordingly assurance given pandemic expected result continued directors report pages inclusive comprise particular expectation met investors disruption adult immunisations impact strategic report pages inclusive comprise cautioned place undue reliance weighted first half shingrix despite potential remuneration report drawn forwardlooking statements shortterm pandemic disruption continue expect presented accordance reliance upon f fn ao h cr e tw ore ra snr h rl aio tko ask r ean ng bd es yuta ont nce dem r te han eint gt ia e rr ose u psu sb n cj ye c nt f rt wo h l oics rs h pu r rm e el cp itt seio e tn os e rot xnr yp ln trg yo nd ii nogo cn u od b g mel eu iad frni og n mi ci n g e ao ex lw ss ett ih n ti tnga lecn mld ua edr r ne ek tc se ao ts nhrd dea na f liun ctn eugu nre ea l e bgs aea ra gnle p e res h fi etib c mia nas e l e nd e c limon ng itnl ais e tih c nc io n w np dia hn hl ta e rw ce ta orn e nd p h pre rts l vi sa ih db eil li dlt bes suf u bt ch j hee c lad w tir e tc ht eo rs estimate group cautions investors number gilead announced february website important factors including document could cause actual results differ materially planning assumptions well operating profit gsks website wwwgskcom gives additional information expressed implied forwardlooking statement guidance dividend expectations assume material group notwithstanding references make interruptions supply groups products material annual report gsks website none factors include limited mergers acquisitions disposals material litigation information made available website constitutes discussed principal risks uncertainties investigation costs company save part annual report shall deemed pages annual report impacts already recognised provisions incorporated reference herein covid pandemic forwardlooking made change groups shareholdings viiv statements made behalf group speak healthcare assumptions also assume material date made based upon changes healthcare environment unexpected knowledge information available directors significant changes pricing result government date annual report competitor action guidance factors divestments product exits announced datefront cover image taken short film gsks use human genetics advanced technology increase probability successful new medicines click gskadvancedtechcom watch search us head office registered office glaxosmithkline plc great west road brentford middlesex tw gs united kingdom tel registered number wwwgskcom